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GUEST EDITORS
Controversies in Neurology 2018, Warsaw, Poland
This year’s CONy was once more an exciting event. Again we experienced an exciting four-day 
conference with top-line faculty discussing and debating many of the pressing questions clinical 
neurologists face in all fields of neurology. These leading experts helped to illuminate the program 
made in their subspecialties in recent years, but the stress was, of course, on the unknown and on the 
issues still under investigation. The program included not only Multiple Sclerosis, Stroke, Dementia, 
Headache, Movement disorders, Epilepsy and Neuroimmunology, In addition, there were three sessions 
dedicated to important issues which have a special local relevance Wilson’s disease program, and the 
History of Neurology in Poland. 
The present special issue of the Journal of Polish Neurological Society, devoted exclusively to the 
12th meeting on Controversies in Neurology includes abstracts of invited lectures and free communi-
cation presented at the meeting. It is a tribute to this event allowing it to remain immortalized in an 
international academic journal. 
We look forward to more debates and enlightening discussions in CONy 13th, which will take place 
in Madrid, Spain (April 4–7, 2019) (http://www. comtecmed. com/cony/2018/Default. aspx). 
A.D. Korczyn
Sackler School of Medicine Tel-Aviv University, Israel
Dear Authors and Readers,
On behalf of prof. Amos Korczyn and myself as the Guest Editors of this supplementary issue of 
”Polish Neurological Review” journal, I would like to welcome you to the 12th World Congress on Con-
troversies in Neurology which is organized this year in Warsaw, Poland. ”Polish Neurological Review” 
is the official educational journal of Polish Neurological Society and the CONy congress is organized 
under auspices of our society. I hope all your abstracts will be a valuable teaching offer and will also 
convince participants to visit specific sessions and posters on plenty of highly interesting topics in-
cluded in the Congress programme.
I wish all of you a great time in Warsaw, both scientific, educational and cultural as well.
J. Slawek
President of Polish Neurological Society
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ALZHEIMER’S DISEASES AND DEMENTIA
Does cognitive stimulation have value in the treatment  
of MCI and early AD?
R. Bullock
Research, Kingshill Research Centre, UK
Cognitive stimulation is a range of activities aimed at improving cognitive and social functioning. 
The interventions can be administered in groups or to individuals, so appear to be an effective use of 
resources. However, the published results to date only deliver low quality evidence at best, mainly from 
high-income countries. Before definitive recommendations can be made to make cognitive stimulation 
an available and reimbursed intervention, further studies need to be conducted, particularly in lower 
income countries. Until that time the value of cognitive stimulation in MCI and AD remains limited. 
The roads to decode the genetic architecture  
of neurodegenerative diseases
O. Chiba-Falek
Neurology, Duke University School of Medicine, USA
Large multi-center genome-wide association studies (GWAS) found associations between multiple 
genomic loci and neurodegenerative diseases of aging. While GWAS candidate genes were inferred by 
proximity to the associated SNPs, for many disease-associated loci the precise target genes have yet to 
be identified. Furthermore, the specific causal genetic variants and the molecular mechanisms through 
which they exert their pathogenic effects remain largely unknown. The large majority of GWAS asso-
ciated SNPs are in noncoding, intergenic and intragenic, regions of the genome, suggesting regulatory 
function. Moreover, expression quantitative trait (eQTL) studies from our lab and others, described 
the cis-association of disease-associated variants with gene expression in brain tissues vulnerable to 
disease pathology, however, the particular functional variants that directly influence gene expression 
have yet to be defined and validated. In the post-GWAS era the key question is how to move forward 
from association to causation in the research arena of the genetic etiologies of age-related neurode-
generative diseases? Our research focuses on mechanistic understanding of noncoding regions in loci 
associated with neurodegenerative disorders. To decode GWAS-discoveries we apply a multifaceted 
strategy, combining in silico, in vitro and in vivo approaches. Particularly, we utilize single cells from 
brain regions affected in Alzheimer’s-Parkinson’s spectrum diseases to examine neuronal vs. glia dis-
ease-specific changes in chromatin accessibility and gene expression, integrate epigenome datasets, 
and complement these experiments using aging-induced iPSC-derived neuronal models. This talk 
will feature advancements and challenges in the study of SNCA in relation to synucleinopathies, and 
TOMM40-APOE in the context of dementias. 
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Predicting clinical improvement after shunting  
in hydrocephalus — why it is so difficult?
M. Czosnyka 
Division of Neurosurgery, Dept of Clinical Neurosciences, University of Cambridge, UK
Normal Pressure Hydrocephalus (NPH) is probably an only type of reversible dementia. Starting from 
1950’, when the first CSF shunts became available, there was a remarkable outbreak of enthusiasm 
about shunting for hydrocephalus. Different criteria, apart from clinical symptoms and radiography, 
have been considered. Large ventricles, distorted neural tracks, decrease CBF in white matter around 
ventricles and other specific loci in a brain, “DESH” picture — all seem to be informative but not very 
specific. New look with high-resolution MRI seems to open novel horizons; dynamic MRI-CSF flow 
can be also helpful. From physiological measurement, infusion test with compensatory parameters 
has equal number of enthusiasts and critics. Measurement of pulse amplitude of ICP or a slope of 
amplitude-pressure line is advocated as useful in selected centers. Slow vasogenic waves in ICP and 
pressure-volume compensatory reserve is used rarely. Long-term (72 hours) CSF drainage can be con-
sidered as “trial shunting”. Role of biochemistry is not very strongly documented, although promising. 
None of the tests/measurements have alone strong predictive power. Probably combinations of them 
will be more useful. There is no ideal predictive test in hydrocephalus. Nowadays, we shunt elder 
patients with more co-morbidity. Therefore typical profile of average NPH patient is more heteroge-
neous than 40–50 years ago. Excluding co-morbidities with confirming faulty CSF circulation seems 
to be a plausible strategy. Finding a difference between two states: “too much water” (NPH) and “not 
enough brain” (atrophy) is challenging, as there is possibly a sizeable area of overlap. 
Should agitation in ad be treated with antipsychotics?
T. Gabryelewicz
Department of Neurodegenerative Disorders, Mossakowski Medical Research Centre Polish Academy of Sciences, Poland
Behavioral symptoms such as agitation and aggression are of great importance to family and caregiv-
ers as these tend to be the most distressing. When nonpharmacologic management strategies are not 
sufficient to alleviate patients’ behavioral symptoms, pharmacologic treatment may be indicated. The 
reason for initiating drug therapy must be clearly defined at the outset, and the desired management 
goals must be identified. Such decisions will need to balance the potential benefits and harms of a par-
ticular intervention as compared to other therapeutic options for the individual patient. The use of an 
antipsychotic medication in patients with AD can be appropriate, particularly in individuals with dan-
gerous agitation, aggression or psychosis, and can minimize the risk of violence, reduce patient distress, 
improve patient’s quality of life, and reduce caregiver burden. There is consistent evidence that these 
drugs can cause side effects, like drowsiness, rigidity, unusual movements. Studies have linked some 
of these to a higher risk of death for people with dementia. The FDA has placed a “black box” warning 
on these drugs describing the risks. In clinical trials, the benefits of antipsychotic medications in AD 
are modest. Decisions about the treatment of agitation should be an outgrowth of the initial assessment 
and an understanding of the goals and preferences of the patient and the others involved with the 
patient. Agitation in AD patients is an ominous sign, frequently leading to nursing home placement. 
Is it justified to treat patients with neuroleptic drugs in spite of their significant adverse effects?
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Pharmacological treatment of Alzheimer disease in 2028
E. Giacobini
Internal medicine, Rehabilitation and Geriatrics, University of Geneva Hospitals, Switzerland
Given the average duration of clinical trials (Phase I to Phase III) of 9–10 years at an average cost 
of 5–7 billion $ (SCOTT, 2013) is not too early to consider today the possibility of a pharmacological 
treatment for 2028. The cause of the disease still escape us and the major investment made so far in 
developing anti-abeta interventions have not given clinically relevant results, therefore, we are limit-
ed to design therapies based on results derived from molecular imaging (PET). This approach moves 
from traditional neuropathological criteria into a phenotype-targeted therapy which may or may not be 
casually related. The multistate transition model (C. Jack et al. 2016, 2017) utilizes transition rates to 
estimate the frequency of each state based on long-term follow up of cognitively unimpaired individ-
uals from 50 to 90 years. The most recent one (C. Jack, 2017) combines three different imaging-based 
measurements in vivo: a-beta aggregation, tauopathy, and neurodegeneration, evaluated with repeated 
PET tested in the same subject. Subtyping based on these criteria makes it possible to design a differ-
entiated therapy targeting specific pathologies in the individual patient. This approach emphasizes 
the critical need to continue our research in order to find the cause of the disease the best therapy 
within the next ten years. 
Is amyloid deposition a non-specific manifestation of aging?
P. Giannakopoulos
Medical Direction, University Hospitals of Geneva, Switzerland
PET amyloid imaging has been initially considered as the main tool to investigate the beginning of 
the AD process in cognitively intact individuals. The percentage of PET-amyloid positive controls is of 
6% at age 60 but reaches 50% at age 90 in community-based sample pointing to the fact that amyloid 
deposition (as amyloid plaque formation) is closely related to the aging process. In fact, increased PiB 
binding has been reported in almost 20–30% of cognitively preserved elders mainly in posterior cingulate 
cortex, precuneus and prefrontal cortex. Compared with amyloid-negative, amyloid-positive controls 
showed a moderate decline in verbal and visual episodic memory over 36 months but no changes in 
non-memory functions. Most importantly, the absence of amyloid in MCI cases is associated with 
cognitive stability at 36 months. Increased PET-PiB binding is associated with brain atrophy, cortical 
thinning but also decreased cortical metabolism, aberrant functional connectivity at rest and decreased 
task-related deactivation of the default mode network. Altogether these data suggest that contrasting 
with CSF Ab and tau changes that sign a biological diathesis to neurodegeneration, amyloid positivity 
in the human brain are present as a part of the aging process representing a critical step preceding the 
installation of AD pathophysiology. However, not all cases with elevated PET-PiB bindings evolve to 
AD and several cases develop dementia not necessarily related to amyloid aggregation. Several recent 
contributions revealed that neurodegeneration takes place without a temporal link with fibrillar am-
yloid deposits. Alternative but less frequent pathways exist starting from tau deposition with modest 
Ab pathology. 
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Is inflammation a valid target for intervention in AD?
P. Giannakopoulos
Medical Direction, University Hospitals of Geneva, Switzerland
Immunological mechanisms in the human brain have been recently shown to be involved in 
Alzheimer disease (AD) lesion propagation via the activation of microglia and astrocytes that lead to 
the release of pro and anti-inflammatory mediators. These mechanisms may be triggered by external 
factors (systemic inflammation, obesity, hypertension, cardiovascular risk factors) but their conse-
quences show an impressive inter-individual variability. The ligand-receptor interaction that controls 
the expression of microglia is perturbed in AD with increasing activation of this cellular population 
due to Aß accumulation that in turn increase Ab production given the activation of cytokines and 
intracellular signaling pathway. It remains, however, unclear why Ab continues to accumulate and 
why AD pathology progresses despite chronic microglia activation. In the same line, the activation 
of astrocytes in AD may allow for removing Ab peptide preventing its accumulation in extracellular 
space but may also favor the formation of Ab aggregates via the production of a very large number of 
proinflammatory cytokines. After the failure of several disease-modifying treatments in AD, focusing 
on neuroinflammation appears an ultima ratio choice. The pertinence of this approach is, however, 
questionable given the complexity and instability of the inflammatory reactions in the human brain that 
have been documented by the accumulation of negative data for non-steroidal anti-inflammatory drugs, 
COX-2 selective compounds, and nutraceuticals. The main obstacle is the number of targets and their 
double role in human biology: microglial phenotypes are multiple and rapidly changing, most of the 
cytokines overexpressed in AD have a double role (deleterious but also protective), astrocytes control 
neuronal homeostasis via their trophic function but may contribute to Ab-mediated toxicity and tau 
hyperphosphorylation. Is there a real chance to identify one molecule or a combination of agents that: 
a. decreases the detrimental effect of neuroinflammation but preserve the normal immune response to 
lesion formation, and b. decrease Aß production and tau abnormal phosphorylation without affecting 
key pathways for neurotrophy and survival? Is it possible to reach this objective in the absence of valid 
biomarkers and animal models for neuroinflammation, modest results in molecular imaging, and, last 
but not least, no definite knowledge about the temporal evolution and staging of neuroinflammatory 
phenomena? One should not forget that amyloid-based clinical trials had an impressive cost but still 
have been broadly failed despite a simpler biology. Investing on neuroinflammation due to the absence 
of therapeutic promises may be risky leading to future disappointments. 
Genomic analysis points to pathways  
of neurodegeneration
J. Hardy
Department of Molecular Neuroscience, UCL Institute of Neurology, UK
As we identify many causative and risk genes for neurodegenerative syndromes through positional 
cloning, exome sequencing, and genome-wide association studies it is becoming clear that these are 
mapping to specific pathways. In this lecture, I shall discuss this phenomenon and its importance in 
delineating specific vulnerabilities of specific neuron types. For Alzheimer’s disease, I will outline that 
the current evidence supports the view that the microglial response to membrane damage is critical and 
that this suggests that Ab disruption of neuronal membranes may be the initiating event. For fronto-
temporal dementia, many of the genes involved are components of the endosomal/lysosomal pathway. 
For Parkinson’s disease some genes are also lysosomal or endosome/lysosome components whereas 
others, particularly in early onset disease, are involved in mitophagy. For FTD/ALS many genes are 
ubiquitin proteasome genes whereas for pure ALS genes the majority are RNA metabolism genes. For 
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the ataxias, many genes are involved either in Ca homeostasis (Purkinje cells) or ubiquitin proteasome 
(granule cells). I will discuss how these vulnerabilities are likely to be related to the functions of the 
relevant neurons and how understanding these vulnerabilities may help us as we seek treatments. 
General anesthesia does not increase the risk of dementia 
L. Honig
Neurology, Taub Institute, and Sergievsky Center, Columbia University Medical Center, USA
In clinical practice, it is common to have patients present with a history of onset of dementia symp-
toms after surgery with anesthesia. Most often, in the postoperative period, symptoms of sedation and/
or delirium may occur, with confusion, disorientation and often psychosis, such as hallucinations 
and/or delusions. Following resolution of the postoperative period, family members and associates 
may note symptoms of dementia such as memory or language problems. Patients and their families 
often associate the surgery, and in particular, the general anesthesia that commonly is used, as an 
etiological, causal factor, relating to onset of dementia symptoms. The alternate possibility is that in 
the postoperative state, whether due to the stress of surgery, sedation or other effects of anesthetics, 
and sensorium-affecting effects of opioids often used intraoperatively and postoperatively are simply 
“unmasking” dementia symptoms in persons with the underlying neurodegenerative disease, who are 
otherwise well-compensated and managing without obvious problems. Furthermore, once a patient 
has manifested delirium symptoms, there is a heightened sensitivity of family members and associates 
towards their mental state, and small lapses in memory or cognition are noticed more than they likely 
would have been prior to the operative period. Despite some animal experiments attempting to show 
that anesthetics might affect beta-amyloid and tau accumulations, the timing of the symptoms, and 
the epidemiological evidence all strongly militate against the likelihood of any effect of anesthetics 
on the risk of dementia. Rather operative periods are simply mileposts, at which dementia symptoms 
may be first noticed for the reasons described above.
Obstructive sleep apnea does not increase  
the risk of dementia
L. Honig
Neurology, Taub Institute, and Sergievsky Center, Columbia University Medical Center, USA
Obstructive sleep apnea (OSA) is increasingly diagnosed in Europe and North America. This is both 
due to a likely real increased prevalence of this condition due to increasing obesity in the population, 
and also due to ascertainment, with increased diagnosis due to the more widespread availability of 
sleep studies, instrumentation, and laboratories. Given the increasing prevalence of both OSA and 
Alzheimer’s disease in the aging population, it is unsurprising that some have argued that there might 
be a connection between the presence of OSA and dementia risk. In part, this is driven by the idea 
that decreased oxygenation of the blood, might somehow cause either amyloid and tau pathology or 
independent neurodegeneration. And in part, this is driven by the observation that persons with OSA, 
provided with nocturnal continuous positive airway pressure (CPAP) may feel subjectively, and in some 
studies even objectively, more alert and wakeful during the daytime hours. Despite these observations, 
there is little evidence that nocturnal hypoxic episodes, such as are found with obstructive sleep be-
cause either beta-amyloid or tau degenerative changes, nor that they cause other brain changes that 
would result in reversible dementia. In persons with apparent concomitant Alzheimer’s disease and 
OSA, controlled trials of CPAP have indeed sometimes shown mild improvements in alertness, atten-
tion, and executive function, but have not “cured” or significantly benefited persons of their primary 
cortical dementia symptoms such as language, memory, and visuospatial dysfunction. Thus, evidence 
to date does not support an etiologic effect of OSA on the risk of dementia.
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The term Alzheimer’s disease should be dropped  
as it is impeding future research — Con
D.S. Knopman
Neurology, Mayo Clinic, USA
The term Alzheimer’s disease has unfortunately come to mean many things to different people. How-
ever, as a term that has been in the public eye for several decades, it would be needlessly confusing to 
abandon it. The very identity of the many advocacy groups around the world revolves around the term 
Alzheimer’s disease. Politicians have targeted Alzheimer’s disease for additional funding. Changing 
the name would create confusion. To borrow terminology from the commercial sphere, the “brand 
identity” of Alzheimer’s disease is a major asset for the field. It is a rallying point for fundraising both 
private and public, and it is a rallying point for advances in public policy. There is no question that the 
parallel usages of the term Alzheimer’s disease as a synonym for amnestic dementia, on the one hand, 
and a neuropathological diagnosis, on the other hand, can sometimes lead to misrepresentations of 
mechanisms and misunderstandings of clinical diagnoses. Personally, this writer favors the use of the 
term Alzheimer’s disease to be limited to a pathologically defined disease based on a particular bur-
den of neuritic amyloid plaques and an isocortical distribution of neurofibrillary tangles. That means 
that persons with mild cognitive impairment or dementia that is believed to be due to Alzheimer’s 
disease would be diagnosed as mild cognitive impairment due to Alzheimer’s disease or dementia due 
to Alzheimer’s disease. That terminology would clearly indicate the two key features of the diagnosis, 
first the syndromic designation (ie MCI or dementia) and second the presumed etiology.
Can the diagnosis of AD be made solely  
on biomarker evidence?
D.S. Knopman
Mayo Clinic, Rochester MN, USA
This title captures an important issue now facing the field. What is behind the question is a concept 
that has existential value for the field: “What do we mean by the term ‘Alzheimer Disease (AD)?’” (1) 
Is AD a clinical diagnosis? I would say “No, unlike the term ‘dementia,’ it is not simply a description 
of a set of symptoms”. Unfortunately, many lay people and many scientists and clinicians outside of 
the specialist community often use the term “AD” to mean “dementia”. That seems like an obviously 
flawed use of terminology because there are many other conditions including common ones that also 
cause dementia and even cause amnestic dementia. (2) Is AD a “clinicopathological entity?” Such usage 
of the term AD has been proposed by some members of the dementia research community, and they 
use the term “AD” to stand for the combination of a clinical syndrome of amnestic dementia that is 
reliably or invariably associated with a particular neuropathological substrate of beta-amyloidosis and 
neurofibrillary tangle deposition. Those who use the term this way have also extended the biological 
correlates to include biomarkers of beta-amyloidosis and neurodegeneration. While there is some merit 
to this approach, the research community has clearly demonstrated that the link between amnestic 
dementia and the AD pathobiology is not nearly as invariant as other diseases (eg, Huntington disease 
or progressive supranuclear palsy). Thus, there are many individuals with amnestic dementia who 
lack AD pathobiology and vice versa, many individuals with non-amnestic presentations who have 
pure AD pathobiology. Thus, I reject the notion of AD as a clinicopathological entity. (3) Is AD a neuro-
pathological designation? I think this is the most legitimate and least ambiguous use of the term “AD” 
In this view, the term “AD” stands for the combination of beta-amyloidosis and neurofibrillary tangle 
deposition. Both CSF beta-amyloid and amyloid PET measurements have been validated as reliable 
proxies for brain amyloidosis; and further that CSF tau and tau PET similarly stand for neurofibrillary 
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tangle formation. But getting back to the question of this debate: Can the diagnosis of AD be made 
solely on biomarker evidence?”, this is the background upon which the debate will occur. In particular, 
with the availability of biomarkers, the field is now able to detect the pathobiology of AD antemortem. 
So should the field be able to diagnose “AD” on biomarker evidence in both cognitively normal people 
and persons who are overtly symptomatic?
Why have we failed to cure AD?
A.D. Korczyn
Sackler School of Medicine Tel-Aviv University, Ramat-Aviv 69978, Israel
The most popular target in AD clinical trials has been beta-amyloid. However, while this protein 
has a central role in early onset AD, particularly in those patients carrying mutations in APP, PSEN1 
or PSEN2 genes, there is no convincing evidence that it is involved in the pathogenesis of late-onset 
AD. Additionally, elimination of beta-amyloid has not led to clinical improvement or to arrest disease 
progression. Therefore, attempts should be directed at other targets, including APOE, inflammation 
and cardiovascular risk factors. 
The term “Alzheimer’s disease” should be dropped  
as it is impeding future research
A.D. Korczyn
Sackler School of Medicine Tel-Aviv University, Ramat-Aviv 69978, Israel
Most early-onset AD (EOAD) cases are familial due to dominant mutations in a few genes. Late 
onset dementia has a similar pathology to the early onset disease but does not have the same genetic 
background. In fact, it is a multifactorial disorder. The amyloid deposition in EOAD is due to overpro-
duction, and all those who carry the mutation will accumulate amyloid and develop dementia. In the 
late-onset disease, amyloid is not overproduced but rather its clearance is reduced. There is no proof 
that amyloid is toxic in the late disease, and its removal has not led to clinical improvement. Thus 
calling senile dementia “AD” has been counterproductive. 
Pathological role of chronic hypoxia in the pathogenesis  
of Alzheimer’s disease
W. Le
Neurology, 1st Affiliated Hospital of Dalian Medical University, China
Alzheimer’s disease (AD) is the most common neurodegenerative disease mainly caused by genetic 
and environmental perturbation. It is believed that abnormal tau phosphorylation, altered amyloid 
b (Ab) metabolism and chronic neuroinflammation play important role in the disease pathogenesis. 
Our previous studies have documented that chronic hypoxia is one of the important environmental 
factors that may trigger the AD development and aggravate the disease progression. Recently, we have 
conducted a series of investigations to determine the pathological effects of chronic hypoxia on the 
onset and development of AD, and we have identified the possible molecular mechanisms underlying 
the chronic hypoxia-mediated AD pathogenesis. Based on our studies we have found that chronic 
hypoxia can cause long-lasting inflammation in the brain, and specific tau phosphorylation, mitochon-
drial disruption and chronic inflammation in the brain. Moreover, we have further documented that 
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epigenetic modulation of DNA methylation might be the key player in the chronic hypoxia-mediated 
neurodegeneration in AD. Our findings may represent a new opportunity for the therapeutic interven-
tion of this devastating disease. 
Transmission of misfolded proteins in neurodegenerative 
disorders: a common mechanism of disease progression
V.M.Y. Lee 
Center for Neurodegenerative Disease Research, University of Pennsylvania, Philadelphia, PA
The deposition of b-sheet rich amyloid aggregates formed by disease-specific proteins is a common 
feature of many neurodegenerative diseases and are believed to cause neuronal dysfunction directly 
or indirectly. Recent studies have strongly implicated cell-to-cell transmission of misfolded proteins 
through templated recruitment as a common mechanism for the onset and progression of various neu-
rodegenerative disorders. Emerging evidence also suggests the presence of conformationally diverse 
“strains” for each type of disease protein, which may be another shared feature of amyloid aggregates, 
accounting for the tremendous heterogeneity within each category of diseases. In Alzheimer’s disease 
and other age-related tauopathies, the normally soluble tau protein accumulates as insoluble neuro-
fibrillary tangles whereas in Parkinson’s disease and other related synucleinopathies, the highly soluble 
α-synuclein protein are converted to aggregated Lewy bodies in neuron and glia. Finally, in FTLD-TDP 
and ALS, TDP-43 forms aggregates in the brain and spinal cord. We have developed mouse models of 
these neurodegenerative diseases and have used them to test the “transmission” hypothesis and the 
“strain” hypothesis in order to elucidate mechanisms of progressive spread of this pathology as well 
as to explore the molecular basis of strain heterogeneity. 
Does general anesthesia increase the risk of dementia?
G. Logroscino
Department of Basic Medicine Neuroscience and Sense Organs — Department of Clinical Research in Neurology of the University of Bari  
at “Pia Fondazione Card G. Panico“ Hospital, University Of Bari Aldo Moro, Italy
There is extreme interest in studying the possible relationship between anesthesia and the onset and 
progression of cognitive disorders. This is also determined by the increasing number of elderly subjects, 
in the age of higher risk for cognitive decline and dementia, who undergo surgery. A significant number 
of patients who are cognitively normal undergoing anaesthesia will develop symptoms of cognitive 
dysfunction in a limited period of time, generally hours or days. There is general disagreement, however, 
about the real risk and the prognosis. This is probably due to lack of consistency across the definition 
of cognitive changes. Post-operative delirium is a good indicator of increased risk of developing cog-
nitive impairment and dementia. Following anesthesia, the decline in cognition is observed in some 
individuals and this group may be characterized by specific vulnerability for future decline associated 
with the onset of a specific dementia process. We need to consider that exposure to anesthetics has 
been shown associated with AD pathology in vitro. Clinical studies are less concordant. Consistently, 
a recent meta-analysis of epidemiological studies showed no clear association in 13 high quality stud-
ies but the association was significant when restricted to studies using medical records. Preoperative 
assessment of cognitive changes may be useful to establish the real risk of the patient undergoing 
surgery. The cognitive preoperative assessment would allow focused management including specific 
referral for patients at risk, delirium prevention, specifically optimizing care through more constant 
observation and monitoring. This could allow more timely treatment options. The debate is still open. 
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Can the diagnosis of AD be made solely  
on biomarker evidence? 
G. Logroscino
Department of Basic Medicine Neuroscience and Sense Organs — Department of Clinical Research in Neurology of the University of Bari at “Pia Fondazi-
one Card G. Panico“ Hospital, University of Bari Aldo Moro, Italy
Alzheimer’s disease (AD) is a progressive neurodegenerative disease characterized by the deposition 
of amyloid plaques and neurofibrillary tangles. Cerebrospinal fluid measures of amyloid-beta, total-tau, 
and phospho-tau are clinically available and allow detection in vivo of both amyloid and tau pathology. 
With the use of labeled tracers that bind amyloid plaques, the amyloid PET is now clinically available 
for the detection of amyloid pathology and tracers for tau pathology are becoming available. Structural 
MR permits to study the progression of neurodegeneration. Therefore, AD is now a clinically and bio-
logically entity with biological fluid and imaging evidences of pathology in vivo. We are able to identify 
an individual with evidence of amyloid deposition with or without evidence of neurodegeneration 
before the clinical onset of disease or with the presence of minimal clinical signs (preclinical or pro-
dromal AD). Biomarkers in vivo have improved both the accuracy of diagnosis, distinction of clinical 
phenotypes and anticipation of diagnosis. This process is required because the clinical diagnosis is 
achieved when neurodegeneration may have started several years before and reached a severe stage. 
Starting optimal therapy at this stage would be ineffective. In conclusion, the diagnosis of AD depends 
on the definition of disease. If we define the disease based on the underlying pathology, we can reach 
a diagnosis based only on biomarkers. However, AD is a complex disorder, determined by the different 
type of pathological lesions and amyloid driven diagnosis may be limited among the elderly. 
Is obstructive sleep apnea an important  
risk factor for dementia? 
G. Logroscino
Department of Basic Medicine Neuroscience and Sense Organs — Department of Clinical Research in Neurology of the University of Bari  
at “Pia Fondazione Card G. Panico” Hospital, University of Bari Aldo Moro, Italy
Obstructive Sleep Apnea Syndrome (OSAS) is characterized by episodes of upper airway obstruc-
tion during sleep that results in intermittent hypoxemia and arousal. OSAS causes hypoxia and also 
decrease the quality of sleep because the sleep is fragmented. Overtime OSAS determine daytime 
sleepiness, cognitive dysfunctions, and functional decline. The progression of subsequent functional 
decline may induce over time dementia. The underlying brain damage results from heterogeneous 
processes including reduced cerebral blood flow, ischemic brain lesions, white and grey matter lesions 
and loss. The neuropsychology of cognitive impairment in OSAS is still under investigation. The first 
domains involved include attention, executive functioning, and motor control but on long-term also 
long-term episodic memory is affected. Several studies involving total sleep loss, sleep reduction and 
clinically related sleep fragmentation report impaired performance on tasks of frontal lobe function. 
The mechanisms of OSA-cognitive impairment association are probably not only degenerative. Recent 
studies show that dementia risk is higher in subjects with OSAS and vascular changes and the severity 
of cerebrovascular impairment was related to the severity of OSAS. Medications as antipsychotics, 
narcotics, and anxiolytics could increase the risk of cognitive impairment are subjects with OSAS. 
CPAP therapy should be therefore considered for OSA both in subjects with MCI and with dementia. 
13
Invited Speakers Abstracts
www.journals.viamedica.pl
Is amyloid deposition a non-specific  
manifestation of aging?
L. Middleton
Neuroepidemiology and Ageing (NEA) Research, School of Public Health, Imperial College, London
High amyloid brain load, mainly in amyloid plaques (APs), together with a high intra-cerebral load 
of intracellular tau-enriched neurofilament tangles (NFTs) and brain atrophy, as the pathological land-
marks of Alzheimer’s disease (AD). Indeed, the 2011 (and currently being revised) NIA/AA diagnostic 
criteria for research purposes postulate that the presence of biomarker-based evidence of the above 
neuro-pathological findings are key criteria for the diagnosis of AD. Of note, most of the current drug 
discovery and development programmes of the pharmaceutical industry are targeting amyloid cascade 
key components as the amyloid hypothesis is thought to represent the core aetiological pathway of this 
otherwise multi-factorial disease. However, increasingly emerging longitudinal and case-control studies 
suggest that up to 30% of clinically probable AD patients have below-threshold amyloid load. On the 
other hand, high amyloid load, as documented by amyloid positron emission tomography (PET) or 
in cerebrospinal fluid (CSF) studies is found in ~40–50% of patients with mild cognitive impairment 
(MCI) and 15–30% in cognitively healthy volunteers of a similar age group. These figures increase 
with increasing age and several studies in older old individuals show increased amyloid load with 
increasing age. Furthermore, population-based neuro-pathological studies confirm the presence of high 
levels of post mortem APs and NFTs in the brains of individuals with no history of significant cognitive 
decline, in particular, those who are APOE4 carriers. These findings and discrepancies prompted the 
hypothesis of this debate. Our two speakers, both well-known experts in the field, will outline the pro 
and con arguments, leading to a wider discussion among the audience on this very important issue.
Can the diagnosis of AD be made solely  
on biomarker evidence?
L. Middleton
Neuroepidemiology and Ageing (NEA) Research, School of Public Health, Imperial College, London
Alzheimer’s disease (AD) is a devastating and relentlessly progressive neurodegenerative late onset 
disease, which is reaching epidemic proportions world-wide, due to the unprecedented increase of 
longevity. AD is defined by the progressive deterioration of memory, executive function and other 
cognitive domains that result in a progressive inability of patients to function within the society and 
their own family. All therapeutic trials of novel disease modifying therapies have failed, reflecting our 
significant gaps of knowledge of the precise biological mechanisms underpinning the disease aetiolo-
gy. Furthermore, there is an emerging consensus that increasing and accumulating disease pathology 
precedes by (perhaps) decades the clinical onset. Thus, an optimal intervention aimed at arresting or 
reversing AD seems to be in the pre-clinical stages, prior to the disease clinical onset. However, we do 
know that, even in the oldest old, the risk of AD does not exceed 40%, thus 60% of individuals may 
never develop significant cognitive decline. Identifying high-risk-for AD individuals remains a major 
challenge in drug development and in secondary prevention strategies. More recently, it has been 
suggested that the biomarker — based evidence of an abnormally high brain amyloid and tau load 
(pathophysiological AD biomarkers), together presence of findings suggestive of neurodegeneration, 
such as hippocampal atrophy, FDG-PET abnormalities or high tau can constitute sufficient basis for the 
diagnosis of AD, even in the absence of any cognitive decline. Thus, there is increasing popularity for 
biomarker-based disease diagnosis in the pre-clinical stage; similar to the pre-clinical diagnosis of forms 
of cancer. However, there are several lines of argument against this concept. Firstly, the pathological 
significance of the biomarker-based profile in AD is not comparable to that of cancer diagnosis based 
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on pathology. Secondly, the specificity and sensitivity of the proposed AD-biomarker profile remain 
to be validated. Thirdly, we know that ~30% of clinically probable AD cases do not carry this profile 
and that a significant number of cognitively healthy older old individuals who do have this biomarker 
profile are disease free and may well never develop AD. Unlike cancer, AD is primarily a clinical dis-
tinct entity who’s pathological and biological underpinning mechanisms are not, as yet, known with 
some precision; our understanding of AD is, probably 20 years behind other common diseases, such 
as cancer. Finally, it would be ethically and medically improper, in the light of our current knowledge, 
to suggest to a cognitively healthy individual that she/he has AD; probably the disease that they dread 
the most, as they grow old. This is different from suggesting high risk, although such statement must 
also be supported by strong and unequivocal scientific evidence.
Is inflammation a valid target for intervention  
in Alzheimer’s disease? Pro
A. Nordberg
Neurobiology, Care Sciences and Society (NVS), Karolinska Institutet, Sweden
Emerging evidences are underlying the importance of neuroinflammation in Alzheimer’s disease 
(AD) and other neurodegenerative disorders leading to dementia. Most interestingly neuroinflammation 
appears to have an active role in the pathogenesis of different proteinopathies which strongly moti-
vate to more deeply understand the involvement and time course of early inflammatory processes and 
their possible causal role in AD disease progression to unravel the relationship and coupling between 
astrogliosis and different proteinopathies, synaptic functions and cognition. The rapid development of 
in vivo molecular imaging techniques including positron emission tomography (PET) provides unique 
possibilities for early detection of pathophysiological processes and understand the time course and 
interaction between different processes in the brain leading to cognitive impairment. Inflammatory 
processes including astrocytosis and microglia activation well known from post-mortem studies can now 
be studied in vivo by PET. The prominent initially high and then declining astrocytosis in AD during 
disease progression, contrasting with the increasing beta-amyloid plaque load, suggest that astrocyte 
activation is implicated in the initiation of AD pathology. Astrocytosis thereby seem to occur earlier in 
disease time course than tau deposition and cerebral glucose hypometabolism. Astrocytosis may thus 
not be a reflection of solely dysfunctional non-neuronal cells in AD but a consequence of phenotypic 
astrocytic changes initiated at very early disease stage contributing to the development of AD disease 
pathology and at such a tentative target for new therapeutic interventions. 
Is TBI a risk for dementia? Pro
D. Perl
Pathology (Neuropathology), Uniformed Services University of the Health Sciences, USA
Many epidemiologic studies have investigated whether prior head trauma represents a risk factor 
for the subsequent development of dementia. Here, we will not consider the risk of dementia among 
contact sports participants and will address the potential risks for dementia following a single prior 
episode of moderate to severe head trauma. The majority of such studies have identified that a prior 
incident of moderate-severe head trauma is associated with an enhanced risk for the subsequent de-
velopment of dementia. It has been assumed that this risk resulted in the subsequent development of 
Alzheimer’s disease in exposed patients. Few studies have investigated the neuropathology or clinical 
phenomenology of such cases in order to confirm this assumption. Sayed, et al. (2013), using the NACC 
database, showed a statistically higher tendency for behavioral changes and parkinsonian features 
among patients enrolled with dementia following TBI when compared to dementia patients without 
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a prior history of TBI, suggesting that a clinical phenotype separate from that of typical Alzheimer’s 
disease might emerge following TBI. Neuropathology studies of such cases are rare. Crane, et al (2016) 
studied 7,130 participants of the three large longitudinal studies that were screened for a history of TBI 
with loss of consciousness. They showed that TBI with loss of consciousness was associated with an 
increase in Lewy body formation, the progression of parkinsonian features and an increased risk for 
incident Parkinson disease but not Alzheimer’s disease-related pathology. Finally, I will present the 
findings from a well-documented representative case which highlights many of these issues. 
The term “Alzheimer`s disease” should be dropped  
as it is impeding future research
R. Perneczky
Department of Psychiatry and Psychotherapy, Ludwig-Maximilians-Universität München, Germany
The prevalence of dementia and its healthcare and socio-economic impact are exploding worldwide 
and drug development success rates need to be improved urgently; the traditional linear model of phar-
maceutical R&D has become outdated and virtually all new drugs have failed since the cholinesterase 
inhibitors were introduced to the markets two decades ago. Drug development has been more successful 
in other fields of medicine such as infectious diseases and cancer, in which translational models are 
applied, linking population-based cohorts and genetic data with potential drug targets and study end-
points. This powerful translational approach is fuelled by technology platforms such as neuroimaging, 
-omics and fluid biomarkers. The dementia field requires a significant cultural change to discover and 
develop effective disease-modifying treatment options and advanced knowledge about the relevant dis-
ease mechanisms must be translated to improved diagnostic, prognostic and preventative approaches. 
The present debate focusses on the usefulness of the term “Alzheimer’s disease” and it is discussed if 
it is still required and helpful in research or if it should be dropped to accelerate scientific progress.
How can robotic technology help in long-term  
care of dementia patients?
K. Rejdak
Neurology, Medical University of Lublin, Poland
A person with amnestic mild cognitive impairment (MCI) and early stages of Alzheimer’s disease 
(AD) has difficulties in instrumental activities of daily living, which depend on memory and executive 
functioning. With the progress of the disease, the help needed for the execution of daily tasks normally 
increases, leading to a burden on the shoulders of informal caregivers, and in many cases to institu-
tionalization. The number of elderly adults and the incidence of cognitive impairment among them 
are increasing. As a result, the resources allocated to assisting elderly people will not prove sufficient 
in the foreseeable future. Robotic assistants could be a way to help people remain safe in their own 
homes, ensuring their independence in everyday life. In this context, several social robots, which are 
human or pet-like robots such as NAO, Paro, KASPAR, PaPeRo, AIBO, and iCat aim at providing social 
support, engagement, and independence for people with special needs? Thus, people with cognitive 
impairment constitute a group, which may particularly benefit from healthcare robots. The project: 
Robotic Assistant for MCI Patients at home (RAMCIP) is an EU Horizon 2020 funded project. RAMCIP 
aims to research and develop real robotic solutions for assistive robotics for the elderly and those suf-
fering from Mild Cognitive Impairments and dementia. This is a key step to developing a wide range 
of assistive technologies. We have adopted existing technologies from the robotics community, fused 
those with user-centered design activities and practical validation, with the aim to create a step-change 
in robotics for assisted living. 
16
Polski Przegląd Neurologiczny, 2018, vol. 14, supplement A
www.journals.viamedica.pl
Trend of antipsychotic prescription  
at the time of dementia diagnosis
D. Religa1, 2, S. Bukhari1, E. Schwertner1, J. Secnik1, B. Winblad1, 2, M. Eriksdotter1, 2
1Neurobiology, Care Sciences and Society, Karolinska Institutet, Sweden 
2Theme Aging, Karolinska University Hospital, Sweden
Introduction: Within the last 10 years, multiple studies and recommendations have been made 
to limit the use of antipsychotic use in patients with dementia. To date, there was no original data 
presented in Sweden on trend regarding antipsychotic drug use in this patient group. The aim of this 
study was to evaluate the change of antipsychotic drug use in relation to implemented guidelines in 
Primary and Specialist care. 
Material and methods: This was a cross-sectional cohort study using. Data was collected at the time 
of dementia diagnosis using Swedish Dementia Quality Registry (SveDem) between May 2007 and 
December 2015. 55 215 patients were selected for the study. Multivariate logistic regression was used 
to calculate odds ratio (OR) and 95% confidence intervals (CI) for having antipsychotics prescribed in 
different time periods. 
Results: Antipsychotics use changed from 10.1% in 2007–2008 to 5.2% in 2014–2015. In an adjust-
ed model with 2007–2008 as reference; 2014–2015 had a decreased risk of AP use for All [OR 0.49 
(0.38–0.64)], Primary care [OR 0. 51 (0.34–0.76)] and Specialist care [OR 0.52 (0.389–0.70)]. 
Conclusions: Compared to 2007–2008, there was a decrease in risk of AP use at the time of dementia 
diagnosis the following years. We conclude that both specialist units and primary/communal care units 
decreased their risk of AP use compared to 2007–2008 and there is no significant difference between 
them in our adjusted model. 
General anesthesia and the risk of dementia
I. Santana
Neurology, Centro Hospitalar e Universitário de Coimbra, Portugal 
Neurology, Faculty of Medicine of the University of Coimbra, Portugal
Many patients that undergo surgical procedures and general anesthesia develop postoperative delir-
ium (POD) with an increased long-term risk of death (10–20%), cognitive impairment up to five years 
after surgery and eventually dementia. Rates of POD range from 9 to 87%, depending on the type of 
surgery, settings of care and particularly patient’s age and characteristics. The connection between 
POD and a further development postoperative cognitive dysfunction (POCD) is controversial, ranging 
from 10% to 20% at 6 months, maybe because there are mutual predisposing risk factors that increase 
transitory or definitively brain vulnerability to cognitive decline. Well-known underlying risk factors 
for both syndromes are age ≥ 65 years of age, previous cognitive decline and sensorial deprivation. 
Intra and perioperative insults and procedures already identified include perfusion deficits and hy-
poxic events, particularly during heart or vascular surgery, systemic inflammation, pain, sleep distur-
bances and consequent use of medications with anticholinergic actions. Nonetheless, evidence-based 
recommendations are lacking regarding the specific anesthesia agents to use, general versus regional 
anesthesia, systemic arterial pressure monitoring, and management or disallowed medication and 
analgesia. Conversely, a cognitive reserve which is promoted by educational/cultural attainment and 
cognitive/physical activity is highlighted as an underlying preventive player and another link between 
POD, exacerbation of cognitive decline and dementia. Evaluation of both, cognition and neurocogni-
tive reserve may be a key in understanding which modifiable factors can preserve cognitive function 
in later life after surgery, providing a target for preventive interventions and stratification of patients 
according to their risk to POCD. 
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Is traumatic brain injury a risk for dementia?
B. Tousi
Cleveland Clinic Lou Ruvo Center for Brain Health, USA
The concept of association between neurodegenerative disease and head trauma dates back to 1928 
with a description of “punch drunk” in former boxers (Martland, JAMA1928) and the term traumatic 
encephalopathy was introduced later (Parker, J Neurol Psychopathol 1935). Since then, this diagnosis 
has been reported with different contact sports. Previous studies on the association between traumatic 
brain injury and neurodegenerative diseases have controversial findings. Some studies have found 
that blows to the head can raise a person’s likelihood of dementia, as can highly physical sports. The 
recent study of American football players has shown that CTE is a tauopathy with a unique distribution 
as a result of repetitive traumatic brain injuries. 696 of the 19,936 people, with severe head injuries, 
went on to develop dementia, while only 326 of the 20,703 people with milder injuries did the same. 
The risk of dementia was highest in people who sustained severe, traumatic head injuries between the 
ages of 41 and 50. This large study adds to prior published work indicating that a history of traumatic 
brain injury significantly increases the risk of non-Alzheimer’s dementia, which may be down to the 
effects of chronic brain inflammation caused by head trauma. In working-aged persons, a history of 
moderate-to-severe TBI is associated with an increased risk for future dementia but not for Parkinson 
disease or amyotrophic lateral sclerosis. In a retrospective population-based follow-up study using the 
Finnish Care Register, moderate to severe TBI was associated with an increased risk for Neurodegener-
ative disease, with a higher hazard ratio (HR) of 1. 8 (95% CI 1.6–2.1) compared to mild TBI (Raj, et al, 
Plos medicine 2017). Data is limited in suggesting evidence of an association between mild TBI (with 
loss of consciousness) and dementia. There are limitations in CTE studies such as being retrospective 
or convenient samples. In a study of high school football players who were followed at age 65, there 
was no difference in cognitive abilities between football players and the control group (Deshpande, 
et al. 2017). The pathological findings are not suggestive of an Alzheimer’s type of dementia. More 
longitudinal studies needed to study further this correlation. 
New insights into transmission of tau pathologies  
and interactions of plaques with tangles
J. Trojanowski
Medicine, University of Pennsylvania, USA
We developed novel tauopathy models in nontransgenic (non-Tg) mice by injecting pathological 
tau extracted from postmortem brains of AD (AD-tau), progressive supranuclear palsy (PSP-tau), and 
corticobasal degeneration (CBD-tau) patients into different brain regions of non-Tg mice. This revealed 
differences in tau strain potency between AD-tau, CBD-tau, and PSP-tau as well as differences in cell-
type specificity of tau strain transmission such that only PSP-tau and CBD-tau strains induced astroglial 
and oligodendroglial tau inclusions. Further, we demonstrated that the neuronal connectome, but not 
the tau strain, determined the neuronal spread of tau pathology. Finally, CBD-tau- and PSP-tau-inject-
ed mice showed spatiotemporal transmission of glial tau pathology, suggesting glial tau transmission 
contributes to the progression of tauopathies. Thus, different tau strains determine seeding potency 
and cell-type specificity of tau aggregation that may underlie diverse human tauopathies. We also ex-
amined the link between AD tangles and Ab plaques by injecting human AD-tau into Ab plaque-bear-
ing mouse models that do not overexpress tau. This led to the formation of three major types of AD 
tau pathologies: dystrophic plaque associated neurites (NP tau), neurofibrillary tangles (NFTs) and 
neuropil threads (NTs) which had different temporal onsets and functional consequences on neural 
activity and behavior. We speculate Ab plaques create a unique environment that facilitates the rapid 
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amplification of proteopathic AD-tau seeds initially appearing as NP tau followed by the formation 
and spread of NFTs and NTs, likely through secondary seeding events. This study provides insights 
into a new multistep mechanism underlying Ab plaque-associated tau pathogenesis. 
Does general anesthesia increase the risk of dementia?
M. Tsolaki
3rd Department of Neurology, Aristotle University of Thessaloniki, Makedonia, Greece
Predisposing factors to identify preventive strategies for Alzheimer’s disease (AD) has become in-
creasingly important last years. Surgery and anesthesia have been proposed to increase the incidence 
of post-operative cognitive decline (POCD) and AD. Mechanisms: Animal studies indicate that volatile 
anesthetics may augment the pathological processes of AD by affecting amyloid b processing. Neu-
ro-inflammation plays a pivotal role in POCD. Prevention: BIS-guided anesthesia reduced anesthetic 
exposure and decreased the risk of POCD. Hypertonic saline can improve post-operative delirium (POD). 
The PPARg agonist pioglitazone attenuated the surgery-induced inflammatory changes and rescued the 
associated POCD. Berberine rescued POCD in twenty-month-old male C57BL/6 mice. Administration 
of NADPH oxidase inhibitor apocynin (APO) could rescue POCD. Depth of anesthesia: Small clinical 
trials have demonstrated increased POD and POCD in patients who were relatively deeply anesthetized. 
Kind of anesthesia: Available randomized controlled trials suggest that there is no significant differ-
ence in the incidence of POD or POCD when general anesthesia and regional anesthesia are compared. 
Type of surgery: POCD is associated with non-cardiac surgery and even sedation for non-invasive 
procedures such as coronary angiography. Recently the focus of POCD has shifted from the type of 
surgery or anesthetics to patient susceptibility. Besides old age, mild cognitive impairment has been 
shown to increase the risk of developing POCD and AD. The use of CSF or PET to diagnose AD many 
years before symptoms appear may identify susceptible individuals. Recent meta-analysis, however, 
suggests: Further well-designed studies are warranted to better characterize the relationship of interest. 
The syndrome of normal pressure hydrocephalus:  
a case for splitter and lumper
U. Wuellner
Movement Disorder Section, Neurology, University Clinic Bonn & DZNE, Germany
When normal pressure hydrocephalus (NPH) was initially conceptualized by Hakim, Adams and 
Fisher in 1965, they lumpily described 3 patients with ventriculomegaly and cognitive impairment 
improving after ventriculoarterial (VA) shunting (J Neurol Sci and NEJM). The three split up in at least 
two categories: a 16-year-old-boy and a man in his forties’, both with traumatic brain injury, one with 
subdural hematoma, the other with skull-fracture and severe contusion. The third patient presented 
with cognitive impairment, gait disturbance, and urine incontinence. While this case seems to corre-
spond to what today is considered the Hakim-triad, an elevated CSF cell count was recorded. Neither 
CT-scans nor MRI were available but pneumoencephalography only and the many causes of reduced 
CSF flow over the convexity could not be imagined. Adams in his textbook stated that the syndrome 
of NPH may follow various conditions including SAH, chronic meningitis etc., but — according to 
the observations in their initial paper — “in at least one-third of our cases is presumably due to an 
asymptomatic fibrosing meningitis”. Leinonen and Alafuzoff, who analyzed post-mortem findings in 
10 patients with presumed iNPH, however, found no evidence of such but severe vascular pathology 
in four (considered as causative) and amyloid-b (Ab) aggregates in three. Thus, neuropathological 
characteristics of iNPH as a distinct disease still need to be discovered and we are left with Adams’ 
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statement that the most consistent improvement is attained in those NPH patients in whom a cause 
had been established. 
The sensitivity and predictability of the clinical  
criteria of NPH for the response to shunting
C. Wikkelso
Institute of Neuroscience and Physiology, University of Gothenburg, Sahlgrenska Academy, Sweden
The clinical criteria are described in several iNPH guidelines like the International guidelines (A. 
Marmarou 2005) and recently the Japanese Guidelines (E. Mori 2012). The criteria are operational and 
not standardized or validated. There are no pathophysiological specific markers for diagnosing iNPH. 
The sensitivity and predictability of the criteria are sparsely investigated and by nature very difficult 
to evaluate. Parts of the criteria; like age, unknown cause, Evans Index (EI) 0.3 are obligatory and rela-
tively simple to apply. However, none of these have any relevance if symptoms and signs of iNPH are 
lacking (EI 0.3 are seen in 20.6% of healthy individuals older than 70 years). Operating on patients with 
symptoms and signs compatible with iNPH will improve up to 84% (European Multi-Centre Study, 
P. Klinge 2012). In single centre studies, the improvement rate is often lower even if supplementary 
methods are used. Using supplementary methods can be positive predictive for criteria for surgery, 
but will also exclude many patients from successful treatment (P. Klinge 2012). There are few studies 
addressing the phenotype of iNPH and its sensitivity and predictability. Data on 429 iNPH patients 
showed a broad-based gait in 75%, shuffling gait in 65% and freezing of gait in 30%; pathological 
Romberg test in 53% and retropulsion in 46%; impaired bladder control in 85%. Sixty-eight % of the 
patients improved after surgery highlighting the low sensitivity and predictability of symptoms and 
signs (S. Agerskov submitted). 
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EPILEPSY
Can psychogenic seizures be reliably diagnosed  
by observing behavior or should continuous EEG  
always be required? — No
E. Beghi
Department of Neurology, IRCCS Istituto Mario Negri, Italy
Psychogenic non-epileptic seizures (PNES) are neither paroxysmal behavioral changes resembling 
epileptic seizures without organic cause nor ictal, peri-ictal and inter-ictal EEG changes that charac-
terize epilepsy. The gold standard for diagnosis is the recording of a typical event with video-EEG to 
confirm the absence of electrographic changes on the ictal tracing. The high prevalence of PNES in 
settings where drug-resistant epilepsies are common reflects the difficult diagnostic approach when 
the ascertainment is based only on the semiology of seizures and inter-ictal EEG findings. Several vid-
eo-documented signs are implicated (including preserved awareness, eye flutter and modification by 
others) but none of them, individually taken, has high sensitivity. The inter-rater reliability of neurol-
ogists and psychiatrists (the two specialists most commonly involved in the management of seizures) 
is sub-optimal when the diagnosis of PNES is based on the assessment of video-recordings alone. The 
reliability of the diagnostic approach is even poorer when PNES have non-motor behavioral changes. 
Witnesses’ reports are even less useful for the diagnosis of PNES because only two signs have been 
identified as diagnostic predictors (side-to-side head movements and eyes closed) but the sensitivity 
was low for both. There are no data on the diagnostic yield of video-supported induction of PNES. 
In a recent consensus conference on the diagnosis of PNES (unpublished), experts concluded that no 
single sign can confirm or exclude the diagnosis of PNES. The contribution of continuous video-EEG 
monitoring can be also unhelpful because a typical event cannot be invariably captured and the in-
ter-rater reliability is only moderate. 
AED treatment issues in the elderly
E. Ben-Menachem
Neurology, Institution of Clinical Neuroscience, Sahlgrenska Academy, University of Göteborg, Sweden
The results of clinical trials of antiseizure drugs (AEDs) and the experience of treating the younger 
adult cannot be extrapolated to the elderly. Older persons with epilepsy invariably have more somatic 
comorbidities and different etiologies than younger patients. Most often (50%) the etiology is cere-
brovascular disease. Tumors and dementia are also thought to be major contributing etiologies in the 
elderly. Therefore, it is important to consider when choosing and dosing an AED, the physiological 
and metabolic changes that can occur with the aging process. The therapeutic window for treatment 
is often much smaller in older, more fragile patients. Factors such as enzyme induction and kidney 
function are considerations that must be included in every choice of an AED in this group, Treatment 
options and evidence for efficacy and effectiveness of the available AEDs will be discussed in the 
perspective of the aging patient. 
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Is there an advantage to continue trying new AEDs  
indefinitely in refractory patients? — No
E. Ben-Menachem
Sahlgrenska University Hospital, Sahlgrenska University Hospital, Sweden
This debate concerns the question if patients should be offered to try new antiepileptic drugs (AED) 
indefinitely. There are many reasons why continuing with AEDs without offering other alternatives 
can prevent the patient from achieving seizure freedom or at least a reduction in seizure frequency 
and severity. It is generally accepted that patients, after trying one or two appropriate AEDs, should 
be evaluated for epilepsy surgery possibilities. It is important not to delay this evaluation. Additional 
trials of AEDs can result in improvement but the statistics imply that this is most often not the case. 
By primarily concentrating on switching AEDs, there can be a delay is efforts to improve the situation 
in other ways as through diet or neuromodulation. Other activities include improving the social envi-
ronment and consideration of side effects of AEDs. 
Do antiepileptic drugs increase the risk  
of depression or suicidality? — Yes
I. Blatt
Department of Neurology, Sheba Medical Center, Israel
Psychiatric adverse effects (PAEs), including depression, are reported in 15–20% of patients with 
epilepsy on antiepileptic drugs (AEDs). In 2008 the FDA issued a warning of increased risk for sui-
cidal ideation and behavior during treatment with AEDs, based on findings of a meta-analysis of 199 
trials of 11 AEDs. An expert consensus statement by an ILAE task force concluded that some (but not 
all) AEDs can be associated with PAEs which can lead to suicidal ideation and behavior. The actual 
suicidal risk was considered very low but remained to be established. PAE risk varies considerably 
with different AEDs; GABAergic effects play an important part in depression. Barbiturates, vigabatrin, 
tiagabine, topiramate, levetiracetam, zonisamide, and felbamate seem to be associated with higher risks 
compared with other AEDs. In a retrospective study, 16% of 1394 outpatients on a second-generation 
AED experienced PAEs. The average rate for a single AED was 8.4%; 6.1% resulted in dosage change 
and 4.3% led to AED discontinuation. There were fewer PAEs with gabapentin and lamotrigine, and 
more with levetiracetam and tiagabine. Low rates of PAEs were seen with vigabatrin, felbamate, oxcar-
bazepine; intermediate rates with topiramate and zonisamide. Non-AED predictors, most significantly 
prior psychiatric history, affected the rates of AED-related PAEs, but when these were controlled for, 
relative PAE rates for the different AEDs remained similar. Patients with clinically relevant risk factors 
are relatively more vulnerable to AED PAEs, but the main finding reported in multiple studies remains 
robust: AEDs increase depression and suicidality risk. 
Can we rely upon fMRI to localize language  
and memory when planning epilepsy surgery? — No
I. Blatt
Department of Neurology, Sheba Medical Center, Israel
Epilepsy surgery success can be compromised by postoperative memory decline, particularly verbal 
memory decline after dominant temporal lobe resections. It is therefore essential to reliably evaluate 
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memory functions pre-operatively, identify pre-surgical memory deficits and predict post-operative 
memory outcomes. Neuropsychological testing and intra-carotid amobarbital procedure are helpful but 
have their shortcomings. Direct cortical stimulation is very helpful when necessary. fMRI is a promising 
non-invasive imaging procedure of brain activity but has pitfalls and limitations. Memory-fMRI has is 
still not sufficiently reliable for pre-operative individual patient counseling and decision making. fMRI 
is not a direct measure of cortical neuronal activity, but an indirect tool which images the time course 
of BOLD signal changes, analyzing a vascular response of neuronal activity. Although several fMRI par-
adigms have been developed to assess memory functions, they are predictive of post-operative memory 
outcome at the group level, comparing groups of patients to groups of controls. To be clinically relevant 
memory fMRI needs to be predictive on a single-subject basis. Memory-fMRI paradigm development is 
challenging and has not yet produced robust activation which can be reliable in single patients. Normal 
functioning patients may show poor memory fMRI activation. Post-surgical memory-fMRI changes have 
been observed without verbal memory function decreases. The reproducibility of memory-fMRI results 
has been assessed in Alzheimer’s disease but not in epilepsy patients. Other technical problems include 
tissue-air interfaces and draining veins in the mesial temporal regions that interfere with the BOLD signal. 
Memory-fMRI is still not ready to be relied upon when planning epilepsy surgery. 
Is there an advantage to continue trying new antiepileptic 
drugs indefinitely in refractory epilepsy? — Pro
M. Brodie
Epilepsy Unit, Scottish Epilepsy Initiative, UK
It is well known that most patients who attain seizure freedom do so with their first or second antie-
pileptic drug (AED) schedule. There are, however, some people who tolerate AEDs poorly and it may 
take some time to find an acceptable regimen for them. Others will respond to the addition of a particu-
lar drug with a distinct mechanism of action after failing treatment with a range of other options due 
to lack of efficacy. Some patients will become seizure free with a combination of 2 or 3 AEDs mostly 
with different mechanisms of action. In our own recently published outcome study in 1795 newly 
diagnosed patients followed for up to 30 years, 24%, 15%, 14%, 7% and 7% attained seizure freedom 
for at least one year on an unchanged 3rd, 4th, 5th, 6th and 7th schedule, respectively. I will also present 
some individual cases, who have responded unexpectedly well to the addition of a specific AED with 
a distinct mechanism of action, after more than 10 other drug schedules have failed due to adverse 
effects and/or lack of efficacy. Continuing to aim for seizure freedom or settling for the best tolerated 
and/or most effective regimen often depends on the attitude of the patient and his or her acceptance 
of a few seizures each month. Nevertheless, while always trying to be honest, I rarely tell my patients 
that seizure freedom will never be attained. After all, hope springs eternal!
When using combination antiepileptic drug therapy,  
we should preferentially prescribe drugs  
with different mechanisms of action-pro
M. Brodie
Epilepsy Unit, Scottish Epilepsy Initiative, UK
Despite the availability of a range of novel antiepileptic drugs (AEDs) with different mechanisms 
of action, outcomes for adolescents and adults with the common epilepsies have been unchanged 
over the past 20 years. Nevertheless, it is possible to make some patients seizure free with suitable 
combinations of 2 or 3 AEDs. Since we do not understand the pathophysiology of pharmacoresistant 
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epilepsy, it makes sense to target a range of pharmacological mechanisms in the hope of finding the 
right schedule for each individual patient. The only combination that has proven synergism is sodium 
valproate with lamotrigine, which are mechanistically dissimilar. We are aware now that fast and slow 
sodium channel blockers can be regarded as working differently on the sodium channel i.e. is not 
mechanistically identical. In our outcome audit exploring seizure freedom with combination therapy, 
the top 10 successful duotherapies all contained AEDs with different mechanisms of action, including 
phenobarbital (a GABAergic drug) and phenytoin (a sodium channel blocker), which was third on the 
list. The positive conclusion to this debate is particularly self-evident since the majority of available 
AEDs possess different mechanisms of action!
When using combination antiepileptic drug therapy,  
should be preferentially prescribe drugs with different 
mechanisms of action? — Con
M. Holtkamp
Neurology, Epilepsy-Center Berlin-Brandenburg, Charité — Universitätsmedizin Berlin, Germany
From a mechanistic point of view, it seems possible that antiepileptic drugs with the same mecha-
nism of action, e.g. the sodium-channel-blockers (SCB) lamotrigine and oxcarbazepine, do not have an 
additive effect in regard to efficacy but synergistically produce more typical adverse effects compared 
to the combination of a SCB with a non-SCB. One study analyzed the pooled data of some randomized 
controlled trials on the SCB lacosamide and exactly produced the results mentioned above (Sake et 
al. 2010 CNS Drugs). However, in that study, patients with SCB seemed to have more severe epilepsy 
with higher current and lifetime numbers of antiepileptic drugs. Thus, a more unfavorable response 
to additionally administered lacosamide in this patient group is not surprising. Other studies failed to 
demonstrate any outcome differences when comparing combinations of two SCB to combinations of 
a SCB with antiepileptic drug acting via a different mechanism of action. Personal experiences have 
shown that in most patients e.g. lamotrigine can be combined with another SCB without clinically 
relevant adverse events as long as the doses and serum concentrations are within moderate ranges. 
Do antiepileptic drugs increase the risk of depression  
or suicidality or are we just witnessing the natural history 
of mood disorders in epilepsy when depression occurs? 
M. Holtkamp
Department of Neurology, Epilepsy-Center Berlin-Brandenburg, Germany
Newer antiepileptic drugs (AED), e.g. those launched after 1990, are not more efficacious compared 
to standard AED, but it seems that they are generally better tolerated. The latter aspect may justify the 
high prices health care systems have to pay within the first decade when new compounds are protect-
ed by patent and low-cost generics are not available. Interestingly, depression and may be some other 
psychiatric disorders inversely have been more often reported with newer AEDs such as brivaracetam, 
levetiracetam, perampanel, and zonisamide, while standard AED such as carbamazepine and valproate 
are even administered in psychiatric patients as mood stabilizers, effects which are also observed in 
some epilepsy patients affected by depression. However, we cannot exclude that in the last decades 
physicians have become more sensitive to detect and to report depression in epilepsy patients. Thus, 
in older days when there were few alternatives to carbamazepine, the lower rates of mood disorders 
may be explained by underreporting. In that case, depression indeed may be majorly attributed to the 
natural course of epilepsy and less so to AED. 
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Can psychogenic seizures be reliably diagnosed  
by observing behavior or should continuous EEG  
always be required?
J. Jedrzejczak
Department of Neurology and Epileptology, Medical Center of Postgraduate Education, Poland
With the growth of intensive EEG-video monitoring, it became apparent that psychogenic no epi-
leptic seizures (PNES) are more common than was previously believed. Epileptic seizures and psy-
chogenic seizures often coexist in the same patient. Diagnosis traditionally relied on identification of 
bizarre or atypical paroxysmal behavioral changes, especially in patients with known psychological or 
psychiatric disorder. The ictal activity itself may present with discontinuous, uncoordinated activity 
with erratic progression. Pelvic thrusting thrashing or flailing movements, jerking movement tremors 
and the lack of gradual slowing in the rate of clonic activity are more common in PNES. However, no 
single feature of PNES has proved to be pathognomonic, although recent studies found that diagnosis 
is associated with a distinct cluster of signs. It is true that in the differential diagnosis of seizures, the 
combination of Video EEG monitoring (VEM) with the history of patients and witnesses offers a di-
agnostic “gold-standard”. However, VEM not infrequently fails to capture the events and it will not 
differentiate certain types of frontal lobe epileptic seizures (ES) from PNES. Moreover, in some cases 
there is limited availability of VEM. The aim of presentation is to discuss if, when, and to what extent 
visual information and alternative PNES screening tools allow experienced epileptologists to predict 
the diagnosis of psychogenic nonepileptic seizures without the aid of EEG. To look at the pros and cons 
of clinical diagnosis of psychogenic nonepileptic seizures based on holistic approach. 
Should we preferentially use vagus nerve stimulation  
early in patients with both seizures and depression?  
— our experience
Z. Petelin Gadze1, D. Mijatovic2, 3, F. Derke4, G. Mrak5, V. Sulentic1, S. Nankovic1,  
Z. Poljakovic1, I. Cajic1, A. Bujan Kovac1, A. Desnica5, J. Nemir5
1Department of Neurology, Referral Centre of the Ministry of Health of the Republic of Croatia for Epilepsy,  
University Hospital Centre Zagreb, School of Medicine, University of Zagreb, Croatia 
2Umag Section, Istrian Health Centre, Croatia 
3Faculty of Medicine, University of Rijeka, Croatia 
4School of Medicine, University of Zagreb, Croatia 
5Department of Neurosurgery, University Hospital Centre Zagreb, School of Medicine, University of Zagreb, Croatia
Background: Vagus nerve stimulation (VNS) is a viable treatment option in drug-resistant epilepsy 
and depression. In patients with drug-resistant epilepsy polytherapy is necessary that emphasizes 
greater incidence of side effects which further impair quality of life, on the physical, psychosocial and 
neurocognitive level. Our study aimed to examine the quality of life in patients with drug-resistant 
epilepsy who had undergone VNS implantation. 
Material and methods: The study included 27 patients with drug-resistant epilepsy with implanted 
VNS — case group (14 M, 13 F; mean age 34.7 ± 28.3 years) and 18 controls — patients with drug-re-
sistant epilepsy without implanted VNS (10 M, 8 F; mean age 45.2 ± 30.8 years). The quality of life 
was examined using the questionnaires “Quality of life in epilepsy” (QOLIE-31 validated Croatian 1.0 
version) and “Beck Depression Inventory I” (BDI I validated Croatian version). For statistical analysis 
nonparametric Mann-Whitney test for independent samples was used. The study was approved by the 
Ethical Committee of the University Hospital Centre Zagreb. 
Results and conclusion: The Mann-Whitney test showed significant difference in the QoLIE-31 score 
between the case and the control group (p = 0.041). In the case group we have noticed that younger 
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patients had lower score of QoLIE-31 and higher score of BDI-I then the older ones. Our results show 
positive influence on the quality of life and mood improvement following VNS implantation in patients 
with drug-resistant epilepsy. VNS can be an effective treatment when used early in patients with both 
seizures and depression. 
Can we rely upon fMRI to localize verbal  
memory when planning epilepsy surgery? 
W. Theodore
Epilepsy Section, NIH, USA
Several studies have shown that fMRI can identify brain regions important for verbal memory in 
patients with epilepsy being considered for surgery. There is a significant correlation between lat-
erality indices when the intracarotid sodium amytal test and fMRI are compared in the same patient. 
Moreover, asymmetric activation left mesial temporal or language network activation during verbal 
encoding predicts verbal memory decline after left temporal lobectomy. A model including left fMRI 
activation during delayed recognition, side of seizure onset, and preoperative verbal memory score 
correctly predicted worse verbal memory in 90% (Dupont, et al 2010). These data suggest that fMRI is 
at least as accurate as the intracarotid sodium amytal test (Wada) for preoperative memory mapping. 
The Wada is invasive, suffers from many procedural vagaries, and has been shown to have limited pre-
dictive value for post-operative deficits. Only 10 cases of global amnesia have been reported over more 
than 50 years after epilepsy surgery, and all had independent preoperative evidence for contralateral 
dysfunction or atypical language dominance. The Wada has been declining in use, and many centers, 
perhaps a majority, no longer perform it at all. fMRI can replace it. 
Can psychogenic non-epileptic seizures be diagnosed by 
assessing behavior without concomitant EEG recording? 
M. Tripathi
Neurology, Professor, India
Psychogenic nonepileptic seizures are not uncommon. Any center involved in the management of 
episodic events which occur in epilepsy would be seeing about 5–25% of persons with nonepileptic 
events. About 5–15% would be PNES. The diagnosis of PNES is based on red flags obtained in the 
history of such patients. There are several clinical clues on history and examination. Over the years 
several biomarkers for the diagnosis have also been researched into. These could be serum prolactin, 
BDNF, non-EEG markers of the autonomic nervous system and the gold standard which is the EEG 
being non-ictal when the clinical event is happening. The gold standard has always been the unequiv-
ocal documentation of the habitual events having the clinical phenomenology of PNES and no ictal 
patterns on the simultaneous EEG. About 5–10% of patients with epilepsy will have a combination of 
pseudoseizures with true seizures. These can be documented only with simultaneous video EEG. Just 
depending on manifest behavior could help circumvent costly and labor-intensive video EEG monitoring 
in the epilepsy monitoring unit. Based on the clinical history and video of the patient during the event 
a reasonably confident diagnosis can be made. Practically most often doing a good clinical history and 
video observation with neuropsychological scales is enough to make a diagnosis of pseudoseizures. 
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HEADACHE
Head injury can precipitate the onset of migraine 
M. Ashina
Neurology, Danish Headache Center, Rigshospitalet Glostrup, Denmark
Post-traumatic headache (PTH) is one of the most common secondary headache disorders. It occurs 
for the first time in close temporal relation to trauma or injury to the head and/or neck. PTH shares many 
clinical symptoms of primary headaches, including migraine. Having any of migraine-like symptoms 
does not necessarily mean head injury precipitate the onset of migraine. Recent imaging data showed 
that PTH and migraine are associated with differences in brain structure. This suggests differences in 
their underlying pathophysiology. 
Behavioral therapy is more effective, better tolerated,  
and safer than preventive medications for migraine
S. Baskin
Behavioral Medicine, New England Institute for Neurology and Headache, USA
Diary studies have shown significant correlations between levels of daily stress as a trigger for mi-
graine attacks. Stress-related factors may also progress episodic migraine to a more chronic state. Other 
risk factors for progression include frequency of attacks, obesity, psychiatric comorbidities, medication 
overuse and sleep issues; all modifiable by behavioral interventions. Cognitive behavioral sleep therapies 
have been shown to reverse chronic migraine back to episodic migraine. Poor medication adherence can 
result in ineffective treatment of acute attacks, medication overuse headache (MOH), and greater risk of 
preventive medication side effects. Comprehensive behavioral treatments for migraine and MOH com-
monly incorporate motivation enhancement strategies to maximize preventive medication adherence 
and optimize acute care. Relaxation training, biofeedback training, and cognitive behavioral therapy 
have a good evidence base and are recommended in numerous treatment guidelines for the prevention 
of migraine. Behavioral therapy outcomes equal outcomes with preventive medication alone with less 
adverse events and there is some evidence that outcomes are enduring. Combination behavioral and 
medication treatment can enhance outcomes. Cognitive behavior therapy targeted for migraine with 
comorbid depression has shown promise on measures of headache, depression, anxiety, and quality 
of life compared to routine primary care. The thesis of this presentation is that headache medicine is 
mostly behavioral therapy. Effective clinicians perform a comprehensive behavioral assessment and 
optimize acute and preventive care utilizing headache diaries and behavioral change strategies. It is 
my position that all these strategies follow principles of behavior that are the most significant change 
agents in the management of migraine. 
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Insufficient sleep in tension-type headache:  
a population-based study
M.K. Chu1, S.-J. Cho3, J.-H. Oh2, W.-J. Kim4, K.I. Yang6, C.-H. Yun5
1Kangnam Sacred Heart Hospital, Hallym University, South Korea 
2Jeju National University School of Medicine, South Korea 
3Dongtan Sacred Heart Hospital, Hallym University College of Medicine, South Korea 
4Gangnam Severance Hospital, Yonsei University, College of Medicine, South Korea 
5Clinical Neuroscience Center, Seoul National University Bundang Hospital, South Korea 
6Soonchunhyang University College of Medicine, Cheonan Hospital, South Korea
Background: Insufficient sleep is a common problem in general population and is prevalent among 
migrainuers. Although tension-type headache (TTH) is the most common type headache, information 
regarding the association between TTH and insufficient sleep is limited. 
Objectives: To investigate the prevalence and impact of insufficient sleep among individuals with TTH.
Material and methods: We selected a stratified random population sample of Koreans aged 19 to 
69 years and evaluated them with a 60-item semi-structured interview regarding headache and sleep. 
A difference of one hour or more between sleep need and average sleep time indicated insufficient sleep. 
Results: Of 2,695 participants, 727 (27.0%) and 570 (21.2%) were classified as having insufficient 
sleep and TTH, respectively. The prevalence of insufficient sleep among individuals with TTH (28.8%) 
was significantly higher compared to that among individuals with non-headache (20.4%, p = 0.001). 
TTH participants with insufficient sleep had higher visual analogue scale scores for headache intensity 
(4.7 ± 1.8 vs. 4.3 ± 1.9, p = 0.018), and impact of headache (Headache Impact Test-6, 44.9 ± 7.0 vs. 
43.6 ± 6.1, p = 0.001). Multivariable analyses revealed that aged 50 s, insomnia, poor sleep quality, 
short sleep time and poor sleep quality were significant factors of insufficient sleep among individuals 
with TTH. 
Conclusions: A significant proportion of participant with TTH experienced insufficient sleep. In-
sufficient sleep was associated with an exacerbation of symptom of TTH. 
Non-invasive vagus nerve stimulation in primary headaches
O. Daniel
Headache Center, Laniado Medical Center, Israel
Clinical observations and results from recent studies support the use of non-invasive vagus nerve 
stimulation (nVNS) for treating primary headaches. The most common types of Primary Headache 
Disorders are Migraine and Cluster Headache. According to evidence-based recommendations, the 
only primary symptomatic treatments for CH attacks are subcutaneous sumatriptan and inhaled oxy-
gen. Approved Labeling for sumatriptan in CH indicates a maximum of two doses per day, which may 
be inadequate for many patients, including those with frequent Attacks, and may lead to Medication 
Overuse Headache with multiple daily dosing. This treatment is also associated with injection site 
reactions (e.g., pain, swelling) and neurologic symptoms (e.g., dizziness, tiredness) and has cardiovas-
cular contraindications. Hence, the limited therapeutic options for the acute treatment of CH reflect 
an Unmet Medical Need. Many well-controlled trials support nVNS efficacy in the acute treatment of 
Episodic Cluster Headache and Migraine with or without Aura. 
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Head injury can precipitate the onset of migraine
O. Daniel
Headache Center, Laniado Medical Center, Israel
Headaches are variably estimated as occurring in 25 to 78 percent of persons following mild TBI. 
Paradoxically, headache prevalence, duration, and severity are greater in those with a mild head in-
jury compared with those with more severe trauma. According to the International Headache Society 
(IHS) criteria, the onset of headache should be within seven days after the injury. Recurring attacks 
of migraine with and without aura can result from mild head injury. The impact can also cause acute 
migraine episodes, often in adolescents with a family history of migraine. Originally termed “Football-
er’s Migraine” to describe young men playing soccer who had multiple migraines with aura attacks 
triggered only by impact, similar attacks can be triggered by mild head injury in any sport. Moreover, 
among US soldiers with post-traumatic headaches mainly associated with blast trauma, most were of 
the migraine-type. Biochemical and epidemiologic studies suggest that trauma may be the main eti-
ologic factor of migraine in some cases. Differentiating the different types of post-traumatic migraine 
has diagnostic, therapeutic, and legal implications. 
PFO in neurological diseases (migraine, stroke)  
to close or not to close… — Pro…
I. Domitrz
Department of Neurology 2nd Faculty of Medicine, Warsaw Medical University, Poland
The frequency of PFO in general population varies from 6 to 30%, in the majority epidemiological 
studies 20–25%. Several studies have investigated the prevalence of patent foramen ovale in patients 
with migraine. Such data finding out significantly higher prevalence of PFO in patients with migraine 
with aura suggest that there may be a possible a relationship between migraine with aura and PFO. The 
PFO is generally considered to be associated with first-ever and recurrent cryptogenic ischemic stroke 
in young patients without any other risk factors for stroke. The prevalence of PFO was significantly 
higher in such patients. It is widely accepted that migraine with aura can directly cause an ischemic 
stroke. Some studies confirmed the decrease of the prevalence of attacks of migraine with aura after 
percutaneous closure of PFO. Because in many PFO associated conditions it can be difficult to deter-
mine the degree to which the PFO is a causative factor in the disease process, it should be recommend 
a comprehensive diagnostic evaluation to exclude other obvious etiologies of PFO associated conditions 
before implicating the PFO and proceeding with closure. However, in the properly selected patient 
population, there is growing clinical experience and experimental evidence suggesting that closure of 
PFO is a safe and effective treatment modality. Confirmation of a relationship between PFO and stroke 
or PFO and migraine may lead to another effective treatment such as percutaneous PFO closure and/
or antiplatelet/anticoagulant treatment, as a routine procedure. 
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Monoclonal anti-bodies towards CGRP and CGRP receptor 
will be first-line treatment for the prevention of migraine
L. Edvinsson
Dept Medicine, Inst Clinical Sciences, Lund University, Sweden
CGRP is a very potent vasodilator with distribution in all vascular regions with similar localization 
of CGRP receptors, however the detailed functional is incompletely known. CGRP has been shown 
to be released in primary headaches and blocking this peptide or its receptor reduces symptoms. The 
available prophylactic treatments rest on therapies that were originally not designed for migraine treat-
ment. The molecular mechanisms of CGRP distribution, release and coupling to the pathophysiology 
is being elucidated. Blocking CGRP is useful both rapid and long-term in attack prevention. Can it be 
particularly useful in different subtypes of migraine? This has received novel interest because amazingly 
the phase II/III trials were positive without AEs. It is worth pointing out that (i) no patients developed 
hypertension related to the treatment during the trials. (ii) Males (age about 65 y) were exercised on 
treadmill until the development of angina pectoris. They received the CGRP receptor anti-body Er-
enumab or its vehicle; interestingly there was no difference. (iii) It has been postulated that blocking 
the trigeminovascular reflex might exacerbate any cerebral ischemia or a stroke during CGRP blockade. 
Available trials have not supported this hypothesis BUT the CGRP trials have so far mainly been on 
subjects of middle age and thus not in a population of high risk for stroke or AMI. (iv) Studies on the 
CGRP anti-bodies show lack of passage of the blood-brain barrier hence this limits CNS side-effects. 
Monoclonal antibodies to CGRP will become first-line 
treatment for the prevention of migraine
H. Göbel
Kiel Migraine and Headache Center, www.schmerzklinik.de, Germany
CGRP plays a crucial role in the pathophysiology of migraine. Adding so-called monoclonal anti-
bodies, the effect of these inflammatory substances can be stopped for several weeks and the prob-
ability of migraine attacks can be significantly reduced. Currently, 4 antibodies are being developed 
and tested in numerous studies. Erenumab (AMG 334), Galcanezumab (LY2951742), Fremanezumab 
(TEV-48125), Epzinezumab (ALD403), /ul the new immunotherapy, in contrast to all other available 
preventive medicines, has been specifically developed for migraine prevention for the first time. The 
onset of action is fast and initially to be expected within a few days. With the previously available 
conventional preventive medication, this can often only be achieved after weeks or even months. Side 
effects of the current migraine preventives such as weight gain, mood changes, tiredness, reduced 
drive or drowsiness do not occur. The degree of efficacy varied significantly between the treated study 
participants. Should the currently available data be confirmed, more patients in future will be able 
to reduce their burden of migraine and return to a normal life. In this debate, it should be discussed, 
for which patients the new therapy options are useful. It must also be discussed whether it should 
become a first-line treatment, or whether it should only be used when the current therapy options 
have proven to be ineffective. 
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Behavioural therapy is more effective, better tolerated  
and safer then preventive medication for migraine — No
H. Hamburger
Department of Neurology, Amsterdam Sleep Centre, The Netherlands
Many patients suffering from migraine have frequent attacks ranging from 1 to 4 per month. Pre-
ventive medication is given when the frequency is high, acute care medications do not work, there is 
too much disability and for other reasons. Most doctors will start their preventive treatment urging the 
patient to utilize various sensible behavioural changes. These include more or better sleep, cognitive 
behavioural therapy and dietary measures. When these fail, which is frequently the case; there is no 
other way of treating these patients than medication. Preventive medication has proven to be successful 
in the majority of the patients, but they do not always work, have to be taken once or more per day and 
often have many adverse effects. When preventive medication used is dosed low and increased slowly, 
the adverse effects can be limited. A combination of more than one drug can be used to limit the side 
effects and increase efficacy. At present onobotulinumtoxin A, injected once per 3 months and several 
antiepileptic and antidepressant medications are often used. Soon we will have CGRP antibodies, 
once per month or every three months, as a good way to prevent most migraine attacks. This type of 
medication is efficacious and the side effects are limited. Using preventive medication, the sufferers 
of this painful and disabling disease, affecting 12% of the adult population, can lead a normal life. In 
conclusion: routine and novel medication for prevention of migraine attacks are often more powerful 
than giving advice, talking to patients and convincing. 
Episodic vertigo can be a manifestation of migraine,  
at times, unaccompanied by headache — No
M.J.A. Láinez
Department of Neurology Hospital Clínico Universitario; Universidad Católica de Valencia, Spain
The association between vestibular symptoms, including dizziness and vertigo, and headache has 
been reported in several studies, but migraine and vertigo are among the most common health concerns 
in the general population. The link between migraine and vertigo was described long time ago, but 
the relation of causality has never been established The diagnostic criteria for vestibular migraine is 
described in the International Classification of Headache Disorder (ICHD), third edition, beta version 
but it is included in the appendix criteria. The reason to include entities in the appendix is that there 
is not enough scientific evidence to include these entities in the definitive classification. It is clear 
that vertigo could be a manifestation of migraine, especially in patients with migraine with Braunstein 
aura (referred by 60% of the patient) and could also be a symptom of vestibular migraine. But there is 
no evidence that episodic vertigo could be a manifestation of migraine unaccompanied by headache. 
Nutraceuticals are safe and effective  
as migraine treatments
M.J.A. Láinez
Department of Neurology Hospital Clínico Universitario; Universidad Católica de Valencia, Spain
The use of complementary and alternative medicine has increased in patients with neurological 
disorders, and now appears to be in widespread use among many patients, even in tertiary headache 
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care. Between these alternatives, nutraceuticals are the most preferred by headache patients. Many 
studies with different compounds or combinations have proved efficacy and safety as preventive 
treatment of headaches. There are 11 studies published with feverfew; based on these studies the 
American Academy of Neurology concluded that feverfew is probably effective for migraine prevention 
with level B evidence. Riboflavin has demonstrated efficacy and tolerability for migraine prevention in 
adults based in case-series and several open-label studies. Magnesium has been used as an acute and 
preventive treatment of migraine. There are several studies of the intravenous use in acute migraine, 
with positive and negative results. Oral magnesium supplementation has been studied for adult and 
pediatric migraine prevention in several randomized clinical trials. The balance of evidence is in favor 
of oral magnesium for migraine prophylaxis. Coenzyme Q10 has also been used in the prophylactic 
treatment of migraine; after several studies published coenzyme Q10 has shown efficacy in migraine 
prevention. There are several studies using different combinations of these nutraceuticals with positive 
results. The safety and tolerability of the mentioned compounds have been excellent. In summary, 
nutraceuticals are safe and effective in the prophylactic treatment of migraine.
The criteria for the diagnosis of trigeminal neuralgia 
should be changed to allow a sensory loss  
in the trigeminal distribution — Con
S. Maarbjerg
Danish Headache Center, Department of Neurology, Rigshospitalet – Glostrup, Denmark
A few studies documented sensory abnormalities in classical trigeminal neuralgia (CTN) at bedside 
examination. Several studies using quantitative sensory testing documented sensory abnormalities 
including both gain and loss of sensory function. Importantly, most clinical studies reported no sen-
sory abnormalities at bedside examination in CTN and according to clinical experience, CTN patients 
rarely spontaneously report the sensory loss, and rather it is a subtle finding at careful examination. In 
previous editions of the International Classification of Headache Disorders (ICHD) the TN diagnostic 
criteria included a criterion stating that there are no sensory abnormalities in CTN. However, in the 
recent 3rd edition the diagnostic criteria were changed such that they no longer include a criterion on no 
sensory abnormalities. The diagnostic criteria are meant to be used worldwide by physicians no matter 
the level of experience in neurology, headache and facial pain. Deleting the criterion on no sensory 
abnormalities involves a risk of less experienced physicians wrongfully diagnosing CTN in a patient 
presenting with facial pain and sensory abnormalities. Such combination of symptoms could point 
to grave underlying disease other than CTN such as carotid dissection, cavernous sinus pathology or 
a space-occupying lesion in the cerebellopontine angle cistern. The talk will argue that by deleting the 
criterion on no sensory abnormalities in CTN, and thereby increasing the sensitivity of the diagnostic 
criteria, the trade-off in loss of specificity involves a risk of misdiagnosing other serious neurological 
disease presenting with facial pain and sensory abnormalities as CTN. 
Medical cannabis is not effective in chronic headache
D.D. Mitsikostas
National & Kapodistrian University of Athens, Athens, Greece
The use of cannabis for medicinal purposes is deeply rooted though history, dating back to ancient 
times. Currently, although clinical trials of cannabis for neuropathic pain have shown promising results, 
there has been little research on its use specifically for primary headache disorders, including migraine, 
cluster headache, and medication overuse headache. However, this evidence is primarily limited to 
case-based, anecdotal, or laboratory-based scientific research; no placebo-controlled clinical studies 
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examining the use of cannabis as mono-therapy for primary headache there are. There is some evidence 
highlighting the potential value of cannabis in combination therapies, as a supplement to traditional 
treatments, or as a secondary treatment in refractory cases, including the medication overuse headache, 
but again this evidence is far from any recommendation. At this time, a multicenter, double-blind, pla-
cebo-controlled study is being performed to examine the safety and efficacy of dronabinol (a synthetic 
cannabinoid) metered dose inhaler for the symptomatic treatment of migraine (clincaltrials. gov, NCT 
Identifier: NCT00123201). The trial completed and when published, this study could give valuable 
insights into the efficacy and risks of cannabinoids for the acute treatment of migraine attacks. For mi-
graine prevention, there is no similar trial. For patients suffering from refractory cluster headache who 
are in a desperate and vulnerable situation, illicit psychoactive substances might often be considered 
a last resort, but still, this indication stands far away from any scientific evidence favoring the use of 
cannabis in cluster headache treatment, as in any other headache subtype. 
Nutraceuticals are safe and effective  
as migraine treatments
D.D. Mitsikostas
National & Kapodistrian University of Athens, Athens, Greece
Nutraceuticals became sexy in medicine. Several agents including riboflavin, coenzyme Q10, mag-
nesium, butterbur, petasites, feverfew, omega-3 polyunsaturated fatty acids, folic acid have been tested 
for prevention of primary headache disorders, migraine in particular. Notably, several neurological 
societies recommend their use in varying degrees of detail (e.g. the American Academy of Neurology 
and American Headache Society, the Canadian Headache Society, and the European Federation of Neu-
rological Societies). Whether the scientific documentation is good or not remains debatable, however. 
None of the nutraceuticals got the A degree or class I scientific documentation resulting in the lower 
level recommendation, but their use is expanding dramatically in real life as long people suffering from 
headaches prefer them because of pharmacophobia and nocebo behaviors mainly. The lack of specific 
and mechanism-based drugs for the prevention of primary headaches support these fears. Because 
nutraceuticals do not require a prescription, many patients rely on their own judgment as to when 
and which one to take, often without consultation or guidance from their physician. Thus, nutraceu-
ticals turn out to be a significant alternative choice for prevention of primary headaches and headache 
specialists should provide accurate and unbiased information for their potential efficacy and safety. 
Medication overuse headache
A. Rapoport
Neurology, the David Geffen School of Medicine at UCLA, USA
Dr. Lee Kudrow, a headache specialist from Los Angeles, in 1978 was the first to report on how overuse 
of analgesics could worsen chronic headaches such as migraine. He also demonstrated the beneficial 
effects of withdrawal of the offending medicine and the added benefit of an effective preventive med-
ication (low dose amitriptyline in his study). The term “rebound headache” became popular and then 
changed to “medication overuse headache”. The overused medication soon included any acute care 
medication used too frequently, even migraine-specific triptans and ergots. It was shown that opiates 
and butalbital containing medications were the worst offenders and NSAIDs the least troublesome. 
Although NSAIDs can also cause MOH, they often work as preventives at first or at lower frequencies, 
without causing MOH. When Topamax (topiramate) was studied as a preventive migraine medication, 
a clinical trial demonstrated that it seemed to work even when the patient was not withdrawn from the 
overused medication. When Botox (onabotulinumtoxinA) was studied as a Chronic Migraine preventive 
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medication, it too was shown in a trial to work even when a patient was not withdrawn from overused 
medication. So, the question is, when a patient is on either topiramate or onabotulinumtoxinA as a daily 
preventive and is overusing an acute care medication, should they go through a detoxification or not. 
There is no correct answer, but many feel that it is better for the patient, and the outcome might be 
better if the patient is withdrawn. Often, a preventive will not even be needed. 
Pipeline in headache treatment
A. Rapoport
Neurology, the David Geffen School of Medicine at UCLA, USA
There are several promising new and future treatments for migraine and cluster headache which 
will listed here. Calcitonin gene-related protein (CGRP) is a neurotransmitter found ubiquitously in 
the central and peripheral nervous system. Many oral small molecule CGRP receptor antagonists have 
shown efficacy in the acute care of migraine, without constricting blood vessels; but none have been 
approved for use. New types are in phase 2 and 3 trials. Monoclonal antibodies to CGRP or its receptor 
have completed phase 2 and 3 trials and seem to be effective in reducing headache days per month, 
with few significant adverse events and a dosing schedule of monthly or quarterly. Lasmiditan, in the 
newer class of ditans, is a serotonin1F receptor agonist which is effective like a triptan but does not 
constrict blood vessels. Multiple devices have been approved in the US and Europe including: a tran-
scranial magnetic stimulator for the acute and preventive treatment of migraine; a supraorbital nerve 
stimulator for the acute and preventive care of migraine and a non-invasive vagal nerve stimulator for 
the acute care of cluster headache and soon preventive care. Not yet approved are a sphenopalatine 
ganglion stimulator for cluster headache acute care and prevention; caloric vestibular stimulator for 
prevention of migraine; occipital nerve stimulator for chronic migraine and cluster headache and 
a non-invasive neuromodulator placed on the arm for treating migraine. We have a lot to look forward 
to for treating our migraine patients who often need special techniques, alone or in combination, for 
significant improvement. 
Medication overuse headache (MOH) can be treated with 
preventive medications without detoxification — Yes
J. Schim
The Headache Center, the Neurology Center of Southern California, USA
MOH is usually treated with detoxification from the offending agent first. There is evidence that 
preventive medications work regardless of detoxification. The relationship between medication over-
use and headaches has been known for decades. Overuse of ergots was noted to be associated with 
a variety of ill effects, including increased headaches. However, not all individuals who overuse acute 
medications develop medication overuse headache. While there is evidence in favor of discontinuation 
of medication overuse to improve headache frequency, there is also evidence that instituting prevention 
therapy, even without educating the patient about medication overuse issues, can improve headache 
control. The mechanism of MOH is still unclear. Even without detoxification, headaches can improve 
with preventive medications alone. 
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Medication overuse headache (MOH) can be treated with 
preventive medications without detoxification — No
R. Shapiro
Department of Neurological Sciences, Robert Larner College of Medicine, University of Vermont, USA
Preventive medications for medication overuse headache (MOH) are sometimes effective without 
withdrawal of overused acute medications. However, are such preventive medications fully effective 
without detoxification? Few data address this question. Topiramate appeared to be equally effective at 
reducing headache days (~3.5 per month), whether or not overused acute medications were present 
at baseline, in a European randomized controlled trial (Diener et al. 2007). However, would subjects 
in the MOH group have shown an even greater response to topiramate had acute medications also 
been withdrawn? By contrast, topiramate did not reduce the number of headache days when medica-
tion overuse was present in a US trial (Silberstein et al, 2007). Notably, MOH subjects in the US trial 
were more likely to be overusing analgesics or opioids, whereas subjects in the European trial more 
often took triptans. In subgroup analyses of phase III (PREEMPT) trial program assessing Botox for 
a chronic migraine, subjects showed equal reductions in headache days regardless of whether or not 
acute medications were overused (opioids were excluded). Again, Botox efficacy was not assessed for 
subjects who were overusing acute medications but then withdrew from them. In a US retrospective 
study of outcomes of preventive treatments for MOH (Bigal et al, 2004), all subjects were instructed to 
withdraw overused acute medications (45% butalbital, 30% opioids), but only those that successfully 
did so significantly reduced headache days. In conclusion, further studies are necessary to clarify 
whether optimal treatment of MOH with preventive medications also requires the withdrawal of 
overused acute medications. 
Episodic vertigo can be a manifestation of migraine,  
at times, unaccompanied by headache
M.M. Wysocka-Bakowska 
ENEL-MED Medical Centre, Poland
Vertigo or dizziness is experienced by 51.7% of migraine patients. Patients with migrainous vertigo 
(MV) may experience attacks of vertigo both with and without headache, most patients show an asso-
ciation between vertigo and headache. Migraine and vertigo are observed in strong correlation since 
early childhood: Migraine equivalents in children; Benign paroxysmal vertigo; Paroxysmal vomiting. 
Locomotion sickness in childhood is experienced by over 60% of migraineurs. Locomotion sickness and 
migraine in childhood; are very common, mostly in boys, decreasing with age, as migraines decrease 
in frequency. With age observed transformed migraine, the occurrence of vertigo and vertebrobasilar 
insufficiency (VBI) seem to be related to the vascular and vestibular system. Migrainous aura and 
cortical spreading depression concern mostly occipital lobes of the brain. Complications of migraine, 
such as vascular ischemic accidents, occur more often in the posterior area of the brain: in occipital 
lobes, and in the brain stem. Except for migraine headache, there are other important features of the 
attack, such as oversensitivity to light, sounds, odors, symptoms exacerbated by sudden movements! 
Vestibular oversensitivity, brain hypersensitivity to stimulation and impaired habituation to stimuli, are 
typical of migraine and vertigo. Nausea and vomiting are typical for migraine and vestibular syndromes. 
The co-occurrence of those two conditions is higher than expected from the combined prevalence of 
both disorders in general population; vestibular symptoms associated with migraine can represent 
the most common cause of vertigo. Vestibular migraine (VM) was integrated as an independent entity 
(ICHD-3 beta, A1. 6.5). Similar descriptions of several different conditions: VM Vestibular Migraine; 
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MBA, migraine with brainstem aura; HM hemiplegic migraine. Migraine can often co-occur with other 
vestibular disorders (such as Méniere’s disease) and benign paroxysmal positional vertigo (VPPB). 
Nutraceuticals are safe and effective  
as migraine treatment
M.M. Wysocka-Bakowska
ENEL-MED Medical Centre, Poland
The burden of migraine is well documented and shows evidence that many patients, mostly women 
are seriously limited by migraine. In over 38% of patients, migraine attacks are hardly controlled with 
abortive medications, and there is a need for prophylactic treatment. Most drugs recommended for 
abortive treatment of migraine attack and for prophylaxis of migraine are not perfect, have several lim-
itations and contraindications. Patients are looking for a safer and more natural alternative treatment. 
There is long list and broad spectrum of nonspecific treatments of various origin, believed to be safer 
and more “natural” for the abortive and prophylactic treatment of migraine. The list of nutraceuticals 
believed to be effective is long Several works on the effectiveness of Fever few, Riboflavine, Co Q 10, 
are available in literature worldwide, and many more, on each continent. We should also consider very 
high placebo effect in migraine patients. Nonpharmacologic treatment, acupuncture, Yoga, relaxation 
technics, physiotherapy, and psychotherapy may offer an important complimentary ways of migraine 
management. We should not neglect this options, and try to consider them, carefully discussing with 
each individual patients. It is especially important for high-risk patients, who cannot tolerate most 
medications such as triptans, betablockers or antiepileptic drugs, like valproic acid or topiramate, 
which are all not perfect, even if very helpful for many other migraine sufferers. 
The criteria for the diagnosis of trigeminal neuralgia 
should be changed to include sensory loss  
in the trigeminal distribution — Pro
J. Zakrzewska
Pain Management Centre, Oral Medicine, UCLH NHS Foundation Trust, UK
Trigeminal neuralgia is defined by the International Headache Association as recurrent unilateral brief 
electric shock like pains, abrupt in onset and termination within the distribution of the trigeminal nerve 
and triggered by innocuous stimuli. In the criteria for classical trigeminal neuralgia, it is stated that no 
clinically evident neurological deficit is found. On the other hand the International Association for the 
Study of Pain does state that sensory changes may be present especially to light touch. In recent cohort 
studies, mild clinical sensory changes have been detected in up to 70% of patients. Using qualitative 
sensory testing sensory changes especially to touch and temperature can be detected not just in those 
with MS but those with no other changes including those with or without concomitant pain. Further 
investigations with conventional MRI have not shown any reason for these sensory changes. However, 
more sophisticated imaging such as diffusion tensor imaging DTI does show structural changes which 
could account for these findings. In view of these findings, clinically mild sensory loss should be in-
cluded in the diagnostic criteria for trigeminal neuralgia but should not be essential criteria. 
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HISTORY OF NEUROLOGY IN POLAND
To Warsaw from Lvov — Orzechowski, Frey,  
Rose, Choróbski
J. Bojakowski
Department of Neurology, Medical University of Warsaw, Poland
The lecture is devoted to those people, born in Sub-Carpathian (Lvov) region, who came to work 
in Department of Neurology during first years of its existence in Warsaw. The University of Warsaw 
has been reconstituted in 1915. Five years later Department of Neurology has been established. The 
circumstances of teaching neurology before and after 1920 are shortly characterized. The persons of 
Kazimierz Orzechowski, Łucja Frey, Maksymilian Rose and Jerzy Choróbski are recalled, to gratitude 
and express the admiration for Lvovians — the University of Jan Kazimierz and Jagiellonian University 
absolvents supported the Department of Neurology in Warsaw University. 
Professor Irena Hausmanowa-Petrusewicz  
and the Warsaw School of Neurology
A. Friedman
Neurology, Medical University of Warsaw, Poland
Professor Irena Hausmanowa-Petrusewicz headed the Department of Neurology of the Medical Acad-
emy in Warsaw for 30 years from 1958 up to 1988. During that time she promoted 63 doctoral theses 
and 14 habilitations. Due to her very high position in the world of neurologists, most of the promoted 
doctors were offered by Professor Irena Hausmanowa-Petrusewicz a possibility to go for at least one-year 
fellowship to best neurological centers in Europe and America. This was a reason why several of her 
pupils became later heads of various departments of neurology in Warsaw and also abroad. Professor 
Irena Hausmanowa-Petrusewicz created first in the Polish history of neurology stroke unit in the Depart-
ment of Neurology and Intensive Care Neurology Unit. She formed for the first time Children Ward of 
Neurology. She was the one who organized first Post-stroke Rehabilitation Ward located in Konstancin 
near Warsaw. Due to her involvement in muscular disorders, she created Morphology of Muscles and 
Nerves lab. She organized first in Europe Muscular Disorders Out-patients Clinic. Definitely, Professor 
Irena Hausmanowa-Petrusewicz had an enormous impact on Polish neurology and merits the title of 
Creator of Warsaw School of Neurology. 
The scientific and clinical input of E. Flatau
D. Koziorowski
Department of Neurology, Medical University of Warsaw, Poland
Professor Edward Flatau was born in 1968 in Płock. Graduated with honors in medical studies from 
the Moscow State University. His lecturers there included, among others, professors Aleksiej Kowze-
wnikow and Siergiej Korsakow. Then he conducted academic research in Berlin, where he deepened 
his knowledge of anatomy, histology and pathological anatomy of the nervous system. Despite many 
scientific offers (i.e. university of Buenos Aires), he returned to Warsaw. His work was in the clinical and 
scientific field. As the head of the Department of Neurology at the hospital on “Czyste”, he undertook 
a wide variety of clinical activities. He was the first organizer of the neurobiological laboratory, which 
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he initially founded in his own home. Later it was transformed into the Neurobiological Laboratory 
of the Institute of Marceli Nencki, which he directed for the rest of his life. Scientific studies resulted 
in many prominent publications. One of the most outstanding is: “Atlas of the human brain and fiber 
course” published in Berlin in 1894. The contribution to research on dystonia, which he made with 
Władyslaw Sterling, is quoted to this day and is a most important piece of study. Edward Flatau was an 
outstanding scientific researcher, a talented clinician, and a first-class educator. He was characterized 
by a rare perseverance at work, tireless energy and an exceptional ability to organize teamwork. He 
died in Warsaw in 1932. 
Polish neuropsychiatrists in the Russian empire
B. Lichterman
Medical History, Russian History and Cultural Studies, The Sechenov University, Russia
After Poland was divided between Austria, Prussia and Russia in the end of 18th century many Polish 
physicians lived and worked in Russian Empire. For example, Jan (Ivan) Mierzejewski (1838–1908) 
was a professor of psychiatry and nervous diseases of Imperial Medico-surgical (later Military medical) 
Academy in St. Petersburg (1877–1893), chairman of St. Petersburg society of psychiatrists and First 
Congress of Russian psychiatrists. His illustrious pupils include Vladimir Bekhterev, Leonid Blumenau 
and Alexander Shcherbak (1863–1934). The latter was elected to the chair of nervous and mental dis-
eases at Warsaw University. In 1911 he moved to Sebastopol and founded Romanovsky (later the IM 
Sechenov) Institute for Physical Therapy. My grandfather Boleslav Likhterman (1902–1967) was one 
of his pupils. My grandfather’s uncle Dr. Maurycy (Moriz) Urstein (1872–1940) from Warsaw authored 
more than 100 publications on psychiatry and neurology. He was a pupil of Emil Kraepelin in Germany. 
In the Russian-Japanese war in 1904–1905, he was a military doctor in Russian Army. In WW1 he was 
a director of Russian Red Cross hospital and studied mental disorders after brain injuries. Neurology 
of brain and spinal cord injuries was also a subject of interest of professor Władysław (Vladimir) Dzi-
erżyński (1881–1942) who studied and worked in Russia until his emigration to Poland in 1922. He 
authored a first Polish textbook on neurology. To conclude, physicians of Polish origin made significant 
contributions to Russian and international neurology and psychiatry. 
The Circles of Edward Flatau (1868–1932)
A. Ohry
Rehabilitation Medicine, Sackler Faculty of Medicine, Tel Aviv University, Israel
[Organized with the assistance of Prof. Piotr Jacek Flatau (1953–) Polish-American physicist] When 
we tried to organize the “Flatau circles”, we found that the connections of the founding father of 
modern Polish neurology, Edward Flatau (1869–1932), were spread over (at least) three countries: 
13 neurologists on the “German list”, 6 on the “Russian list”, and 21 on the “Polish list”. We are not 
sure that this is the whole list. Flatau was also influential in establishing Polish medical periodicals 
“Neurologia Polska” and “Warszawskie Czasopismo Lekarskie”. I will focus my introduction on two of 
Flatau’s pupils: Teofil Simchowicz (1879–1957) and Jakub Mackiewicz (1887–1966). 
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The long shadow of the Spanish flu
L. Spinney
Writer and journalist, Paris, France
The Spanish flu (1918–1920) infected one in three people on earth and killed between 50 and 100 
million of them. For its sheer scale and the virulence of the viral strain that caused it, the disaster was 
anomalous in the annals of flu pandemics. I will present theories that address why it was in a league of 
its own and look at how this exceptionally dangerous pathogen affected every part of the human consti-
tution, including the central nervous system. Neurological and psychiatric effects were evident while 
the pandemic raged, and in the months, years and possibly even decades that followed. Because the 
virus also affected fetuses in the womb, it left an indelible mark on a generation that has only recently 
passed away. For these reasons, I will argue, the Spanish flu cast a very long shadow over humanity. 
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MULTIPLE SCLEROSIS
The only certain measure of the effectiveness of multiple 
sclerosis therapy is serum neurofilament level — Con
G. Arrambide
Servei de Neurologia-Neuroimmunologia; Centre d’Esclerosi Múltiple de Catalunya, (Cemcat), Vall d’Hebron Institut de Recerca,  
Hospital Universitari Vall d’Hebron; Universitat Autònoma de Barcelona, Spain
Increased neurofilament light (NfL) levels reflect the degree of axonal damage occurring in the central 
nervous system (CNS), leading to their consideration as potential biomarkers for multiple sclerosis 
(MS), especially to evaluate treatment response. To date, most studies assessing the value of NfL levels 
were carried out using cerebrospinal fluid (CSF) samples, but lumbar puncture is a relatively invasive 
procedure that is performed mostly for diagnostic purposes and not for follow-up. Therefore, more 
recent studies have focused on the reliability of measuring NfL levels in serum. Different assays have 
been tested, and the most sensitive appears to be a single-molecule array (Simoa) assay. However, se-
rum NfL levels cannot be currently considered the only certain measure of treatment efficacy for the 
following reasons: there is a need for technical standardization to allow a direct comparability between 
centres, studies, and possibly even different platforms, given the high cost of the Simoa technique 
renders it inaccessible to most institutions. Furthermore, in the daily clinical practice, a biomarker that 
can be classified as positive or negative is probably more useful and easy to interpret. Therefore, cut-
off values should be established in healthy controls, should probably be stratified by age, and should 
be determined for the different treatments currently available for MS. Finally, the study population is 
small in most studies, so there is still a need for larger, longitudinal studies with a longer follow-up 
and availability of other clinical and radiological markers of treatment response, which itself may vary 
depending on the disease phenotype. 
No evidence that cognitive dysfunction is improved  
by disease-modifying drugs in multiple sclerosis
J. Cerqueira
Life and Health Sciences Research Institute, School of Medicine, University of Minho, Portugal 
2CA — Clinical Academic Centre Braga, Portugal 
Neurology, Hospital de Braga, Portugal
Cognitive dysfunction is very common in Multiple sclerosis (MS) patients. Not only do many early 
MS patients, and even persons with the radiologically isolated syndrome, display cognitive impair-
ments, but also individual cognitive performance often deteriorates during the course of the disease. 
Cognitive difficulties are a key determinant of employment and autonomy, independently of motor 
deficits. Therefore, it is important to identify strategies to improve such difficulties. DMDs are effective 
at controlling relapses and most are also able, to some extent, to prevent disability progression, probably 
including cognitive dysfunction. Given the high prevalence of already installed cognitive dysfunction, 
it is also important to understand their impact on existing cognitive difficulties. A careful review of the 
available evidence in the literature reveals two main conclusions. Almost all DMDs have some sort of 
evidence suggesting a positive impact on cognitive dysfunction with relatively short-term use. However, 
most studies are poorly designed and do not seem robust enough for firm conclusions to be drawn. 
Moreover, the comparison between studies is complicated by the use, in each study, of a different set 
of cognitive tests. In conclusion, we will show that, notwithstanding novel data in the future, there 
is, at the present, no strong evidence to support an effect of DMDs in improving cognitive function. 
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Are there diagnostic markers which can reliably  
differentiate MS from isolated CNS SLE? — Con
J. Chapman
Neurology, Sheba Medical Center, Israel 
Neurology and Neurosurgery, Sackler Faculty of Medicine, Tel Aviv University, Israel
Multiple sclerosis (MS) and systemic lupus erythematosus (SLE) are syndromes. Lupus has labo-
ratory markers but no diagnostic neurological manifestations since there are 19 clinical syndromes 
associated with it. Multiple sclerosis is a mainly clinical syndrome with no diagnostic blood markers. 
The clinical criteria for MS of transient deficits are quite common in neuro-SLE, some cases due to 
vascular incidents and some inflammatory (cerebritis). MRI criteria for MS include the localization of 
lesions, their shape and conformation, and signal on specific sequences. Unfortunately, none of these 
are highly specific for MS and can be seen in strokes due to vasculitis. The diagnostic blood markers 
of SLE are commonly found in patients with MS. The CSF markers of MS, the oligoclonal bands, and 
intrathecal IgG synthesis are commonly found in SLE. Furthermore, even in patients with classical MS 
we sometimes find significant autoimmune systemic disease, including SLE and APS. Therapy for MS 
and SLE overlap to a significant extent including anti-CD20 medications. Better understanding and 
definition of the pathogenic mechanisms underlying these 2 syndromes will probably define specific 
diseases which will serve as the basis for diagnosis and treatment.
Is the central vein sign really helpful in differentiating MS 
from other white matter disease? — No
C. Constantinescu
Neurology, University of Nottingham, UK
Ultra-high field MRI, available in a restricted number of centers almost exclusively for research 
purposes, led to the recognition of the central vein sign (CVS) as a marker for the MS white matter 
lesions. Some criteria have been proposed for MS, e.g. ≥ lesions with CVS or ≥ 40–50% of the lesions 
having CVS. Efforts are made to detect the CVS at 3T MRI. The reason the CVS is not (yet) helpful: 
Additional corroborating information (evoked potentials, CSF, clinical features) is more helpful. 
Currently, CVS is consistently detected at ultra-high field MRI only and is restricted to research. The 
number of results even from 7+T MRI studies is too small. The CVS is not helpful when the number 
of lesions is limited. The central vein sign has limited value for the more relevant differential diagnosis 
situations, where a distinction between MS and other conditions is essential e.g. ADEM, sarcoidosis 
etc. Some conditions, e.g. neuro-Behçet may have lesions centered around a vein. CVS may be helpful 
diagnostically in microangiopathy in persons of a certain age with cardiovascular risk factors. Knowing 
the co-morbidity, clinical features adds information to the white matter changes. Inflammatory and 
microangiopathic lesions often coexist, and diagnosis needs time and remains clinical. A few illustra-
tive cases will be discussed. 
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Should we consider immune reconstitution  
for patients with more active MS? — No
C. Constantinescu
Neurology, University of Nottingham, UK
In this debate, I will briefly discuss the word “consider” and the notion of (more) active MS before 
focusing more on the immune reconstitution (IR), defined as re-building of the immune system after 
a global depletion. Depletion of specific cell populations e.g. B cells, will not be addressed in detail. 
IR is what happens to the immune system when recovering from global depletion. Contemporary 
MS treatments relevant in this context are alemtuzumab, cladribine, and haematopoietic stem cell 
transplantation (HSCT). IR mechanisms are diverse and vary between treatments. Reconstitution after 
HSCT occurs by increased thymic output and naïve lymphocytes, while homeostatic proliferation with 
increased effector memory cells and a relatively reduced thymic output characterizes reconstitution 
after alemtuzumab. This explains the high frequency of secondary autoimmunity after alemtuzumab. 
IR has both positive and negative consequences. The latter include the risk of infections and second-
ary autoimmunity. Despite great hopes HSCT offers, there is no class I evidence for its efficacy and it 
is currently not recommended outside of properly designed trials in specialized centres. Cladribine, 
a “pulsed” IR offers promise but the mechanisms of IR and safety are not fully known. IR may be dan-
gerous in MS even without systemic immune suppression. Severe inflammatory rebound after stopping 
natalizumab or fingolimod can trigger IR inflammatory syndrome (IRIS). Indiscriminate offering of 
drastic immunosuppression followed by IR to any patient with more active disease should be avoided. 
Progressive multiple sclerosis patients have  
a higher burden of autonomic dysfunction compared  
to relapsing remitting phenotype
L. Crnosija1, I. Adamec1, A. Junakovic1, M. Krbot Skoric1, M. Habek1, 2
1Department of Neurology, UHC Zagreb, Croatia 
2School of Medicine, University of Zagreb, Croatia
Objective: To determine differences in autonomic dysfunction in patients with relapsing remitting 
multiple sclerosis (RRMS) and progressive MS (PMS). 
Material and methods: Valsalva maneuver, deep breathing test, and tilt-up test were performed in 
40 patients with RRMS (pwRRMS) and 30 patients with PMS (pwPMS), and results were expressed 
in the form of a Composite autonomic scoring scale (CASS). Additionally, heart rate variability (HRV) 
analysis was performed on the whole sample. 
Results: pwPMS had significantly higher adrenergic, cardiovagal, sudomotor indices and total CASS 
compared to pwRRMS (p = 0.029, p = 0.018, p= 0.001, and p = 0.001, respectively). Disease duration 
positively correlated with adrenergic, cardiovagal, sudomotor indices and total CASS (rs = 0.294, p = 
0.02; rs = 0.275, p = 0.027; rs = 0.409, p = 0.001 and rs = 0.472, p = 0.001, respectively), and Expanded 
Disability Status Scale (EDSS) positively correlated with cardiovagal and sudomotor indices and total 
CASS (rs = 0.264, p = 0.033; rs = 0.411, p = 0.001 and rs = 0.402, p = 0.001, respectively) in all the 
patients. Compared to pwRRMS, pwPMS had significantly lower SDNN, low frequency (LF), and high 
frequency (HF) during both supine and tilt-up phase (all p-values 0.006). There were no significant 
differences in LF/HF when supine, but pwPMS had significantly lower LF/HF (3.18 ± 2.63 vs. 5.65 
± 4.71, p = 0.008) and higher HF expressed in normalized units (HFnu) (34.37 ± 20.39 vs. 23.41 ± 
15.76, p = 0.021) during tilt-up. 
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Conclusions: pwPMS have a higher burden of autonomic dysfunction. Differences in the pattern 
of autonomic dysfunction have been found, with the greatest discrepancy in parasympathetic and su-
domotor function. Autonomic dysfunction in pwMS is in correlation with disease duration and EDSS. 
Should treatment be stopped in patients who had  
apparently inactive diseases for 5 years?
A. Czaplinski
Department of Neurology, Neurozemtrum Belleville, Switzerland
Effective DMTs are essential to guarantee the highest possible well-being to people with MS. For 
the same reason, there are circumstances in which ongoing DMT should or must be stopped to avoid 
that risk or costs overcome the benefits. There is a wide agreement that DMTs must be stopped in 
case of a serious adverse event potentially related to the drug, in patients becoming pregnant, and in 
subjects who are not adherent to treatment. In addition, some data and our practical experience may 
support the highly controversial concept of treatment cessation in patients with so-called “benign 
RRMS” seen in 5–10% of MS patients. Given the fact, that the label “benign multiple sclerosis” is often 
temporary as apparently benign disease often becomes disabling there is no general recommendation 
for stopping treatment. However, an individualized approach to the use of DMTs in MS patients with 
apparently inactive diseases should always be taken into consideration. On the other hand, growing 
evidence supports the notion that there may be a time in the disease course of some individuals with 
the initially relapsing disease when treatment with current DMTs can safely be stopped. MS patients 
who gradually accumulate irreversible disability without experiencing relapses and MRI inflammatory 
activity — i.e., have transitioned to the SP phase of the disease — most likely do not benefit signifi-
cantly from any of currently available DMT, which should be therefore discontinued in this group of 
subjects. In those patients, priority should be given to symptomatic treatment, physical therapy, and 
management of disability. 
Is bone marrow transplantation the ultimate  
treatment in aggressive disease? — Yes
M. Freedman
Medicine, University of Ottawa and the Ottawa Hospital Research Institute, Canada
Aggressive MS usually means continued, damaging disease that will cause severe and irreversible dis-
ability. The 2 most outstanding features of aggressive disease are the amount of damaging inflammation 
and the rapidity with which it occurs. All current therapies can be effective for many non-progressive 
forms of MS, but none have been able to completely stop all ongoing inflammation. Patients with the 
aggressive disease will often have tried and failed at least one of these therapies. With time being of 
essence, a full ablation of the immune system will remove the damaging autoimmune cells along with 
the rest of the immune system, thereby fully stopping the immune attack of the CNS. A new immune 
system derived from autologous stem cells is fully immunocompetent yet is immune tolerant of the 
CNS. The timing is key — interceding early enough before cumulative damage leads to unrelenting 
progression. Treatment-related morbidity and mortality is now well below 1%. 
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Is the central vein sign really helpful in differentiating MS 
from other white matter disease? — Host
M. Freedman
Medicine, University of Ottawa and the Ottawa Hospital Research Institute, Canada
MS cannot be diagnosed in the absence of clinical signs and symptoms of a typical demyelinating 
syndrome. However, there are many scenarios where signs and symptoms of disease are atypical and 
there is need of reliable ancillary tests to help secure an accurate diagnosis. The white matter appearance 
of MS lesions is not specific to MS and such changes can occur with numerous other entities, which 
can often lead to misdiagnosis. The pathology of an MS lesion is the hallmark perivenous inflamma-
tion. MRI is now sensitive enough to pick up the appearance of a vessel in the midst of a white matter 
lesion, especially using new MRI techniques such as SWI. How specific is the appearance of a “central 
vein” for a white matter lesion due to MS? Can it really lead to less misdiagnosis? How often do MS 
lesions lack the central vein sign? If sensitivity and specificity are really high, then why is it now not 
part of every standard MRI regimen for diagnosing MS?
Magnetization transfer ratio, fractional anisotropy,  
parallel and perpendicular diffusivity to evaluate  
multiple sclerosis plaques
E. Gonzalez-Toledo1, A. Thompson2, R. Williams3, H. Sun1
1Radiology, LSU School of Medicine, USA 
2NA, Booker T. Washington High School, USA 
3NA, Wiley College, USA
Introduction: Multiple sclerosis (MS) is a degenerative, immune-mediated disease of the central nerv-
ous system with demyelination and progressive atrophy. Magnetic resonance is the imaging modality of 
choice for diagnosis. Magnetization transfer is a sequence that can evaluate the lipoprotein content in 
the plaques. Diffusion tensor imaging is based on the measurements of water molecules following the 
white matter fibers. Fractional anisotropy measures nerve fiber integrity. Parallel diffusivity measures 
the axonal damage and perpendicular diffusivity, demyelination. 
Material and methods: We examined 12 patients, 4 men and 8 women, mean age of 39 yo (SD = 5) 
with a 1.5 T magnet. We measured magnetization transfer (MTR), fractional anisotropy (FA), parallel 
(PAD) and perpendicular diffusivity (PED) in Â 27 plaques and the adjacent normal tissue as control. 
We compared the relationship of values of MTR, FA, parallel, and perpendicular diffusivity using 
Spearman Correlation and we calculated the p-value to differentiate normal tissue from MS lesions. 
Results: Comparison between normal tissue and MS plaques showed significant correlation for p. 
Conclusion: Perpendicular diffusivity is related to myelin sheath and was the measurement that 
better correlated with magnetization transfer ratio. There was no correlation with fractional anisotropy 
and moderate correlation with parallel diffusivity. For these reasons measurement of perpendicular 
diffusivity can give an accurate picture of myelination. A and perpendicular diffusivity have a great 
probability to differentiate normal brain from lesions in multiple sclerosis (p = 0.1)
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Cognitive dysfunction is improved by MS specific  
disease modifying drugs (DMD) — Pro
A. Kalinowska
Department of Neurology, Division of Neurochemistry and Neuropathology, Poznan University of Medical Sciences, Poland
Cognitive impairment, although once underestimated, is now considered one of the key symptoms of 
multiple sclerosis (MS). It can occur as early as at the time of clinically isolated syndrome (CIS) (Amato 
et al. 2008). Disease-modifying drugs (DMDs) used for MS, especially when applied early in MS course, 
are likely to prevent and/or slow down disease progression. Therefore, we may expect that they will 
stabilize or even improve cognitive function, as well. Apart from the above-mentioned conclusion, the 
beneficial effect of DMDs on cognition in MS has been shown in several controlled studies. For instance, 
significant improvement in neuropsychological outcomes was shown for interferon beta-1B (Pliskin et 
al. 1996, Kappos et al. 2009), interferon beta-1A (Fischer et al. 2000), and stabilization occurred with 
glatiramer acetate (Schwid et al. 2007) and natalizumab (Weinstock-Guttman et al. 2012). Also, there is 
a number of uncontrolled trials supporting such notion. The challenge with assessing DMDs impact on 
cognition is that pivotal clinical trials did not use cognitive functions as primary endpoints, and where 
sometimes assessed only in subgroups of patients. Despite several methodological shortcomings, the 
evidence suggests that DMDs may have beneficial effects on cognitive functions. However, this could 
be secondary to effects on clinical parameters (i.e. relapses) (Patti 2012). Most likely, combining DMD 
with cognitive rehabilitation could provide even better response. 
MS is primarily an inflammatory disease with secondary 
neurodegeneration — Con
A. Kalinowska
Department of Neurology, Division of Neurochemistry and Neuropathology, Poznan University of Medical Sciences, Poland
Multiple sclerosis is a heterogeneous demyelinating disease of the central nervous system (CNS), 
with inflammatory and neurodegenerative components, typically causing relapses and remissions of 
diverse neurological symptoms, followed by accumulation of disability in patients. The exact patho-
mechanism of MS is not known. The predominant hypothesis assumes that the disease is primarily 
driven by myelin-autoreactive T cells, which are abnormally activated by environmental factors in 
immunologically susceptible subjects. It was supported by animal models, which have obvious limi-
tations in the human translation of data. However, the primarily inflammatory hypothesis has several 
flaws. Firstly, while all currently approved MS therapies are directed at the inflammatory component, 
none of them are definitive cures and the response to therapy is variable across the patient population. 
Also, if one assumes that axonal degeneration is a result of multifocal inflammatory response, then 
in primary progressive MS, where brain lesions are typically scarce, it is not plausible. This suggests 
that there is another pathomechanism leading to disease progression, which may be either primary 
neurodegeneration, or failure of neuroregeneration strategies. The main evidence for the primary role 
of degeneration in MS was provided by a neuropathological study by Barnett and Prineas (Annals of 
Neurology 2004). They showed that in newly forming symptomatic lesions there is extensive oligo-
dendrocyte apoptosis with activation of microglia, but few or no lymphocytic infiltrates or myelin 
phagocytes. Oligodendrocyte degeneration could lead to the liberation of autoantigens, resulting in 
a secondary immunological reaction, whose severity and course are dependent on the individual im-
munological profile of the patient. 
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Are MS therapies safe and effective in the elderly?
J. Kruja
Neurology, Faculty of Medicine, University of Medicine, Albania 
Neurology, UHC Mother Teresa, Albania
Multiple sclerosis (MS) is a chronic and disabling autoimmune disease with significant neurodegen-
erative and inflammatory components. The onset of the disease happens mainly between 20 and 40 
years. It was accepted that the natural history data of persons with MS reveal survival approximately 
38 years after diagnosis. The use of disease-modifying therapies (DMTs) influenced the longevity too, 
and approximately 90% of people with onset of MS in their 20s may live into their 70s (according 
to Hurwitz, 2011). On the other hand older patients present with increased medical complexity and 
decreased health-related quality of life (HRQOL) requiring a comprehensive and multidisciplinary 
approach and making the treatment choice more difficult. The main question in this condition is if we 
may continue to use the MS therapies in the elderly patients avoiding the side effects and the influence 
on other age-related diseases and one the other hand preserving their effectivity? Shall we continue 
for the lifetime the DMTs ore have we to interrupt the medications, if yes, when it is the better time 
and/or criteria to do it?
The only certain measure of the effectiveness of multiple 
sclerosis therapy is serum neurofilament level: host
J. Kuhle
Department of Neurology, University Hospital Basel, Switzerland
Neurofilaments are highly specific neuronal proteins. They have come closest to clinical application 
by their higher concentrations repeatedly demonstrated in cerebrospinal fluid (CSF) in all stages of 
MS, during relapses, their responsiveness to disease-modifying treatments in relapsing and progressive 
MS and their associations with measures of inflammatory and degenerative MRI outcomes. Digital 
single-molecule array (Simoa) technology improves the accuracy of bioassays in the quantification of 
neurofilament light chain (NfL) in serum and plasma. NfL marks a common final path of neuroaxonal 
injury independently of specific causal pathways. CSF and blood levels of NfL are highly correlated 
across various diseases including MS, suggesting that blood measurements likely are useful in assessing 
response to treatment and predicting future disease activity. Other biomarkers have not been studied 
to similar extent. Such measures, especially in blood, need further validation to enter the trial arena 
or clinical practice. 
Monoclonal antibodies to CGRP will not become first-line 
treatment for the prevention of migraine
C. Lampl
Headache Medical Center, Ordensklinikum Linz, Barmherzige Schwestern
Migraine is a very disabling disorder with severe impact on patients’ lives and substantiale costs to 
society in terms of healthcare costs and lost productivity. Prevention is a key component of migraine 
therapy. Numerous preventive options exist, however not been adequately applied to patient’s need-
ed. In the 2015 Global Burden of Disease Study, migraine was the seventh leading cause of disability 
globally and the leading neurological cause of disability, accounting for over half of the years lost to 
disability from all neurological disorders. These may indicate that there is a need for improved preven-
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tive treatments for migraine. Monoclonal antibodies against CGRP or its receptor are new promising 
therapies. They have a long half-life that makes them suitable for therapies requiring chronic activity 
such as migraine prevention and allows for less frequent dosing, e.g., once or twice monthly. Four 
monoclonal antibodies are currently in development for migraine prevention: three against CGRP 
itself: galcanezumab (LY2951742), eptinezumab (ALD403), and fremanezumab (TEV-48215) and one 
against the CGRP receptor erenumab (AMG-334). Initial safety and tolerability data from phase II trials 
appear excellent for the anti-CGRP monoclonal antibodies. However, there are some unknown facts 
to be discussed: Their long-term safety is entirely unknown at this time. The full range of CGRP’s 
physiologic functions is complex. CGRP is a potent vasodilator, and thus, a theoretical risk exists that 
CGRP blockade could hinder vasodilation in physiologically appropriate situations such as cardiac or 
cerebrovascular ischemia. Additionally, since antibodies have a relatively long half-life, any untoward 
effects could not be quickly reversed. CGRP receptors are found outside of the nervous and vascular 
systems, including in the adrenal glands, kidneys, pancreas, and bone. The effect of chronic CGRP 
antagonism on other organs is unknown. Their site of action in migraine prevention is unclear. The 
cost of treatment, once the monoclonal antibodies become commercially available, will certainly be 
high. In a healthcare system of limited resources, this cost will need to be balanced with the magnitude 
of benefit. An important group of patients, those that failed more than two preventive categories, was 
largely excluded from the trials, and thus, it is unknown what benefit this population would derive. 
Episodic vertigo can be a manifestation of migraine,  
at times, unaccompanied by headache
C. Lampl
Headache Medical Center, Ordensklinikum Linz, Barmherzige Schwestern
The manifestations of migraine-associated vertigo are quite varied and may include episodic true 
vertigo, positional vertigo, constant imbalance, movement-associated disequilibrium. Symptoms can 
occur before the onset of headache, during a headache, or, as is most common, during a headache-free 
interval. Consequently, many patients who experience migraines have vertigo or dizziness as the main 
symptom rather than headache. Although the definition of migraine-related vertigo and the continu-
um of the symptom complex remains poorly defined, the relationship is clearly more than a chance 
association. The clinical presentation of vestibular symptoms that often correlate with migraine in-
cludes — but is not limited to — dizziness, motion intolerance with respect to head, eyes, and/or body, 
spontaneous vertigo attacks (often accompanied by nausea and vomiting); diminished eye focus with 
photosensitivity; sound sensitivity and tinnitus; balance loss and ataxia, cervicalgia (neck pain) with 
associated muscle spasms in the upper cervical spine musculature. While migraine is often associated 
with benign recurrent vertigo of adults or paroxysmal vertigo of childhood, some migraine patients also 
present with true benign paroxysmal positional vertigo (BPPV) even after the migraine headache event 
has ceased. This is thought to be caused by a combination of vascular events along with an alteration 
of neural activity associated with the migraine event. Verapamil and amitriptyline are particularly 
useful because of their anticholinergic properties may help control vertigo independently of whether 
they are useful for migraine. 
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The only certain measure of the effectiveness of multiple 
sclerosis therapy is serum neurofilament level: host
D. Leppert
Novartis Pharma AG 
Department of Neurology, University Hospital Basel, Switzerland
Neuroaxonal damage is a hallmark of multiple sclerosis (MS) leading to brain atrophy, translating 
into progressive disability. Magnetic resonance imaging (MRI) is the current standard to quantitate 
brain atrophy but is retrospective by nature. There is a need for a real-time, easy to perform and less 
costly biomarkers to monitor disease course and drug response, both in clinical trials and in routine 
clinical practice. Neurofilament light chain (NfL) is a structural protein specific to neurons. Earlier 
studies were done in cerebrospinal fluid (CSF) and demonstrated that NfL levels are increased in MS 
and several neurological conditions that affect neuronal integrity. The recent advancement of assay 
sensitivity has now allowed measurement of NfL in serum and plasma to a degree that physiological 
levels in healthy subjects can be quantified, and a linear correlation between levels in serum and CSF 
has been demonstrated. In MS, a number of studies have shown that elevated NfL correlates with re-
lapse activity and long-term disability worsening. Moreover, NfL has been established as drug response 
marker. However, these results are derived from cross-sectional comparison between patient cohorts 
in clinical trials, and longitudinal evaluation in retrospective studies. The question is now whether (a) 
normative databases can be established, (b) the pharmacokinetics in CSF and blood can be elucidated 
and (c) cut-off values can be established as a premise for the use of NfL for evaluation of disease activity 
and therapeutic decision making in individual patients. 
In patients with clinical evidence of MS-like disease  
and a confirmatory MRI, CSF examination can  
be avoided in most cases
R.A. Linker 
Department of Neurology, University Hospital Erlangen
In the recent years, cerebrospinal fluid (CSF) examination for diagnostic work-up of relapsing-re-
mitting multiple sclerosis (RRMS) was only needed for delimitation of differential diagnoses. The 
2010 McDonald criteria for the diagnosis of RRMS were only based on clinical evidence and magnetic 
resonance imaging (MRI) data. In the 2010 McDonald revision, the presence of oligoclonal bands 
(OCB) in the CSF was only part of the criteria for primary progressive MS. Yet, recent data suggest 
that incorrect interpretation of non-specific white matter abnormalities is the most common reason 
for misdiagnosing RRMS. Thus, basing the diagnosis of MS solely on non-specific MRI lesions needs 
utmost caution. According to the recently published 2017 McDonald criteria, CSF examination may 
again help to establish the diagnosis of RRMS. In the setting of a first clinical demyelinating event 
and evidence for dissemination in space on MRI, the presence of OCB in the CSF may serve to prove 
the dissemination in time thus allowing for an earlier and at the same time still accurate diagnosis of 
RRMS. In the present discussion forum, we will tackle the question in which settings CSF analyses 
will allow for a faster diagnosis of RRMS. We will discuss which patients should definitely undergo 
CSF examination and whether the absence of OCB in the CSF excludes the diagnosis of MS. Finally, 
we will address whether it is sufficient to only examine OCB in the CSF work-up or if further, more 
sophisticated CSF parameters are also of interest. 
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In patients with clinical evidence of MS-like disease  
and confirmatory MRI, CSF examination can  
be avoided in most cases
J. Losy
Department of Clinical Neuroimmunology, Poznan University of Medical Sciences, Poland
Diagnosis of MS is based on careful clinical evaluation and MRI examination of the brain and spinal 
cord. An important role in final diagnosis and in differential diagnosis of MS plays the examination of 
cerebrospinal fluid. One of the most important results we look for examining CSF is the presence or 
absence of oligoclonal bands. Their presence in the CSF and not in serum reflects intrathecal immu-
noglobulin synthesis in the CNS. Oligoclonal bands are present in about 90% of patients with MS, but 
they are not specific for MS and may be also present in other neurological diseases. About 5–10% of 
patients with MS never show these CSF abnormalities. Therefore CSF analysis itself cannot confirm 
or rule out a diagnosis of MS and must be part of the total examination. According to the current 2017 
revisions of the McDonald criteria of MS, CSF examination is recommended when clinical and MRI 
evidence is insufficient to support a diagnosis of MS, when there is a presentation other than a typical 
clinically isolated syndrome, when clinical, imaging and other laboratory features are atypical of MS 
and in population in which MS is less common (e.g. children, older individuals) Can this examination 
be avoided in certain cases? According to 2017 criteria, CSF examination is not mandatory in unequiv-
ocal demonstration of DIS and DIT based on clinical and MRI data in absence of atypical clinical or 
imaging features or in patients with a typical clinically isolated syndrome supported by characteristic 
MRI findings. 
Second-line therapies should be first-line in patients  
with aggressive disease
J. Losy
Department of Clinical Neuroimmunology, Chair of Neurology, Poznan University of Medical Sciences, Poland
Disease modifying therapies approved for relapsing multiple sclerosis, which interfere with a variety 
of immunological mechanisms, reduce relapse rate, accumulation of disability and MRI activity. Most 
patients start with first-line therapy including interferon beta, glatiramer acetate, dimethyl fumarate 
or teriflunomide. In the case of treatment failure and breakthrough disease activity, second-line ther-
apy with more powerful drugs such as natalizumab, fingolimod or alemtuzumab are recommended. 
These drugs can also be chosen for highly active forms of the disease based on careful risk-benefit 
stratification. In subgroup analysis in patients with highly active MS, natalizumab reduced annual-
ized relapse rate by 81% (AFFIRM Study) and 76% (SENTINEL Study), as well as reduced the risk of 
disability progression sustained for 24 weeks by 64% (AFFIRM Study) and 58% (SENTINEL Study). In 
another study in 70 patients with highly active RRMS (at least 2 relapses and progression of disability 
of at least 1 point during the year before treatment, sustained for at least 6 months). After two years 
of natalizumab treatment 48% patients were free from disease activity. Post-hoc subgroup analysis of 
FREEDOMS study demonstrated that 0.5 mg fingolimod in rapidly evolving severe RRMS patients (at 
least 2 relapses in the year before baseline and at least 1 Gd+ lesion at baseline) reduced ARR by 67% 
versus placebo over 24 months (54% in the overall study population). Alemtuzumab is also highly 
effective medication and can be a good choice for therapy in aggressive MS. 
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Should we consider immune reconstitution for patients 
with more active MS?
J. Losy
Department of Clinical Neuroimmunology, Chair of Neurology, Poznan University of Medical Sciences, Poland
Currently we face two main approaches in MS therapy. One approach is chronic/maintenance 
therapy that is given continuously and adjusted to the progress and activity of the disease. Another 
approach and concept is immune reconstitution therapy (selective or non-selective) inducing immune 
reset with the potential for drug-free remission. In this approach such drugs like cladribine, alemtu-
zumab or ocrelizumab may be examples. Cladribine, purine nucleoside analogue, selectively depletes 
lymphocyte population. The results have shown that cladribine reduces relapse rate, progression of 
the disease and MRI activity. When administered in short pulsed course, delivered in two cycles. That 
generates long-lasting lymphopenia and maintained drug-free remission for additional years. The effects 
are greatest in patients with highly active disease, Cladribine is recommended by EMA in patients 
with highly active disease in whom the clinical benefits are bigger than risks of long-term lowering in 
lymphocyte numbers. Treatment with alemtuzumab, anti CD52 monoclonal antibody (two cycles of 
i.v. administrations), produces also lymphopenia immune reset and results in disease remission, which 
can extend beyond period of active treatment. Alemtuzumab is used as a second-line treatment and 
recommended as well in highly active, aggressive forms of MS. The anti CD-20 antibody, ocrelizumab, 
given every 24 weeks , produces selective depletion of a segment of B cell lineage and is effective in 
RRMS and beneficial in PP MS. HSCT (haematopoietic stem cell transplantation) shows that antigen 
receptor repertoire can be altered and is used in aggressive MS. 
Is the switch from ethical to generic  
drugs safe and justified? No!
R. Milo
Neurology, Barzilai Medical Center, Israel 
Faculty of Health Sciences, Ben-Gurion University of the Negev, Israel
As intellectual property protections are beginning to expire, cheaper generics for small molecule 
drugs (e.g. fingolimod), biosimilars for interferon-beta (IFN-b) and follow-on glatiramoids for the non-bi-
ologic complex drug (NBCD) glatiramer acetate (GA) are entering the vibrant market of MS therapies. 
In contrast to generics for small molecule drugs where only pharmaceutical equivalence and bioe-
quivalence are required for demonstrating therapeutic equivalence, the greater complexity of biologics 
and the possibility of structural modifications and differences in bioavailability and immunogenicity 
introduced by manufacturing differences make their comparability to their innovator products more 
difficult, and may result in unpredictable differences in efficacy or safety. These complexities and the 
lack of appropriate regulation in some parts of the world may explain why several IFN-b biosimilars 
failed to show therapeutic or biological equivalence to their innovator products. Therefore, additional 
preclinical testing and properly conducted clinical trials are needed and strict regulation is essential. 
The NBCD GA is a heterogeneous mixture of potentially millions of distinct, synthetic polypeptides, 
which presents even greater degree of complexity as no two glatiramoid mixtures prepared by dif-
ferent manufacturers can be shown to be “identical”. The innovative GA (Copaxone®) and several 
glatiramoids show some similarities using conventional methods, but also substantial differences in 
their physico-chemical properties, immunogenicity, gene expression, impact on biological pathways, 
safety profiles and most importantly — clinical efficacy. These differences should preclude their use as 
“generics” for GA, and call for more stringent regulations and carefully designed, comparative clinical 
trials to ensure the efficacy and safety of follow-on glatiramoids. 
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Progressive forms of MS respond to agents used  
for relapsing forms of the disease. Yes!
R. Milo
Neurology, Barzilai Medical Center, Israel 
Faculty of Health Sciences, Ben-Gurion University of the Negev, Israel
Several disease-modifying therapies (DMTs) used for the treatment of relapsing forms of MS (RMS) 
have shown some efficacy in progressive forms of the disease: Selective B-cell depletion using ocreli-
zumab consistently improved clinical and radiological measures of disease progression in primary-pro-
gressive (PP) MS patients, while rituximab was effective in a subgroup of younger PPMS patients with 
inflammatory lesions. Recently, the selective sphingosine-1-phosphate (S1P) modulator siponimod 
demonstrated positive effect on clinical and MRI measures in patients with secondary-progressive (SP) 
MS, suggesting beneficial effect of S1P receptor modulators in both RMS and SPMS. Treatment with 
several other MS drugs did not meet primary endpoints in clinical trials in PPMS or SPMS, however, 
beneficial effect was demonstrated in sub-groups of younger patients or those with more inflammatory 
disease characteristics, or on some other clinical and MRI endpoints. Inflammation and neurodegener-
ation co-exist in all stages and all forms of MS as part of a continuum, making the differences in these 
pathological traits more quantitative than qualitative. There is also evidence that inflammation drives 
neurodegeneration in MS, and that inflammation tends to be more sequestered and trapped within the 
central nervous system in the progressive forms of the disease. Thus, drugs used to treat RMS which 
target mainly inflammatory pathways may have an impact on inflammation and subsequent neuro-
degeneration in progressive MS, especially if they cross the blood-brain barrier. Moreover, most MS 
drugs have some effect on mechanisms involved in neurodegeneration, and may contribute to reduced 
brain damage and neuroprotection in progressive MS. 
Hydrodynamic hypothesis as an attempt to explain  
the Uhthoff’s phenomenon mechanism
P. Nogal1, J. Opara2
1Department of Ophthalmology, MV Sante Vision, Switzerland 
2Department of Clinical Rehabilitation, Jerzy Kukuczka Academy of Physical Education in Katowice, Poland
The worsening of visual symptoms caused by heat and physical exertion in Multiple Sclerosis (MS) 
has been described in 1890 by Uhthoff and named by him in 1961. This condition was to become known 
as Uhthoff`s phenomenon (Up) and was later found to be caused by a rise in body temperature. Over 
80% of MS patients develop a panoply of neurological signs during hyperthermia, 60% of which are 
“new” to that patient. There are few theoretical explanations of pathomechanism of this phenomenon 
which is still controversial, i.e. decreasing of conduction in demyelinated optical nerve, effects of 
serum calcium, blockade of ion channels, circulatory changes, heat shock proteins, hyperpolarization 
reduced by blocking electroneutral Na+ movement; and unidentified humoral substances. We would 
like to present our own original hydrodynamic hypothesis which is based on Bernoulli’s rule (1738) 
and the phenomenon of pressures equalization in the eyeball (intraocular and choroid blood pressure) 
in patients with arterial hypotension (Lauber 1936, Reese and McGavic 1942). This symptom could be 
intensified in MS patients in increased body temperature due to physiological blood circulation decen-
tralization, or in bleeding (for example menstruation); hypovolemia with decreased blood viscosity and 
density in reduced haematocrit. It creates a relative ocular hypertension with the intensified press on 
fundus with intraocular vessels, optic disc, and retinal nerve fibers. This causes secondary intracranial 
pressure increase, due to Bernoulli’s phenomenon related to the circulation of fluids between brain 
and eyeball, where obstructed intraocular flow determines an obstacle to a normal circulation in this 
hydraulic “cerebrophtalmic loop”. 
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Cognitive dysfunction is improved  
by disease modifying drugs
F. Paul
Clinical Neuroimmunology, Charitè Universitätsmedizin Berlin; NeuroCure Clinical Research Center, Germany
Cognitive dysfunction is a highly frequent symptom in people with multiple sclerosis (MS), prev-
alence rates of up to 70% are reported. Cognitive dysfunction may occur at disease onset but tends to 
increase in frequency as the disease advances. As current disease-modifying drugs (DMD) were aimed 
at reducing relapse rates and eventually disability progression when investigated in clinical trials, ev-
idence that these medications may beneficially influence cognitive function or may prevent cognitive 
decline over the course of the disease is meagre. Insights into effects of DMD on cognitive function 
mainly stem from open-label studies or post hoc analyses of exploratory endpoints in pivotal trials. This 
session will touch upon the controversial debate as to whether cognitive function can be influenced 
by DMDs and whether cognitive deterioration should trigger switch or escalation of immunotherapy. 
In patients with clinical evidence of MS-like disease  
activity and a confirmatory MRI CSF examination  
can be avoided in most cases — Con
U. Rot
Department of Neurology, University Medical Centre Ljubljana, Slovenia
CSF examination in suspected MS has an added value to the clinical and paraclinical evidence of 
dissemination in time and space because it reveals inflammatory nature of the disease. This is espe-
cially important in patients with early MS who often have cellular CSF and in patients with atypical 
clinical presentation. The novel, 2017 criteria for MS allow the diagnosis in patients with a first 
symptom (clinically isolated syndrome, CIS), positive CSF oligoclonal bands (OB) and MRI evidence 
of dissemination in space without evidence of dissemination in time. Enhancing lesions are seen in 
approximately 50% of patients with CIS. On the other hand evidence of dissemination in space is 
present in more than 70% and positive OB in 85% of CIS patient’s therefore early diagnosis of MS can 
now be made in a substantial proportion of CIS patients with the help of CSF. CSF findings also have 
prognostic information. For example, it was shown that OB-positive status predicted worse disability 
in patients with MS. Neurofilament light chain (Nfl) protein is integral part of axonal structure and is 
released in the CSF with axonal damage. Correspondingly increased levels of Nfl predicted relapses, 
disability progression, development of gadolinium-enhancing lesions and recovery after attack. In 
addition, markers of microglial activation (YKL-40) were also found to be associated with relapses and 
disability progression in patients with MS. 
Are MS therapies safe and effective in the elderly?
O. Stuve
Department of Neurology and Neurotherapeutics, University of Texas Southwestern Medical Center, USA 
Neurology Section, VA North Texas Health Care System, Medical Service, USA 
Department of Neurology, Klinikum rechts der Isar, Technische Universität München, Germany
A first-time diagnosis of MS is relatively uncommon during childhood and after age 50. Consequently, 
MS is widely considered a disease of young adults, and the diagnosis is most commonly established 
during the second or third decade of life between the age of 18 and 45. In this regard, MS is very simi-
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lar to other autoimmune diseases, including systemic lupus erythematosus, rheumatoid arthritis, and 
Sjögren’s syndrome. The mechanisms that confer relative disease resistance during childhood, early 
adolescence, and senescence are unknown. Clinically and pathologically, early inflammatory MS ap-
pears to be different from degenerative MS. In new, active lesions there is evidence of macrophage and 
lymphocyte infiltration, as well as endothelial activation. In contrast, old chronic-inactive plaques are 
often glial scars with decreased numbers of axons. Often, very few inflammatory cells can be detect-
ed. A recent histopathological study in elderly patients (median 76 years) with longstanding disease 
(median 372 months) found that inflammatory infiltrates declined to levels similar to those found in 
age-matched controls and the extent of axonal injury, too, was comparable with that in age-matched 
controls. Given that CNS inflammation and adaptive immune responses are diminished in elderly MS 
patients, it is not surprising that the efficacy of immunomodulatory or immunosuppressive agents can 
typically only be demonstrated in young or middle-aged recipients. In addition, due to the fact that 
adaptive immune responses in the elderly are altered and diminished, these agents may put elderly 
MS patients at greater risk for infectious and neoplastic complications. 
Is the switch from ethical to generic drugs safe  
and justified? — Pro
O. Stuve
Department of Neurology Neurotherapeutics, University of Texas Southwestern Medical Center, USA 
Neurology Section, VA North Texas Health Care System, Medical Service, USA 
Department of Neurology, Klinikum rechts der Isar, Technische Universität München, Germany
Numerous disease-modifying therapies (DMT are currently approved for the treatment of relaps-
ing-remitting multiple sclerosis (RRMS), and recently the first agent was approved for patients with 
primary-progressive MS (PPMS). Many of the recently approved molecules are the result of rationale 
drug design: They have a known molecular or cellular target, and their biological effects can be meas-
ured. Thus, generic versions of these agents can be tested for efficacy, safety, and other pharmacolog-
ical properties. Another question is whether the benefits of individual DMTs justify their enormous 
cost, or whether less expensive alternatives should be thought. The United States (US) Census Bureau 
reported that US inflation-adjusted median household income was $51,939 in 2013. The number of 
medically-related personal bankruptcies in the US is well above 50% of all filings. Families with health 
insurance reported average out-of-pocket medical expenses of $17,749, while uninsured individuals 
averaged $26,971. Patients with MS have the highest personal costs for medications of any chronic 
disorder assessed in a study funded by the Robert Wood Johnson Foundation: An average of $34,167 
per annum in 2009 when the price of DMTs was between $22,272 and $33,804. Prices have doubled or 
even tripled for some agents since 2009. With the increase in the number of treatments, the economics 
of competition that we were taught in economics 101 certainly does not hold true. We are currently 
unable to evaluate the merits of a less expensive approved DMT for less severe disease, as nearly all 
agents are priced similarly. 
 Is bone marrow transplantation the ultimate treatment  
in aggressive disease? — Con 
B. Weinshenker
Department of Neurology, Mayo Clinic, USA
Bone marrow transplantation is undoubtedly an effective and potent treatment that can be considered 
in patients with aggressive inflammatory forms of MS. However, the following are now indisputable: 
(1) It is not effective for progressive MS without ongoing inflammation; (2) It is not a cure, and reacti-
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vation of MS disease activity may occur in a sizeable proportion of patients who are followed 5 years 
following transplantation; (3) Some, albeit a low proportion of patients die of complications of this 
treatment; (4) Other non-transplantation-based pharmacotherapies are now available for MS that are 
likely safer, easier to administer, and approach the effectiveness of transplantation. While some may 
argue that more aggressive approaches to immunoablation might lead to even greater efficacy than 
current regimens, the trend in some institutions has been toward lesser toxicity with less aggressive 
treatment. Confident complete elimination of clones of autoreactive T-cells, especially in certain hard 
to eradicate locations in the nervous system, is not feasible with current methodology. Treatment may 
improve, but a new strategy that “guarantees” a high long-term remission rate is what is required before 
bone marrow transplantation may be considered the standard “the ultimate treatment” for any patients 
with MS, aggressive or otherwise. 
Are MS therapies safe and effective in elderly? — Yes
B. Weinstock-Guttman, K. Kavak, C. Vaughn
UB Neurology, Jacobs School of Medicine and Biomedical Sciences, Jacobs MS Center for Treatment and Research, USA
The average age of persons with multiple sclerosis (PwMS) is increasing worldwide. Improvements 
in treating the vascular comorbidities associated with aging as well as new available MS disease-mod-
ifying therapies (DMTs) contribute to more stable disease and to longevity. Recent estimates suggest 
that as much as 10–15% of PwMS are 65 years old. Aging PwMS are rarely included in clinical trials 
for DMTs. Approximately 30% of PwMS 65 years or older still have relapsing-remitting disease that is 
highly amenable to treatment. Furthermore, approximately 8% of PwMS present with very late-onset 
multiple sclerosis (VLOMS) acute onset after age 60 requiring treatment with DMTs. Older PwMS 
have a higher tolerance for DMT-related risks. To evaluate the effects of DMT discontinuation in 
aging PwMS, we extracted 135 participants from the New York State Multiple Sclerosis Consortium 
with stable disease who were at least 50 years of age and ≥ 15 years’ disease duration. Of these 35.6% 
worsened in EDSS after discontinuation (34.1% in patients 55 years and 37.7% in patients 55 years 
or older). Patients ≥ 50 who continued treatment with interferon beta or glatiramer acetate were no 
more likely to experience EDSS or Timed 25-Foot Walk (T25FW) worsening over time than patients 
50 years on same medications. Conclusion: Aging PwMS represent a challenge to the MS community. 
A stable disease course does not protect against disability progression after treatment discontinuation. 
Additional studies are needed to assess benefit and safety on use of DMTs in aging PwMS. 
Progressive forms of MS respond to agents used  
for relapsing forms of the disease — Con
R. Zivadinov
Buffalo Neuroimaging Analysis Center, Department of Neurology, Jacobs School of Medicine and Biomedical Sciences,  
University at Buffalo, State University of New York, USA 
Center for Biomedical Imaging at Clinical Translational Science Institute, University at Buffalo, State University of New York, USA
Multiple sclerosis (MS) is a chronic inflammatory demyelinating autoimmune disease of the cen-
tral nervous system. The pathogenesis of MS includes inflammatory and neurodegenerative disease 
processes that affect both white and gray matter. These pathogenic mechanisms underlie the relapsing 
and progressive course of MS. The majority of MS patients are diagnosed with relapsing MS that ex-
perience acute relapses with neuropathologic evidence of focal inflammatory demyelinating lesions 
within the brain and spinal cord, which are usually followed by remissions along with residual and 
escalating disability. A subset of patients (10–15%) is diagnosed as primary-progressive MS (PPMS) 
and manifest gradual disability and occasional plateaus, and are considered as a distinct subgroup. The 
prediction of long-term individual prognosis and conversion to progressive phase is not yet possible. 
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Because revised MS diagnostic criteria allow early diagnosis, most patients are starting disease-modi-
fying therapy (DMT) in an early phase of the disease. Currently, there are 16 approved MS DMTs, but 
their long-term benefits to conversion into progressive MS course remains unclear. At this time, it is 
also currently unknown whether progressive forms of MS respond to agents used for relapsing forms 
of the disease. Apart from the current insight in terms of peripheral T-cell activation and T-cell driven 
CNS auto-immunity, other additional immune cells may have bigger role in the disease initiation and 
propagation. Future studies should show whether, expanding our research observations towards more 
encompassing approach of the innate immune system, interplay between B- and T-cells may unravel 
new novel and potent DMTs for treating progressive MS. 
Is the central vein syndrome really helpful in  
differentiating MS from other white-matter disease? — Pro
R. Zivadinov
Buffalo Neuroimaging Analysis Center, Department of Neurology, Jacobs School of Medicine and Biomedical Sciences,  
University at Buffalo, State University of New York, Buffalo, USA 
Center for Biomedical Imaging at Clinical Translational Science Institute, University at Buffalo, USA
While the magnetic resonance imaging (MRI) has played a crucial role for diagnosing and moni-
toring of patients with multiple sclerosis (MS), the current MRI criteria for MS diagnosis still have 
imperfect sensitivity and specificity, and erroneously diagnosed cases are commonly encountered. 
Therefore, more accurate and pathologically specific MRI criteria are still needed to exclude other 
disorders that can mimic MS. Recently, the North American Imaging in Multiple Sclerosis (NAIMS) 
Cooperative proposed the “central vein sign” (CVS) as a novel MRI biomarker to improve the accuracy 
and speed of MS diagnosis. The evidence supports that the presence of the CVS in individual lesions 
can accurately differentiate MS from other diseases that mimic MS. The NAIMS consensus statement 
aims to provide recommendations for the definition, standardization, and evaluation of the CVS for the 
diagnosis of MS. However, many questions remain currently unanswered. The CVS predictive value 
for the development of clinical MS in patients with suspected demyelinating disease is still unknown. 
The lack of standardization for the definition and imaging of CVS currently limits its clinical imple-
mentation and validation. Large, prospective, multi-center trials including patients at first presentation 
of neurological signs are currently needed to evaluate the clinical value of the CVS for MS diagnosis. 
Until its diagnostic value has been formally established, care should be taken when using the CVS in 
routine clinical practice. 
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Can multiple sclerosis be reliably differentiated  
from isolated CNS lupus? — Pro
A. Kalinowska
Department of Neurology, Division of Neurochemistry and Neuropathology, Poznan University of Medical Sciences, Poland
Differentiation of systemic lupus erythematosus (SLE) from multiple sclerosis (MS) may pose a clinical 
challenge, especially when neuropsychiatric symptoms are accompanied by white matter lesions within 
the central nervous system (CNS). The clinical tools lack discriminative power. In MS the currently 
applied McDonald criteria are designed to confirm the diagnosis in subjects with high likelihood of 
MS and a typical clinical picture but are not designed as a differentiation tool. Anti-dsDNA antibodies, 
which are a hallmark of SLE, could be absent in neurolupus. In SLE nervous system is involved in 
up to 75% of patients. In 30–40% of neuropsychiatric SLE, neurological symptoms occur around the 
time of lupus diagnosis, so they can manifest as clinically isolated neurological syndrome (CIS) before 
other systemic manifestations occur. If CNS pathology in lupus is associated with anti-phospholipid 
(aPL) syndrome, then the diagnosis will be confirmed by aPL antibodies measurement. When they are 
absent, neuroradiological measures could aid in the reliable distinction between the two disorders. 
Firstly, lesion load is typically higher in MS, especially with longer disease duration, but this will 
be less helpful at disease onset. In this case, differentiation could be made based on MRI volumetric 
measurements. Brain volumetry shows different patterns of atrophy in MS, where it is present early 
(including CIS), and in SLE, where it should not appear until late stages of the disease. Once normative 
MRI data are established, we are likely to have a reliable tool in distinguishing SLE from MS, even 
early in the disease course. 
MS and isolated CNS SLE
I. Kurkowska-Jastrzebska
2nd Department of Neurology, Institute of Psychiatry and Neurology, Poland
An extremely important diagnostic problem for a neurologist is to distinguish multiple sclerosis 
from other demyelinating diseases. There are some biomarkers which may help us to differentiate be-
tween MS and other diseases, no one of them is, however, enough reliable to be a sufficient criterion 
of recognition or exclusion. Systemic lupus erythematosus (SLE) restricted to the CNS, presenting as 
a demyelinating syndrome and myelopathy are one of the examples that sometimes cause diagnostic 
problems and can be easily misdiagnosed with MS. The symptoms indicating possible SLE pathology 
in a patient with the first clinical demyelinating syndrome are known as “red flags”. Renal involvement, 
livedo reticularis, rash, arthritis, arthralgia, myalgia, headache, meningismus, seizures accompanying 
symptoms of demyelization should be considered as possible SLE. The various antibodies and proteins, 
and magnetic resonance imaging help also in proper diagnosis, however, some patients still need obser-
vation to make a final diagnosis. Here, we tried to answer a questions if we can properly differentiate 
isolated CNS-SLE from MS, if there is a necessity for considering SLE always when diagnose MS since 
SLE with CNS involvement is rare, what biomarkers we may rely on the most and if any older/novel 
biomarkers give hope for better understanding pathology and distinguishing of these two diseases. 
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Neuroinflammmation and neurodegeneration
J. Leszek
Department of Psychiatry, Wroclaw Medical University, Poland
Neuroinflammatory response is primarily a protective mechanism in the brain. However, excessive 
and chronic inflammatory responses can lead to deleterious effects involving immune cells, brain cells 
and signaling molecules. Neuroinflammation induces and accelerates pathogenesis of neurodegener-
ation disorders like Alzheimer’s disease (AD), Parkinson disease (PD) or Multiple sclerosis (MS). The 
sustained release of inflammatory mediators works to perpetuate the inflammatory cycle, activating 
additional microglia, promoting their proliferation, and resulting in further release of inflammatory 
factors. Interactions between activated glia and neurons around ABeta plaques maintain a chronic, 
self-sustaining inflammatory state in affected brain. Receptors of innate immunity participate in trig-
gering and driving inflammatory reactions. For example, Toll-like receptors(TLRs) and receptor for 
advanced glycation end product(RAGE), major receptors of innate immunity, play a central role in 
perpetuation of inflammation. Proinflammatory molecules,which are elevated in neurodegenerative 
diseases, can increase the expression of TLRs in CNS cells. RAGE activation should be perceived as 
a primary mechanism which determines self-perpetuated chronic inflammation, and RAGE cooperation 
with TLRs amplifies inflammatory signaling. In this presentation, I highlight and discuss that RAGE-TLR 
crosstalk emerges as an important driving force of chronic inflammation in neurodegeneration disorders 
like AD. It is important to emphasize that RAGE-TLR crosstalk may be considered as a potential target 
for the future treatments in neuroinflammatory diseases.
NMO immunosuppression should be withheld  
in pregnant patients
F. Paul
NeuroCure Clinical Research Center, Charité Universitätsmedizin Berlin, Germany
Neuromyelitis optica spectrum disorders (NMOSD) are severe autoimmune conditions of the CNS 
with the predominant affection of the optic nerve, spinal cord, and brain stem. In up to 80% of patients, 
serum antibodies to the astrocyte water channel aquaporin-4 are detected that are associated with an 
increased risk of recurrent disease following the first attack. Thus, immediate initiation of immuno-
suppressive treatment following the first attack is warranted in seropositive patients. As NMOSD also 
affect women in fertile age, the question how an NMOSD diagnosis impacts the course of a pregnancy 
and vice versa is raised by many female patients, including the critical issue as to whether immunosup-
pression should be stopped before or during pregnancy in light of the potential risks. This presentation 
will summarize current knowledge on course and complications of pregnancy in patients with NMOSD 
and provide arguments in favor of withholding immunosuppression in pregnant women. 
All pathology in NMO is AQP4-IgG  
and complement dependent
F. Paul
NeuroCure Clinical Research Center, Charité Universitätsmedizin, Berlin, Germany
Attacks in NMO are believed to result from binding of AQP4 to its target antigen, the astrocyte wa-
ter channel AQP4, with subsequent complement activation and other mechanisms leading to tissue 
damage and macroscopically visible NMO lesions. Drugs targeting complement activity have shown to 
significantly reduce relapse activity in NMO, further underscoring the role of complement in disease 
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pathogenesis and lesion formation. However, recently other players of the immune system such as 
neutrophils or T cells have been identified as contributing to lesion evolution, and not all lesions seem 
to be characterized by complement activation and tissue necrosis. This presentation will provide argu-
ments against a standalone role of complement and will shed light on additional disease mechanisms 
we are now beginning to understand.
All pathology in NMO is AQP4-IGG  
and complement dependent — Pro
B. Weinshenker
Department of Neurology, Mayo Clinic, USA
The pathology of lesions in neuromyelitis optica spectrum disorders (NMOSD) with aquaporin-4 
IgG has been shown to be necrotic with prominent antibody and complement activation, evidenced by 
C9neo antigen detection indicating terminal complement activation. While other pathologies are now 
reported in NMOSD, including diffuse non-lesional astrocyte hypertrophy, and non-lytic lesions without 
demyelination despite the loss of immunoreactive aquaporin-4 and inflammation, the significance of 
these pathologies remains unclear; they are not clearly associated with the cardinal manifestations of 
NMOSD, namely optic neuritis and myelitis. Whether or not there are cognitive, emotional or other 
behavioral phenomena in patients with NMOSD as a result of these pathologies is uncertain and the 
subject of ongoing study. Experimental models of passively induced NMO by transfer of pathogenic 
immunoglobulin into rodents clearly establish that in the absence of any one of AQP4 expression (AQP4 
knockout mice), AQP4-IgG (use of control IgG) and complement (failure to administer concomitant 
human complement), pathological changes cannot be produced. Selective complement depletion is 
highly effective in the prevention of NMOSD attacks. It would be more accurate to argue that “all acute 
attacks of optic neuritis and myelitis in NMOSD are likely AQP4-IgG and complement dependent”, but 
if these manifestations could be controlled by effective treatment, most patients and physicians would 
be pleased with the results and would consider that at least 90% of NMOSD has been vanquished. 
NMO immunosuppression should be withheld  
in pregnant patients — Con 
B. Weinshenker
Neurology, Mayo Clinic, USA
Traditionally, immunosuppressive medication has been withheld in patients with MS and many other 
autoimmune diseases because of potential teratogenic risks to the fetus and possibly because of additional 
risks to the mother who is already in a somewhat immunosuppressed state because of pregnancy. However, 
neuromyelitis optica spectrum disorders (NMOSD) are an exception, although not the only exception, to 
this general rule about the use of immunosuppressants during pregnancy. The principal target antigen 
of NMOSD, aquaporin-4, is expressed in placenta, especially in early pregnancy. A number of pregnan-
cy-related complications occur at significantly increased frequency in patients with NMOSD, such as 
spontaneous abortion and preeclampsia. While the risk of a relapse during pregnancy is reduced in MS, 
it does not seem to be the case in MS, and, as is the case for MS, the risk of relapse is greatly increased 
postpartum. Unlike MS where relapses tend to be mild and generally self-limited or easily treated with 
a brief course of corticosteroids, NMOSD attacks are often severe, leave permanent sequelae and may 
require complex treatments such as plasma exchange. Use of certain effective immunosuppressants such 
as azathioprine and rituximab that are widely used to prevent attacks of NMOSD appears to be relatively 
safe and well tolerated to mother and infant when administered either immediately before conception 
or continued throughout pregnancy. For these reasons, in patients with recently active NMOSD, immu-
nosuppression should be administered with either azathioprine or rituximab throughout pregnancy.
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Welcome remarks
U. Fiszer
Department of Neurology and Epileptology, Centre of Medical Postgraduate Education, Poland 
Committee of Neurological Sciences, Polish Academy of Sciences, Poland
The 12th World Congress on Controversies in Neurology offers a unique opportunity to welcome 
distinguished and well-known experts from all over the world, who kindly agreed to share their ex-
perience during this important meeting. We have noticed an unprecedented technological progress 
in diagnostics and therapy of numerous neurological diseases. Nevertheless, there is still a wide dis-
parity between what patients expect and what practicing neurologists consider as being adequate and 
available to provide in terms of services. In the future, the escalation in human lifespan will depend 
on healthier lifestyles and the availability of improved biomedical advances and biotechnologies. Here 
comes a valid question: would it correspond with the decrease of neurological cases in this popula-
tion? At the same time, one of the present major public health issues becomes obesity, which causes 
dyslipidemia, metabolic dysfunction, and inflammation. These changes could lead to neural death. 
Therefore, one should ask whether the dietary intervention in combination with physical exercise 
may be considered an effective therapy against neurological disorders? Another attention-drawing 
phenomenon concerns the bi-directional gut-brain-microbiota axis, which, if subjected to pathological 
changes, may increase the risk of other neurodegenerative diseases. The topics discussed during the 
Congress will focus on a number of contemporary controversial and unresolved issues in neurology. 
The fact that the 12th World Congress on Controversies in Neurology takes place in Warsaw, a city with 
a great history and remarkable tradition, but also tragic past — a city which is booming again — makes 
us here very pleased and proud. 
Challenges for neurology in the informatics era 
R. Frackowiak
Blue Brain Project, EPFL, Switzerland
The human brain is massively redundant in its organization. When brain systems are damaged, or 
when reinforced by learning mechanisms, they reorganize by strengthening synaptic connections, or by 
engaging new pathways or constituent brain regions. Can the mechanisms underpinning reorganization 
be enhanced or modulated? What is the implication for slowly progressive neurological disorders? 
Clinical scientists have deployed non-invasive functional imaging to examine such reorganization 
and better methods of detecting pre-clinical neuronal loss have been found recently. This work has 
paralleled methodological advances in MR imaging that reflect physical features of the brain quanti-
tatively. These techniques have been complemented by novel analysis methods that allow complex 
image classification and hence more sensitive and precise diagnoses. The eventual clinical ambition 
of the Human Brain Project is to link genetic and proteomic levels of brain organization with rules that 
govern the cellular segregation of protein expression. From protein expression rules that determine 
cellular morphology should predict connectivity and so on until a constructive process of predictive 
simulation discovers the mechanisms of emergent properties. In this way, we hope to define brain 
systems as interacting brain regions organized as behavior-specific modules. This framework provides 
a new approach to understanding mechanisms of compensation for neurodegeneration and the basis of 
functional plasticity at the mesoscopic level. I will describe these ideas with reference to pre-clinical 
states in conditions such as Alzheimer’s disease. Frackowiak RSJ, Markram H. (2015) the future of 
human cerebral cartography: a novel approach. Phil Trans R Soc; B 370: 20–32. 
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With the use of atypical neuroleptics, tardive syndromes 
have practically disappeared
P.J. Garcia Ruiz
Department of Neurology Fundacion Jimenez Diaz. Madrid. Spain, Garcia Ruiz Pedro J, Spain
Tardive syndrome including tardive dyskinesia (TD) is one of the most frequent side effects of 
neuroleptics. Over the last three decades, a number of so-called atypical neuroleptics have entered 
the clinical practice. These new atypical neuroleptics are characterized by predominant action upon 
serotonin rather than dopamine and theoretically they exert much less tardive syndromes compared 
with the classic neuroleptics. However and although the new antipsychotics are associated with less 
sedation and weight gain, they still are associated with tardive syndrome including the much feared 
tardive dystonia and the still frequent TD. In fact, recent epidemiological studies put into questions 
the apparent reduction in neuroleptics-related tardive syndrome. This controversy will review recent 
epidemiological and neuropharmacological data on the subject. 
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PARKINSON’S DISEASES AND OTHER 
MOVEMENT DISORDERS
Neuroimaging diagnostic workup in parkinsonian  
syndromes: always DAT SPET first: a joint debate with  
European Association of Nuclear Medicine (EANM)
J. Arbizu
Nuclear Medicine, University of Navarra Clinic, Spain
In recent years different neuroimaging biomarkers have been included in the clinical diagnostic 
criteria of neurodegenerative diseases. One of the possible explanations could be related to the remark-
able progress and advances undergone by imaging techniques in the last decade. Specifically, nuclear 
medicine molecular imaging, such as positron emission tomography (PET) or single photon emission 
computed tomography (SPECT). However, these techniques have largely contributed to our knowledge 
regarding the physiopathology of different neurodegenerative diseases, but also to diagnosis in the early 
phases of the disease, when structural changes are not yet evident. The diagnosis of neurodegenerative 
diseases presenting as a parkinsonian syndrome may be complex in the early phases due to the initial 
overlapping of symptoms between different diseases. Diagnostic accuracy improves with disease pro-
gression, when some atypical signs, incompatible with the diagnosis of idiopathic Parkinson’s disease 
(PD), become evident. In this scenario, the possibility of in vivo noninvasive imaging of the integrity 
of the dopaminergic nigrostriatal pathway, neuronal activity of the basal ganglia and cortex, as well 
as myocardial sympathetic innervation may be useful to complement the clinical diagnosis, thereby 
improving the specificity and facilitating decision making. This variety of molecular neuroimaging 
techniques with common objectives has resulted in some degree of controversy regarding the role of 
each technique. Consequently, it is necessary to define their use in the clinical diagnosis of patients 
with parkinsonian syndromes of uncertain origin. 
Real-time MR-guided gene therapy for Parkinson’s  
disease and AADC deficiency in children
K. Bankiewicz
Neurosurgery and Neurology, University of California San Francisco, USA
Gene transfer technology can correct genetic mutations in the brain. Neuro gene delivery via direct 
intraparenchymal injections of adeno-associated viral (AAV) vectors is a locally administered treatment 
that requires accurate delivery to maximize safety/efficacy. Gene therapy using adeno-associated virus 
(AAV2) carrying the amino acid decarboxylase (AADC) gene has the potential to improve the clinical 
response to levodopa when infused into the putamen of Parkinson’s patients (PD) or to generate dopa-
mine production in children with AADC gene mutation after administration to substantia nigra and 
ventral tegmental area. Neurotrophic factors hold great promise in the treatment of PD. Prior clinical 
trials have shown possible benefit but may have been limited by inadequate anatomical vector delivery 
or off-target vector distribution. Using intraoperative MRI and co-infusing the vector with gadoteridol 
allows real-time visualization of infusions. The infusion strategy evolved during the trial to maximize 
anatomical coverage. Analysis of bilateral MR-guided putaminal infusions of over 30 PD patients and 
3 children with AADC deficiency in ongoing Phase Ib/2 clinical trials were performed. In both PD and 
AADC, deficient children AADC gene transfer significantly increased clinical outcome as manifested 
by 4 hrs. increases in ON time in PD patients at 12 months and increase of motor performance and 
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reduction or elimination of oculomotor crises in AADC-deficient children. PET with (18FDOPA) de-
tected expression (AADC trials) and effects of gene therapy (GDNF). These results show that advances 
in surgical techniques have markedly improved vector delivery and that AAV2-AADC has strong ther-
apeutic potential in both indications presented here. 
Is PD a prion disease? — Yes
E. Bezard
Institute of Neurodegenerative Diseases, University of Bordeaux, France
Parkinson’s disease is characterized by the presence of Lewy Bodies that are intraneuronal protein-
aceous cytoplasmic inclusions and by severe neuronal losses in several brain regions associated with 
deposits of aggregated proteins. Synuclein has been identified as a major protein component of Lewy 
Bodies and heavily implicated in the pathogenesis of Parkinson’s disease. In the past few years, evidence 
has emerged to explain how this aggregate-prone protein can undergo spontaneous self-aggregation, 
propagate from cell to cell, and mediate neurotoxicity. Current research now indicates that oligomeric 
forms are probably the toxic species. Such peculiar behaviour of misfolded oligomeric Synuclein has 
led to the proposal that it might actually behave as a prion. The speaker will review some of the data 
in favour of such hypothesis without neglecting alternate explanations. 
The etiology of sporadic Parkinson’s disease
A. Friedman
Department of Neurology, Medical University of Warsaw, Poland
The role of genetics in familial Parkinsonism is well known. There is no question that the known 
and also unknown mutations cause the symptoms in the affected individuals. The situation in sporadic 
Parkinsonism is much less clear. Some studies suggest that the main role in etiology play environmen-
tal factors, either through nose or gut. On the other hand, it is known that patients with the sporadic 
disease more often than the control subjects have in their families other subjects with the symptoms of 
Parkinson’s disease. Does it mean that the sporadic cases are also genetic? Is this related only to a kind 
of susceptibility that is genetic dependent? Or maybe the genetics has no role whatsoever in sporadic 
Parkinson’s disease? The answers to these questions are the base of our debate. 
Parkinson Disease (PD) with lysosome dysfunction  
and PD associated with mitochondrial dysfunction  
are different diseases
N. Galvez-Jimenez
Neurology, Cleveland Clinic Lerner College of Medicine and the Wertheim College of Medicine, USA
There is evidence for neuronal cell organelle failure, as causing PD. This is not new, however, as 
early work on the understanding of this complex disorder was that of dopamine-producing nigral cell 
dysfunction. Since its original description, evidence has accrued supporting mitochondria and/or lys-
osomes as contributors for apoptosis. There is evidence linking PD as a consequence of autophagy-lys-
osomes pathways (ALP) and ubiquitin-proteasome system (UPS) failure. Alpha-synuclein is widely 
distributed in brain tissue and the accumulation and clumping of such protein has been found widely 
distributed in PD, Lewy body disease, Alzheimer’s disease and others. Hence, ALP failure results in 
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accumulation of unwanted toxic-synuclein containing proteins, furthering inhibition of ALP function 
by binding tightly to the receptor on the lysosomal membrane, enhancing neuronal cell degradation. 
This complex and toxic intra-neuronal cell environment affects mitochondrial function with activation 
of the instrumental mitochondrial-dependent apoptosis. Current evidence suggests many different mor-
phological types of cell death co-existing in the PD brain, some induced by mitochondria programmed 
dependent cell death and other independent processes resulting in necrosis. Linking the consequences 
of these two organelle failure is of utmost importance for furthering the understanding of neuro-de-
generation via mitochondrial oxidative stress, accumulation of oxidized dopamine species, reduced 
glucocerebrosidase enzymatic activity, lysosomal dysfunction and alpha-synuclein accumulation. It 
has been suggested dopamine abnormal oxidation links mitochondrial and lysosomal dysfunction in 
PD. Today we will ask ourselves if there is a unifying theory or if PD differs when due to lysosomal 
dysfunction versus mitochondrial dysfunction. 
Parkinson’s disease is not genetic (in most cases)
D. Goldstein
Clinical Neurocardiology Section, National Institute of Neurological Disorders and Stroke, NIH, USA
In 1997 A53T mutation of the gene encoding alpha-synuclein was found to cause PD in a rare kindred 
with autosomal dominantly transmitted PD. In the same year, Lewy bodies, a pathologic hallmark of 
PD, were reported to contain abundant alpha-synuclein. Since then several genome-wide association 
studies have confirmed an association of alpha-synuclein genetic variants with PD, and about 20 rare 
genetic forms of PD have been described. Most PD patients, however, have no family history of PD, 
and in those with a family history, there is no identified genetic abnormality. Post-encephalitic PD was 
common in people who contracted von Economo’s encephalitis in the early 20th century, and Japanese 
encephalitis, the leading cause of viral encephalitis currently in Southeast Asia, is also associated with 
later development of parkinsonism. 1-Methyl-4-phenyl-1, 2,3,6-tetrahydropyridine evokes immediate, 
permanent parkinsonism, and environmental exposures to pesticides and heavy metals increase PD 
risk. The concept has emerged recently of PD resulting from autotoxic effects of products of oxidation 
of dopamine such as 3,4-dihydroxyphenylacetaldehyde (DOPAL). No genetic animal model reproduces 
the drastic putamen dopamine depletion that characterizes PD. Moreover, it is now known that PD 
entails marked myocardial norepinephrine deficiency, and whether genetic animal models have this 
abnormality has not been explored. At this point, it seems most likely that PD is rarely genetic. Instead, 
relatively common genetic changes may bias toward the development of PD, but for the disease to be 
expressed may require interactions of genetics with aging, environmental exposures, and auto toxicity. 
The heart of Lewy body diseases is the heart
D. Goldstein
Clinical Neurocardiology Section, National Institute of Neurological Disorders and Stroke, NIH, USA
Lewy body diseases such as Parkinson’s disease (PD) and dementia with Lewy bodies (DLB) feature 
depletion of the catecholamine, dopamine, in the nigrostriatal system — especially in the putamen. Many 
in vivo neuroimaging and several indirect post-mortem immunohistological studies have indicated that 
Lewy body diseases also entail severe loss of cardiac sympathetic noradrenergic nerves. Here we tested 
directly whether Lewy body diseases are associated with myocardial norepinephrine deficiency. We 
simultaneously assayed apical myocardial concentrations of norepinephrine, dopamine (from which 
norepinephrine is synthesized in storage vesicles in sympathetic nerves), and 3,4-dihydroxyphenylglycol 
(DHPG, the main neuronal metabolite of norepinephrine) in patients with autopsy-proven Lewy body 
diseases (PD, DLB, or pure autonomic failure) and in control subjects. Compared to controls, Lewy body 
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disease patients had a 96% mean decrease in tissue norepinephrine content (p = 0.0001), accompa-
nied by a 90% mean decrease in dopamine (p = 0.0001) and an 89% decrease in DHPG (p = 0.0001). 
The results demonstrate drastic cardiac norepinephrine deficiency in Lewy body diseases, establishing 
these conditions as neurocardiologic disorders. 
REM sleep behavior disorder should be considered  
as a precursor and marker of synucleinopathies  
and promote therapeutic intervention
T. Gurevich
Movement Disorders Unit, Neurological Institute, Tel Aviv Medical Center, Sackler School of Medicine,  
Sagol School of Neuroscience, Tel Aviv University, Israel
Initially, REM sleep behavior disorder (RBD) was felt to be an idiopathic clinical entity. Revolutionary 
observation of Schenck et al in 1996 that individuals initially diagnosed with RBD eventually developed 
Parkinson’s disease (PD) paved the way to the long line of research that demonstrated that idiopathic 
RBD represents the premotor stage of PD and other alpha-synucleinopathies, which is going along with 
the Braak’s theory of rostral propagation of neurodegeneration beginning in the brainstem. Synuclein-
opathy was found to be the underlying pathology on the autopsy of 94% of RBD patients in the largest 
pathological study. Longitudinal cohort studies have shown that up to 90% of patients with RBD are 
eventually diagnosed with PD, dementia with Lewy bodies, or multiple system atrophy. The majority 
of idiopathic RBD patients meet the criteria for prodromal PD and possess additional biomarkers of 
synucleinopathy. In view of the fact that RBD is the earliest known symptom of neurodegeneration 
and carries a pronounced risk of full-blown clinical syndrome of synucleinopathy development, along 
with the evidence that disease-modifying interventions may be more successful if applied at the earliest 
stage of disease, therapeutic interventions must be implemented during the stage of idiopathic RBD 
(prodromal alpha-synucleinopathy), before irreversible damage appears. As Dr. James Parkinson noted, 
“It is obvious, that the chance of obtaining relief will depend in a great measure on the period at which 
the means are employed. As in every other disease, so here, the earlier the remedies are resorted to, 
the greater will be the probability of success”. 
Parkinson’s disease associated with lysosome  
dysfunction is a different disease from that  
associated with mitophagy dysfunction
J. Hardy
Department of Molecular Neuroscience, UCL Institute of Neurology, UK
In this debate, I will argue that typical Parksin’s disease is generally associated with problems with 
lysosomal function. This disease is associated with Lewy bodies. In contrast, much early-onset disease, 
which has a more restricted clinical picture, largely occurs without Lewy Bodies, is associated with 
deficits in mitophagy. This disease used to be called Autosomal Recessive Juvenile Parkinsonism. I will 
suggest that, as the original nomenclature suggests, these are generally different disease. However, 
I will acknowledge that it is not possible to cleanly separate either the etiologies or pathologies of these 
diseases and will discuss what the purpose of naming diseases is.
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Is Braak staging true for all Parkinson disease?
K. Jellinger
Institute of Clinical Neurobiology, Institute of Clinical Neurobiology, Vienna, Austria, Austria
Braak et al. [1] proposed that cases with Lewy pathology (LP) in peripheral nervous system, spinal 
cord, and brain stem should be considered as prodromal Parkinson disease (PD), suggesting a hypoth-
esized progression of PD pathology. While most studies assessing typical PD cases show that the vast 
majority (80–100%) fit the Braak staging scheme, a number of pathological studies argue against it. 
People with incidental Lewy body disease and PD can show LP in SN or other brain areas without the 
involvement of the DMV [2]. The Braak staging is mainly valid for PD patients with young onset, long 
duration and predominant motor symptoms, but not for others, e.g., late onset and rapid course PD 
[3]. 10–15% of PD cases that are associated with genetic mutations show a pattern of LP that is quite 
distinct from that of idiopathic PD, fitting the Braak staging scheme [4]. The hypothesized cell-to-cell 
transmission [5] for PD has produced a paradigm shift in research into the propagation of the majority 
of late-life neurodegenerative conditions. In view of the currently discussed “prion-like” spreading of 
pathologic a-synuclein, the validity of Braak staging of LP and its relationship to neurodegeneration 
in various subtypes of PD warrants further study. 
R E F E R E N C E S
1. Braak H, et al., Neurobiol Aging 2003; 24: 197–211.
2. Jellinger KA, Biochim Biophys Acta 2009; 1792: 730–740.
3. Rietdijk CD, et al., Front Neurol 2017; 8: 37.
4. Surmeier DJ, et al., Nat Rev Neurosci 2017; 18: 101–113.
5. Braak H, Del Tredici K, J Parkinsons Dis 2017; 7: S73–S87. 
Is PD a prion disease? — Con
A. Korczyn
Tel-Aviv University Medical School, Israel
The idea that neurodegenerative diseases are actually prion disorders has been spread uncritically. 
The main support for this theory comes from laboratory experiments which are prone to artifacts. The 
clinical evidence is meager and not convincing.
As far as PD is concerned, it is unclear which alpha-synuclein species is the presumed villain, is 
involved only in cell-to-cell transmission or is the same species also neurotoxic, and why it has cell 
specificity.
In any case, there is a critical difference between transmissible and transmitted.
Is PD more common in patients with ET? — Con
D. Koziorowski
Department of Neurology, Medical University of Warsaw, Poland
Essential tremor (ET) is one of the most common diseases in the world. Parkinson’s disease (PD) is 
the second most common neurodegenerative disease in the world. The prevalence of both diseases 
increases with age. There are no case-control studies, to my knowledge, that demonstrated the higher 
occurrence of PD in patients with ET. Neuropathologically, both diseases are completely different. PD 
is a typical neurodegenerative disorder with well-known pathology with synuclein inclusions. The 
neuropathology of ET is not strictly neurodegenerative and affects a different brain area (cerebellum) 
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and has a different pathology (torpedo incisions). Most PD cases are sporadic. The genetic basis of PD 
occurs in about 10% of patients. We have many genes, mutations that are responsible for the monogenic 
forms of PD. In many cases of ET family history is common, but there are no certain genes that would 
be associated with typical mendelian forms of the disease. Clinical manifestation includes completely 
different symptoms. Parkinson’s disease is a complex syndrome and in some cases, tremor does not 
occur at all. On the other hand, position and kinetic tremor are axial symptoms of ET. The coexistence 
of both diseases is high due to their prevalence. However, there is not enough epidemiological evidence 
to determine whether a prior diagnosis of PD was more prevalent in the ET cases. Neuropathology, 
genetics, and symptomatology do not show the relationship between these disorders. 
With the use of atypical neuroleptics, tardive syndromes 
have practically disappeared 
J. Kulisevsky
Movement Disorders Unit, Neurology Department, Sant Pau Hospital, Autonomous University of Barcelona, Universitat Oberta de Catalonia, Spain
Tardive syndromes (TS) remain a prevalent and potentially irreversible motor complication of chronic 
dopamine-receptor blocking agents (DR-BA). It occurs most commonly associated with antipsychotics 
but can present with other DR-BA used as antiemetics or prokinetics. The most common TS is “tardive 
dyskinesia” (TD). Diagnosis of TS is clinical and is typically made in people who have taken DR-BA 
for at least three months and have characteristic abnormal purposeless, rapid, repetitive, stereotypic, 
involuntary movements affecting the tongue, lips, face, trunk, and extremities. TD occurs in > 20% 
of people who use first generation antipsychotics (FGA) continually for > 3 months, and every year 
about 5% of those who continually use these drugs begin to show signs of TD. After the introduction of 
clozapine and a number of other second generation antipsychotics (SGA) (like olanzapine, quetiapine, 
risperidone, ziprasidone), evidence suggests that patients treated with these drugs have less risk for 
developing TS than those treated with FGA like haloperidol. Available evidence indicates that the use 
of SGA reduces the cumulative risk for TD by one-third or that SGA has a decreased annual liability of 
TD (1% vs 5% for FGA). A recent Meta-Analysis (Carbon 2017) disclosed a global mean TD prevalence 
of 25.3% across 41 selected studies with significantly lower rates with SGA (20%) vs FGA treatment 
(30%). A particular low TD prevalence (7.2%) was found in the treatment arms with FGA-naive sub-
jects, relative to SGA-treated cohorts with likely prior FGA exposure (p < 0.001). 
Vagotomy: a clue to the pathogenesis of PD?
M. Lew, A. Jocson
Department of Neurology, Division of Movement Disorders, Keck/University of Southern California (USC) School of Medicine, USA
Gastrointestinal dysfunction is a common prodromal non-motor symptom of Parkinson’s disease. 
Studies reveal pathologic aggregates of GI tract a-synuclein may exist many years prior to clinically evi-
dent PD. The Braack hypothesis entails that a-synuclein pathology arises in the enteric nervous system 
and progresses retrograde to the CNS. A-synuclein fibrils have the capacity for antero- and retrograde 
transport along the vagus nerve and aggregates have been detected in the dorsal motor nucleus of the 
vagus (DMV) in rats injected in the duodenum with a-synuclein. Mice models with gastric exposure to 
rotenone showed a-synuclein aggregation with secondary spread to the CNS. Hemivagotomy not only 
prevented abnormal protein accumulation in the DMV of these animals but also prevented neuronal death 
in the ipsilateral SNpc. These models suggest that vagotomy may diminish a pathway of introduction for 
peripheral a-synuclein transport and modify the risk/pathogenesis of PD. In Danish and Swedish cohorts, 
PD risk in truncal vagotomy patients versus the general population was lower compared to matched 
controls. Neither study, however, met statistical significance. The Swedish study reported lost decrease 
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in risk 20 years from vagotomy. The PD index rate for truncal vagotomy patients was statistically signifi-
cantly lower after 20 years in the Danish study. Interestingly, for both studies, there was a higher risk for 
PD in selective vagotomy patients. Conflicting data clearly exist. This will fuel a lively debate regarding 
whether vagotomy modifies the pathogenesis and subsequent risk of developing PD. 
Is Braak staging true for all Parkinson’s diseases?
A. Ludolph
Neurology, University of Ulm, Germany
Parkinson’s disease was defined clinically by James Parkinson in 1817. One hundred years later, 
Lewy described the morphological hallmark of Parkinson’s disease, the Lewy body. During the recent 
20 years, attempts are being made to (re)classify Parkinson’s disease by genetic means. This con-
troversy is concerned with the definition of Parkinson’s disease; is it defined clinically, is it defined 
neuroanatomically/neuropathologically or is its definition genetic? It is still accepted since Charcot 
that a neurological disease is defined by the famous clinical neuroanatomical relation. Therefore the 
gold standard remains that a clinical disease is mirrored by its neuropathology and neuroanatomy. 
Therefore, the question whether Braak staging is true for all Parkinson’s disease must be answered by 
Charcot’s and Lewy’s definition — with a clear-cut yes. However, the question remains, whether all 
genetic forms which are associated with a Parkinsonian syndrome do reflect Parkinson’s disease as 
defined by James Parkinson and Lewy. I will make the argument, that this is not the case in a number of 
mutations. It is clear, that some autopsies from patients with specific genetic mutations and associated 
with clinical PD or Parkinsonism do not show the typical features of Braak staging. However, in my 
view, this means that these mutations are not associated with Parkinson’s disease and Lewy’s concept 
and therefore they are associated with a Parkinsonian syndrome and consequently do not reflect the 
entity PD, but rather a similar, but unrelated entity. 
Neuroimaging diagnostic workup in Parkinsonian  
syndromes: always DAT SPECT first — Con
S. Morbelli
Nuclear Medicine, San Martino University Hospital, University of Genoa, Italy
Dopamine Transporter (DAT) SPECT with [123I]FP-CIT is by far the most widely used radiotracer to 
image nigrostriatal pathway in Europe. The assessment of the integrity of the nigrostriatal dopaminergic 
pathway with DAT SPECT has been approved by the FDA and the EMA both for the differential diagnosis 
between parkinsonian syndromes (PK) on one side and essential tremor or non-neurodegenerative PK on 
the other side as well as between DLB and AD. However the in the era of diagnosis in preclinical stages 
and with the increasing attention devoted to atypical parkinsonism, new individualized flowcharts need 
to be implemented for the use of molecular imaging in PK in specific settings. In this framework two 
tracers able to explore other (extra-dopaminergic) pathways might be used, even before DAT SPECT, 
to support the clinical diagnosis in patients with PK. In recent years it was demonstrated that the di-
agnostic accuracy of ¹⁸F-FDG-PET for discriminating PD/DLB from atypical PK is considerably higher 
with respect to ¹²³I-IBZM-SPECT, a post-synaptic D2-receptor imaging modality, previously proposed 
in this setting (notably each PK shows a peculiar pattern of hypometabolism). Several new perspectives 
have also been provided on the use of cardiac 123I-MIBG imaging in the evaluation of prodromal DLB 
and premotor PD. Finally, a recent prospective longitudinal study compared the diagnostic accuracy of 
DAT SPECT and MIBG scintigraphy, concluding that MIBG method appears to be reliable and accurate 
for excluding non DLB dementias, avoiding over-diagnosis, especially when parkinsonism is the only 
core feature exhibited by the patient. 
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Is PD more common in patients with essential tremor?
R. Pahwa
Neurology, University of Kansas Medical Center, USA
Parkinson’s disease (PD) is a neurodegenerative disorder whose prevalence increases with aging. 
Essential tremor (ET) is the most common movement disorder and its prevalence is greater than five 
times of PD. Although ET can start at any age, it often begins more disabling with advancing age. El-
derly patients often develop mild parkinsonian features secondary to aging or they may also develop 
other parkinsonian disorders like PD. The gold standard for diagnosis these conditions continue to be 
clinical criteria. Although these are two exclusive movement disorders, due to overlapping features 
between the two conditions there is continuing controversy if ET is a risk factor for the development 
of PD. Since ET is considered a genetic disorder, ET patients and their family are concerned about the 
risks of developing PD in the future. In this session, the speakers will debate this controversial topic. 
Animal models are useful in understanding  
PD pathogenesis — Pro
B.O. Popescu
Department of Clinical Neurosciences, “Carol Davila” University of Medicine and Pharmacy, Romania 
Laboratory of Molecular Biology, “Victor Babes” National Institute of Pathology, Romania 
Department of Neurology, Colentina Clinical Hospital, Romania 
Parkinson’s disease (PD) is the second most frequent neurodegenerative disease, characterized by 
the slow spread of alpha-synuclein pathology over decades and a multitude of motor and non-motor 
clinical signs. As in other neurodegenerative disorders, data from experimental studies in classical 
animal models for PD did not translate into similar results in PD patients. One of the main limitations 
of the PD models is targeting solely dopaminergic neurons, therefore not being able to reproduce the 
complex pathological aspects of PD, including non-motor degeneration. However, from each such mod-
el, valid pieces of information can be integrated in our understanding of PD pathogenesis. Moreover, 
the current development of new animal models, such as alpha-synuclein expressing models, seems 
to be much closer to PD pathological scenario as compared to classical lesion-based models, and will 
probably add more valuable information in future. 
Is vagotomy protective against PD?
I. Rektorova
Movement Disorders Centre, First Department of Neurology, Faculty of Medicine and St. Anne’s University Hospital, Brno, Czech Republic, 
Central European Institute of Technology, CEITEC MU, Masaryk University, Brno, Czech Republic
The a-syn has the propensity for spontaneous misfolding and displays prion-like properties in vitro, 
including cell-to-cell propagation. Animal studies showed both retro- and anterograde axonal trans-
port of a-syn fibrils in the vagal nerve. However, so far we lack formal evidence that similar prion-like 
spreading occurs in human PD patients. 
If the vagal nerve constitutes a major highway for centripetal spreading of a-syn pathology, it follows 
that vagotomy could be protective against PD. Three principal types of vagotomy have been employed: 
full truncal vagotomy; selective vagotomy where only vagal branches to the stomach are cut, and the 
most refined superselective vagotomy, where only the corpus and fundus is denervated. When the 
stomach of mice was exposed to the neurotoxin rotenone, a-syn aggregation and subsequent spreading 
to the brain stem via the vagus has been demonstrated. Both partial sympathectomy and hemivagotomy 
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significantly delayed the development of motor symptoms in the animals. Moreover, hemivagotomy 
prevented accumulation of a-syn in the ipsilateral dorsal motor nucleus of vagus (DMV) and prevented 
cell death in the ipsilateral substantia nigra pars compacta (SNc). Nowadays, data from two recent epi-
demiological studies suggest and provide some preliminary evidence that the truncal vagotomy might 
decrease the risk of PD after > 5 years of follow-up when compared with the background population, 
and also when compared with the selective/super-selective vagotomy group. 
REM sleep behavior disorder (RBD) should be considered 
as a precursor and marker for alpha-synucleinopathies 
and promote therapeutic intervention
I. Rektorova
Movement Disorders Centre, First Department of Neurology, Faculty of Medicine and St. Anne’s University Hospital, Brno, Czech Republic, 
Central European Institutes of Technology, CEITEC MU, Masaryk University, Brno, Czech Republic
Rapid eye movement sleep behaviour disorder (RBD) is characterized by dream enactment and com-
plex motor behaviours during rapid eye movement (REM) sleep and loss of normal REM sleep muscle 
atonia during polysomnography. The prevalence of idiopathic RBD (iRBD) was previously estimated to 
be between 0.38% and 0.5% within the general population; probable RBD (without polysomnographic 
confirmation) is likely even more frequent, affecting 5–6.8% of the older general population after age 
60–70 years. Postmortem evidence shows that some RBD patients have degeneration within the areas 
that control REM sleep and have Lewy bodies and neurites in these areas (synucleinopathy was the 
underlying pathology in 94% of autopsied patients in the largest multicenter autopsy series of RBD). 
Therefore, it seems most likely that RBD is caused by synucleinopathic degeneration. Consistent with 
early neurodegeneration, patients with RBD demonstrate subtle motor, cognitive, and autonomic 
impairments. Approximately 50% of patients with spontaneous RBD will convert to a parkinsonian 
disorder within a decade. Ultimately, nearly all (81–90%) patients with RBD develop a neurodegen-
erative disorder. Among patients with Parkinson’s disease, RBD predicts a non-tremor-predominant 
subtype, gait freezing, and an aggressive clinical course. RBD arises from degeneration of the circuits 
that control healthy REM sleep and the more classic motor and cognitive symptoms associated with 
synucleinopathies develop as degeneration spreads rostrally into the brain structures that control these 
behaviors. Although this idea remains speculative, it nonetheless fits well with Braak’s classic staging 
model of Parkinson’s disease pathogenesis, which proposes that neurodegeneration starts in the brain 
stem before ascending rostrally. Neuro-protective strategies for targeting a-synuclein in RBD could be 
beneficial in slowing or even halting the progression of synucleinopathies. 
Is PD more common in patients with ET? — Pro
J. Slawek
Department of Neurology, Neurological-Psychiatric Nursing Department, Medical University of Gdansk, Poland 
Department of Neurology, St. Adalbert Hospital, Copernicus, Poland
Both Essential tremor (ET) and Parkinson’s Disease (PD) are common, especially in the elderly and 
may be misdiagnosed. Several epidemiological studies suggest that ET is linked to PD, increasing its 
lifelong risk 4–5-fold (LaRoia& Louis 2011). ET is no longer considered a benign disorder (many pa-
tients present parkinsonian, cognitive symptoms, cerebellar pathology), with increased risk for PD and 
Alzheimer’s Disease. Comparing the risk of atypical parkinsonism and PD in prior ET patients — it was 
more prevalent in PD (7.1 vs 2.4%) (Louis&Frucht 2007), confirmed by others (Tan et al. 2008), with 
3 years follow-up (Benito-Leon et al., 2009). There are several clinical overlapping features suggesting 
a common pathophysiology. Both may present action and rest tremor, the latter observed in 30% of ET 
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patients. Developing PD the rest tremor starts on dominating side of ET (Thenganatt&Jankovic 2016). 
The substantial number of patients may present both ET-PD phenotype with bradykinesia, olfactory 
deficits and mild dopaminergic deficit on DAT imaging. Benign tremoulous parkinsonism may represent 
this overlap. Incidental Lewy bodies were observed in locus ceruleus in 24.2% of ET brains (Louis et 
al., 2007). The most recent publication showed Lewy bodies in 25% of ET cases, which was higher 
than in controls (Choe et al., 2016). Genetic studies demonstrated links between ET and PD (LINGO1 
and its paralog LINGO2) (Vilarino-Guell et al., 2010), and also the association between a known PD 
risk variant, LRRK2 R1628P, with ET. Subjects carrying the R1628P variant had twice the risk of de-
veloping ET (Chao et al., 2015).
Measuring self-conscious emotions (self-disgust, shame 
and guilt) in patients with Parkinson’s disease (PD)
M. Tsatali1, M. Tsolaki2, P. Overton3, A. Vivas4
1Psychology Department, 1International Faculty of the University of Sheffield, City College, Greece 
21st Department of Neurology, Medical school, Aristotle University of Thessaloniki, Greece 
3Department of Psychology, The University of Sheffield, UK 
4Psychology Department, International Faculty of the University of Sheffield, City College, Greece
In considering PD patients’ emotion recognition and expression deficits in basic emotions, little is 
known about their self-conscious emotions like self-disgust, shame and guilt. In the current study, the 
goal was to measure whether the two groups (PD patients and controls) differ in the aforementioned 
emotions. Forty-five (45) PD patients and 45 matched Healthy Controls (HC) were recruited. Specifically, 
participants completed the Self-Disgust Scale (Overton et al. 2008) and TOSCA (Test of Self-Conscious 
Affect, which measures shame and guilt) scales. A 2 × 3 MANOVA was conducted to test whether 
self-conscious emotions differed between the two groups as measured by scales administered. Results 
showed that self-disgust, as well as shame levels, were increased in PD patients as compared to the 
control group (p= 0.002). Levels of guilt were also higher in PD patients; however, this increase was not 
significant. Additionally, a 2 × 3 MANCOVA, with the HADS depressive scores as a covariate variable, 
was also conducted to identify whether the main effect of group was still significant after controlling for 
depression scores. After controlling for depression, PD and HC differed significantly only on self-disgust 
levels (p = 0.027). Overall, according to the findings of the current study, PD patients seem to have 
higher levels of trait self-conscious emotions when compared to HC and this result seems to be more 
robust for self-disgust. Further analysis will shed light on the other factors affecting the relationship 
between PD and self-conscious emotions. 
Neuroimaging diagnostic workup in Parkinsonian  
syndromes: always DAT SPECT first? — Pro 
E. Van de Giessen
Neuroimaging Committee, European Association of Nuclear Medicine, Netherlands 
Radiology and Nuclear Medicine, Academic Medical Center, Netherlands
Imaging of dopamine transporters (DAT) in the striatum in the brain using single photon emission 
tomography (SPECT) is a well-established method to distinguish neurodegenerative from non-neurode-
generative parkinsonism’s. In neurodegenerative parkinsonism’s the dopaminergic cells with projections 
to the striatum degenerate, resulting in a decline of dopamine transporters and loss of signal on the 
SPECT scan. It is a useful clinical tool that can detect neurodegeneration early in the disease process. 
Therewith it is often a good first step to help the clinician in the diagnostic process, e.g. to answer 
the question whether a patient has essential tremor or suffers from neurodegenerative Parkinsonism. 
During this session, the advantages and limitations of DAT SPECT will be discussed, including scan 
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technique, analysis method, correlation with clinical measures, and suitability for particular clinical 
questions, costs, and possibility to use the method for follow-up. 
Animal models are useful in understanding  
PD pathogenesis
L. Vecsei
Department of Neurology, Faculty of Medicine, Albert-Szent-Györgyi Clinical Center, University of Szeged and MTA-SZTE Neuroscience Research Group, 
Hungary
Parkinson’s disease (PD) is the second most common neurodegenerative disease after Alzheimer’s 
disease. Nigrostriatal dopaminergic neurodegeneration is shared with other parkinsonian disorders: 
including some genetic forms of Parkinsonism, but many of these disorders do not have Lewy bodies. 
An ideal animal model of PD should exhibit age-dependent and progressive dopaminergic neurode-
generation, motor dysfunction, and abnormal alpha-synuclein pathology. Mitochondrial oxidative 
phosphorylation, autophagy-lysosomal metabolism, ubiquitin-proteasome protein degradation, and 
endoplasmatic reticulum stress/unfolded protein response are impaired cellular functions in PD (Jiang 
and Dickson 2018). Many rodent models have been developed to investigate PD using genetic or tox-
in-based strategies, but all have significant limitations. On the other hand, there are several promising 
therapeutic agents for the treatment of PD. Therefore we need much better models of the disease 
(Majláth et al. 2016, Török et al. 2016, Chen et al. 2017, Tronci and Francado 2018, Francado 2018). 
REM sleep behavior disorder (RBD) should be considered 
as a precursor and marker for alpha-synucleinopathies 
and promote therapeutic intervention — Con
L. Vecsei
Department of Neurology, Faculty of Medicine, Albert-Szent-Györgyi Clinical Center, University of Szeged  
and MTA-SZTE Neuroscience Research Group, Hungary
Much interest has arisen around the association between RBD and a group of neurodegenerative 
diseases involving abnormal aggregation of the protein alpha-synuclein, comprising Parkinson’s disease 
(PD), multiple system atrophy (MSA), dementia with Lewy bodies (DLB), and pure autonomic failure 
(PAF) collectively termed „the synucleinopathies”. Recently, it was published that excessive daytime 
sleepiness predicts neurodegeneration in idiopathic RBD. The Movement Disorder Society (MDS) has 
proposed a set of the research criteria for prodromal PD, which specified RBD as the most predictive 
prodromal marker with the highest likelihood ratio. Thus, there is increasing attention on searching 
the biomarkers that might predict the progression of RBD toward PD, such as olfactory loss, color 
vision deficit, depression and mild cognitive impairment. Clinical data suggest that isolated RBD in 
middle-aged and older adults could herald future synuclein-related neurodegeneration, dignifying it 
as an early marker of later degeneration. However, in some other studies, the presence of autonomic 
dysfunction does not seem to either predict or be associated with further neurodegeneration. RBD 
should be considered part of a broader spectrum of neurodegeneration, in line with the proposed 
Braak’s staging model of synucleopathies, in which central and peripheral autonomic degeneration is 
predicted to occur at the earliest stages. Recent findings focus on alpha-synuclein aggregation inhibitors 
and their therapeutic role, with special attention to heat shock proteins, immunotherapy (active and 
passive), the potential of targeting the Ser129 phosphorylation site, and the antibiotic possibilities. 
Some controversies of RBD in clinical practice will be discussed. 
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Clinical genetics of tauopathies
Z. Wszolek
Neurology, Mayo Clinic Florida, USA
A discovery of MAPT gene mutations in 1998 opened the road to understanding of pathophysiolog-
ical implications of tauopathies. The list of tauopathies is growing and includes progressive supranu-
clear palsy, corticobasal degeneration, Pick disease, chronic traumatic encephalopathy, globular glial 
tauopathy, argyrophilic grain disease, primary age-related tauopathies, and frontotemporal dementia 
with Parkinsonism linked to chromosome 17. Alzheimer disease, the most common neurodegenerative 
disorder is considered to be both amyloidopathy and tauopathy. Many of the newer tauopathies can 
be diagnosed only on pathological grounds. Some of them are clearly the genetic disorders usually 
transmitted in autosomal dominant fashion. As a matter of fact the younger the symptomatic disease 
onset is, the higher the chance that this tauopathy is of inherited form. Interestingly in about a half of 
autopsied LRRK2 gene mutation carriers, the tau pathology is present. The LRRK2 Parkinson disease 
(PD) is the most common form of genetic PD described so far. The carriers of LRRK2 mutations usually 
clinically present with classic PD phenotype, and their illness is usually well responsive to medical 
and surgical therapies utilized in PD. During my lecture, I will discuss the clinical presentations of 
common tauopathies and their genetic forms.  
The etiology of Parkinson disease  
is predominantly genetic — Pro
Z. Wszolek
Neurology, Mayo Clinic Florida, USA
I would argue that in almost all cases of Parkinson disease (PD), there is a genetic background. In 
some cases, the genetic factors are very strong and lead to the development of the first symptoms very 
early in life. The earlier symptomatic disease onset of PD, the more likely it is that the pathogenic 
variant will be found in genes already known to be associated with PD. In such cases, the targeted 
clinical genetic testing could be very rewarding. If there is also a positive family history of PD in other 
family members, and if they are willing to provide the blood or saliva specimens, the exome sequenc-
ing might be successfully utilized and even more cost-effective than targeted clinical genetic testing. 
Eventually, whole genome sequencing will be the method of choice to establish the precise genetic 
causation of PD for the cases with positive family history or with early symptomatic disease onset. But 
even for sporadic cases such genetic testing might be very much considered for possible participation 
in clinical trials. Such clinical trials might be specifically devised to recruit the research subjects with 
known genetic mutation status. The PD genome-wide association studies albeit not so helpful for the 
immediate translational utility also demonstrated the presence of multiple genetic risk factors contrib-
uting to the etiology of PD. We are only at the beginning of our understanding of the genetic nature of 
PD. In near future, a novel genes associated with PD undoubtedly will be identified. 
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REHABILITATION
Is vagotomy protective against PD? — No
A. Benazzouz
Institut des Maladies Neurodégénératives, Univ. de Bordeaux, France
Parkinson’s disease is the second most common neurodegenerative disorder after Alzheimer dis-
ease. It is characterized by the manifestation of motor symptoms, attributed to the degeneration of 
dopamine neurons in the pars compacta of substantia nigra and fibers in the striatum. The majority 
of drug treatments of Parkinson’s disease focus on replacing and mimicking the effects of dopamine to 
improve symptoms. However, they cannot delay or stop the disease progression. Several experimental 
studies focused on the use of strategies to prevent or block the degeneration of dopamine neurons; 
however, even if they worked in animal models, they have aborted in Parkinsonian patients. One of 
the hypotheses for the etiology of Parkinson’s disease is that a neurotropic pathogen enters the brain 
by a nasal and/or gastric route by axonal transport through the vagal nerve. From experimental animal 
models, it has been shown that alpha-synuclein forms can be transmitted to the brain from the gut 
and that vagotomy, which is a surgical procedure in which the vagus nerve is resected, can eliminate 
transport of pathological proteins from the gut to the central nervous system. Hence, Vagotomy can 
be a very interesting approach to prevent cell death and the development of Parkinson’s disease. This 
hypothesis is supported by some epidemiologic studies showing that truncal vagotomy conferred a pro-
tective effect on subsequent Parkinson’s disease risk, whereas super selective vagotomy was associated 
with a minor or no protective effect. However, the number of studies is limited and no causal effect 
has been demonstrated until now. 
Treatment of a rare fatal disease with common  
symptoms: Tafamidis for TTR-FAP
A. Dori
Neurology Department, Sheba Medical Center, Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel
Transthyretin (TTR) amyloidosis (ATTR) is a devastating hereditary disease which affects multiple 
organs including the peripheral nerves, gastrointestinal tract, and heart, and is fatal within approxi-
mately 10 years. Mutations in the TTR protein destabilize its tetrameric structure, leading to its disso-
ciation into monomers that misfolded and aggregate into toxic amyloid deposits in tissues. TTR is the 
major carrier of thyroxine in rodents’ blood, but in humans, the thyroxine binding sites are virtually 
unoccupied. In vitro studies revealed that thyroxine binding to TTR resulted in its stabilization. This 
launched the search for a nontoxic compound, which could bind the TTR-thyroxine-binding site, and 
development of Tafamidis. This new medicine selectively binds and stabilizes wild-type and mutant 
TTR and halts the amyloidogenic cascade initiated by tetramer dissociation. However, early treatment 
is crucial for effective prevention of disease progression. TTR familial amyloid polyneuropathy (FAP) 
is a rare disorder, which presents with common peripheral and autonomic neuropathy and non-dis-
ease specific symptoms. Therefore, in the absence of ATTR family history, correct diagnosis is often 
delayed, limiting effective treatment. “Red-flag” symptom clusters were therefor highlighted to identify 
these patients. TTR-FAP should be suspected if a progressive peripheral sensory or sensory-motor 
neuropathy is observed in combination with one or more of the following: family history of ATTR, 
autonomic dysfunction, cardiac hypertrophy, gastrointestinal disturbances, unexplained weight loss, 
carpal tunnel syndrome, renal impairment, or ocular involvement. In suspected cases, confirmation 
by transthyretin genotyping and identification of amyloid in tissue biopsy direct early initiation of 
pharmacologic treatment. 
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Clinical phenomenology of TTR Neuropathy
J. Finsteter
Kar Messeri-Institute, Austria
Transthyretin-related (TTR) familial amyloid polyneuropathy (FAP), also known as hereditary amyloid 
TTR-FAP (ATTR-FAP), is an autosomal-dominant, adult-onset, rare; either isolated hereditary neuropa-
thy or associated with multisystem involvement. TTR-FAP is characterized by irreversible, progressive, 
and persistent peripheral nerve damage. TTR-FAP is due to mutations in the TTR gene, of which the 
most frequent is p. Val30Met. Mutations in the TTR gene lead to destabilization and dissociation of 
TTR tetramers into variant TTR monomers, resulting in the formation of amyloid fibrils, which are 
consecutively deposited in various tissues including the peripheral nerves. Deposition of amyloid in 
the peripheral nerves leads to sensory-motor and autonomic neuropathy and several non-neuropathy 
specific abnormalities. Types of TTR variants, age at onset, penetrance, and clinical presentation at-
tributable to a specific mutation may vary between countries. Phenotypic and genetic variability and 
non-disease-specific symptoms often delay diagnosis and lead to misdiagnosis. Suggestive of a TTR-FAP 
are the polyneuropathy, the positive family history, and autonomic dysfunction with gastrointestinal 
disturbances, cardiac involvement, carpal tunnel syndrome, unexplained weight loss, and resistance 
to immunotherapy. If only sensory A-delta or C-fibers are affected, small fiber neuropathy ensues and 
may represent a diagnostic challenge. Diagnostic tests for small fiber neuropathy include determina-
tion of epidermal nerve fiber density, laser-evoked potentials, heat- and cold-detection thresholds, and 
measurement of the electrochemical skin conductance. Pharmacotherapy with tafamidis, a TTR-stabi-
lizing agent, can be highly effective if started early in the disease course. Another therapeutic option, 
particularly in countries where tafamidis is not yet approved is liver transplantation. 
Is physiotherapy helpful in functional motor disorders?
N. Galvez-Jimenez
Department of Neurology, Cleveland Clinic Lerner College of Medicine, USA
Traditionally speaking, disorders of motor control have as predominant underlying pathophysiology 
alterations of the basal ganglia function, connectivity, genetics and/or failure of the normal pallidal 
frequency-firing pattern among others. However, functional motor disorders also known as psycho-
genic movement disorders have a yet unknown underlying unifying pathophysiology in the context of 
patients having a variety of psychiatric and other co-morbid conditions. The traditional view is that of 
a person suffering from psychogenic movement disorders is that who has anxiety, depression, bipolar 
conditions, fibromyalgia, history of sexual abuse, prior traumatic events including local injury among 
many other causes singly and/or in various combinations. The findings on examination are those of 
distractibility, entrainability, give-away or false weakness, induction of movement by non-physiologic 
interventions, variable and inconsistent findings out of proportion on the neurological examination. 
The lack of unifying pathophysiology and/or psychological theory coupled with the complexity of the 
milieu/context in which these disorders occur results in treatments which are extremely challenging 
for some and best fraught with frustrating/poor outcomes and shortcomings for others. Physiotherapy 
has been used by many during the rehabilitation planning with special attention in retraining and 
focusing in basal ganglia and cognitive functions, control attention, focusing on function rather than 
impaired movement and in some cases coupled with supportive psychological therapy, casting of limbs 
and pharmacotherapy including the use of botulinum toxin therapy. We will be discussing opposing 
points of view on this complex condition in search for proper therapy. Therefore asked today: Is phys-
iotherapy helpful in functional motor disorders?
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Is Tai Chi effective in the management  
of Parkinson’s disease?
A. Milert
Department of Physiotherapy, University of Physical Education in Krakow, Poland
Complex movement disorders of patients with Parkinson’s disease (PD) require comprehensive and 
multi-directional health enhancement procedures. Besides current methods of physiotherapy adapted 
to the stages of PD, the forms of exercises until recently considered unconventional are gradually in-
cluded. Among others, these include Tai Chi derived from Traditional Chinese Medicine (TCM). Tai Chi 
is based on natural, smooth, harmonious movements of the trunk and limbs combined with physical 
and mental relaxation. This form of exercise has been practiced for many centuries among the elderly 
in China — for preventive and therapeutic purposes. Clinical studies conducted so far confirm the 
beneficial effects of Tai Chi on improving balance, coordination, muscle strength, gait and reducing 
the risk of falls of the elderly. The presentation will include the main assumptions of Tai Chi practice 
and conclusions from the review of the current scientific literature regarding the effectiveness of Tai 
Chi of patients with PD. The results of the research on the impact of Tai Chi on muscle strength, body 
posture, spatio-temporal gait parameters, balance, and coordination will be discussed. Methodological 
guidelines for individual and group Tai Chi exercises of PD patients will also be presented, depending 
on the stage of the disease. Due to the growing popularity of this form of movement among the elderly as 
well as the lack of reports of adverse impact on the practitioners, it is worth encouraging the inclusion 
of Tai Chi as an attractive, complementary form of therapy for traditional methods of physiotherapy. 
The importance of rehabilitation therapy for clients  
with paralysis due to the conversion reaction
A. Ohry
Rehabilitation Medicine, Reuth Medical Center, Tel Aviv, and Sackler Faculty of Medicine, Israel
For the rehabilitation medicine community, comprehensive therapy approach towards clients with 
paralysis due to somatoform disorder is the logical and self-evident fact. Medicine and psychiatry could 
not find a definite cure for these syndromes. The model that we had developed, was reported in the 
literature and is significantly beneficial for at least 50% in our clinical experience. It is mandatory to 
include in our team approach, members who belong to the behavioral and mental professions. 
Is physiotherapy helpful in functional motor disorders?
T. Simuni
Neurology, Northwestern University, USA
Functional motor disorders (FMD) refer to weakness or movement disorders that are genuine but 
do not relate to an underlying neurological disease. FMDs are responsible for up to 16% of referrals to 
neurology outpatient clinics and are among the top five reasons for referrals. Despite high prevalence, 
the etiology and pathogenesis of FMDs remain obscure. FMD treatment is challenging and overall prog-
nosis has been poor. However, over the last couple years, there has been progress in standardization 
of treatment approaches. Psychotherapy including cognitive behavioral therapy has been used though 
there are limited published data. Comprehensive rehabilitation strategies including physical, occupa-
tional therapies in conjunction with the motor retraining have been increasingly utilized. Consensus 
recommendations for physical therapy of FMDs have been published in 2014. Despite that progress, 
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a small number of intense physiotherapy trials demonstrated beneficial outcome compared to standard 
of care. Long-term data on maintenance of effect are still missing. Future treatment approaches for FMD 
will be based on better understanding of the pathophysiology of the condition. In this debate format 
presentation, the speakers will present the current data, pros, cones and knowledge gaps on the role 
of rehabilitation approaches for management of FMDs. 
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STROKE
The role of phagocytes in brain repair  
after cerebrovascular crisis
J. Aronowski 
Roy M. and Phyllis Gough Huffington Chair in Neurology, University of Texas Health Science Center, McGovern Medical School, Department of Neurology, 
Houston, Texas, USA
Shortly after the onset of intracerebral hemorrhage (ICH), brain tissue macrophages (microglia) are 
activated and assume their healing or damaging phenotype depending on the environmental cues. This 
early event is followed by infiltration of masses of polymorphonuclear neutrophils (PMNs) followed 
by monocytes/macrophages, a process that can often last for days or weeks. PMNs and macrophages, 
similar to microglia can be modified by various signaling events to assume either injurious or bene-
ficial (anti-inflammatory, phagocytic, anti-oxidative and trophic) phenotype, a process that could be 
instrumental in establishing the efficacy of repair of ICH-affected brain. Over the years, we have learned 
that the healing (assisting in repair) phenotype of these phagocytic cells can be achieved by targeting 
specific cellular processes regulation function of these cells. We showed that some of these approaches 
demonstrate robust efficacy in animals’ models of ICH and some of them are currently evaluated in 
clinical trials in patients with ICH. 
The role of the brain microcirculation in acute stroke
O. Bajenaru 
University of Medicine and Pharmacy “Carol Davila” Bucharest, Romania
The clinical consequences of an ischemic stroke are determined by the localization and extent of the 
loss of brain tissue. The ischemic loss of the brain tissue is a direct consequence of the impossibility 
of normal metabolic changes, in particular, oxygen and glucose supply from the vessels to the brain, at 
the level of the blood-brain barrier, which normal integrity and functionality are mainly dependent to 
the integrity of the brain microcirculation. The disruption of the microvascular compartment during 
and after an acute ischemic event is not the same in all patients with a similar occlusion of a cerebral 
artery, in terms of caliber and location; the differences are determined by many other factors, among 
endothelial dysfunction, the presence of previous vascular risk factors, the development of collateral 
circulation, the time duration since the initial occlusion of the artery are most important. These events 
at the level of the microcirculation are the key-elements which allow or not the reperfusion of the brain 
tissue in the ischemic area, even if the therapeutic interventions are performed in therapeutic window. 
Understanding the role of the brain microcirculation during the acute ischemic stroke is essential to 
understand the no-reflow phenomenon, the risk of hemorrhagic transformation and other clinical 
relevant problems related to the failure of the most performant actual acute reperfusion therapies. 
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Should we perform left atrial appendage closure in all  
patients with high risk of stroke and atrial fibrillation  
who can not take oral anticoagulants? — No
D. Bereczki
Department of Neurology, Semmelweis University, Hungary
About 15–20% of all strokes can be attributed to cardioembolism due to atrial fibrillation (AF). In the 
majority of such cases, the left atrial appendage (LAA) is the source of the embolus. Oral anticoagulation 
is recommended by current guidelines to decrease stroke risk in those with AF. Oral anticoagulation, 
however, is contraindicated in some patients, mainly in those with high risk of bleeding. Difficulties 
in adjusting treatment and low compliance may also affect the benefit of oral anticoagulation. Surgical 
excision of the LAA is an option to decrease stroke risk, but thoracotomy and the intervention itself 
have their certain risks and complications. Implantation of an LAA occluder device via the femoral vein 
and transseptal passage is a new method of LAA exclusion from the circulation. Anatomical variation 
of the LAA and strict methodological requirements during implantation of the LAA closure device 
are certainly challenges for the interventionalist. Serious complications were reported in 2–9% in the 
periprocedural period, some of them like cardiac perforation and tamponade, thromboembolism, or air 
embolism, can be life threating. Those who have a thrombus present in the LAA or those with enlarged 
LAA ostium are not appropriate for LAA device closure. Patients older than 75 have higher periproce-
dural bleeding risk. LAA device closure is certainly a significant development for stroke prevention, 
especially in those AF patients who cannot take oral anticoagulation. This technique, however, has 
certain restrictions, therefore, cannot be applied in all patients who have contraindications against 
oral anticoagulants. 
The diabetic brain and stroke
M. Chopp
Department of Neurology, Henry Ford Health System, USA
Diabetes, particularly in the elderly contributes to cognitive and learning deficits. In addition, diabetes 
is a major risk factor for stroke, and approximately one-third of all stroke patients are diabetic. Here, 
I will describe our work on the neurovascular dysfunction in the diabetic brain, first without stroke 
and then after stroke. Type 2 diabetes (T2DM) in the older rat will be shown to induce neurovascular 
dysfunction and significant cognitive loss compared with the non-diabetic aged-matched brain. The 
diabetic brain exhibits increased the loss of axons and oligodendrocytes, reduced myelination and re-
duced spine density, as well as substantial fibrin deposition compared with non-diabetic aged-matched 
brains. In addition, the T2DM aging brain exhibits an impaired glymphatic system, which is highly 
correlated with cognitive loss. Stroke in the T2DM brain greatly exacerbates neurovascular dysfunc-
tion and neurological sequelae in the diabetic brain. The diabetic brain post-stroke exhibits increased 
inflammation and axonal damage. In addition, stroke in the diabetic animal induces significant cardiac 
dysfunction which drives post-stroke cognitive dysfunction. Molecular mechanisms underlying the 
exacerbation of neurological outcome and neurovascular function after stroke in the T2DM animal will 
be described, including the roles of substantially reduced microRNA-126, an important non-coding RNA 
which plays a vital role in orchestrating neurovascular and cardiovascular health. Novel restorative 
therapies using exosomes, nano-sized bilipid layer particles containing noncoding RNAs and proteins 
which promote neurovascular remodeling and enhance both neurological and cardiovascular recovery 
in the T2DM animal with and without stroke will be described. 
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Should we perform left atrial appendage closure  
in patients with high risk of stroke and atrial fibrillation 
who cannot take oral anticoagulants?
G. Chrysant
Cardiology, INTEGRIS Heart Hospital, USA
Patients with nonvalvular atrial fibrillation are at increased risk of thromboembolic events like 
stroke and require systemic anticoagulation. For patients with a high risk of bleeding or who have ex-
perienced clinically significant bleeding, left atrial appendage closure (LAAC) affords a roughly 90% 
reduction in stroke risk. The left atrial appendage can be ligated surgically, percutaneously, or can have 
the appendage filled with a nitinol-based self-expanding device. The most notable and studied is the 
Watchman device. The PROTECT-AF study, PREVAIL study and the ASAP study show noninferiority 
to warfarin and a good safety and efficacy profile. The ASAP trial demonstrated the safety and efficacy 
of LAA closure with aspirin and Plavix without a warfarin transition. The patient population averaged 
a CHADS-VASc score of 2–3 and the vast majority (in some cases 90%) of patients had experienced 
clinically important bleeding. There is 5-year follow-up data further demonstrating safety and efficacy. 
Commercially, LAAC has been promoted as an alternative to warfarin therapy. Since the pivotal trials 
mentioned above, many patients with atrial fibrillation have been placed on novel oral anticoagulants 
that have been proven to be a safer alternative to warfarin as it pertains to bleeding events. There are 
no direct comparison trials between LAAC and novel oral anticoagulants; therefore, some important 
questions remain regarding who and how many patients should receive LAAC. 
Should secondary stroke prevention include NOACs  
in addition to antithrombotics?
L. Csiba
Neurology, Debrecen University, Hungary
Recently, the efficacy of rivaroxaban plus aspirin combination was investigated for secondary 
vascular prevention (1). More than 27 000 patients with stable atherosclerotic vascular disease were 
randomized for rivaroxaban (2.5 mg twice daily) plus aspirin (100 mg once daily), or lonely rivarox-
aban (5 mg twice daily), or lonely aspirin (100 mg once daily). The composite of cardiovascular death, 
stroke, or myocardial infarction were the primary outcome. The study was stopped for the superiority 
of the rivaroxaban-plus-aspirin group. The rivaroxaban-plus-aspirin group had only 4.1% primary out-
come event while the lonely aspirin group experienced 5.4% (p < 0.001). The major bleeding events 
occurred in more patients in the rivaroxaban-plus-aspirin group (3.1%) vs. 1.9% in the aspirin group 
(p < 0.001). There were fewer deaths (3.4%) in the rivaroxaban-plus-aspirin group as compared with 
4.1% in the aspirin-alone group. The lonely rivaroxaban therapy resulted in more major bleeding events 
without significant decrease of a composite of cardiovascular death, stroke, or myocardial infarction. 
The benefit was consistent in the post-stroke subgroup (more than 1000 patients). The benefit was 
also present in patients with baseline blood pressure below or above the mean and in patients with 
baseline cholesterol levels below or above the median, confirming the conclusion that the benefits of 
combination therapy are additive to standard secondary preventive interventions. On contrary, the 
lonely rivaroxaban (5 mg twice daily) alone did not result in better outcome but more major bleeding 
events. Should secondary stroke prevention include NOACs in addition to aspirin? My answer: yes. 
Eikelboom JW, et al. N Engl J Med. 2017; 377(14): 1319–1330. 
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Small asymptomatic intracranial aneurysm  
— to intervene or not?
V. Demarin
Neurology, International Institute for Brain Health, Croatia
Unruptured intracranial aneurysms (UIA) are relatively common finding, occurring in approximately 
2–3% of the population. Most of these lesions are incidentally found, asymptomatic and typically carry 
a benign course. In making the treatment decision, understanding the natural history of an aneurysm is 
imperative and the size, location, shape of an aneurysm, age and existing risk factors should be evaluated. 
A number of studies were investigating the risk of rupture and growth of asymptomatic aneurysms in 
order to establish the best therapeutic approach. In the International Study of Unruptured Intracranial 
Aneurysms (ISUIA), a large-scale prospective epidemiologic cohort study, 5-year cumulative rupture 
rate for patients without a history of SAH with aneurysms located in ICA, ACoA, ACA, and MCA was 
0% for smaller aneurysms of less than 7 mm. For the same size of an aneurysm located in PCA and 
PCoA, it was 2.5%. These rates are often equalled or exceeded by the risks associated with surgical or 
endovascular repair. In many other studies, size was also found as being predictive for aneurysm growth 
and eventual rupture, while in others hypertension, young age and posterior circulation were found 
to be significant risk factors for rupture. PHASES score was introduced to contribute to predicting the 
risk of growth and rupture. Careful examination of each patient in electing therapeutic approach is 
mandatory. In the majority of patients with small UIAs intervention is not an option. 
What should be the optimal imaging to select patients  
for thrombectomy beyond 3 hours: Is CTA enough  
or should CTP be added?
R. Eichel
Shaare Zedek Medical Center, Jerusalem, Israel
Until recently patients with Acute Ischemic Stroke (AIS) and Large Vessel Occlusion(LVO) in the 
anterior circulation were eligible for Endovascular Treatment (EVT) up to 6 hours from symptom onset 
(as defined last seen normal) of there stroke. The Current Trials DAWN and DEFUSE 3 lead to new 
guidelines and extend our ability to treat AIS patients with LVO up to 24 hours but with additional 
need to evaluate the infarct core by the use of CT Perfusion (CTP) or MRI Diffusion (MR-D). With these 
new guidelines, CTP or MRI-D becomes a “Must” in assessing AIS patients to be eligible for EVT after 
6 hours of stroke onset. CTP and MRI — D are in need of some basic cooperation of patients during 
performing the imaging and standardized analysis of CTP is not readily available in all comprehensive 
stroke centers. So some believe that the current approach of AIS patients with up to 6 hours symptom 
onset, with using CT head without contrast (using ASPECT to grade ischemic tissue) and CTA, is also 
enough to evaluate penumbra size and guide us in our decisions for patients over 6 hours. Besides 
of missing high-quality data to prove such a new rudimentary approach of selecting patients, the use 
of CTP and MR-D has additional value in guiding us in our treatment decisions. CTP and MR-D are 
known to increase the sensitivity of identifying patients with AIS, especially when trying to diagnose 
patients with uncommon symptoms or distal occlusions, that are sometimes missed when evaluating 
them CTA alone. This presentation intends to show the superiority of adding CTP or MR-D to a stand-
ard AIS neuroimage evaluation. 
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Should we perform left atrial appendage closure in  
patients with high risk of stroke and atrial fibrillation  
who can not take oral anticoagulants — Pro
M. Grygier
Chair and 1st Department of Cardiology, Poznan University of Medical Sciences, Poland
According to current European Society of Cardiology (ESC) Guidelines, patients with atrial fibrillation 
(AF) are at risk of stroke and should be treated with antithrombotic therapy based on the risk factors for 
stroke and bleeding as evaluated by the CHA2DS2-Vasc and HAS-BLED scores, respectively. Warfarin 
and new oral anticoagulants (OAC) reduce significantly the thrombo-embolic risk associated with AF. 
However, some patients even at high thrombo-embolic risk cannot be treated with oral anticoagulants 
due to major contraindications or intolerance of these drugs. Moreover, platelet inhibition, as it was 
shown in few studies, is ineffective in stroke prevention. Ninety percent of thrombi leading to stroke 
in patients with non-valvular AF is formed in the left atrial appendage (LAA). In order to reduce the 
risk for stroke in these patients, percutaneous LAA occlusion has been developed. Randomized trials 
(PROTECT AF, PREVAIL) have shown that closure of LAA with Watchman device (Boston Scientific, 
USA) is non-inferior to warfarin in stroke prevention in warfarin eligible patients. Efficacy regarding 
stroke prevention in OAC ineligible patients has also been shown in few recently published registries. 
Current ESC Guidelines state that endovascular LAA occlusion may be considered in patients with 
a high risk of stroke and contraindications for long-term anticoagulation (Class IIb recommendation). 
One year data from EVOLUTION registry confirms safety and efficacy of such treatment strategy which 
should be used more widely. 
Should closure of PFO be the standard of care  
in patients with ESUS?
W.D. Heiss
Neurology, Max Planck Institute for Metabolism Research, Germany
Stroke is among the leading causes of mortality and serious long-term disability. Around one-third 
of the patients hospitalized with stroke are under the age of 65 years. Around 25% of all strokes are 
cryptogenic, and this reaches approximately 50% in the younger age group. Epidemiologic data reveal 
significant association between patent foramen ovale (PFO) and cryptogenic stroke both in the younger 
and older patient populations. Despite medical therapy, the rate of stroke recurrence in patients with PFO 
is estimated to be 25% within a 4-year period. Observational data and meta-analyses of observational 
studies suggest that percutaneous transcatheter closure of PFO is safe and has a low recurrence rate of 
stroke as compared to medical therapy. However, several randomized controlled studies published up 
to 2013 have not shown the superiority of PFO closure over medical therapy. An exploratory analysis 
of long-term data from 1 trial found a significantly reduced stroke risk with closure. Recently published 
trials also reported positive results. Pooled analyses of these additional data will almost certainly find 
a statistically significant benefit of closure. As pointed out in the recent Viewpoint by Kamel (2017) the 
studies on which the meta-analysis was based have some methodological shortcomings and therefore 
decisions to close or not to close a PFO must still be based on the individual data in a single patient. 
Nonetheless, the combined clinical, epidemiological, and trial evidence indicate that PFO can cause 
ischemic stroke and that closure can reduce the risk of recurrence. 
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Small asymptomatic intracranial aneurysm  
— to intervene or not? — Pro
A. Kobayashi
Department of Neuroradiology, Department of Cerebrovascular Interventions, Institute of Psychiatry and Neurology, Poland
Unruptured intracranial aneurysms are present in up to 10% of the general population. The risk 
of rupture is low and the occurrence is 2–20 per 100,000 populations per year. The treatment of pa-
tients with an aneurysm-related subarachnoid haemorrhage (SAH) is indisputable, but the treatment 
of asymptomatic aneurysms is still a matter of debate. Intracranial aneurysms apart from causing 
SAH can also cause several other neurological symptoms resulting from mass effect and also sentinel 
headaches. These can also be debilitating or increasing the risk of a SAH. The ISUIA trial showed that 
small unruptured aneurysms have a lower risk of bleeding and those located in the anterior circulation 
and less than 7 mm are associated with a higher risk of intervention than rupture. Nevertheless, the 
ISUIA trial was biased by the fact that it was a non-randomized, observational study where surgical 
or conservative management was left to the physician’s discretion. The trial showed that all posterior 
circulation aneurysms and those found in patients with a previous SAH from another aneurysm should 
be considered for treatment regardless of size. More recent studies show that not only size is associated 
with rupture risk and subsequently with the indication for surgical treatment. These factors include 
location (anterior and posterior communicating arteries), female gender, daughter sac and irregular 
morphology, aneurysm growth, increasing time from the first diagnosis, Finnish or Japanese origin, 
hypertension, smoking, elderly age, earlier SAH from another aneurysm. All of the above together with 
family history of SAH should be considered before the decision for intervention. 
Small unruptured intracranial aneurysms  
— to intervene or not?
H. Mattle
Neurology, University of Bern, Switzerland
Saccular unruptured intracranial aneurysms (UIAs) are increasingly detected as an incidental finding 
because of today’s frequent use of cranial imaging. They have a prevalence of 3% in the adult popu-
lation. When they are large the risk of rupture is substantial and calls for treatment. However, small 
UIAs (5 mm) have a low risk of rupture. Nevertheless, some UIAs do rupture and cause subarachnoid 
hemorrhage. This indicates that rupture risk cannot be determined solely by their size or location. In 
addition to size and site of the aneurysm, additional factors such as aneurysm growth, advanced pa-
tient age (≥ 70 years), smoking, hypertension, previous SAH from another aneurysm, and the patient’s 
ethnic origin may increase the risk of rupture. Scores like PHASES and UIATS help to predict aneu-
rysm rupture risk, but surgery or endovascular preventive treatment carries a risk as well. Therefore, 
what strategy to chose, to treat or wait and see, and what strategy will save more quality-adjusted life 
years for a given patient is often difficult to decide. Furthermore, anxiety caused by the awareness of 
having an aneurysm can make the decision for the best management of an individual patient even 
more complicated. In such a situation treatment approaches are debatable and often controversial. The 
speakers of this debate will address their points of view whether to treat an UIA or whether to wait 
with treatment and monitor the patient. 
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Should closure of PFO be recommended treatment  
and standard of care in patients with ESUS?
H. Mattle
Neurology, University Hospital of Bern, Switzerland
Thrombi that dislodge from the venous system are caught in the pulmonary vasculature. In the 
presence of right-to-left shunts, however, thrombi can cross paradoxically to the arterial circulation 
and cause ischemic stroke or infarcts in other organs. This is the case in patients with a patent foramen 
ovale (PFO) that represents the most common cause of a right-to-left shunt. In stroke patients with 
PFO and no identifiable source of thromboembolism, the risk of recurrent stroke is as low as 1.2% per 
year. Randomized controlled trials (RCTs) have shown that percutaneous closure of the PFO in cryp-
togenic stroke can reduce the recurrence risk to 0.5% per year and thus provide a substantial benefit 
in the future. However, the RCTs have included only patients from 16 to 60 years of age. Therefore, 
many questions of management of patients with PFO remain unresolved to date. Should PFOs in pa-
tients older than 60 years or younger than 16 years be closed after cryptogenic stroke? Should PFOs 
in patients with cryptogenic stroke and many vascular risk factors be closed, or how to manage PFOs 
in patients with concurrent stroke etiology? Which PFO is pathogenic and which PFO is only an in-
nocent bystander? Should PFOs that are identified incidentally in healthy persons be closed? These 
are some of the many questions that cannot be answered with the current evidence on PFO closure. 
The speakers of this debate will address many of those questions and hopefully shed some light on 
the controversy on PFO closure. 
From neurobiology to evidence-based medicine  
concepts in neurorehabilitation
D.F. Muresanu
Chairman Department of Clinical Neurosciences, University of Medicine and Pharmacy “Iuliu Hatieganu”, Cluj-Napoca, Romania
Nowadays, it is still difficult to find the correct therapeutic approach for brain protection and re-
covery in stroke, especially because we do not fully understand all of the endogenous neurobiological 
processes, the complete nature of the pathophysiological mechanisms and the links between these two 
categories. Endogenous neurobiological processes, such as neurotrophicity, neuroprotection, neuro-
plasticity, and neurogenesis, are central to protection and recovery and represent the background of 
endogenous defense activity (EDA). Stroke pathological cascades contain a limited number of patho-
physiological processes. It is characterized mainly by excitotoxicity, oxidative stress, inflammation, 
apoptotic-like processes and important metabolic disturbances. Pathophysiological processes share 
some common mechanisms with EDA (e.g. excitotoxicity and neurotrophicity together with neuro-
plasticity have, as a common important driver, the NMDAR activity; inflammation has an important 
contribution for neuroregeneration, stimulating neuroplasticity, via trophic factors). Postlesional brain 
regulation is currently better understood. Every lesion in the nervous system triggers in the first minute 
an endogenous neuroprotective reaction. An endogenous repair process, combining neuroplasticity 
and neurogenesis follow this as a second answer. All these processes are initiated and regulated by 
endogenous biological molecules. The biological reality of the nervous system is far more complex. 
In fact, there is an endogenous holistic process of neuroprotection and neurorecovery that should 
be approached therapeutically in an integrated way. The current tendency to exclusively frame drug 
activity in terms of single mechanisms and single focus effect might distract from other paradigms 
with greater explanatory power and hinder the development of more effective treatment strategies. 
A change of concept is required in pharmacological brain protection and recovery in stroke therapy. 
This presentation briefly reviews the current and future considerations in this therapeutic strategy, 
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including an integrated pharmacological approach, focusing on drugs with multimodal activity rather 
than single mechanism drugs, which usually are chemical drugs. In line with this strategy, the current 
presentation will also highlight the result of CARS Trial, one of the latest double-blind placebo rand-
omized controlled trial in the field. 
Can diet prevent stroke? — No
M. Niewada
Department of Experimental and Clinical Pharmacology, Medical University of Warsaw, Poland
Diet is not a single dietary pattern, so it is difficult to establish what really works for stroke prevention 
— is it specific component or total food/caloric intake. Certainly, excess salt intake increases hyperten-
sion risk and consequently stroke risk, but so far many specific diet components were inconsistently 
reported in clinical studies on stroke risk. Relevant clinical data interpretation is challenging as it is 
not feasible to control for many cofounders, which can affect stroke outcomes much more than just 
diet. Consequently related epidemiological paradoxes were reported, i.e. obesity paradox which refers 
to the more favorable prognosis for obese stroke survivors. INTERSTROKE study showed the relation 
between diet and stroke risk but it was susceptible to biases and not causal, making the population 
attributable risk estimates uninterpretable. Moreover, diet was the only one risk factor reported conflict-
ing impact on stroke risk for different regions. Randomized data on diet benefits are still limited. The 
largest PREDIMED trial is neither a pure test of a Mediterranean-style diet nor a pure test of extra-virgin 
olive oil and nuts and shares with Lyon Diet Heart Study the interpretation challenges. Generalizability 
of PREDIMED findings is limited as all the study participants lived in a Mediterranean country and 
were at high cardiovascular risk. Association between diet and stroke risk was substantially smaller 
in prospective PREDIMED study compared to INTERSTROKE. Individual impact of diet on stroke risk 
is therefore highly uncertain. 
What should be the optimal imaging to select patients  
for thrombectomy beyond 3 hours, is CTA enough  
or should CTP be added
D. Ryglewicz
1st Neurological Department, Institute of Psychiatry and Neurology, Poland
Recanalization of main stem cerebral arteries may lead to a good clinical outcome, but also may 
increase the risk of clinical deterioration. The time between stroke onset and artery reopening has been 
shown to be the most important determinant of hemorrhagic transformation. In the US according to the 
AHA and ASO recommendation therapeutic window for intravenous thrombolysis in severe stroke is 
3 hours and in mild stroke 4.5 hours, in Europe (ESO recommendation) 4.5 hours. These recommen-
dations were created on the basis of experimental studies and available statistical data of patients with 
good clinical outcome treated in the different time of stroke onset. These are statistical data, but in 
the real life, each patient is different. Size of ischemic brain tissue which may be salvage with reper-
fusion depends not only on stroke onset time. The efficiency of collateral circulation has a significant 
impact on the volume of infarct area. The DAMN study has shown that on the basis of neuroimaging 
examination we may prolong the time up to 24 hours. The mismatch between the severity of clinical 
deficit and the infarct volume seems to be a good indicator for thrombectomy above statistical 6 hours. 
Is CTA sufficient to evaluate the effects of cerebral circulation or should we additionally perform CTP 
according to DAMN study?
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What should be the optimal imaging to select patients for 
thrombectomy beyond 3 hours: Is CTA enough or should 
CTP be added? 
A. Shuaib
Department of Medicine, Stroke Program, University of Alberta, Canada
Acute stroke care has improved significantly during the last decade. Advances in brain imaging al-
low for better patient selection for thrombolysis and thrombectomy and increasing number of patients 
are being successfully treated. In addition, imaging is helpful in detection of abnormalities that may 
increase the risk of complications, especially intracranial hemorrhage (ICH). Imaging is also very help-
ful in allowing for patient selection beyond the traditional 4.5 hours’ time-window, especially where 
thrombectomy is being considered. Whereas there are several modalities of imaging available in the 
acute stroke settings, CT and CTA are sufficient for proper patient selection in decision making for 
thrombectomy. A plain scan with an ASPECTS score or 6 and good collaterals on CTA are allowed to 
proceed to thrombectomy in patients with MCA or T-occlusions. Most recent trials (with the exception 
of DAWN) where thrombectomy was compared to the standard of care (in treatment time windows 
of up to 12 hours) utilized CT and CTA as sufficient. My presentation will argue that CT and CTA are 
sufficient to make decisions regarding patient selection for thrombectomy beyond 3 hours from time 
of onset. 
Can diet prevent stroke?
H. Sienkiewicz-Jarosz
1st Department of Neurology, Institute of Psychiatry and Neurology, Poland
Objectives: The purpose of this presentation is to discuss the role of diet, especially Mediterranean 
diet and DASH (Dietary Approaches to Stop Hypertension) in primary and secondary stroke prevention. 
Material and methods: The INTERSTROKE study showed, that diet may be one of ten most important 
modifiable risk factors for stroke, although there were some regional differences in the direction of the 
effect (South Asia vs all other regions) as well as in the effect size (younger vs. older stroke patients). 
Recent data has brought some evidence that Mediterranean diet may protect against cardiovascular 
disease and specifically stroke, decreasing 5-year stroke risk by approximately 30%. Similarly, DASH 
diet, which differs from the Mediterranean diet with the contribution of fat, low-fat dairy products, 
sweets, sugar-containing beverages and alcohol has been shown to be inversely correlated with ischemic 
stroke risk. There is insufficient evidence from RCTs for any effect of whole grain diets, low glycaemic 
index diets or high polyphenols intake on cardiovascular outcomes. The research on the dietary pattern 
after stroke on secondary stroke risk is limited. 
Conclusion: There is still some controversy regarding the role of specific diets in secondary stroke 
prevention, stronger evidence exists for the role of diet in the primary prevention of cerebrovascular 
diseases. However, apart from pharmacological therapy, healthy diet, regular physical activity, and 
weight loss in overweight or obese patients may represent an interesting approach to stroke prevention 
with low risks and high potential benefits from a public health perspective. 
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Is the identification of rare/short atrial fibrillation episodes 
sufficient to prescribe anticoagulants?
A. Slowik
Neurology, Jagiellonian University, Poland
Current treatment guidelines offer oral anticoagulant (OAC) to patients with atrial fibrillation 
(AF) taking into account risk of thromboembolic event (CHA2DS2-VASc) and risk of bleeding. These 
guidelines do not account for AF burden (pattern, frequency, duration), and do not indicate, if atrial 
high rate episodes (AHREs) (no symptomatic, 190 beats/minute, detected with long-term continuous 
monitoring by cardiac implantable electronic devices, CIEDs) including subclinical atrial fibrillation 
episodes (SCAF) warrant life-long OAC treatment. Increasing number of studies using CIEDs bring 
new data on AHRE natural history and the risk of thrombo-embolic events. The incidence of AHRE 
in patients without the history of AF is high (approximately 25% after 1 year and 35% after two years 
of follow-up). Interestingly, patients with short AHREs may develop longer AHREs or new clinical 
AF. AHREs also increase the annualized risk of stroke and thromboembolic events or silent ischemic 
brain lesions, however, lower, as compared to patients with clinical AF. Growing number of evidence 
indicate the correlation between AHRE duration and stroke risk. Interestingly, it is thought that AHRE 
may be a biomarker of embolic risk since there is lacking evidence of a temporal relationship between 
AHRE and stroke. All these data indicate that at least some of AHRE victims may benefit from OAC 
treatment taking into account stroke risk and AHRE burden; recent EHRA Consensus indicates OAC 
for patients with the threshold of 5.5 hours/day of SCAF burden and at least two CHA2DS2-VASc 
risk factors. However, clinical trials addressing this question are ongoing (ARTESiA, NCT01938248; 
NOAH-AFNET6, NCT02618577). 
Should closure of PFO be recommended treatment  
and standard of care in patients with ESUS?
J.D. Spence
Stroke Prevention & Atherosclerosis Research Centre, Robarts Research Institute, Western University, Canada
Patent foramen ovale (PFO) is very common (~25% of the population), so among patients with 
stroke who have a PFO, ~80% of PFOs are incidental. Even among patients with cryptogenic stroke 
and a PFO, only ~half are causally related. This created a major problem for the clinical trials of PFO 
closure: if most patients with stroke and PFO have an incidental PFO, it is very difficult to show the 
benefit of closure. A paradoxical embolus is by definition a pulmonary embolus. This is why the studies 
have shown a greater benefit of PFO closure vs. antiplatelet agents, than vs. therapies that included 
anticoagulation. Clinical clues to paradoxical embolism include dyspnea or a Valsalva maneuver at 
the onset of stroke, waking up with stroke, a previous history of deep vein thrombosis, varicose veins, 
prolonged sitting (such as a long airplane ride), migraine, and sleep apnea. Among patients with par-
adoxical embolism, Transcranial Doppler (TCD) saline studies are more sensitive and predictive than 
trans-esophageal echocardiography. TEE missed 15% of right-left shunts seen on TCD, and of these 
47% were large shunts. Patients with a larger right-left shunt on TCD were more likely to have recurrent 
TIA/stroke. Before embarking on PFO closure it is crucial to evaluate whether the PFO is incidental, 
or probably causal. A careful history and a TCD saline study will refine the decision for PFO closure. 
Patients with paradoxical embolism should probably be anticoagulated so closure (which requires 
antiplatelet agents) may increase the risk of pulmonary embolism.
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Can diet prevent stroke? 
J.D. Spence
Stroke Prevention and Atherosclerosis Research Centre, Robarts Research Institute, Western University, Canada
There can be no doubt that the Cretan Mediterranean diet can prevent stroke. In the Seven Countries 
Study, it was discovered that the coronary risk in Crete was only one fifteenth what it was in Finland. 
In the Israeli diet study, the Mediterranean diet was better for diabetes and insulin resistance than 
a low-fat diet or a low-carbohydrate diet. In the Lyon Diet Heart Study, in secondary prevention, among 
patients with a prior coronary event, the Mediterranean diet reduced stroke by more than 60% in four 
years, compared to a “prudent Western diet” that approximated the low-fat diet then recommended. 
This was twice the effect of simvastatin in the contemporaneous 4S trial. In primary prevention, the 
Mediterranean diet was equally impressive. In the Spanish PREDIMED trial, in high-risk primary 
prevention, there was a significant reduction of cardiovascular events in both Mediterranean arms of 
the study (Mediterranean diet supplemented by mixed nuts, and Mediterranean diet supplemented by 
olive oil), compared with a low-fat diet. With the Mediterranean diet supplemented by nuts, there was 
a 47% reduction of stroke in five years. Besides cholesterol, red meat contains carnitine and egg yolk 
contains phosphatidylcholine, which result in formation of toxic trimethylamine n-oxide (TMAO). 
TMAO levels in the top quartile increased risk 2.5-fold in three years in patients referred for coronary 
angiography. Patients at risk of stroke should consume a Cretan Mediterranean diet, avoiding egg yolk 
and red meat. This dietary pattern definitely reduces the risk of stroke.
Should secondary stroke prevention of vascular diseases 
include NOAC’s in addition to aspirin? — No
J. Streifler
Former Head, Neurology Unit and stroke program, Rabin Medical Center, Petach Tikva, Israel 
Senior Lecturer, Sackler School of Medicine, Tel Aviv University, Israel
Antithrombotics (AT), in particular antiplatelet (AP) agents, are first line treatment in secondary 
stroke prevention. AP includes ASA, clopidogrel and dipyridamole (which can augment ASA effect 
with sustained release dipyridamole [Aggrenox]). The anticoagulant (AC) group includes warfarin and 
NOAC’s. AP treatment prescribes first for more than 75% of patients, as it blocks the coagulation cascade 
initiated by endothelial injury in brain arteries affected by atherosclerosis processes. In cardio-embolic, 
venous thrombosis and coagulation abnormalities, AC’s are more effective — therefore used as first line. 
Arterial disease warfarin was inferior to ASA, with more bleedings, not recommended as an alternative. 
The NOAC group has lower bleeding rates. The addition of low dose Rivaroxaban (5 mg/day) to 100 
mg ASA in patients with stable (atherosclerotic) cardiovascular disease (CVD) was more effective in 
the composite outcome than ASA alone, associated with higher bleeding rates. Rivaroxaban alone was 
not superior to ASA alone and with similar higher bleeding risk. Triple AT combination in AF patients, 
who need coronary artery stent insertion is a matter of debate; attempts to reduce a duration or to 
convert to dual therapy are ongoing, in part successful. Thus, even with NOAC’s bleeding rates raise 
concern and its addition to AP remains problematic. Adopting this strategy for stroke patients may be 
hazardous at present. Another approach was to compare NOAC to ASA for patients with cryptogenic 
strokes, yet only for those with the embolic type. These strokes are called “embolic stroke of unknown 
source” (ESUS). However, one of the 2 studies, still recruiting, was prematurely stopped for futility.
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Does carotid stenosis cause cognitive decline — No
J. Streifler
Former Head, Neurology Unit and stroke program, Rabin Medical Center, Petach Tikva, Israel 
Senior Lecturer, Sackler School of Medicine, Tel Aviv University, Israel
Asymptomatic significant (≥ 50%) carotid stenosis (ASCS) is frequently found in elderly, mainly in 
patients with several vascular risk factors. Its most feared complication is stroke. The same risk factors 
are associated with the increased risk for cognitive decline (CD). Associated brain imaging pathology 
manifestations are “small vessel type”, including leucoaraiosis, microbleeds, and lacunar infarctions 
(often “silent”). Overt strokes are also important contributors to CD. Thus, is there an association between 
ASCS and CD? Yes! The natural history of ASCS is, however, quite benign. Studies, done with “best 
medical treatment” (BMT, including statins), show an annual stroke risk of < 1%. This is why carotid 
endarterectomy (CEA), done for stroke risk reduction in ASCS patients, is still under investigation. 
Studies done before current BMT was introduced show only modest benefit (~1% annual risk reduction). 
Advocating surgery for such patients would mean screening for ASCS (and operating all appropriate 
candidates). The US task force, however, is advising against such screening. The association between 
ASCS and CD, its significance and possible treatment approaches, is supposedly more complicated.
Development of preclinical diagnostics  
of neurodegenerative diseases — illusions or reality?
M. Ugrumov
Lab of Neural and Neuroendorcine Regulations, Institute of Developmental Biology RAS, Russia
Numerous attempts to develop a preclinical diagnosis of neurodegenerative diseases (NDD) — Parkin-
son’s and Alzheimer’s disease, by searching peripheral biomarkers as changes in biological fluids and 
non-motor functions were not successful. A drawback of this methodology is the search for markers in 
patients at clinical stage without guarantees that they are characteristic for preclinical stage. Indeed, all 
markers detected so far are nonspecific. We propose to upgrade this methodology, using only markers 
found both in patients and animals at modeling clinical and preclinical stages of NDD. Detection of 
the same marker in patients and symptomatic animals is believed to indicate adequate reproduction of 
pathogenesis along this metabolic pathway, and detection of this marker in presymptomatic animals 
proves its specificity for preclinical stage. We showed that 50% and 20% of the markers found in blood 
of patients were characteristic of MPTP-treated symptomatic and presymptomatic mice, respectively. 
Besides, we propose a different approach to early diagnosis of NDD — a provocative test that has long 
been successfully used in internal medicine. We showed that the systemic administration of a-me-
thyl-p-tyrosine, a reversible inhibitor of dopamine synthesis (provocative agent), to MPTP-treated mice 
at presymptomatic stage results in a reversible decrease in dopamine level in the striatum up to the 
threshold (30%) and short-term motor disorders. In controls, although the dopamine level decreases 
under a-methyl-p-tyrosine administration, it does not reach the threshold level and is not accompanied 
by motor disorders. Thus, we proposed a new complex methodology for the development of preclinical 
diagnosis of NDD.
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Wilson’s disease
Wilson’s disease epidemiology
O. Bandmann
Sheffield Institute for Translational Neuroscience (SITraN), University of Sheffield, UK
There is ongoing uncertainty about the incidence and prevalence of Wilson’s disease (WD). Scheinberg 
and Sternlieb first estimated the prevalence of five WD to be five per million. Subsequently, a preva-
lence figure of 30 per million with a heterozygote carrier frequency of one in 90 was frequently quoted. 
However, considerably higher incidence and prevalence figures have been reported for population 
isolates, the highest being 885 per million, from within the mountainous region of Rucar in Romania. 
Different strategies including both biochemical and genetic screening have been used to establish the 
frequency of WD in the general population. A large number of different ATP7B mutations can cause 
WD, but studies can be further confounded by the uncertain relevance of some sequence variants with 
unproven pathogenicity. We undertook the largest genetic prevalence study on WD in the UK. The 
entire ATP7B coding region was sequenced in 1000 control samples from a perinatal blood spot screen. 
In addition, three mutation hot spots (exon 8, 14 and 18) were sequenced in 5000 controls. Using very 
strict criteria to assess the pathogenicity of the detected sequence variants, we calculated a revised 
figure of 0.040 or 1:25 of heterozygote mutation carriers in the UK. The resulting predicted frequency 
of individuals carrying two pathogenic ATP7B mutations was 142 per million, more than four times 
the often quoted prevalence figure of 30 per million. Future studies need to determine whether this 
apparent high genetic prevalence can be validated in other cohorts.
Kinnier Wilson and Wilson’s disease
E. Broussolle
Department of Neurology C, Université de Lyon and Institut des Sciences Cognitives Marc Jeannerod UMR 5229  
and Hôpital Neurologique Pierre Wertheimer, France
British physician, Samuel Alexander Kinnier Wilson (1878–1937) was one of the world’s greatest 
neurologists of the first half of the 20th century. Early in his career, Wilson spent one year in Paris in 
1903 where he learned from Pierre-Marie. He subsequently retained uninterrupted links with French 
neurology. He also visited in Leipzig German anatomist, Paul Flechsig. In 1904, Wilson returned to 
London, where he worked for the rest of his life at the National Hospital for the Paralysed and Epilep-
tic (today the National Hospital for Neurology and Neurosurgery) in Queen Square, and also at Kings’ 
College Hospital. He wrote on “the old motor system and the new”, on disorders of motility and muscle 
tone, on the epilepsies, on aphasia, apraxia, tics, and pathologic laughing and crying. Wilson’s most 
important contribution was his publication in 1912 in Brain of a newly recognised illness he called 
‘‘Progressive lenticular degeneration, a familial nervous disease associated with liver cirrhosis’’, which 
was later named hepatolenticular degeneration or Wilson’s disease. Wilson analysed 12 clinical cases, 
four of whom he followed himself, but also four cases previously published by others and a further 
two that he considered in retrospect had the same disease as he was describing. The pathological 
profile combined necrotic damage in the lenticular nuclei of the brain and hepatic cirrhosis. When 
describing these patients, Wilson introduced for the first time the terms extrapyramidal syndrome and 
extrapyramidal system, stressing the role of the basal ganglia in motility.
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Introduction — the importance of proper management  
of Wilson’s disease
A. Czlonkowska
2nd Department of Neurology, Institute of Psychiatry and Neurology, Warsaw, Poland
Wilson’s disease (WD) is an exceptionally rare genetic disorder. Patients with WD, when treated 
properly, have a similar life expectancy as healthy people. However, when no treatment is given, the 
disease progresses and can lead to death in several years, usually due to liver failure or neurological 
impairment causing immobility and then medical complications. Although diagnostic methods are 
now widely available, it usually takes several years since the onset of symptoms to diagnose WD. Be-
cause the symptoms of WD are diverse, the diagnosis must be supported by laboratory studies, such 
as copper metabolism (ceruloplasmin, urinary copper excretion) and genetic analysis. Moreover, liver 
biopsy, imaging of the liver and brain, and incorporation of radioactive copper are helpful. A complete 
workup for WD should be offered to all siblings of patients with WD, including those without symp-
toms, and to other family members, regardless of their age, who have hepatic, neurologic, or psychiatric 
symptoms. In WD, prognosis depends largely on the patient’s clinical state at diagnosis and on the 
patient’s compliance. Although current pharmacological treatments for WD are lifelong, up to a half of 
patients stop taking medications, reduce their doses, or take medications irregularly. Diagnosis of WD 
is difficult, and patients treated for WD need a lifelong follow-up and require multidisciplinary care 
(hepatologist, neurologist, and psychiatrist). Thus, each country should have a WD centre with phy-
sicians experienced in WD care. Patient support groups are also important in the management of WD.
Wilson’s disease — neurological presentation
P. Dusek
Department of Neurology and Centre of Clinical Neuroscience, 1st Faculty of Medicine, Charles University and General University Hospital, Czech Republic
Neurological presentation of Wilson’s disease (WD) is common, and it affects approximately 50% of 
patients. Neurological symptoms occur later compared to hepatic manifestations, typically in the 3rd 
or 4th decade. Most common symptoms include various combinations of movement disorders, namely 
tremor, dystonia, Parkinsonism, and chorea associated with dysarthria, dysphagia, and drooling. Dam-
age to the central nervous system in WD is caused by the toxic effect of accumulated copper. It can 
be visualised as atrophy and increased signal of affected regions on T2 weighted magnetic resonance 
images. T2 hyperintensities may reflect tissue oedema, demyelination, gliosis and rarefaction, whereby 
the latter 2 abnormalities are irreversible. The best treatment for neurologic symptoms is prevention; 
they do not occur when adequate lifelong anti-copper treatment is initiated in the asymptomatic or 
hepatic stage of the disease. Currently, there is no consensus about the optimal treatment of the neu-
rologic manifestation and different WD centers favour Zinc, chelating agent, or combination of both. 
Neurological deterioration, sometimes irreversible, that is observed after the initiation of the treatment 
in 20–50% patients remains the most arduous problem in the WD treatment.
Clinical manifestations of Wilson’s disease — other organs
K. Dzieżyc
2nd Department of Neurology, Institute of Psychiatry and Neurology, Poland
Wilson’s disease (WD) presents mainly with hepatic and neuropsychiatric features. However, copper 
accumulates not only in the liver and brain, but also in other organs. The clinical manifestation of WD 
involves opthtalmological, renal, cardiac, skin, osteoarticular, or endocrinological disturbances. The 
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most typical ophthalomological sign is Kayser-Fleischer ring as a result of copper accumulation in the 
cornea. Sunflower cataract is rare, but also characteristic sign. Degeneration of the retina observed in 
WD patients as a marker of neurodegeneration correlates with the degree of impairment of the nervous 
system. Cardiac injury may include arrhythmia, cardiomyopathy, and autonomic dysfunction. Electro-
graphic abnormalities detected in WD patients include left ventricular atrophy, biventricular hyper-
trophy and early depolarisation. In most patients cardiac disturbances are mild. Renal abnormalities 
include tubular dysfunction and nephrolithiasis. Bone demineralisation is a common manifestation 
in patients with WD. Endocrine system manifestations, such as infertility or repeated miscarriages, 
growth and puberty disturbances, hypothyroidism, and hypoparathyroidism, are also observed. Al-
though the increased risk of spontaneous abortion in well treated WD patients, it is possible to become 
pregnant. Other clinical aspects of WD include pancreas involvement, immunological disturbances, 
presence of lipomas, and skin changes. Awareness of other possible WD manifestations is important 
in the differential diagnosis of WD.
New Wilson’s like disease: a treatable metabolic manga-
nese disorder causing Parkinsonism and dystonia
A. Federico
Department of Medicine, Surgery and Neurosciences, University of Siena, Italy
A new metabolic genetic condition related to manganese accumulation into the brain and particularly 
into basal ganglia has been described some years ago and was characterised mainly in early infantile 
and child age by dystonia and in adult by dystonia parkinsonian syndromes. This condition was due 
to genetic mutation in a manganese transport protein able to transfer manganese from tissue outside 
the cells and eliminates trough urines. Metal accumulation is evident by MRI showing metal deposits 
mainly in basal ganglia. We described our experience on this syndrome, describing the clinical phe-
notype in childhood and adulthood, the MRI abnormalities and the effect of chelating treatment by 
EDTA on manganese level and on the clinical symptoms. Some experimental data will be also reported 
investigating the in vitro apoptotic process in cultured fibroblast, showing that this process is abnor-
mally regulated in the patients samples if related to normal subjects.
Wilson’s disease: current anti-copper therapy is sufficient
T. Litwin
2nd Department of Neurology, Institute of Psychiatry and Neurology, Warsaw, Poland
Wilson’s disease (WD) is one of the few genetic, neurodegenerative disorders which could be suc-
cessfully treated with pharmacological treatment, if early diagnosed and correctly treated. Currently 
few groups of drugs are used in WD treatment: 1) chelators (d-penicillamine and trientine), which 
produce increase copper urinary excretion; and 2) zinc salts which inhibit the copper absorption from 
digestive tract. Both kinds of treatment lead to negative copper body balance, what stop the tissue 
copper pathological accumulation in the course of disease, as well as clear affected organs from copper 
overloading. Additionally, in case of acute liver failure or progressive liver disease without effect of 
pharmacological anti-copper treatment, liver transplantation is established as definitive treatment of 
WD. Historically, non-treated WD led definitively to death due to hepatic or neurological complica-
tions. Since the currently available WD treatment was discovered and the progress in WD diagnosis, 
including DNA testing and diagnosis algorithms appeared, the prognosis for WD patients remarkably 
improved. Actually, it seems that, beside the different expert opinion about pharmacological agents 
used in WD treatment, the early WD diagnosis, as well as correct and long-life treatment of WD, are 
the key factors of WD treatment success.
91
Invited Speakers Abstracts
www.journals.viamedica.pl
Role of botulotoxin type a in the complex treatment  
of the hypokinesia in patients with Wilson’s disease
S. Lobzin, N. Tcinzerling, V. Goldobin, E. Klocheva
Neurology, North-Western State Medical University n. a. I.I. Mechnikov, Russia
Introduction: Hypokinesia is common extrapyramidal sign in patients with Wilson’s disease; it leads 
to significant disturbances of life quality and reduces independence of personal living skills. 
Aim: To evaluate effectiveness of Botulotoxinum in complex treatment of rigidity and extrapyramidal 
signs in female patient with trembling and rigidity symptoms. 
Material and methods: Female patient (onset of disease — 8 years). She was on permanent complete 
bed rest due to severe hypokinesia and rigidity; no voluntary movements were possible; severe joint 
contractures; permanent hyperkinetic disorders and severe pseudobulbar syndrome were described. 
The patient was on constant therapy (dophaminergic, neurotrophic, copper eliminating agents). 
Results: Due to non-sufficient results of constant base line therapy, Botulotoxinum (Dysport®, Bofur 
Ipsen, 1000 U) was added. Positive result was observed starting from the 14th day. It has been resulted 
in the appearance of voluntary movements in upper and lower limbs, increase of movements, and de-
crease of hyperkinesia and pain syndrome. Evaluating of injected muscles showed significant decrease 
of muscle hypertonia during one month (from grade 4 to 2 Ashworth scale). After 1,5 month after the 
injection the patient managed to eat by herself; after three months managed to change position from 
bed to wheelchair without assistance. 
Conclusions: Complex therapy of severe Wilson’s disease using Botulotoxinum was recognised as 
effective.
Wilson’s disease: pathogenesis,  
genetic and epigenetic factors
V. Medici
Department of Internal Medicine, Division of Gastroenterology and Hepatology, University of California, Davis, USA
Wilson’s disease is an autosomal recessive genetic disease caused by mutations affecting the ATP7B 
gene with consequent accumulation of copper in the liver and in the brain. ATP7B transporter is in-
volved with both copper biliary excretion and trafficking within the hepatocytes. Missense and nonsense 
mutations are the most frequent and, in general, absence of ATP7Base activity has been correlated 
with earlier and more severe clinical presentation. The most common mutation in patients of Europe-
an descent is the missense H1069Q, possibly associated with neurological presentation according to 
some studies. However, studies attempting to link phenotype and genotype in Wilson’s disease have 
not shown convincing results. This could be related to the high prevalence of compound heterozy-
gotes, but other genes may be contributing to the pathogenesis and disease severity. Environmental 
and nutrition factors could affect the phenotype of Wilson’s disease. In particular, animal models have 
shown a possible involvement of epigenetic mechanisms of gene expression regulation in the disease 
onset and progression. Copper accumulation is associated with inhibition of the expression and ac-
tivity of the enzyme S-adenosylhomocysteine hydrolase (SAHH), which is the bi-directional enzyme 
responsible for the synthesis of homocysteine. When SAHH is inhibited, the resulting accumulation 
of its substrates, SAH, is associated with inhibition of DNA methylation reactions with consequent 
effects on methylation status. In conclusion, Wilson’s disease is a complex disease with challenging 
pathogenic mechanisms that most likely involve the interaction between genetic, metabolic, and en-
vironmental factors.
92
Polski Przegląd Neurologiczny, 2018, vol. 14, supplement A
www.journals.viamedica.pl
Acquired copper deficiency in ten patients with and with-
out Wilson’s disease
F. Ory-Magne1, A. Poujois2, N. Djebrani-Oussedik3, P. Chaine2, F. Woimant2
1Department of Neurology, Toulouse University Hospital, France 
2Department of Neurology, AP-HP, Lariboisière University Hospital, National Reference Centre for Wilson’s disease and other rare copper diseases, France 
3Toxicology Department, National Reference Centre for Wilson’s disease and other rare copper diseases, France 
Introduction: Acquired copper deficiency (ACD) is a rare condition, usually diagnosed from hae-
matological changes. 
Objectives: Characterise the diagnosis features and evolution of patients with ACD. 
Material and methods: Clinical, biological and MRI data were analysed at diagnosis and during 
follow-up. 
Results: 10 patients with ACD were studied: three with Wilson’s disease (WD-CD) and seven without 
WD (CD). Mean time to diagnosis was twice longer in WD-CD than in CD patients. Only 1 patient with 
WD-CD was diagnosed on pancytopenia, all other patients had a progressive posterior cord syndrome 
associated with anaemia and lymphopenia. Electrodiagnostic tests diagnosed a lower limbs sensory 
neuropathy in six patients. Spinal cord MRI was normal in 3/7 CD patients and in all WD-CD patients. 
Serum copper, exchangeable copper and urinary copper excretion were low. All WD-CD patients had 
an iron deficiency associated. A decrease copper intake after bariatric or other digestive surgeries and 
a chronic use of denture adhesive paste containing zinc were the aetiologies of CD patients. All WD-
CD patients were on zinc salts. CD patients received cooper supplementation, while doses of zinc 
salts were reduced by two third or stopped in WD-CD patients. Evolution was different between the 
2 groups of patients. Haematological disturbances resolved gradually in two months in CD patients, 
while it took 15 months in WD-CD. Neurological symptoms improved in 7/9 patients after a mean 
follow-up of two years. 
Conclusions: Anaemia and lymphopenia associated or not to a posterior cord syndrome must raise 
the possibility of an ACD, even in WD patients.
Is liver transplantation a reasonable alternative in neurologic 
Wilson’s disease patients resistant to chelators?  
Lessons from the French experience in 18 cases
A. Poujois1, R. Sobesky2, F. Woimant1
1Department of Neurology, AP-HP, Lariboisière University Hospital, National Reference Centre for Wilson’s disease and other rare copper diseases, France 
2Hepatobiliary Centre, DHU Hepatinov, AP-HP, Paul Brousse Hospital, National Reference Centre for Wilson’s disease and other rare copper diseases, France
The discovery of chelators and zinc for Wilson’s disease (WD) turned a life-threatening illness into 
a chronic disease. Despite this substantial progress, few patients with severe neurologic presentation 
are from the onset resistant to classical chelation and develop severe handicap or die. Liver transplan-
tation (LT) improves survival in case of hepatic failure, but its indication in severe neurological forms 
without liver failure is controversial. To evaluate the effect of LT in patients with severe neurological 
worsening resistant to active chelation, we studied French WD patients who underwent a LT for pure 
neurological indication between 1994 and 2016. Neurologic impairment with Unified WD Rating Score 
(UWDRS) and modified Rankin score (mRS) were assessed before LT and at the last follow-up. The 
primary outcomes were the survival rate and disability at last follow-up. Prognosis factors were further 
assessed. Eighteen patients had LT. They were highly dependent before LT (mRS 5 in 16/18 patients). 
Neurological symptoms were severe (mean UWDRS 101.3 ± 22.1), with dystonia and Parkinsonism. 
The cumulated survival rate was respectively 88.8%, 82.5%, 72.2% at 1, 3 and 5 years. At last fol-
low-up, 14 patients were alive. Their mean mRS and UWDRS were significantly lower (p = 0.0001 and 
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p = 0.0003) compared to the pre-LT state. Severe sepsis (p = 0.011) and ICU admission (p = 0.001) in 
the month before LT were significantly associated with death. LT is a therapeutic option, that should 
be proposed in selected neurologic WD patients resistant to decoppering therapies, as it allows them 
to gain physical independency with a reasonable risk.
Brain atrophy and neurological impairment  
in Wilson’s disease 
L. Smolinski1, T. Litwin1, B. Redzia-Ogrodnik2, K. Dziezyc1, A. Czlonkowska1
12nd Department of Neurology, Institute of Psychiatry and Neurology, Poland 
2Department of Radiology, Institute of Psychiatry and Neurology, Poland
Objectives: To determine whether brain volume was associated with neurological and functional 
impairments and with copper overload markers in patients with Wilson’s disease. 
Material and methods: In 48 treatment-naïve patients, we assessed neurological and functional 
impairments, with the Unified Wilson’s Disease Rating Scale; measured normalised brain volumes, 
based on magnetic resonance images and assessed copper overload indices, i.e., the concentration of 
non-ceruloplasmin-bound copper and the presence of corneal copper deposits. We correlated brain 
volume measures with neurological and functional impairment scores and copper overload indices. 
Results: Neurological and functional impairments correlated with all brain volume measures, in-
cluding the total brain volume and the volumes of white matter and grey matter (both peripheral grey 
matter and deep brain nuclei). Moreover, higher non-ceruloplasmin-bound copper concentrations were 
associated with lower brain volumes, and patients with corneal copper deposits had significantly lower 
brain volumes than patients without these deposits. 
Conclusions: Our findings provided the first in vivo evidence that the severity of brain atrophy is 
a correlate of neurological and functional impairments in patients with Wilson’s disease and that brain 
volume could serve as a marker of copper toxicity.
Wilson’s disease — liver presentation
P. Socha
Gastroenterology, Hepatology, Nuritional Disorders and Paediatrics, the Children’s Memorial Health Institute, Poland
There are 2 major clinical presentations of Wilson’s disease — liver and neurological (rare in children). 
Liver symptoms may vary in severity — from asymptomatic forms, to cirrhosis and acute liver failure. 
There are adult guidelines and recently elaborated paediatric position paper on diagnosis and therapy 
of Wilson’s disease. Diagnostic criteria for adult, paediatric, neurological and liver presentations are 
similar and use the same scoring system, which is a combination of different clinical symptoms and 
laboratory tests (ceruloplasmin concentration, 24-hour urinary copper excretion, copper content in 
the liver and molecular analysis). WD should be considered in the differential diagnosis of children 
already above the age of 1 year, presenting with any sign of liver disease ranging from asymptomati-
cally increased serum transaminases to cirrhosis with hepatosplenomegaly and ascites or acute liver 
failure. Biochemical tests may be less sensitive in very young children. Pharmacological therapy is 
mainly based on chelating agents, like penicillamine and trientine and zinc preparations. It was proven 
to be very effective, but the major problem on long term is poor compliance. Chelating agents should 
be preferably used in patients with signs of significant liver disease, such as cirrhosis or abnormal 
INR. Zinc salts could be used in pre-symptomatic children identified through family screening, or as 
maintenance therapy after de-coppering with chelators, as long as serum transaminase levels remain 
normal. Liver transplantation is indicated only in selected cases, mainly with acute liver failure and 
medical decision can be based on a special prognostic scoring system.
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Transcranial brain parenchyma sonography in Wilson’s 
disease and healthy controls: quantification  
and correlations with clinical parameters
G.G. Tribl, M.C. Trindade, K.J. Almeida, R.C. Alves, D.C. de Andrade,  
E.T. Fonoff, M.J. Teixeira, E.R. Barbosa, E.J.L. Alho, E. Bor-Seng-Shu
Division of Neurology and Neurosurgery, University of Sao Paulo (USP) School of Medicine, Brazil
Transcranial sonography (TCS) allows easy access, rapid, low-cost, and radiation free imaging of 
brain parenchyma. In Wilson’s disease (WD), TCS has shown an even higher sensitivity than conven-
tional MRI. We compared TCS findings in patients with predominantly neurological, treated Wilson’s 
disease (n = 40 / m = 22) and healthy, matched controls (n = 49 / m = 29) and correlated TCS findings 
with clinical data, including: serum copper and iron parameters, Unified Wilson’s Disease Rating Scale 
(UWDRS), Addenbrooke’s Cognitive Examination–Revised, Mini Mental State Examination, and Beck 
Depression Inventory (BDI). Highly significant differences between patients and controls were found 
for the hyperechogenicity of lenticular nucleus, substantia nigra, thalamus, and midbrain tegmentum/
tectum, and for the values of the midbrain axial area and of the third ventricle width. The echogenic 
area sizes of lenticular nucleus, substantia nigra, and caudate nucleus allowed highly accurate discrim-
ination between patients and controls (areas under the curve 95.4%, 79.4%, and 80.5%, respectively). 
In WD, both dystonia and dysarthria correlated with the hyperechogenicity of lenticular nucleus, the 
midbrain axial area, and the third ventricle width. Parkinsonism, UWDRS total and neurological scores, 
and reduced cognitive performance correlated with an increased third ventricle width. Symptoms of 
depressed mood (BDI15) correlated with a reduced midbrain axial section area. Male sex correlated 
with substantia nigra echogenic area and serum ferritin levels. TCS hyperechogenicity can clearly 
differentiate treated WD patients with neurological manifestations from healthy subjects. Particular 
TCS findings correlate with various dimensions of WD symptoms. The discriminative capacity of TCS 
in detecting brain involvement should be further tested in early-stage WD cohorts.
China’s experience on treatments of Wilson’s disease
X.P. Wang
Shanghai TongRen Hospital, School of Medicine Shanghai Jiao-Tong University
Wilson’s disease (WD), also named hepatolenticular degeneration, is an autosomal recessive genetic 
disorder caused by defects of ATP7B gene. This disease occurs sporadically all over the world. It is 
found in individuals aged 3–80 years, but mainly in children and adolescents. Clinical presentations 
of WD are highly varied, mainly consisting of hepatic and neurological symptoms. Hepatic symptoms 
include acute and chronic liver diseases, such as fulminant hepatic failure (also named as abdominal 
Wilsonian disease) and liver cirrhosis. Neurological symptoms mainly include extrapyramidal symp-
toms and neuropsychiatric symptoms. The extrapyramidal symptoms are dystonia and tremor. Once 
diagnosed with WD, the patient should have a low-copper diet and receive anticopper treatment for 
the rest of their life. The medicines for WD patients are d-penicillamine, sodium dimercaptosuccinate, 
dimercaptosuccinic acid, trientine, zinc preparation, tetrathiomolybdate, etc. Traditional Chinese 
medicine has also shown to be associated with significant positive outcomes in the treatment of WD. 
WD patients treated with an anti-hepatolenticular degeneration decoction exhibited increased copper 
excretion. Positive treatment effects (80–90%) can greatly improve the quality of life. Unfortunately, 
diagnosis of this disease is usually difficult. However, thinking of it and finding it out. Over some dec-
ades, an increasing number of clinical studies have used molecular genetics techniques as the clinical 
diagnosis index, leading to increased accuracy in diagnosis. About 24 000 of WD in-patients in China 
have been studied at a few of University hospitals from Hefei to Shanghai.
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Determination of copper poisoning in Wilson’s disease  
and other metal dysbalances using laser ablation  
inductively coupled plasma spectrometry (LA-ICP-MS)
R. Weiskirchen
Institute of Molecular Pathobiochemistry, Experimental Gene Therapy and Clinical Chemistry, RWTH University Hospital Aachen, Germany
Wilson’s disease (WD) is an autosomal recessive disorder occurring in about one in 30,000 people 
due to mutations in the Wilson’s disease (ATP7B) gene. Affected persons build up extensive copper 
accumulates in the body. The main accumulation and storage sites of copper are liver and brain. We 
have previously introduced novel LA-ICP-MS techniques for quantitative imaging of various metals in 
tissue obtained from experimental WD models or clinical samples from WD patients (Boaru et al., J Cell 
Mol Med 2015; 19: 806–814; Weiskirchen and Uerlings, Cell Mol Med: OA 2015; 1: 3). These innovative 
metal imaging techniques have extended the repertoire of analytical possibilities in WD diagnosis. Here 
we have optimised and extended these studies and showed that the accumulation of copper in the brain 
of ATP7B null mice is majorly found in special regions, while hepatic copper is distributed uniformly 
within the liver. Gene therapy in ATP7B null mice with an AAV8 vector expressing a codon-optimised 
version of the Atp7B gene directed under control of the a1 antitrypsin promoter resulted in a massive 
reduction of hepatic and cerebral copper as assessed by LA-ICP-MS (Moreno et al., J Hepatol, in press; 
Uerlings et al., submitted). These data highlight the fact that LA-ICP-MS technology is one of the most 
powerful and sensitive techniques allowing simultaneous imaging and quantification of various trace 
metals with good sensitivity in experimental WD models. The applicability of the LA-ICP-MS tech-
nology in the diagnosis of WD, other metal-associated disorders, or potential future applications in 
experimental research and clinical daily routine will be discussed.
Wilson’s disease treatment — we need more options
K.H. Weiss
Internal Medicine IV, University Hospital Heidelberg, Germany
Wilson’s disease is a rare genetic disorder of impaired copper transport and excretion, caused by 
loss of function of the ATP7B copper-transporter. Wilson’s disease is clinically primarily characterised 
by varying degrees of liver, neurological and psychiatric manifestations related to damage toxicity of 
excess copper causes to the liver and brain. Treatment of Wilson’s disease remains largely unchanged 
since the introduction of chelators and zinc. With the current standard treatments, improving symptoms 
can take several years and patients with neurological symptoms show a poorer response to therapy 
than hepatic patients. Thus considerable unmet medical needs still exist, what will be discussed in 
the presentation. These unmet needs include more effective copper control, improving symptoms and 
associated disabilities, reducing the risk of neurological worsening after the treatment initiation and 
simplification of dosing regimen for improved compliance.
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Alzheimer’s disease and dementia
Comorbidity variations of depression  
and dementia in the elderly
M. Beridze, A. Dubenko, V. Korostiy, N. Sofilkanych
Department of Neurology, Neurosurgery and Psychiatry, Uzhhorod National University, Ukraine
Material and methods: Cornell Dementia Depression Scale (CSDD), Mini Mental State Examination 
(MMSE) and clock drawing test. 
Results: 231 patients aged 70 years and older with cognitive impairment of varying degrees were 
examined. The results of the study revealed the presence of moderate cognitive impairment syndrome in 
118 patients, unequivocally proven dementia symptoms in 113. Depressive disorders have been detected 
in 88 patients. Depending on the psychopathological structure of the depression syndrome, five major 
clinical types were identified: anxiety, hypochondria, apathy, drowsiness and psychotic depression 
with delirium. In analysing the possible pathogenetic mechanisms of the development of depressive 
disorders in Alzheimer’s disease, three variants of their formation were identified: depression caused 
primarily by reactive and situational mechanisms (38.5%), arising spontaneously, i.e. regardless of the 
connection with psycho-traumatic factors (27.7%), and the intermediate between these two variants of 
depressive disorders (33.8%), in which, along with the reactive-situational content of emotions, there 
was often a pronounced affection of anxiety or anxiety, the primary sense of guilt, characteristic circa-
dian rhythm with attenuation of depression symptoms closer to evening, ideator and motor retardation. 
Conclusions: A clinical picture of depression in Alzheimer’s disease or vascular dementia can occur 
with atypical manifestations, and a number of symptoms of dementia can be mistakenly classified as 
a manifestation of depressive disorder. In a number of cases, patients with initial manifestations of 
dementia can establish the psychogenic (nosogenic) nature of depression. In the vast majority of cases, 
the biological pathogenetic relationships of Alzheimer’s disease and depression are suspected.
Progressive non fluent aphasia: two different clinical cases
I. Buxhelaj1, 2, O. Cibuku1, 2, E. Halili1, 2, J. Kruja1, 2, A. Kuqo1, A. Quka1
1Neurology, UHC Mother Teresa, Albania 
2Neuroscience, Faculty of Medicine, University of Medicine, Albania
Introduction: Progressive non fluent aphasia (PNFA) is a common variant of Frontotemporal De-
mentia (FTD). It is well known the overlap of FTD symptoms and Motor Neuron Disease (MND) or 
Parkinsonism. We present two clinical cases with symptoms of PNFA, with more progressive clinical 
deterioration, associated to MND and Parkinsonism.
Material and methods: Case 1: A 64-year-old male, presented with a two years history of PNFA with 
lately gait disturbances, difficulty in swallowing and pseudo-bulbar affect. The patient had a family 
history of an autosomal dominant (AD) pattern. A physical exam revealed pyramidal signs, as well 
as fasciculations and atrophy in limb muscles and low score MMSE and MOCA. EMG confirmed the 
diagnosis of MND. Brain MRI showed atrophy of bilateral frontal and temporal lobes. Diagnosis: FTD-
MND. He passed away six months after. Case 2: A 61-year-old male, with 18 months history of PNFA 
with lately difficulty in managing the left hand and slow movements. Positive family history of AD 
inheritance. Bilateral rigidity and apraxia, bradykinesia, more prominent on the left arm, low score 
MMSE and MOCA, signs of depression. No signs of autonomic dysfunction. Normal EMG. Brain MRI 
revealed brain atrophy, prominently on the frontotemporal areas. Non responsive to L-Dopa. Diagnosis: 
FTD and Cortico Basal Degeneration. 
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Conclusions: The overlap of MND symptoms and Parkinsonism in FTD can lead to a more rapid 
clinical deterioration and a poor outcome, compared to other FTD variants. Genetic tests, neuroimaging 
and neuropathology may bring further insights in understanding these complex pathologies.
A protein-protein interaction connecting neuroinflammation 
and neurodegeneration in Alzheimer’s disease
F. Cioffi1, W. Adamski1, R. Bansal3, K. Broersen1, J. Parkash3, R. Veerhuis4, H. Wienk2
1Nanobiophysics, MIRA Institute for Biomedical Technology and Technical Medicine, Faculty of Science and Technology, Universiteit Twente, The Netherlands 
2Department of Chemistry, Bijovet Center for Biomolecular Research, Utrecht Universiteit, The Netherlands 
3Biomaterials Science and Technology, MIRA Institute for Biomedical Technology and Technical Medicine, Faculty of Science and Technology,  
Universiteit Twente, The Netherlands 
4Department of Psychiatry, VU University Medical Center, The Netherlands
Neuroinflammation is associated with Alzheimer’s disease (AD) and it is considered a secondary 
response to amyloid-beta (Ab) deposition and neuronal cell death. The neuroinflammatory response 
is driven by interferon-gamma (IFNg)-mediated microglia activation, but how neuroinflammation and 
neurodegeneration are connected is unclear and is a subject of this study. We show that IFNg can interact 
with Ab and modulates its aggregation behaviour by using biopysical techniques. Moreover, the exposure 
of microglia to the formed IFN-g-Ab complex resulted in an enhanced pro-inflammatory response com-
pared to the individual interaction partners. We suggest that the interaction between Ab and IFNg may 
explain the observed connection between neurodegeneration and neuroinflammation in AD.
Eye gaze and aging: the role of working memory  
and inhibitory control
T. Crawford1, E. Smith1, D. Berry2
1Psychology Department, Lancaster University, UK 
2Psychology Department, Keele University, UK
Eye-tracking is increasingly used to study cognitive and biological markers for the early signs of 
neuropsychological and psychiatric disorders. However, in order to make further progress in our under-
standing of these early indicators, a more comprehensive understanding of the neurotypical age-related 
effects on eye-tracking is essential. Speculation on the cause of the observed age-related differences in 
the antisaccade tasklargely centres around 2 sources of cognitive dysfunction: inhibitory control and 
working memory. The inhibitory control account views cognitive slowing and task errors as a direct 
result of the declining of inhibitory cognitive mechanisms. An alternative theory considers that a dete-
rioration of working memory is the cause of these age-related effects on behaviour. The current study 
assessed inhibitory control and working memory processes underpinning saccadic eye movements in 
young and older participants. This was achieved with three experimental conditions that systematically 
varied the extent to which working memory and inhibitory control are taxed in the antisaccade task; 
a memory-guided task was used to explore the effect of increasing working memory load; a Go/No-go 
task was used to explore the effect of increasing inhibitory load; a “standard” antisaccade task retained 
the standard working memory and inhibitory loads. The results revealed that neurotypical ageing is 
associated with changes in both inhibitory control and working memory. Increasing the inhibitory load 
was associated with increased reaction times in the older group, whilst the increased working memory 
load and the inhibitory load contributed to an increase in the anti-saccade errors.
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Is dementia a psychiatric or neurological disease? Differ-
ent angles of the same illness — a psychiatrist’s view
A. Dawidowska
Psychogeriatry, Waitemata District Health Board, New Zealand
Introduction: Dementias are illnesses with well-known neuropathology, but it is not only “an illness”, 
it is a change in one’s experience of surroundings, processing of information, understanding and com-
prehending of feelings and emotions. Neurology and psychiatry offer different angles of understanding 
patients suffering from dementia. 
Material and methods: The author, based on personal experience, discusses different angles of 
medical understanding of dementia and consequent differences in therapeutic approaches. In the 
context of the long historical relationship between neurology and psychiatry, the increased awareness 
of the complexity of the nervous system, the rapid emergence and advancements of neuroscience over 
last 2 decades, the author analyses what makes dementia a psychiatric or a neurological disorder and 
how both neurology and psychiatry can collaborate to improve the outcomes of treatment in major 
neurocognitive disturbances. 
Conclusions: The author concludes that psychiatry offers unique opportunity to integrate patients’ 
experiences into evidence-based physical medicine. By unique focus on human emotions and behaviour 
in health and disease, acknowledging the overlap between neuronal disturbances and psychological 
distress, psychiatry offers the enhancing of well-being and treatment beyond the use of pharmacolog-
ical drugs.
Bexarotene and astaxanthin modulate cholesterol  
and amyloid-beta metabolism in cerebrovascular  
endothelial cells
E. Fanaee-Danesh1, M. Zandl1, V. Roca Agujetas2, C. de Dios2, N. Albrecher1,  
C. Tam Amersdorfer1, C. Chakravarthi Gali1, A. Chirackal Manavalan1, Y. Sun1,  
A. Kober1, M. Reiter1, A. Colell2, U. Panzenboeck1
1Institute of Pathophysiology and Immunology, Elham Fanaee-Danesh, Austria 
2Institut d’Investigacions Biomèdiques de Barcelona IIBB-CSIC, Vicente Roca Agujetas, Spain
Introduction: This study investigated the effects of a pharmacologic retinoid-X receptor (RXR) ag-
onist, bexarotene, and a PPAR-a agonist and strong antioxidant, astaxanthin, on pathways of cellular 
cholesterol metabolism, APP processing, Aß production and transfer at the BBB. 
Material and methods: Primary, porcine brain capillary endothelial cells (pBCEC) were incubated 
with Bex (≤ 100 nM) or Asx (≤ 10 nM) for 24 hours. ApoA-I, ABCA1, LRP1, and BACE1 mRNA expression 
and ABCA1, apoA-I, and Ab oligomer protein levels were determined by RTQ-PCR and immunoblotting. 
In vivo effects on cerebrovascular endothelial cells were investigated using 3xTg AD and non-TG mice 
gavaged with 100 mg/kg Bex, 80 mg/kg Asx, or vehicle control (7 d). 
Results: Cerebromicrovascular endothelial cells isolated from 3xTg AD mice treated with Bex, revealed 
elevated mRNA expression of apoE, ABCA1, and LRP1, whereas Asx treatment resulted in increased 
LRP1 mRNA expression. Both, Bex and Asx reduced BACE1 mRNA expression as compared to cells 
isolated from untreated and from non-Tg treated animals. Bex or Asx treatments dramatically reduced 
levels of soluble Ab oligomers in brain and mBCEC of 3xTg AD mice. Bex treatment of mice further 
revealed up-regulated ABCA1, apoE and LRP1, as well as down-regulated BACE1 mRNA expression 
detected in brain homogenates. 
Conclusions: Our results strongly suggest that these two different nuclear receptor agonists exert 
beneficial effects on cholesterol and Ab metabolism in cerebrovascular endothelial cells.
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Stopping statins in the oldest old with dementia  
and severe dependency
D. Justo, A. Kremer, I. Nachimov, M. Ioffe
Geriatrics, Sheba Medical Center, Tel-Hashomer; Sackler School of Medicine, Tel-Aviv University, Israel
Objectives: To study the association between stopping statins and mortality rates during the following 
year in the oldest old — many of whom with dementia and severely dependent. 
Material and methods: A historical prospective study. Included were all patients (n = 369) aged 80 
years old or more (mean age 87.8 years), hospitalised in a single acute geriatrics department during 
one year. The study group included 140 patients in whom statins were stopped upon admission due 
to lack of indication, polypharmacy, malnutrition, etc. The control group included 229 patients who 
did not use statins in the first place. All-cause 1-year mortality rates were studied. 
Results: Compared with the control group, patients in the study group were younger (87.1 vs 88.2 
years, p = 0.044), had higher prevalence of ischaemic heart disease (46.4 vs 18.8%, p0.001), lower 
prevalence of pressure ulcers (0.7 vs 4.8%, p = 0.035), less nursing-home residency rates (5.7 vs 19.7%, 
p0.001), and lower incidence of hypoalbuminaemia (36.0 vs 57.8, p0.001). Both groups had high, but 
comparable prevalence of dementia (42.1 vs 51.5%, p0.05) and severe dependency (52.1 vs 60.7%, 
p0.05). Still, there were no differences between the groups in terms of 1-year mortality rates in the 
crude analysis (31.4 vs 27.1%, HR 0.87, p = 0.438), as well as following propensity score matching 
(27.7 vs 25.9%, HR 0.89, p = 0.680). 
Conclusions: Stopping statins in the oldest old, many of whom with dementia and severely de-
pendent, is safe.
Neurosyphilis combined with acute anterior  
thalamic infarction
J. Lee1, H. Rhee2, S. Yoon1, K. Park1
1Neurology, Kyung Hee University Hospital, South Korea 
2Neurology, Kyung Hee University Hospital at Gangdong, South Korea
The most common presentations of neurosyphilis are neuropsychiatric manifestations. However, 
neurosyphilis can also cause a variety of neurological diseases, such as stroke or dementia. Here, we 
report on a patient who was diagnosed with neurosyphilis combined with acute anterior thalamic 
infarction. A 65-year-old right-handed man was brought to our memory disorder clinic by his wife, 
who reported that over the past 6 months, the patient had experienced personality changes such as 
apathy, abulia, and emotional lability. The patient’s wife recalled him having fairly good memory; 
however, his memory had deteriorated dramatically over the prior two weeks. He could not remember 
the names of familiar people, and presented with reduced verbal fluency and word-finding difficulty. 
The patient was diagnosed with neurosyphilis based on the results of positive treponemal serology, 
lymphocytic CSF pleocytosis with elevated protein levels, and positive CSF VDRL reaction. However, 
his brain MRI demonstrated focal hyperintensities in the left anterior thalamus and right basal ganglia 
on diffusion-weighted imaging. The above lesions were confirmed to be acute ischaemic cerebral infarc-
tions based on low signal intensity on the apparent diffusion coefficient map. After a 14-day treatment 
course with penicillin G, symptoms of apathy, abulia, emotional lability, disorientation to time and 
place, and reduced verbal fluency noticeably improved. However, the relatively recent symptoms of 
short-term memory impairment and word-finding difficulty persisted, suggesting thalamic amnesia 
remained. Considering neurosyphilis as a dementing illness, the mechanism of cognitive impairment 
may be direct invasion of brain parenchyma, as well as strategic infarction by meningovascular syphilis.
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Frontal cognitive dysfunction with apraxia of eyelid  
opening after traumatic brain injury: a slowly  
progressive delayed complication
M.-Y. Park, D. Shin, M. Kim
Neurology, Yeungnam Medical Center, South Korea
Apraxia of eyelid opening (AEO) has been suggested to be a dysfunction of the supranuclear control 
of the levator palpebrae superioris caused mainly by basal ganglial lesion. The hypometabolism of the 
medial frontal lobe may be a pathophysiologic mechanism in frontal lobe dysfunction and AEO. We 
report two patients who developed frontal cognitive dysfunction with AEO, as a delayed complication, 
4–6 years after traumatic brain injury (TBI) progressively. Their MRI showed encephalomalacia with 
low signal intensity in medial frontal cortex, which suggests loss of cortico-spinal tract fibers in the 
medial frontal cortex, which was not shown in initial brain CT scans. Delayed pathologic changes 
after TBI may contribute to the development of frontal cognitive dysfunction and AEO in these cases. 
Therefore we need to make a close observation if the patients have TBI, especially severe enough to 
loss of consciousness even their brain imaging scans do not show abnormal finding initially. 
Analysis of TOMM40 rs2075650 polymorphism frequency  
in Polish Alzheimer’s disease patients
M. Prendecki1, M. Kowalska1, J. Kosinska2, J. Florczak-Wyspianska3,  
J. Ilkowski4, M. Stanski2, W. Kozubski3, J. Dorszewska1
1Laboratory of Neurobiology, Department of Neurology, Poznan University of Medical Sciences, Poland 
2Students Scientific Neurobiological Association, Poznan University of Medical Sciences, Poland 
3Chair and Department of Neurology, Poznan University of Medical Sciences, Poland 
4Department of Emergency Medicine, Poznan University of Medical Sciences, Poland
Alzheimer’s disease (AD) is a progressive demented disorder with poorly understood pathogenesis. 
Currently, the variants in TOMM40 gene were shown to play an important role in developing AD. The 
poly-T variants (rs10524523) may influence age at onset of AD, while rs2075650 polymorphism is an 
AD risk factor. Both loci may be co-inherited with pathogenic APOE E4 allele. The aim of the study was 
the frequency analysis of TOMM40 rs2075650 polymorphism in Polish AD patients. The peripheral 
blood of 69 subjects with AD, 54 control volunteers (UC) and 48 control persons with family history 
of AD (RC) was collected for plasma and DNA isolation. The APOE and TOMM40 genotypes were 
determined by qPCR, HRM and capillary electrophoresis. The G allele of TOMM40 rs2075650 was 
significantly overrepresented in Polish AD patients as compared to UC and RC (OR = 6.94, 95%CI: 
2.82–17.1, p0.0001 and OR = 2.86, 95%CI: 1.41–5.80, p = 0.0037 respectively), and was more specific 
than APOE E4 (OR = 5.15, 95%CI: 2.38–11.1, p0.0001; and OR = 1.90, 95%CI: 1.02–3.51, p = 0.05) as 
compared to UC and RC, respectively. Moreover, G/G genotype was accompanied with slightly earlier 
age at onset (69.8 vs 72.5 years, p = 0.508) and faster disease progression (5.06 vs 4.78 MMSE/year, p = 
0.821), as compared to A/A variant. Subsequently, 24.6% of AD patients were carriers of both rs2075650 
G and APOE E4 alleles, as compared to 3.70% of UC (OR = 8.83, 95%CI: 1.94–40.1, p = 0.0009). It 
seems that G allele of TOMM40 rs2075650 polymorphism is a significant risk factor for developing AD 
in Polish population, providing additional information to APOE genetic status.
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Preliminary results of screening of the mild cognitive  
impairment and dementia in Almaty
S. Turuspekova, R. Tsoy, B. Demesinova, M. Idrisova
Department of Nervous Diseases No 1, Kazakh National Medical University named after S.D. Asfendiyarov, Kazakhstan
Data on the prevalence of mild cognitive impairment (MCI) and dementia are absent in Central 
Asia, particularly in Kazakhstan. Moderate cognitive impairments, according to several authors are 
an intermediate stage between normal aging and dementia. The prevalence of MCI varies from 16% to 
20%, indicating a high risk of transformation of MCI into dementia. Forty-six point eight million peo-
ple worldwide suffer from dementia. Five point two per cent are people over the age of 60. The main 
aim of the work was to reveal the prevalence of MCI and dementia among people over 60 years old in 
Almaty. 236 respondents aged from 60 to 95 years took part in the screening (mean age of patients 67.5 
± 5.5). The primary material was collected using the CHAMP Clinic Questionnaire and the MOCA 
test (cut point ≤ 26), based on the Almaty city hospital, which numbers are more than 60,000 people, 
10,265 of them are over 60 years old (17.10%). We identified light cognitive impairment — 52.12% 
(123 respondents), mild cognitive impairment — 33.05% (78 respondents), normal cognitive function 
— 14.41% (34 respondents) and 0.42% (one respondent) with dementia. Numerical values indicate 
a high percentage of dementia syndrome development, from 1 to 5 years, in the absence of preventive 
care. Kazakhstan is a middle-income country and a growing trend of an aging population; we urgently 
need to conduct a screening of the population to identify MCI and dementia. This will reduce the risk 
of transition of moderate CI to dementia.
Disrupted cholinergic transmission in mice with Alzheimer’s 
disease-like tauopathy (AD) but not in mice with  
frontotemporal lobar degeneration-like tauopathy (FTLD)
A. Wysocka, M. Zadrozny, M. Steczkowska, E. Palasz, G. Niewiadomska
Laboratory of Preclinical Studies in Neurodegenerative Diseases, Nencki Institute of Experimental Biology, Poland
An important enzyme associated with the brain cholinergic system is acetylcholinesterase (AChE, 
E.C.3.1.1.7). The AChE staining in cortex and hippocampus coincides with much of the cholinergic 
innervation originating from the basal forebrain.
AChE activity in cortex and hippocampus was evaluated in 2 tauopathic mouse models: Line 1 
(L1), with mild Alzheimer’s disease-like tauopathy and Line 66 (L66) with severe frontotemporal lo-
bar degeneration-like tauopathy (FTLD) relative to age-matched wild-type NMRI mice. Analysis was 
performed in 3 and 12.5-month-old mice to assess cortical and hippocampal cholinergic innervation 
originating from the basal forebrain. For AChE histochemistry, brain sections were stained with the 
method of Geneser-Jansen and Blackstad (1971). Computer image analysis system (NIS-Elements BR 
4.30.00 Software) was used for quantitation of the intensity of staining (ROD, relative optical density) 
measured in the arbitrarily defined areas (75,000 ± 500 mm2) across the entire depth of cortical and 
hippocampal layers.
In cortex and hippocampus intensity of AChE staining was significantly lower in L1 in comparison 
with L66 and NMRI lines of both age groups. Additionally, in L1 mice a characteristic bilaminar pattern 
of laminar distribution of AChE-rich fibres in layers II and V was not clearly visible. AChE histochemical 
staining data suggest that there is an impairment of the basal forebrain cholinergic projection in L1 mice, 
what corresponds with observed lower intensity of ChAT and p75 immunohistochemical staining in 
basal forebrain neurons of these mice. Tauopathy of AD-type seems to be associated with destruction 
and disorganisation of the cholinergic projections extending to both cortex and hippocampus.
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Acute hypoxia induced an imbalanced M1/M2 activation  
of microglia through NF-kB signalling in Alzheimer’s  
disease mice and wild-type littermates
F. Zhang, R. Zhong, W. Le
Center for Clinical Research on Neurological Diseases, the First Affiliated Hospital, Dalian Medical University, China
Alzheimer’s disease (AD) is the most common neurodegenerative disease mainly caused by abnormal 
tau phosphorylation, amyloid b (Ab) deposition and neuroinflammation. As an important environmental 
factor, hypoxia has been reported to aggravate AD via exacerbating Ab and tau pathologies. However, 
the link between hypoxia and neuroinflammation, especially the changes of pro-inflammatory M1 or 
anti-inflammation M2 microglia phenotypes in AD, is still far from being clearly investigated. Here, we 
evaluated the activation of microglia in the brains of APPswe/PS1dE9 transgenic (Tg) mice and their 
wild type (Wt) littermates, after a single episode of acute hypoxia (24 hours) exposure. We found that 
acute hypoxia activated M1 microglia in both Tg and Wt mice as evidenced by the elevated M1 markers 
including cluster of differentiation 86 (CD86), tumour necrosis factor-a (TNF-a), interleukin-6 (IL-6), 
C-C motif chemokine ligand 2 (CCL2) and CCL3. In addition, the markers of M2 microglia phenotype 
(arginase-1 [Arg-1], CD206, IL-4 and IL-10) were decreased after acute hypoxia exposure, suggesting 
an attenuated M2 phenotype of microglia. Moreover, the activation of microglia and the release of 
cytokines and chemokines were associated with Nuclear factor-kB (NF-kB) induction through toll-like 
receptor 4 (TLR4). In summary, our findings revealed that acute hypoxia modulated microglia M1/M2 
subgroup profile, indicating the pathological role of hypoxia in the neuroinflammation of AD.
Diagnostic prospects of early Alzheimer’s disease  
based on blood microRNAs
K. Zoltowska1, S. Nagaraj1, K. Laskowska-Kaszub1, K. Debski2, J. Wojsiat1,  
M. Dabrowski2, T. Gabryelewicz3, J. Kuznicki4, U. Wojda1
1Neurobiology Centre, Laboratory of Preclinical Testing of Higher Standard, Nencki Institute of Experimental Biology of Polish Academy of Sciences, Poland 
2Neurobiology Centre, Laboratory of Bioinformatics, Nencki Institute of Experimental Biology of Polish Academy of Sciences, Poland 
3Department of Neurodegenerative Disorders, Mossakowski Medical Research Centre, Poland 
4Laboratory of Neurodegeneration, International Institute of Molecular and Cell Biology, Poland
Alzheimer’s disease (AD) is the most common cause of dementia in the elderly. One of the major 
challenges in the AD field is deciphering the molecular signatures, characteristic of early stages of the 
disease, in peripheral tissues in patients suffering from mild cognitive impairment (MCI) due to AD. 
In this study qRT-PCR was applied to evaluate microRNA (miRNA) profiles in blood plasma collected 
from 15 MCI-AD patients, whose diagnoses were confirmed by cerebrospinal fluid (CSF) biomarkers, 
20 AD patients and 15 non-demented, age-matched individuals (CTR). 179 plasma miRNAs were 
compared between AD and CTR, and between MCI-AD and CTR. 23 differentially expressed miRNAs 
reported earlier as AD biomarker candidates in blood were confirmed in the current study and 26 novel 
differential miRNAs between AD and CTR were detected. TargetScan, MirTarBase and KEGG database 
analysis of 15 miRNAs that presented statistically significant differences in their expression indicated 
that these may regulate the expression of microtubule associated protein tau (MAPT), proteins involved 
in amyloid precursor protein (APP) processing and proteins regulating apoptosis. The potential of 
these 15 miRNAs to be used as biomarkers was further verified in independent AD, MCI-AD and CTR 
groups. Finally, 6 miRNAs (3 novel in AD context and 3 reported) were selected as the most promising 
biomarker candidates differentiating early AD from controls with the highest fold changes (from 1.32 
to 14.72), consistent significance, specificities from 0.78 to 1 and sensitivities from 0.75 to 1, (patent 
pending, PCT/IB2016/052440). The miRNA panel is promising for diagnostics of early AD.
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Epilepsy
Theory of mind deficits in two neuropsychiatric  
populations: patients with mesial temporal lobe  
epilepsy and schizophrenia 
A. Bala1, L. Okruszek2, M. Szantroch3, A. Rysz3, A. Marchel3
1Faculty of Psychology, University of Warsaw, Poland 
2Institute of Psychology, Polish Academy of Science, Poland 
3Department of Neurosurgery, Medical University of Warsaw, Poland
Introduction: Patients with schizophrenia (SCZ) have been widely reported dysfunctional in their 
ability of emotion recognition as well as understanding of social signals. Interestingly, similar deficits 
have been found in population of patients with mesial temporal lobe epilepsy (MTLE). The common 
feature of both conditions is a dysfunction of limbic system network, which is believed to underlie 
emotional and social processing. The aim of the study was to compare these two clinical populations. 
Material and methods: The study involved patients with MTLE (n = 31), schizophrenia (n = 48) and 
a healthy controls group (HC; n = 47). Groups were matched in terms of age, sex and education. The 
all subjects were examined with a Reading Mind in the Eyes Test (RMET), which evaluates emotion 
recognition and theory of mind. Patients with schizophrenia were additionally assessed with Positive 
And Negative Syndrome Scale (PANSS). 
Results: Results showed, that RMET scores of both epilepsy (p0,001) and schizophrenia (p0,05) groups 
were lower than in HC, but similar to each other (p0,05). In the next step patients with schizophrenia 
were split into 2 groups with respect to the PANSS scores. The analysis showed that SCZ patients 
with high level of positive symptoms performed similar to MTLE (p0, 05) and worse than HC (p0, 05), 
while those with low level of positive symptoms performed similar to control group (p0,05) and better 
than MTLE (p0,05). No differences were found for the median-split with regard to negative symptoms. 
Conclusions: MTLE patients present theory of mind dysfunctions similar to those found in the 
individuals with schizophrenia with high positive symptoms.
Brain MRI post-processing with MAP07 in preoperative 
evaluation of patients with pharmacoresistant epilepsy  
— our experience
A.-B. Kovac1, Z.-P. Gadze1, M. Rados2, S. Nankovic1, V. Sulentic1, I. Cajic1, M.-K. Skoric1
1Department of Neurology, University Hospital Centre Zagreb, School of Medicine, University of Zagreb, Referral Centre of the Ministry  
of Health of the Republic of Croatia for Epilepsy, Croatia 
2Croatian Institute for Brain Research, School of Medicine, University of Zagreb, Croatia
Epilepsy is a chronic disease of the central nervous system that affects 1% of the population. The 
large number of patients with the proper selection of antiepileptic drugs can achieve satisfactory seizure 
control, while the remaining 25–35% have pharmacoresistant epilepsy and are considered as candi-
dates for active neurosurgical treatment. Preoperative evaluation of patients with pharmacoresistant 
epilepsy can be divided into two phases. Phase I includes non-invasive diagnostic procedures — EEG; 
continuous video-EEG polygraphic recording; preoperative neuropsychological testing; brain MRI 
(magnetic resonance imaging), preferentially 3T MRI, with specialised recording techniques including 
MRI spectroscopy, functional MRI and MRI hippocampal volumetry; post-processing of brain MRI; ictal 
brain SPECT (Single-Photon Emission Computed Tomography); PET (Positron Emission Tomography) 
and optionally MEG (magnetoencephalography) with MSI (“Magnetic Source Imaging”). Phase II en-
105
E-Poster Abstracts
www.journals.viamedica.pl
compasses invasive methods in carefully selected patients — Wada test; semi-invasive monitoring with 
sphenoidal electrodes; invasive monitoring (with subdural strip and grid electrodes, depth electrodes, 
and with cortical stimulation procedure). The most significant neuroradiological procedure in proper 
selection of candidates suitable for neurosurgery is MRI 3T. Post-processing of brain MRI with MAP07 
(Morphometric Analysis Program) is a new sophisticated diagnostic procedure. The program offers 
a number of graphical post-processing methods (maps) and facilitates the detection and localisation 
of hippocampal sclerosis, focal cortical dysplasias and other types of cortical malformations, which 
cannot be easily detected by conventional neuroradiological methods. We present our experience 
with MAP07 software in the preoperative evaluation of patients with pharmacoresistant epilepsy and 
selection of candidates for neurosurgical treatment.
Episodic amnesia — vascular or epileptic nature  
related to mild cognitive impairment
A. Cuciureanu1, I.-D. Cuciureanu2, T. Cuciureanu2, 3
1Neurology, CMI Cuciureanu Adina, Romania 
2Neurology, University of Medicine “Gr. T. Popa” Iasi, Neurology, Iasi, Romania, Romania 
3Gastroenterology, University of Medicine “Gr. T. Popa” Iasi, Neurology, Iasi, Romania, Romania
Objectives: To evaluate the diagnosis and the assessment of therapeutic response of patients who 
presented transient, recurring amnesia states and developed mild neurocognitive disorder. 
Material and methods: We have analysed and put under medical surveillance initially for 2 years 
long and after this assessment 3 years more ten patients with repeated amnesic states. We used clinical 
examination, repeated EEG brain scanner, echocardiography, Doppler cerebral, biochemical analysis 
and psychological test. 
Results: All 10 patients underwent a standardised clinical interview, patients aged between 52–68 
years, 3 men and 7 women all had vascular risk factors (hypertension, dyslipidaemia, smoking, obesi-
ty). Tests were performed cognitive and psychological (MMSE, MOCA), being excluded patients who 
had initially MCI or dementia. All 10 patients described attack with sudden onset, 8 to 50 minutes, 
of anterograde incomplete amnesia, repetitive questioning, and progressive recover. Neuroimaging re-
corders showed: 1 case with dural sinus thrombosis, 6 cases with ischaemic lacunae and 3 cases with 
normal brain image in computer tomography. Interictal surface EEG recording was performed with 
non-specific modification. All patients received vascular treatment for 5 years and only 4 anticonvul-
sant therapies. 6 of 10 patients were not presented attacks under vascular therapy and the other four 
after the introduction of anticonvulsant therapy. Psychological assessment after 5 years of evolution 
revealed in 8 cases mild neurocognitive disorders. 
Conclusions: In some cases only therapeutic test can distinguish between transient global amnesia 
and transient epileptic amnesia, but ours patients developed minor neurocognitive deficit related 
probably to vascular risk factors.
Prospects for the use of cannabinoids  
in the treatment of epilepsy
S. Czuczwar, B. Miziak
Department of Pathophysiology, Medical University of Lublin, Poland
There is a broad evidence on the protective activity of synthetic cannabinoid agonists against a variety 
of chemoconvulsants or electroconvulsions in rodents. The interactions between cannabinoid agonists 
(WIN 55,212–2 mesylate — non-selective CB1 and CB2 receptor agonist or ACEA — a selective CB1 re-
ceptor agonist) and antiepileptic drugs (AEDs) have been evaluated. In the mouse maximal electroshock 
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model, ACEA (in subthreshold doses and always co-administered with a fatty-acid amide hydrolase 
inhibitor) potentiated the anticonvulsant action of conventional AEDs, valproate and phenobarbital 
and a newer AED, pregabalin. In no case, the adverse effects of AEDs (impairment of motor coordina-
tion, long-term memory and muscular strength) were enhanced by ACEA. As regards WIN 55,212–2 
mesylate, it potentiated the anticonvulsant activity of carbamazepine, phenobarbital, phenytoin, val-
proate (classical AEDs) and that of lamotrigine, pregabalin and topiramate (newer AEDs). In all cases 
of the combinations with classical AEDs, profound neurotoxic effects were evident. Combinations with 
newer AEDs were free from pharmacokinetic mechanisms or neurotoxic effects. The initial clinical 
data on the add-on treatment with cannabidiol (a non-psychoactive cannabinoid) indicate that in 23 
children and young adults with drug-resistant epilepsy, there was a 39% reduction in responder rate 
and 17% of patients were seizure free. The most frequent adverse effects included somnolence (57%), 
fatigue (57%) and increased concentrations of concomitant AEDs (22%). The experimental data point 
to the beneficial interactions of cannabinoid agonists with newer AEDs. More clinical data are required 
before reliable conclusions can be drawn on this issue. 
Acknowledgements: Supported by DS 475.
Potential benefits of music for patients with epilepsy
F. Derke1, D. Milat2, L. Filipovic-Grcic1, Z. Petelin-Gadze3
1School of Medicine, University of Zagreb, Croatia 
2“Sveti Rok”, Polyclinic, Croatia 
3Department of Neurology, University Hospital Centre Zagreb, School of Medicine, University of Zagreb, Referral Centre of the Ministry  
of Health of the Republic of Croatia for Epilepsy, Croatia
Human race has been living with music since ancient times. People listen to music, play music, 
and create music. The connection of musical sounds and the brain functions is a major challenge of 
modern neuroscience. It has long been proven that music has a psychological effect on human beings, 
including induction and modification of cognitive states, moods and emotions. It is possible that brain 
mechanisms involved in musical processing may be involved in the generation and propagation of 
seizures, manifesting with musical semiology. Hyperexcitable cortical areas may also become sensitised 
to specific musical triggers and may explain the basis of musicogenic epilepsy. On the other hand, 
anticonvulsant role of music has largely been explored in cognitive science. The cognitive effects of 
music are well documented in the literature, although these effects have been subject to scrutiny. In 
our review of available literature, we explored the potential of listening and playing music as a part of 
chronic anticonvulsant therapy. All of the collected data were distributed in three categories: music 
as a factor in reduction of the number of seizures, joint effect of music and pharmacotherapy, and 
the effect of music who underwent neurosurgical procedure. We have presented all our findings in 
infographics. In our review-study all the results clearly indicate that the music would be a powerful 
tool in the service of the neurological rehabilitation. Music activates many brain structures, increases 
cerebral circulation and stimulates the brain, but there is limited evidence of the anticonvulsant effect 
of music in epilepsy.
Are the physical anthropological types associated  
with a presence of epilepsy?
A. Dubenko, A. Kutikov
Epilepsy Department, Institute of Neurology, Psychiatry and Narcology of the NAMS of Ukraine, Ukraine
Introduction: A physical anthropological diversity of any human population is its stable and very 
important characteristic, which influences on various aspects of existence of this population, includ-
ing epidemiological ones. For some neurological pathology an association was confirmed between 
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certain anthropological phenotypic variants (PhVs) and a presence of the disease, peculiarities of its 
symptoms and course. 
Material and methods: To define specific PhVs, an integrated anthropological examination of 51 per-
sons with epilepsy (G40), who formed the main group (MG), and 50 healthy persons, who represented 
a general population of Kharkiv Region (Ukraine) as a control group (CG), was performed. 
Results: It was demonstrated that the presence of epilepsy was associated positively with Uralic 
(17.65% in MG vs 0.00% in CG; p0.05) and Armenoid (11.76% vs 0.00%, respectively; p0.05) PhVs. 
A tendency to be associated positively was indicated also for Atlanto-Baltic PhV (9.80% vs 6.00%, 
respectively). All these PhVs were few represented in the structure of the general population. Medi-
terranean (17.65% in MG vs 20.00% in CG), Dinaric (11.76% vs 12.00%, respectively) and East-Baltic 
(7.84% vs 8.00%, respectively) PhVs were neutrally associated with the presence of epilepsy. A negative 
association with the presence of epilepsy was found out for Alpine (13.73% in MG vs 32.00% in CG; 
p0.05) and Paleo-European (9.80% vs 22.00%, respectively; p0.05) PhVs. 
Conclusions: Thus, it was shown definitely the existence of a specific phenotypic structure of the 
group of patients with epilepsy in comparison with general population and association between the 
presence of epilepsy and certain PhVs for Kharkiv Region.
The role of serum prolactin in diagnosis  
of seizure disorders in children
M. Elsied, A. Soliman, T. Goda, N. Elawdy
Neurology Department, Zagazig University Faculty of Medicine, Magdy Abdelhamed Aidaros Elsied, Egypt
Objectives: The purpose of this study is to review the use of serum prolactin assay in epileptic sei-
zure diagnosis and to differentiate between epileptic seizures from psychogenic non-epileptic seizures 
in children. 
Material and methods: This study was conducted on 48 children aged 1–18 years of age, and com-
prised of four groups: Group 1 consisted of children with epilepsy, which was further subdivided into 
GTCS, CPS and SPS, Group 2 comprised of children suffering from non-epileptic paroxysmal events 
like breath holding spell, syncope and pseudoseizures. Group 3 comprised of children having febrile 
convulsions, Group 4 consisted of children who served as controls. Blood sample was collected within 
2 hours of the event in all the groups, serum prolactin level was estimated by ELISA technique. 
Results: In the present study, significant elevation of serum prolactin level was observed only in 
Group 1 (28.31 ± 15.61) as compared to controls (9.97 ± 2.91), and the highest levels were observed 
in children with GTCS and with status epilepticus, serial seizures. Maximum elevation of prolactin 
was seen within two hours post ictally, as the prolactin levels become normal after two hours of post 
ictal period, the test loses its significance. 
Conclusions: Elevated serum prolactin assay, when measured in the appropriate clinical setting 
within 2 hours after a suspected event, is a useful adjunct for the differentiation of epileptic seizures 
from psychogenic non-epileptic seizure among children.
Doctor–patient relationship and the art of communication
S. Horowitz
Yorktown Science Program, Yorktown School, USA
Patients with epilepsy often experience poor emotional well-being. In one study it was determined that 
38.4% of epilepsy patients showed symptoms of depression (Hecimovic, 2012). A good doctor-patient 
relationship has proved to be a central component, to both the physical and emotional health of the 
patient. Although various studies have looked at the impact that doctor−patient relationships has on 
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health, there are no studies specifically studying the impact it has on patients with epilepsy. The goal 
of this study was to compare neurologists and patient’s perspective on how doctor-patient relationship 
impacts one’s health. Online surveys were created and neurologists were identified with the US through 
pattern matching. A total of 65 patients and 255 neurologists participated in this study. After analysing 
the result from the two different surveys, it was discovered that, doctor−patient relationship plays a crit-
ical role in the emotional well-being of patients, from both the doctor’s and the patient’s perspective. 
Moreover, humour in care, was also seen by both the patients and neurologists as a significant factor 
in establishing communication and fostering better outcomes in care. The findings of this research 
emphasised the importance of doctor−patient relationships, specifically around the patient centred 
care and communication and health. A greater emphasis on doctor−patient communication should be 
broadened, covered throughout the spectrum of one’s training, and covered using various modalities. 
The use of humour within the doctor−patient communication should also be further addressed, as it 
was an important factor in care.
Arterial spin labelling in focal epilepsies
S. Jaiswal, S. Parida, J.M.K. Murthy
Neurology, Care Institute of Medical Sciences, India
Introduction: Arterial spin labelling (ASL) provides a non-invasive means of measuring cerebral blood 
flow (CBF). The technique uses magnetically labelled arterial blood water protons as endogenous tracer. 
The hypothesis is that ASL perfusion changes may occur peri-ictally in patients with focal epilepsy. 
Material and methods: Patients with focal-onset seizures were studied for ASL perfusion changes in 
the peri-ictal period. Based on the MRI findings, the patients were grouped: Group A: MRI positive for 
the lesion; Group B: MRI positive for 2 lesions and Group C: MRI negative for lesion. Areas of hyper- or 
hypoperfusion were correlated with seizure semiology, inter-ictal EEG and MRI findings. 
Results: During the study period, 27 patients (mean age: 39.3 years, range 10–73 years; M:F 9:18) 
with focal epilepsy were studied. The time interval between seizure and ASL study ranged 15’–72 
hours, mean 21.28 hours. Group A: out of 19 patients, 15 (79%) had ASL changes (7 hypo-perfusion, 8 
hyper-perfusion) correlating with MRI lesion. Group B: out of 4 patients, 3 had ALS perfusion of only 1 
lesion. Group C: all the 4 patients had ASL perfusion abnormalities corresponding to the epileptogenic 
focus in the EEG. Time interval between seizure and ASL study: hyperfusion — mean 3 hours (range 
0.25–7 hours); hypoperfusion — mean 17 hours (range 1–48 hours); and no ASL perfusion changes — 
mean 61 hours (range 52–72 hours). 
Conclusions: Peri-ictal ASL helps in localising the possible epileptogenic focus in patients with focal 
epilepsy, even in MRI negative patients. The earlier the study, the higher the yield.
Focal nonconvulsive status epilepticus  
manifested as an antegrade amnesia
D.Y. Kim, J.M. Kim
Department of Neurology, Chungnam National University School of Medicine, South Korea
Introduction: Usual clinical feature of nonconvulsive status epilepticus (NCSE) includes confusion 
or aura continua. Limbic encephalitis predominantly involves hippocampal structures which have 
crucial role in memory registration. Memory impairment is common sequelae of limbic encephalitis. 
We report a woman who had persistent memory impairment as sole manifestation of NCSE. 
Material and methods: A previously healthy 38-year-old woman presented with repeating gen-
eralised seizures and gradual impairment of consciousness into stuporous state. EEG demonstrated 
electrographic seizures in both temporal areas. Brain MRI showed signal increment in bilateral mesial 
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temporal lobes. CSF was positive with anti-NMDA receptor antibody. She was diagnosed as a status 
epilepticus with anti-NMDA receptor antibody encephalitis. Antiepileptic treatment including mida-
zolam continuous infusion and immunomodulating therapy were undertaken. Midazolam continuous 
infusion was continued until when both electrographic seizures and periodic discharges disappeared. 
She recovered from the coma 18 days after the presentation. Her neurologic deficits were completely 
recovered except one. She suffered from persistent antegrade amnesia. Neurocognitive testing indicated 
significant impairment in the memory domain, while other domains were relatively preserved. A fol-
low-up EEG and MRI were unremarkable. FDG-PET revealed focal hypermetabolism in the body of the 
right hippocampus. Antiepileptic drug treatment with higher intensity alleviated her antegrade amne-
sia. We concluded that the antegrade amnesia was a manifestation of persistent focal seizure activity. 
Conclusions: Uncontrolled focal seizure activity can present as a memory impairment and can be 
mistaken for some sequelae of the limbic encephalitis. PET or SPECT could be helpful in discriminat-
ing these two conditions.
Cognitive disorders associated with epilepsy screening  
by Addenbrooke’s Cognitive Examination — revised
V. Korostiy1, A. Dubenko2, T. Litovchenko3, I. Blazhina1
1Psychiatry, Narcology and Medical Psychology, Kharkiv National Medical University, Ukraine 
2Department of Brain Vascular Pathology, Institute of Neurology, Psychiatry and Narcology of the National Academy of Medical Sciences of Ukraine, Ukraine 
3Neurology and Child Neurology, Kharkiv Medical Academy of Postgraduate Education, Ukraine
Introduction: Addenbrooke’s cognitive examination-revised (ACE-R) using for evaluating of the 
cognitive disorders associated with epilepsy (CDAWE) in general medical practice. Neuropsychological 
tools plays an important role in differentiation of CDAWE. All of it stipulates the necessity of application 
for general medical practice of simple and reliable psychometric instruments for early diagnostics of 
cognitive disorders. One of the methodologies worked out for these aims is modified Addenbrooke’s 
Cognitive Examination — Revised — ACE-R. 
Material and methods: The study was conducted in two steps at somatic hospitals and city poly-
clinics. It enrolled 31 patients (18 men and 13 women) with epilepsy spectrum disorders. Work did 
not include patients with mental backwardness, violations of physical development and chemical 
addictions. Diagnostics was conducted by doctors-psychiatrists. The psychometric characteristics of 
ACE-R and the possibilities of its use were estimated to detect CDAWE. The differences in the spectrum 
of cognitive impairments were analysed in patients with different types of CDAWE. 
Results: ACE-R is shown to be an effective neuropsychological tool for the primary diagnosis de-
tection and evaluation of CDAWE in the general medical network. The results of ACE-R use indicate 
that the spectrum of cognitive impairments has substantial differences in patients with different types 
of CDAWE.
Conclusions: ACE-R showed a high sensitiveness for patients with epilepsy. It can be used for 
estimation both clinically outlined organic and subclinical cognitive disorders.
Antiepileptic treatment in patients with  
and without cardiovascular pathology
T. Litovchenko1, V. Grymailo2
1Neurology and Childhood Neurology, Kharkiv Medical Academy of Postgraduate Education, Ukraine 
2Functional Diagnostic, Kharkiv Clinical Railway Hospital No 1, Ukraine
We observed 50 patients with epilepsy and cardio-vascular diseases (CVD) and 50 patients without 
CVD, who were treated with carbamazepine (CMZ) 25%, valproic acid (VPA) 26%, lamotrigine (LTG) 
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24% and levetiracetam (LEV) 25%. Each patient had clinical neurological examination, ECG, EEG, 
lipidogram, heart ultrasound (Tei-index, M-Strain, Strain % evaluation), carotid arteries dopplerog-
raphy. In patients on CMZ sinus bradycardia, sick sinus syndrome, ventricular and supraventricular 
arrhythmias, rise of total cholesterol and low density lipoprotein were reliably more often than in 
patients on VPA, LTG and LEV (p0,01). In patients on VPA rise of triglycerides, increase of intima-me-
dia thickness more than 0,7 mm were reliably more often than in patients on CMZ (p0,05), LTG and 
LEV (p0,01). Patients on VPA with CVD had lowest Tei-index and M-Strain (p0,01) compared with 
patients without CVD after six months of treatment (p0,05). That could be a predictor of diastolic 
heart dysfunction. We revealed heart rate and conductance disturbances in patients who were taking 
CMZ, VPA, LTG, increasing of cardiovascular risk parameters in patients taking CMZ, VPA. Patients 
on CMZ had more significant changes of lipidogram, but patients on VPA had worse results of carotid 
arteries dopplerography. Patients on VAL had negative inotropic effect that was more significant seen 
in patients with CVD (p0,01), so we can say that VAL administration requires careful heart function 
monitoring in patients with heart failure and CMZ — in patients with arrhythmias. Also lipidogram 
and intima-media thickness should be checked more often in patients on VAL and CMZ.
Some aspects of difficulty in management  
of status epilepticus in patients with coma
T. Manjgaladze1, L. Rukhadze2, G. Kilptari3, M. Mgaloblishvili2, G. Chakhava4
1Neurology, LTD “Deka”, Georgia 
2Neurology, Central University Clinic after academic N. Kipshidze, Georgia 
3Reanimatology, Central University Clinic after academic N. Kipshidze, Georgia 
4Neurology, Multiprofile Clinic “Medula”, Georgia
Status epilepticus (SE) is one of the most common neurological conditions, which needs an emer-
gency assistance. In general, the management of SE is more difficult in patients with unknown coma. 
Under our observation there were 6 patients with different aetiologic factors of coma. 3 patients from 
them had immunologic disorder causing status epilepticus. In 4 of the cases, non-convulsive status 
epilepticus was identified. In three cases we have diagnosed progressive forms of main diseases, but 
we could not find out aetiologic factors of manifested immunological disorders. For the treatment, we 
have decided to use anticonvulsive drugs in combination with hormonotherapy and immunoglobuli-
notherapy. At the same time, all the patients were under the general anaesthesia including Ketamine. 
Despite of this, in two cases we could not control the SE development for a long period of time. In all 
of the cases, we have used EEG-monitoring and MRI study in dynamics. These observations showed 
that the lack of control was related to the exacerbation of the main disease or the processes. All in all, 
we have arrived at the conclusion that the acute disorder of the central nervous system and its devel-
opment is very important in the SE management and the SE management itself defines the solution. 
It relates to both of the types of statuses: non-convulsive and convulsive. Moreover, timely diagnosis 
is significant in the management of the refractory SE.
Cases of frontal epilepsy, revealed during EEG  
screening in a psychiatric consultation
O. Mostovaya
Neuropsychiatry, Vinnytsia National Medical University named N. I. Pirogov, Ukraine
Introduction: Frontal epilepsy is a common and difficultly diagnosed disorder. It accounts for 1–2% 
of cases of primary detected epilepsy and 20–22% among recorded cases of focal epilepsy. Epileptogenic 
foci may be located in different departments of a highly differentiated frontal lobe. Depending on the 
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affected area, the main types of seizures are distinguished: Motor, Dorsolateral, Orbitophronal, Frontal 
(front). With violation of mental functions: Zingular, Brake, Combined. The most difficult for diagnostics 
are seizures with violation of mental functions. They are virtually unidentified by neurologists, since 
patients are turning to psychiatrists and do not give cause for EEG research. According to our obser-
vations, the nature of the disorders is in the borderline spectrum. Here are 3 observations of our own. 
Material and methods: The 1st case — a girl G., 19 years old, a student, who after experiencing 
a stressful situation, developed a state of affective excitation, confusion, insomnia. This condition has 
developed sharply. Received neuroleptic and lamotrigine during the appointment of a psychiatrist. 
Well came out of this state, but such attacks began to repeat with less significant stress. The use of only 
neuroleptics did not have an effect. In the EEG study, epileptic activity was detected in the anterior 
parts of the frontal area. MRT without pathology. The appointment of lamotrigine has stabilised the 
condition. The 2nd case is a woman of 42 years and the 3rd case, a woman of 52 years — EEG similar 
to the first case. 
Conclusions: The epilepsy of the anterior part of the frontal lobe is clinically manifested by psy-
chiatric symptoms: paroxysmal of states of control impairment, “the sense of automaticity” of their 
actions, “fog”, confusion, due to the disintegration of mental functions; depressive state is resistant to 
antidepressant treatment. These manifestations are very difficult to differentiate with depressive and 
psychotic episodes. Therefore, all patients with depressive states, disorganisation and/or automatism 
need to do an EEG study.
Functional and structural differences between right  
and left unilateral mesial temporal lobe epilepsies
H. Park, J.W. Yang, S. I. Hwang
Neurology, Gachon University Gil Medical School, South Korea
Hippocampal sclerosis has been the most common aetiology of the mesial temporal lobe epilepsy 
(MTLE) and is regarded as the most crucial anatomical region. However, it is not just a focal disease 
and other cortical and subcortical areas seem to be affected in MTLE. Using resting functional MRI 
(fMRI) and voxel-based morphometry (VBM), we aimed to investigate the functional and structural 
changes in patients with unilateral MTLE with hippocampal sclerosis according to the each side. The 
study group consisted of ten MTLE patients associated with unilateral HS (right n = 6, left n = 4). All 
participants were right-handed and well-controlled, seizure-free state. We obtained T1 and T2* weighted 
images from 3T MRI (Verio, Siemens, Germany). As a result, no characteristic difference was observed 
in the analysis of resting fMRI. Each patient showed individual, inconsistent functional connectivity 
pattern. However, decreased volumes in the widespread extra-hippocampal regions (bilateral insula, 
bilateral thalamus and contralateral hippocampus in the right MTLE and left insula, contralateral 
hippocampus in the left MTLE) were observed in the VBM analysis. These differences could not be 
attributed to a different present disease severity, epilepsy duration, or seizure frequency, since those 
factors did not differ significantly between the left and right-sided MTLE/HS subgroups. Due to lack 
of the number of patients, further study will be required for the concrete conclusion; however, these 
differences could be theoretically explained by different neuronal networks, connections among brain 
areas and structural changes may precede functional changes.
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Super-refractory status epilepticus of unknown aetiology 
with late onset and fatal outcome — case report
V. Sapira1, M. Lungu1, A. Trifan2, I.M. Cojocaru3, G. Socoliuc4, A. Telehuz5
1Neurology, Emergency Clinical County Hospital Sf. Apostol Andrei, Romania 
2Emergency Department, Emergency Clinical County Hospital Sf. Apostol Andrei, Romania 
3Neurology, Colentina Clinical Hospital, Romania 
4Neurology, Sanador Medical Center, Romania 
5Emergency Department, Emergency County Hospital, Romania
Introduction: Super-refractory status epilepticus is defined as status epilepticus that continues 
or recurs 24 hours or more after the onset of anaesthetic therapy, including those cases where status 
epilepticus recurs on the reduction or withdrawal of anaesthesia. It is an uncommon but important 
clinical problem with high mortality and morbidity rates. 
Material and methods: We are presenting the case of a 48-year-old patient, with no previous patho-
logical history, no chronic treatment at home, that came to the Emergency Unit with altered state, GCS 
8 points coma, and initial tonicoclonic convulsive seizures continuous. The patient was an alcohol 
abuser, and in an acute intoxicated state at the time of the arrival (0,5 g/L concentration). The patient 
was submitted to the Intensive Care Unit, where, according to the therapeutical protocol, she received 
treatment, yet she manifested tonicoclonic generalised seizures for over 24 hours. The laboratory tests, 
meaning recurrent cerebral CT, cerebral MRI with angioRM, lumbar puncture with biochemical CSF 
analysis, and all other biological examinations had not detected any pathological alterations. The general 
state unfortunately evolved unfavourably, leading to the patient’s death, 15 days after the submission. 
Conclusions: Epilepsy is not a singular disease, but a variety of disorders. An individual treatment 
pathway should be formulated for people who have super-refractory status epilepticus.
Analysis of SCN1A and SCN2A gene polymorphisms  
in epilepsy patients
K. Wize1, U. Lagan-Jedrzejczyk1, A. Gac2, W. Kozubski3, J. Dorszewska1
1Poznan University of Medical Sciences, Laboratory of Neurobiology, Department of Neurology, Poland 
2Poznan University of Medical Sciences, Students Scientific Neurobiological Association, Poland 
3Poznan University of Medical Sciences, Chair and Department of Neurology, Poland
Epilepsy is considered as a chronic neurological disorder, which requires long-lasting antiepileptic 
drugs (AEDs). The SCN1A and SCN2A genes encodes a subunits of neuronal voltage-gated sodium 
channel, which are targets for different AEDs. It is thought that various genetic variants of these genes 
are involved in the pathogenesis and treatment effectiveness of epilepsy. The aim of the study was to 
analyse the frequency of c.3184 A Æ G polymorphism of SCN1A gene and c.56 G Æ A polymorphism 
of SCN2A gene in Polish epilepsy patients and the control group. There was taken into account kind 
of used treatment among epilepsy group. To this study we enrolled 46 epilepsy patients (aged 20–66) 
and 45 aged matches’ controls (aged 23–66). Genetic study was conducted using HRM method. The 
study has showed that frequency of GG genotype of SCN1A 3184 A Æ G and AA SCN2A 56 A Æ G 
polymorphisms were higher in epilepsy patients than in the control group. AG genotype of SCN1A 
3184 A Æ G polymorphism was less frequent in epilepsy group as compared to controls (p = 0,03) 
and patients with this genotype were mostly treated with polytheraphy consisting of newer and older 
AEDs. Two of three epilepsy patients (67%) with AA genotype of SCN2A 56 A Æ G polymorphism were 
treated with newer AEDs in monotheraphy, despite of the duration of the disease more than 5 years. 
It seems that there is an association between the frequency of occurrence of SCN1A and SCN2A pol-
ymorphisms in epilepsy patients. Further study is needed to confirm the involvement of these genes 
in more personalised therapy.
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Autistic-like disorders in children with resistant forms  
of epilepsy caused by “forced EEG normalisation”  
(Landolt’s) syndrome
S. Yevtushenko1, D. Filimonov2
1Department of Reconstructive Angioneurology and Neurorehabilitation, V.K. Gusak Institute of Urgent and Reparative Surgery, Ukraine 
2Department of Experimental Surgery, V.K. Gusak Institute of Urgent and Reparative Surgery, Ukraine
Introduction: “Forced EEG normalisation” (Landolt’s) syndrome is a special type of behavioural 
disorder in the malignant forms of epilepsy in children. Autistic-like disorders cause by this phenom-
enon develop during decrease or regression of epileptic seizures with normal EEG. The presence of 
antagonism to folic acid in a number of AEDs increases the dopaminergic activity and aggravates these 
manifestations. 
Objectives: To describe early EEG and behavioural disorders in children with “forced EEG normal-
isation” syndrome. 
Material and methods: 18 children aged from 6 to 12 years with resistant symptomatic epilepsy 
were enrolled in the study. Main causes of epilepsy were focal cortical dysplasia (5 children), agenesis 
of corpus callosum (2 children), sclerosis of the hippocampus (3 children), hypoxic-ischaemic foci (8 
children). Necessary clinical tests including AED serum concentration were carried out. 
Results: 13 patients on AED therapy had marked psychomotor and autistic-like disorders with at-
tention deficit and disinhibition (during 2–4 weeks), in absence of epileptic seizures and with normal 
EEG. Previously received AEDs were not cancelled, but enterosorbent, phenibut and bromides were 
assigned. Folic acid was prescribed, as an antagonist of dopaminergic activity. During a “forced EEG 
normalisation” episode, an increase in low-amplitude (up to 20 microvolts) high-frequency beta-rhythm 
and the predominance of theta and delta waves were noted on the EEG. The behavioural disorders 
were normalised in the interval from seven days to two months. 
Conclusions: In the resistant forms of childhood epilepsy, temporary behavioural disorders may 
occur during the AED therapy and EEG normalisation. This may require mild tranquilisation and 
folate therapy.
Influence of lacosamide, a third-generation  
antiepileptic drug on neuroprotection and hippocampal 
cell proliferation in a mouse brain
M. Zagaja1, A. Szewczyk1, J. Luszczki1, 2, M. Andres-Mach1
1Isobolographic Analysis Laboratory, Institute of Rural Health, Poland 
2Department of Pathophysiology, Medical University of Lublin, Poland
Epilepsy, one of the most common diseases of the nervous system, belongs to a group of social illness-
es. Lacosamide (LCM) is a novel third-generation antiepileptic drug (AED), which is recommended as 
add-on therapy in adult and adolescent patients with partial-onset seizures with or without secondary 
generalisation. LCM with its selective enhancement of slow inactivation of voltage-gated sodium chan-
nels stabilises neuronal membranes and thus, exerts its anticonvulsant properties. The aim of the study 
was to evaluate the impact of LCM on neuroprotection and neurogenesis in healthy mouse brain. All 
experiments were performed on adolescent male C57/BL mice. Animals were injected with LCM once 
a day (10 mg/kg) for ten days. The control mice were injected with 0,9% NaCl solution. Fluoro-Jade B 
(FJB) and TUNEL staining were performed to evaluate neurodegeneration and apoptosis of neural cells. 
Additionally, mice were given a BrDU injection for the last five days of the LCM and NaCl treatment 
to quantify the total amount of proliferating cells. Additionally, behavioural studies were conducted. 
FJB and TUNEL staining showed just single nerve cells degeneration or apoptosis in both LCM and 
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control group. No spatial learning and memory disturbances were observed in Morris water maze 
test. In turn, results obtained from BrDU staining showed, that LCM significantly decreased the total 
number of newborn cells compared to the control group. Overall, results demonstrated that chronic 
administration of LCM does not cause nerve cells degeneration; however it decreases hippocampal 
cell proliferation in mice brain. 
Acknowledgements: Project sponsored by NCN GRANT 2015/19/B/NZ7/03694.
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Headache
Eficacy and safety of two dose regimens of subcutaneous 
administration of fremanezumab versus placebo for the 
preventive treatment of episodic migraine 
E. Aycardi1, M. Bigal1, P. Yeung1, T. Blankenbiller1, M. Grozinski-Wolff1,  
Y. Yang1, Y. Ma1, D. Dodick2, S. Silberstein3
1Clinical, Teva Pharmaceutical Industries, USA 
2Department of Neurology, Mayo Clinic, USA 
3Neurology, Jefferson Headache Center, USA
Evaluate 2 subcutaneous dose regimens of fremanezumab for the preventive treatment of episodic 
migraine (EM). 16-week, multicentre, randomised, double-blind, placebo-controlled, parallel-group 
adult EM study. Daily diaries maintained during 28-day baseline period. Patient assigned to one of 
three treatment groups: (1) monthly: 225 mg fremanezumab at months 1, 2 and 3; (2) quarterly: 675 
mg fremanezumab at month 1, followed by placebo injections at months 2 and 3; and (3) monthly 
administration of matching placebo. Primary efficacy endpoint, mean change from baseline to 12-week 
randomisation period in monthly average number of migraine days was analysed using an analysis of 
covariance method or the Wilcoxon rank sum test. The mean number of migraine days was 9.1 days 
during the 28-day baseline period. Fremanezumab-treated patients had significant reductions in the 
number of monthly migraine days during the 12-week period vs. Placebo (-2.2 days from baseline = 9.1 
days), for both regimens (monthly -3.7 days from baseline = 9.2 days; quarterly [-3.4 days from baseline 
= 8.9 days]; p0.0001), and 4-weeks after 1st dose, for both regimens (p0.0001). Fremanezumab-treated 
patients had significant reductions in the number of monthly headache days of at least moderate severity 
(monthly [-2.9 days]; quarterly [-3.0 days]; vs placebo [-1.5 days]; p0.0001), and 4-weeks after 1st dose, 
for both regimens (p0.0001). Fremanezumab treatment resulted in statistically significant reductions 
in the number of monthly days of acute headache medication use (monthly [-3.0 days]; quarterly [-2.9 
days]; p0.0001) vs placebo (-1.6 days). Most common adverse events were injection site reactions. 
These results confirm the efficacy, safety, tolerability, and flexible dosing profile of fremanezumab for 
the preventive treatment of episodic migraine.
ID-Migraine is useful to detect cluster headache  
as well as migraine
S.-J. Cho1, P.W. Chung2, B.K. Kim3, S.K. Kim4, M.J. Lee5, Y. Choi6,  
J.W. Park7, B.S. Kim8, K. Oh9, C.S. Chung5, T.J. Song10, J. Cho11
1Neurology, Dongtan Sacred Heart Hospital, South Korea 
2Neurology, Kangbuk Samsung Hospital, South Korea 
3Neurology, Eulji University School of Medicine, South Korea 
4Neurology, Gyeongsang National University Hospital, South Korea 
5Neurology, Neuroscience Center, Samsung Medical Center, South Korea 
6Neurology, Presbyterian Medical Center, South Korea 
7Neurology, Uijeongbu St.Mary’s Hospital, South Korea 
8Neurology, Bundang Jesaeng Hospital, South Korea 
9Neurology, Korea University College of Medicine, South Korea 
10Neurology, Ewha Womans University School of Medicine, South Korea 
11Cancer Education Center, Samsung Comprehensive Cancer Center, Samsung Medical Center, South Korea
Introduction: The 3-item identification of migraine (ID-M) is a validated tool to screen migraine 
patients in primary care setting and is consisted with the items related to photophobia, nausea and 
disability. Cluster headache has several similar features with migraine and easily misdiagnosed as 
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migraine. We investigated the efficacy of ID-M in detecting cluster headache and differencing migraine 
from cluster headache. 
Material and methods: The patients who visited clinic for headache were asked to administer ten 
questionnaires including three questionnaires from ID-M items. Sensitivity and specificity of ID-M in 
detecting migraine and cluster headache were evaluated among the patients with primary headache 
disorders. Two or more positive responses to three items is considered as positive ID-M. 
Results: A total of 344 patients were enrolled: 42 patients with cluster headache, 211 patients with 
migraine, 73 patients with tension-type headache, and 18 with primary stabbing headache. Sensitiv-
ity of ID-M in detecting migraine and cluster headache were 75.3% and 81.0% and specificity was 
60.2% and 40.7%. The proportion of all positive response to ID-M was 35.5% in migraine and 52.4% 
in cluster headache. 
Conclusions: ID-M is useful to detect severe headache such as migraine or cluster headache. Although 
nausea and photophobia are considered as typical features of migraine, cluster headache should be 
differentiated before the diagnosis of migraine in patients with positive response to ID-M.
Assessment of occupation in Korean cluster headache
Y.J. Choi1, S.J. Cho2, M.J. Lee3, J.W. Park4, J.H. Sohn5, M.K. Chu6,  
H.-S. Moon7, P.W. Chung7, B.K. Kim8, T.J. Song9, B.S. Kim10, K.Y. Park11
1Department of Neurology, Presbyterian Medical Center, South Korea 
2Department of Neurology, Dongtan Sacred Heart Hospital, Hallym University College of Medicine, South Korea 
3Department of Neurology, Samsung Seoul Hospital, Sungkyunkwan University School of Medicine, South Korea 
4Department of Neurology, Uijeongbu St. Mary’s Hospital, The Catholic University of Korea College of Medicine, South Korea 
5Department of Neurology, Chuncheon Sacred Heart Hospital, Hallym University College of Medicine, South Korea 
6Department of Neurology, Gangnam Sacred Heart Hospital, Hallym University College of Medicine, South Korea 
7Department of Neurology, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, South Korea 
8Department of Neurology, Eulji University School of Medicine, South Korea 
9Department of Neurology, Ewha Womans University School of Medicine, South Korea 
10Department of Neurology, Bundang Jesaeng General Hospital, Daejin Medical Center, South Korea 
11Department of Neurology, Chung-Ang University Hospital, Chung-Ang University College of Medicine, South Korea
Cluster headache (CH) is a neurological disorder characterised by recurrent, severe headaches on 
one side of the head. The previous studies have shown that CH has a significant negative impact on 
quality of life. Although there are many studies on overall quality of life, studies on occupations in 
CH have not been investigated. The study was conducted in 17 headache clinics for patients diag-
nosed with CH. The control group consisted of patients with non-cluster headache, such as migraine 
or tension-type headache or healthy adults. Unemployed, students, and housewives were excluded. 
Occupational group, work behaviour and working time were also assessed. Survey of work experience 
and satisfaction with current job due to CH was investigated. A questionnaire was administered to 71 
CH patients and 68 control subjects. Except for the unemployed, housewives, and students, the occu-
pational evaluations were conducted for 57 subjects in each group. In the control group, 52 employees 
were employed, whereas in the CH group only 37 employees were employed. The remaining 18 were 
either employers or freelancers. 50 CH patients (87%) experienced job loss, lack of performance, vol-
untary resignation, and promotion disadvantage at work. However, only 26 of the control group (46%) 
had these experiences. Despite disadvantages in the occupation, job satisfaction was mostly above 
average. This study confirms that CH results in a decrease in the overall work life of patients. There 
is a need to improve the quality of life in the workplace by treating headache with active acute care 
and adequate preventive treatment.
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A tailor-made suit rather than one size fits all:  
why triptans are not the best choice for first  
line migraine attack treatment
E. Czapinska-Ciepiela
Epilepsy and Migraine Treatment Centre, Poland
Triptans are an effective medication against migraine attack. This does not imply that they should 
be considered as the first line treatment. Triptans are only effective for 80% of patients. The effective-
ness of particular triptan cannot be predicted. Therefore, a patient might have to try several different 
triptans before finding the effective one. Secondly, triptans have side effects. Most common are fatigue, 
dizziness, chest discomfort, somnolence and nausea. Due to their vasoconstrictive effect, triptans are 
proscribed in patients with cardiovascular diseases. They are also contraindicated during pregnancy or 
lactation. Triptans are more likely to induce a medication overuse headache than NSAIDs. On the other 
hand, NSAIDs are safe and effective solution for migraine attack recommended by AHS and EFNS. They 
present a high tolerability profile and a low risk of transformation from episodic to chronic migraine. 
A combination of sumatriptan with naproxen proved to be more effective and better tolerated than 
sumatriptan or naproxen alone. This leads to a conclusion that a multi-component medication may also 
be a good choice for the migraine attack treatment. Lamifiban, a 5HT(1F) receptor agonist has presented 
a good efficacy and safety in two clinical trials. Lasmiditan does not have a vasoconstrictive effect of 
triptans, while has all their benefits regarding efficacy. Choosing a first line treatment of a migraine 
attack it is important to take into consideration its severity, patient medical history and possible side 
effects. There is no solution that will be suitable for all patients.
The impacts of migraine attacks on cognition in young  
Iranian chronic migraineurs in resting state
H. Ebrahimi1, M.M. Najaf Abadi1, S. Allahdadian1, J.M. Annoni2, A.A. Najafinezhad1,  
M.R. Asadolahian Sichani1, B. Ansari3, M. Khodabakhsh1
1Medical School, Islamic Azad University, NajafAbad branch, Esfahan, Iran 
2Neurology Unit, Department of Medicine, Faculty of Sciences, University of Fribourg, Switzerland 
3Medical Science, Esfahan University, Iran
Introduction: Chronic migraine disease as a repeated primary headache has multiple vasoconstric-
tions and vasodilatations, which can be gradually damaged to the structure of the human brain. We 
have not known the correlation between each characteristic of migraine attacks and various cognitive 
domains. The present study examines the impact of migraine characteristics on cognitive domains in 
young chronic migraine sufferers (CMs). 
Material and methods: 150 young CMs without aura and 100 healthy controls assessed using Mon-
treal Cognitive Assessment (MoCA), the Frontal Assessment Battery (FAB), and Migraine Disability 
Assessment Questionnaire (MIDAS) selected. Depression and anxiety rates evaluated using Hamilton 
tests. Scores combined for comparison of cognitive domains and analysis of test results using independ-
ent t-student, Spearman’s correlation, logistic regression, and Bonferroni correction for the sub-test of 
batteries. The patients had to be migraine-free during the past three days. 
Results: CMs had lower MoCA scores than controls (OR = 1.15; 95%CI 0/99_1.33), even after the 
adjustment for depression, gender and educational level. CMs displayed visuospatial and attention 
impairments (P = 0.02, P = 0.001). Pain severity had no effect on the MoCA scores, FAB scores and 
MIDAS Grading (P0/05). CMs with a longer duration of migraines displayed a causal relationship 
with the FAB Scores and MOCA visuospatial sub score (P = 0.05). The frequency of attacks was also 
associated with disability in CMs (P = 0.04). 
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Conclusion: Cognitive performance reduction occurred in CMs. Visuospatial and attention mostly 
impaired in CMs. The duration of a migraine complains associated with the degree of impairment 
of FAB Scores, and MOCA visuospatial subtests, suggesting a correlation between cognition and the 
length of the disease.
The positive impact of fremanezumab on work productivity 
and activity impairment in patients with chronic migraine
S. Gandhi1, T. Fitzgerald1, P. Yeung1, J. Cohen1, R. Yang1, E. Aycardi1, R. Lipton2
1HEOR/Clinical/Medical, Teva Pharmaceutical Industries, USA 
2Neurology, Albert Einstein College of Medicine, USA
Evaluate the effect of fremanezumab on work productivity loss and activity impairment in CM 
patients. A 16-week, multicentre, randomised double-blind, placebo-controlled, parallel-group adult 
CM study. Patient’s assignments — 1:1:1 ratio to 1 of 3 treatment groups: monthly dosing: 675 mg fre-
manuzemab followed by 225 mg of fremanezumab at months 2 and 3; quarterly dosing: fremanezumab 
675 mg at month 1, followed by placebo injections at months 2 and 3; and monthly administration of 
matching placebo. Change in Work Productivity and Activity Impairment questionnaire (WPAI) scores 
from baseline to four weeks after last dose (weeks 9–12) was evaluated as an exploratory endpoint. 
Work productivity loss was assessed as the composite of absenteeism and impairment while working 
(presenteeism). Fremanezumab treatment led to larger reductions from baseline in overall work pro-
ductivity loss from baseline to weeks 9–12 (quarterly: -16.6 ± 2.1%, n = 375; monthly: -15.9 ± 2.0%, 
n = 375) relative to placebo (-9.1 ± 2.0%, n = 371). Placebo subtracted differences favoured quarterly 
(-7.5 ± 2.2%, P < 0.001) and monthly: -6.8 ± 2.3%, P = 0.003). Similarly, changes from baseline in 
presenteeism were greater with fremanezumab (quarterly: -15.7 ± 1.9%; monthly: -14.9 ± 1.8%) than 
for placebo (-10.0 ± 1.8%), resulting in significant treatment differences (quarterly: –5.7 ± 2.0%, P = 
0.005; monthly: –4.9 ± 2.1%, P = 0.02). Fremanezumab also reduced impairment of activity outside of 
work in the quarterly dosing arm of the study relative to placebo (-15.0 ± 1.7% vs -11.0 ± 1.7%; treat-
ment difference: -4.0 ± 1.9%, P = 0.03). Fremanezumab treatment resulted in significant improvements 
in work productivity and activity impairment, demonstrating the positive impact of fremanezumab on 
the ability of CM patients to function both at and outside of work.
Glyceryl trinitrate (GTN)-induced headache  
is affected by priming of trigeminal system
P. Gazerani1, B. Cairns1, 2, H. Yassin1, J. Yousefi1,  
A. Sherzaman1, B. Nedergaard3, S. Boldsen4
1Department of Health Science and Technology, Aalborg University, Denmark 
2Faculty of Pharmaceutical Sciences, University of British Columbia, Canada 
3CCBR Aalborg, Center for Clinical and Basic Research, Denmark 
4Forskningens Hus, Aalborg University Hospital, Denmark
Introduction: Infusion of glyceryl trinitrate (GTN) in migraine patients provokes an immediate headache, 
that often is followed by a delayed phase with characteristics of a migraine attack. However, in healthy 
volunteers, only an immediate headache that is less severe and shorter than migraine patients occurs 
following administration of GTN. The higher sensitivity of nervous system in migraine patients has been 
proposed to underlie their more intense and prolonged GTN-evoked headaches. We tested the hypothe-
sis that in healthy humans, a priming pain stimulus would enhance or prolong GTN-evoked headache.
Material and methods: Three priming stimuli, chemical stimulation by capsaicin patch, mechanical 
stimulation by a custom-made headband, or a combination of the two, were used prior to adminis-
tration of sublingual GTN (0.5 mg) to induce headache in healthy volunteers (N = 20; age: 26.2 ± 4.0 
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years). Headache pain characteristics and responses to a battery of quantitative sensory tests were 
assessed. Statistical analysis was performed with STATA using the paneled regression model and post 
estimation tests. 
Results: GTN-induced headache intensity was significantly higher (P0.0001) after the combined 
stimulation, when compared either chemical or mechanical stimulation alone. Combined stimulation 
also produced the largest pain area. Increased sensitivity to noxious mechanical and thermal stimu-
lation was produced by the priming stimuli; however, administration of GTN did not further increase 
this sensitisation. 
Conclusions: The findings confirm that pain sensitisation in healthy subject’s increases the inten-
sity of GTN-evoked headaches. This combined surrogate model of headband-capsaicin-GTN might be 
useful to study features of trigeminal sensitisation in humans that occurs in pathological craniofacial 
pain conditions.
Episodic ataxia with intermittent headache,  
ataxia, and diplopia
I. Gottlob1, M. Thomas1, C. Constantinescu2, G. Maconachie1
1Ophthalmology, University of Leicester, UK 
2Neurology, University of Nottingham, UK
Introduction: Episodic ataxia (EA) is characterised by intermittent periods of headache, ataxia and 
visual problems of variable expression. We characterise the phenotypic spectrum and the genetic basis, 
using next generation sequencing (NGS), of familial EA presenting with episodic diplopia, ataxia and 
environmental triggers. 
Material and methods: 3 affected brothers, with onset within the 3rd decade, their affected mother, 
the unaffected father and 4 offspring were recruited. All affected subjects and their offspring underwent 
full ophthalmology and neurological assessment including eye movement recordings and MRI. Using 
NGS we screened for candidate of known association with EA. The affected subjects were prescribed 
a trial of acetazolamide and 4-aminopyridine. 
Results: The primary presentation of all three brothers was headache, vertical diplopia of variable 
severity and duration, which reversed throughout the day. The mother reported diplopia at the same 
age, although resolved during pregnancy. All affected subjects and offspring had abnormal vertical 
saccades, smooth pursuit and fixation. 2 subjects had endpoint nystagmus. MRI scans were normal. 
The eldest brother had dysarthria and ataxia prior to starting treatment. NGS excluded previously 
reported EA genes including KCNA1, CACNA1A, CACNB4 and SLC1A3 genes suggesting a potential 
novel gene within this family. Acetazolamide did not improve symptoms. 4-aminopyridine reduced 
the frequency of symptoms, including the headache, in the most affected subjects. 
Conclusions: We report a dominantly inherited, aminopyridine responsive EA likely harboring 
a novel gene, possibly a channelopathy. The selection for possible causative gene mutations has been 
thus narrowed.
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Comorbidities and risk factors in a prospective chronic  
migraine registry: study in a series of 723 patients
A. Guerrero, M. Ruiz, M.I. Pedraza, A. Sierra, E. Martínez, J. López,  
A. Chavarría, B. Talavera, D. García-Azorín
Headache Unit, Neurology Department, Hospital Clínico Universitario, Spain
Introduction: Chronic migraine (CM) is a common and disabling evolution of migraine. We aimed 
to analyse clinical characteristics, including comorbidities and risk factors, in a prospective registry 
of CM patients. 
Material and methods: Patients firstly attended in an outpatient headache unit in a tertiary hospital 
(January 2013–January 2018). They were referred from primary care or general neurology offices. We 
diagnosed CM accordingly to ICHD-2R and ICHD-3 criteria. We considered demographic and clinical 
data, previous symptomatic and preventive therapies, comorbidities, and risk factors. 
Results: We included 723 patients (105 males, 618 females), with mean age at inclusion of 40.1 ± 
13.7 years (12–80), and age at onset of migraine of 19.3 ± 9.7 years (3–65). In 349 patients (48.3%), we 
gathered any vascular risk factor, especially smoking in 222 (30.7%) and hormonal contraception (84, 
13.6% of female cases). Other chronic pain conditions were present in 77 (10.7%), including discopathy 
(48, 6.6%) and fibromyalgia (15, 2.1%) symptomatic medication overuse in 497 (68.7%), and mood 
disorders in 94 (13%). Among precipitating factors, 237 patients (32.7%) described stressful events. 
Only 193 (26.7%) migraineurs had received triptans before the referral, and in 380 cases (52.6%) at 
least one oral preventative had been used. 
Conclusions: In our MC population, medication overuse, mood disorders and stressful events are 
frequent risk factors. We consider that previous use of preventatives and triptans should be increased.
Intracranial tumour as a challenge  
for multidisciplinary approach
P. Halczuk, K. Rejdak
Chair and Department of Neurology, Medical University of Lublin, Poland
Clinical symptoms of brain tumours may be different. Sometimes are discreet, lasting for years, and 
sometimes worsen rapidly, even in a few weeks, days or even hours. The 59-year-old patient, previously 
untreated for chronic diseases, was admitted to the Department of Neurology with mild headache and 
acute vision loss in the left eye. Neurological examination revealed blurring and loss of vision in the 
low-side quadrant. Radiological imaging of the head revealed the presence of a pathological mass in 
the left sphenoid sinus with destruction of its walls and infiltration of the optic canal and the presence 
of extravasated blood. Consultations with numerous specialists did not bring the clear diagnosis. The 
patient was not qualified for neurosurgical operation due to the difficult access to the pathological mass. 
Despite symptomatic and supportive treatment, the patient’s condition started to deteriorate three days 
after the admission to the hospital; there were disturbances of consciousness and weakness of the left 
limb and damage of the ophtalmoplegia nerves. Respiratory distress and cardiac arrest occurred shortly 
after. Resuscitation was unsuccessful. Only post mortem examination established the final aetiology of 
the disease, which turned out to be quite surprising considering the symptoms and patient’s medical 
history. This case shows how difficult it is sometimes to define the real cause of disease using conven-
tional diagnostic methods. Different, also rare, aetiological causes may, in fact, entail the same clinical 
symptoms, thus they should be taken under consideration at all stages of diagnostics.
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Association between STX1A c.31-1811CTpolymorphism 
and serotonin concentration in migraine patients
M. Kowalska1, I. Wieczorek2, M. Prendecki1, W. Swierczek2,  
M. Kapelusiak-Pielok3, W. Kozubski3, J. Dorszewska1
1Poznan University of Medical Sciences, Laboratory of Neurobiology, Department of Neurology, Poland 
2Poznan University of Medical Sciences, Students Scientific Neurobiological Association, Poland 
3Poznan University of Medical Sciences, Chair and Department of Neurology, Poland
Migraine is a primary headache disorder that affects 11% of adult population. It is divided into two 
clinical subtypes: migraine with aura (MA) and migraine without aura (MO). Migraine is multifactorial 
disease and may be a result of polymorphisms in numerous genes, e.g. STX1A c.31-1811CT poly-
morphism (rs941298) was associated with MO. The STX1A gene encodes syntaxin 1A, a presynaptic 
membrane protein which controls the synaptic vesicle exocytosis and functioning of ion channels. 
Syntaxin 1A is involved in the regulation of the serotonergic system by affecting the expression and 
location of the serotonin (5-HT) transporter. The reduced 5-HT concentration is a hallmark of migraine 
and may be caused by genetic changes. The aim of the study was to analyze STX1A c.31-1811CT 
polymorphism and 5-HT plasma concentration in migraine patients. The study included 90 migraine 
patients (MA: 39, MO: 51) and 90 controls. Mean age of participants was 36 ± 13 years. The HRMA 
and sequencing were used for genotyping. 5-HT concentration was determined by HPLC/EC technique. 
T allele of STX1A c.31-1811CT was more frequent in migraine patients than controls, but there was 
no statistical difference. TT genotype in MO patients was associated with lower 5-HT concentrations 
(0.012 µg/mL) as compared to controls (0.140 µg/mL) and MA subjects (0.120 µg/mL) with TT genotype 
(p = 0.0088). STX1A c.31-1811CT polymorphism may alter the 5-HT concentration in MO patients. 
The functional studies would assess the effect of polymorphism on syntaxin 1A and 5-HT transporter 
relation. Analysis of STX1A polymorphisms and 5-HT concentration may be useful in optimisation 
of migraine pharmacotherapy.
Headache is the predictor of lacunar strokes:  
data from the stroke registry sits — Kyrgyzstan
I. Lutsenko1, D. Nazhmudinova1, U. Nurbekova2
1Neurology, Kyrgyz State Medical Academy, Kyrgyzstan 
2Neurology, The National Center of Maternity and Childhood Care, Kyrgyzstan
Objectives: To characterise headache in patients with lacunar strokes, and to find a correlation be-
tween headache type, intensivity and stroke outcome. 
Material and methods: We studied a sample of 68 patients with acute lacunar infarction enrolled 
in SITS stroke registry, with confirmed lacunar lesion on DWI scans of MR. Fazekas scale was used for 
leucoareosis evaluation and NIHSS — for the stroke severity at the onset. All patients were interviewed 
on the presence of headache before and in the onset of stroke, it severity was estimated according to 
Visual Analogue Scale (VAS). In ten days after stroke, NIHSS and VAS were repeatedly measured and 
statistical correlation between them was described. 
Results: Headache was present in 90% of observed patients at onset, strongly connected with arterial 
hypertension (p = 0.0001). Systolic blood pressure higher than 156 mm was associated with increasing 
headache in sample (p = 0.01). Headache was diffused and “pressure type” in 78% of all headache 
patients. Mean baseline NIHSS score in patients with headache was 8 (± 1.8), what is minor stroke, 
and mean VAS was 6 (± 2). There was no significant correlation between intensity of baseline headache 
and baseline NIHSS, and lacunar infarct localisation and headache intensity, but strong association of 
dull headache and infarcts with leucoareosis in 3rd stage. In 64% headache significantly decreased to 
10th day of stroke (VAS 3 ± 0.9). 
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Conclusions: In patients with lacunar infarction, headache is moderate, diffuse and “pressure type”, 
not correlates with infarction site and NIHSS scale. Third stage of leucoareosis we found strongly 
associated with headache (p = 0.001).
Influence of accompanying symptoms  
on chronisation of migraine
I. Maryenko, S. Likhachev, I. Pliashko
Department of Neurology, Republican Research and Clinical Center of Neurology and Neurosurgery, Belarus
Introduction: Chronisation of the headache (HA) significantly impairs the quality of life. Thus, 
patients with chronic migraine compared with patients with episodic migraine, the quality of life is 
lower and they are forced to take much more analgesic drugs. Therefore, the important task is detection 
of predictors of chronic migraine. 
Objectives: Identify the predictors of chronic migraine in patients with episodic migraine. 
Materials and methods: The study involved 40 patients, 34 women and 9 men aged from 21 to 
52 years, the average age — 37.5 ± 18.2 years, suffering from migraine (criteria for the International 
Classification of Headache, 2013). All patients completed the following questionnaires: a diary of 
symptoms, accompanying headache (RHRS, 2009), an express questionnaire of vertigo, a pain ques-
tionnaire “PainDETECT”. 
Results: Among the symptoms associated with HA, a high specific gravity of neck muscle tension 
was detected in 20 (66.7%) cases, imbalance in 19 (47.5%), sleepiness in 18 (60.0%) cases, vertigo in 
30 (75.0%) cases. A high specific gravity of position-dependent system vertigo was found in 15 out 
of 30 cases (50%) and kinesia in 18 cases out of 25 (60%) (p 0,05). Analysis of the indicators of the 
PainDETECT questionnaire revealed that 28 (70%) patients had a high probability of neuropathic pain 
component (p 0,05). 
Conclusions: The aggregate of painful and non-painful phenomena, such as vertigo, associated with 
HA, could have a significant impact on the perception of pain. These results point to a high risk of 
developing chronic migraine in patients with a migraine-associated vertigo.
Medication overuse headache — prevalence,  
management and quality of life
G. Mihailescu1, 2, R. Huber1, A.-D. Boangiu2, C. Baetu2, I. Buraga1, 2, S.-M. Nica1, 2
1Neurology Department, University of Medicine and Pharmacy Carol Davila, Romania 
2Neurology Department, Colentina Clinical Hospital, Romania
Introduction: Medication overuse headache (MOH) is frequent having a significant psychosocial, 
social and economic impact, affecting patient’s quality of life (QoL). It is the third most common type 
of headache, with a prevalence of 0,7–1,7%, caused by automedication and easy access to over the 
counter (OTC) medications recommended for headaches or other types of pain and secondary to ex-
cessive TV advertising. 
Material and methods: A prospective study performed on 23 patients (19 women and 4 men), mean 
age 46 years, diagnosed with MOH answering a special questionnaire, completing headache diaries, 
RAND 36 item Health survey v. 10, Hamilton Anxiety and Depression scales and Visual Analogue 
Scale for headache intensity. The treatment was stopping the MOH inducing medication, associating 
prophylactic headache therapy or withdrawal therapy. 
Results: The patients suffered from primary headache (73,91% migraine and 26,09 % tension type 
headache), 52% having a personal pathologic history of headache, 82,6% were women and 35% un-
employed due to headache. Paracetamol and nonsteroidal anti-inflammatory drugs were used, in 39% 
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OTC and 52% automedication associated to medical prescriptions. 61% had lower education (≤ 12 
years). Stopping MOH inducing treatment was the first option. Prophylactic headache medication was 
preferred (52%), some patients needed withdrawal medication or hospitalisation. RAND 36 Item Health 
Survey v. 1.0 was a good prognostic predictor, 52, 17% of the patients having scores 60%. 
Conclusions: MOH is more frequent than diagnosed. TV advertising for analgesics should be reduced. 
Prophylactic therapy should be used more frequently. A multidisciplinary team can reduce the time 
until withdrawal.
Clinical case of familial hemiplegic migraine
E. Veevnik, S. Likhachev
Scientific Department of Neurology, Republican Research and Clinical Center of Neurology and Neurosurgery, Belarus
Migraine and epilepsy are co-morbid diseases. In some cases established its genetic causes. The 
man, 19 years old, since the age of 12 years experienced isolated episodes of numbness, paresthesias 
and weakness in right hand, sometimes accompanied by numbness in right leg, once — by dysphasia. 
One of the attacks was presented by isolated numbness and weakness in left leg. Some attacks were 
accompanied by headache. Regression of symptoms was after 20–40 minutes after sleep or rest. During 
seven years there were 5 attacks. Data of examination (including MRI of brain [3,0], doppler ultra-
sound) were normal. Slow activity in left temporal region was detected in EEG repeatedly. Long-term 
EEG monitoring (free-attack period): paroxysmal activity represented by bilateral high amplitude theta 
waves (predominantly in frontal regions) low index during wakefulness and sleep have been found. 
FHM is an uncommon type of migraine, frequently beginning in the first or second decade; frequency 
of attacks tends to decrease with age. Diagnostic criteria for FHM includes: criteria for migraine with 
aura; the aura includes some degree of hemiparesis and may be prolonged, but completely reversible; 
at least one first-degree relative also has such attacks. Headache usually lasts four to 72 hours, but 
may be completely absent. FHM is inherited in an autosomal dominant manner. Mutations in three 
genes (CACNA1A [FHM1], ATP1A2 [FHM2], and SCN1A [FHM3]) have been found to cause FHM. 
CACNA1A pathogenic variants commonly presenting with nystagmus and other cerebellar signs, 
ATP1A2 — with epilepsy.
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Multiple sclerosis
Sexual dysfunction (SD) in multiple sclerosis (MS)  
population — incidence and management  
as it results from our experience
C. Baetu1, G.M. Bododea2, G. Mihailescu1, A.-M. Enachi1, R. Oana1, I. Ionela, I. Buraga1
1Neurology, Colentina Clinical Hospital, Romania 
2Neurology, Ramnicu Valcea Emergency Hospital, Romania
Introduction: We consider that SD is a painful, but underreported and underdiagnosed symptom 
of the disease and can appear at any stage of the disease. SD is often unrecognised as patients and 
physicians are reluctant to discuss the problem. Our purpose is to share our experience regarding this 
significant problem, its incidence and the major impact of quality of life. 
Materials and methods: We examined 110 patients, males (55) and females. They completed a ques-
tionnaire with multiple questions about their sexual life before and after they were diagnosed with 
multiple sclerosis. 
Results: The most common symptom of SD in men with MS was erectile dysfunction (44%), reduced 
libido (40%), anorgasmia, ejaculatory issues (16%). The frequency of SD was higher in females (64.5%). 
Women reported most frequently reduced libido, difficulty in achieving orgasm. 
Conclusions: Maintaining a healthy sexual life in patients with MS is a priority. The treatment of SD 
requires a multidisciplinary team and cooperation between different specialist, partners and society. 
Studies showed that up to 86% of men felt that MS affected their sexual life. We will present more 
results about SD and also the management of SD in MS population.
Headache in patients with MS — causes and management 
— Colentina Clinical Hospital experience
G.M. Bododea1, C. Baetu2, A.M. Enachi2, I. Buraga2
1Neurology, Ramnicu Valcea Emergency Hospital, Romania 
2Neurology, Colentina Clinical Hospital, Romania
Introduction: The aim of this paper was to share with you the variables and causes of headache in 
patients with multiple sclerosis from our center, management and impact on quality of life. People 
with multiple sclerosis (MS) have an increased incidence of headaches. Some treatments used for MS 
have been demonstrated to exacerbate headaches, leading to a decreased quality of life and possible 
treatment nonadherence. 
Materials and methods: We analysed a number of factors in relation to headache frequency in 140 
of our patients with MS, focusing on headache history, pain description, modifying factors, social 
history, relation to disease. We observed headache characteristics in relation to MS diagnosis, disease 
exacerbations, and physiological conditions. 
Results: More than half of patients reported the presence of headaches before the start of their MS 
symptoms. MS exacerbations caused a worsening of headaches for nearly two-thirds of our patients. 
Majority of our patients were females, with relapsing remitting MS and also secondary progressive 
and under an immunomodulatory treatment. Headache impact on daily life, measured by HIT-6 score 
and PHQ-9 score was very significant. 
Conclusions: There are several hypotheses regarding how headache results from various forms of 
MS pathogenesis and we will present them in the extended paper. Thorough evaluation of headache 
in patients with MS is crucial to optimise patient management to help improve quality of life.
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Characteristics of multiple sclerosis relapses  
and factors affecting relapses frequency in patients  
with immunomodulatory therapy
M. Bozhenko
Department of Neurology, Danylo Halytsky Lviv National Medical University, Ukraine
Our objective was to estimate the relapses of MS and the influence of seasonal and climate factors on 
patients in the Volyn region — the region with the highest MS morbidity in Ukraine. The study included 
100 MS patients (27 males and 73 females) with relapsing-remitting course. The average age of patients 
was 38.59 (s−8.8) years (20–57), the average time from diagnosis in these patients was 9.643 (s−6.23) 
years, the average EDSS rate was 2.957 (s−1.31). 46% of them were employed, 53% were unemployed, 
76% were married, and 24% were not married. From the first symptoms prior to the diagnosis of MS on 
average passed 2227 days, if first symptoms began after 2010, time to diagnosis was reduced to 462 days. 
There were 243 relapses from 2012 to 2017. The average duration of the last relapse was 11,215 (s−6,188) 
days. 19% of patients had visual, 82% — pyramidal, 50% — cerebellum, 32% — sensory, 36% — pelvic 
organs function disorders and 21% had cognitive impairment. The peak of relapses is in the beginning of 
spring (March — 30), then gradually decreases until the middle of summer (July — 14) and again it grows 
from the beginning of winter (December — 26). The amount of relapses was higher in the low-vitamin D 
period compared to the other two seasonal periods (99, 77,67 respectively). We found a significant strong 
correlation between the number of relapses and the radiation balance level (−, 998, *p 0, 05). The lower 
radiation balance level correlates with the higher number of MS relapses.
Evaluation of the long-term treatment effect of teriflunomide 
on cognitive outcomes and association with brain volume 
change: data from TEMSO and its extension study
S. Cavalier1, T. Sprenger2, 3, M.P. Sormani4, J.S. Wolinsky5,  
J. Wuerfel6, K. Thangavelu7, M. Mandel8, L. Kappos9
1MS Global Scientific Communications, Sanofi, USA 
2Department of Neurology, University Hospital Basel, Switzerland 
3Department of Neurology, DKD HELIOS Klinik, Germany 
4Department of Health Sciences, University of Genoa, Italy 
5McGovern Medical School, UTHealth, USA 
6Medical Image Analysis Center (MIAC AG), University of Basel, Switzerland 
7Department of Biostatistics, Sanofi, USA 
8Department of Neurology, Sanofi, USA 
9Neurologic Clinic and Policlinik, University Hospital Basel, Switzerland
Introduction: In a blinded SIENA (Structural Image Evaluation using Normalisation of Atrophy) 
analysis of TEMSO (NCT00134563), teriflunomide significantly reduced brain volume loss (BVL) over 
2 years vs placebo. Here, we explore the relationship between BVL and long-term changes in cognitive 
function in TEMSO and its extension (NCT00803049). 
Material and methods: Effect of teriflunomide on cognitive function was assessed by change from 
baseline in Paced Auditory Serial Addition Test (PASAT)-3 scores in the TEMSO core (N = 1086) and 
extension (N = 740) studies. To evaluate change in PASAT-3 scores over five years, the TEMSO popu-
lation was categorised into groups defined by percentage brain volume change from baseline to Year 
2 (assessed by SIENA). 
Results: Adjusted mean changes from baseline to Week (W)96 in PASAT-3 Z-score were -0.022 and 
0.073 for placebo and teriflunomide 14 mg, respectively (difference vs placebo: P = 0.0435). Over the 
long term, improvements in mean (SD) changes from baseline in PASAT-3 scores were observed with 
teriflunomide 14 mg treatment (Z-scores: W156, 0.194 [0.634]; W276, 0.200 [0.677]. Raw scores: W156, 
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2.36 [7.73]; W276, 2.43 [8.24]). In an association analysis, the group with least BVL from baseline to 
Year 2 demonstrated a significant improvement in PASAT-3 score with teriflunomide treatment over 
five years vs the group with most BVL. 
Conclusions: Teriflunomide significantly improved PASAT-3 performance vs placebo over five years 
in the TEMSO core and extension studies. Significant association of early BVL with long-term cognitive 
changes was observed, suggesting that BVL earlier in the disease course predicts longer term cognitive 
function.
Neurofibromatosis (NF1) and multiple sclerosis (MS)  
— a rare association
A.M. Enachi1, C. Baetu1, G. Mihailescu1, I. Ionescu1, R. Oana1, M.G. Bododea2, I. Buraga1
1Neurology, Colentina Clinical Hospital, Romania 
2Neurology, Ramnicu Valcea Emergency Hospital, Romania
Introduction: Neurofibromatosis 1 (NF1) is a genetic autosomal dominant neurocutaneous disorder. 
There are only a few cases of NF1 associated with multiple sclerosis (MS), 16.6% of the MS patients 
are carriers of the NF1 gene. The mutation in the oligodendrocyte myelin glycoprotein (OMG) gene is 
frequently associated with the primary progressive form of MS. 
Material and methods: Our patient is a 30-years-old female diagnosed with NF1, with a family history 
of neurofibromatosis (mother and grandmother), who presented cafe’-au-lait patches, Crown sign, Lisch 
nodules and dermal neurofibromas. In the last 13 years she developed two episodes of self-limiting 
optic neuritis and a right cerebellar syndrome, for which she was admitted to our clinic. The brain 
MRI showed multiple T2-weighted areas of altered signal in both cerebral hemispheres suggestive for 
MS and the spinal MRI — same type of lesions at the C2−C3 and C4−C5 level. Cerebrospinal fluid ex-
amination showed high levels of oligoclonal bands and IgG index. The visual-evoked potentials were 
significantly bilaterally delayed. Other autoimmune and infectious diseases were excluded and OMG 
gene was absent. Her symptoms ceased under corticosteroid therapy. She underwent immunomod-
ulatory treatment for relapsing-remitting MS with no exacerbations (3 years now — EDSS = 1.5 p). 
Conclusions: The peculiarity of our case is the fact that NF1 usually goes along with primary pro-
gressive MS and no medullar lesions. Our patient has a relapsing-remitting form with a good response 
to immunomodulator treatment.
Vaccines and multiple sclerosis: old dilemmas,  
new approaches
E. Kurmaku, G. Vyshka, J. Kruja
Faculty of Medicine, University of Medicine, Tirana, Albania 
Service of Neurology, UHC Mother Theresa, Tirana, Albania
Introduction: When discussing vaccinations in general and their possible adverse effects (including 
demyelination), the authors offer different opinions, and sources have sometimes warned against using 
a certain vaccine, such as the vaccine against the yellow fever that seems to exacerbate multiple scle-
rosis (MS). Vaccines generally are not accused to cause the onset or an exacerbation of MS; whereas 
tetanus vaccine might even have a protective effect in the clinical course of MS.
Discussion: Genetic and epidemiological studies have picked up populations at risk, such as those 
with Scandinavian or Scottish ancestry; HLA-DR2 haplotype has demonstrated linkage and associa-
tion with susceptibility to multiple sclerosis. In Italy, there is a geographic region (Sardinia), where an 
unexpectedly high prevalence of MS has been found. Studies suggest that HLA-DR2 haplotype to be 
linked with demyelination after hepatitis B vaccination. Several sources underline the importance of 
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post-infectious and post-immunisation proinflammatory cascades in the pathogenesis of demyelination; 
molecular mimicry, re-infection and a “second-hit” immuno-inflammatory process are among the most 
elaborated models that explain satisfactorily the cascade of events. 
Conclusions: We suggest that a control of HLA haplotype should be a logical and precautionary 
measure in subjects that due to several reasons must undergo an intense vaccination programme toward 
excluding remote albeit possible demyelinating complications.
The role of advanced glycation of proteins  
in the aetiopathogenesis of multiple sclerosis
B. Labuz-Roszak1, 2, B. Kumaszka3, 4, A. Damasiewicz-Bodzek3,  
A. Nowak3, K. Tyrpien-Golder3
1Department of Basic Medical Sciences, Faculty of Public Health, Medical University of Silesia, Poland 
2Department of Neurological Rehabilitation, GCR Repty, Poland 
3Department of Chemistry, Medical University of Silesia in Katowice, Faculty of Medicine with Dentistry Division in Zabrze, Poland 
4District Hospital, Strzelce Opolskie, Poland
Introduction: Advanced glycation end products (AGE) are involved in the pathogenesis of many 
diseases, including neurodegenerative diseases such as multiple sclerosis (MS). It is suggested that 
many xenobiotics may initiate abnormal immune response in individuals with certain genetic pre-
dispositions. Many of these compounds can also adversely affect the state of redox balance of the 
body, exacerbating radicalisation and reducing antioxidant defense mechanisms. This can be a bridge 
linking the aetiopathogenesis of MS to the processes of advanced glycation of proteins in the human 
body. The aim of the study was to evaluate the intensity of protein glycaemia in MS and their possible 
involvement in disease activity. 
Material and methods: The study involved an authoritative questionnaire, which helped to survey 
a group of MS patients from the Upper Silesian region (n = 52; mean age — 37.9 ± 9.4 years); control 
blood samples came from healthy volunteers (n = 40; age — 41.1 ± 10.4 years). Concentrations of 
selected parameters of advanced glycation of proteins: AGE, carboxymethyllysine (CML), carboxyeth-
ylolysin (CEL), and their soluble receptor (RAGE) in sera of patients and controls were determined by 
immunoenzymatic method (ELISA), using commercially available kits. 
Results: MS is accompanied by a statistically significant increase of protein glycaemia. The duration of 
the disease and the degree of motor impairment do not appear to affect the progression of the glycation 
processes. However, the disease process associated with MS alters the correlation between individual 
protein glycation products, particularly the correlation between CML and CEL concentrations. 
Conclusions: Advanced glycation of proteins should be taken into account in the aetiopathogenesis 
of MS.
Oligoclonal band multiple sclerosis presenting  
with sudden hearing loss 
I.C. Lupescu1, I.G. Lupescu2, 3, A.O. Dulamea1, 4
1Neurology Department, Fundeni Clinical Institute, Romania 
2Radiology and Medical Imaging Department, Fundeni Clinical Institute, Romania 
3Radiology and Medical Imaging Department, Carol Davila University of Medicine and Pharmacy — Faculty of Medicine, Romania 
4Neurology Department, Carol Davila University of Medicine and Pharmacy — Faculty of Dental Medicine, Romania
Material and methods: A 33-year-old woman without significant medical history presented a first 
episode of neurological deficits with sudden left ear hearing loss, left facial palsy, left facial hypoaesthe-
sia and left eye vision loss, lasting for a month. After 2 episodes of bowel incontinence, she developed 
a headache and a left eye vision loss and was admitted to our department. MRI revealed demyelinating 
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lesions in the left postero-lateral pons, anterior half of cervical spinal cord and deep white matter of the 
left temporal lobe. All laboratory findings were normal apart from low levels of vitamin D. CSF analysis 
was also normal. Visual evoked potentials revealed bilateral prolonged latencies, while auditory evoked 
potentials showed prolonged latencies on the left, thus confirming the left sensorineural hearing loss. 
Based on history and paraclinical assessment, diagnosis of relapsing-remissive multiple sclerosis was 
confirmed. Pulse-therapy was performed with symptom improvement, after which disease-modifying 
therapy was initiated. 
Discussion: Lack of oligoclonal bands may suggest a different immunogenetic profile from other MS 
patients. In our case, the particularity resides in the predominant cranial nerve involvement and low 
lesion load on MRI. While sudden sensorineural hearing loss (SSHL) is more common in MS patients 
than in the general population, there have been only several cases described with SSHL at onset.
Validation of MS-TEQ in Albanian
E. Rraklli1, 2, O. Çibuku1, 2, A. Tela1, 2, I. Buxhelaj1, 2, S. Grabova2,  
P. Djamanti2, A. Quka2, J. Kruja1, 2
1Neuroscience, Faculty of Medicine, University of Medicine, Albania 
2Neurology, UHC Mother Teresa, Albania
Introduction: Disease-modifying therapies for the treatment of Multiple Sclerosis are the best strategy 
currently available to slow the natural course of MS, but on the other hand they are associated with 
inconvenient methods of administration, significant side effects, and low adherence rates. The MS 
Treatment Evaluation Questionnaire (MS-TEQ) is constructed to quantify and explore the barriers that 
get in the way of people taking their DMTs as prescribed. 
Material and methods: As part of the validation process of this questionnaire in Albania, we trans-
lated it from English into Albanian language and then showed it to a small group of local MS patients 
to ensure it was easy for them to understand it. In December 2017 we asked 32 patients to complete 
the MS-TEQ. 
Results: By analysing the data collected from the patients, we revealed that among the patients who 
missed the dose varied significantly by treatment between 9–12, 5% (p0.001), it was highest in IFB 1b 
sc, lowest in GA. It was observed that the time since the diagnosis was made was a significant evocator 
in MDR, lower in patient diagnosed in less than 18 months, compared to 3+ years of MS. 
Conclusions: The results of MS-TEQ are very useful to MS patients and health care provider to come 
up with ways to make easier to take the treatment.
Rapid disease progression following initiation treatment 
with dimethyl fumarate in patient with neuromyelitis  
optica spectrum disorders (NMOSDS)
J. Rudnicka-Czerwiec, M. Popiel, H. Bartosik-Psujek
Klinika Neurologii z Pododdziałem Leczenia Udarów Mózgu, Kliniczny Szpital Wojewódzki nr 2, Poland
Neuromyelitis optica spectrum disorders (NMOSDs) are the group of aggressive autoimmune in-
flammatory demyelinating diseases of the central nervous system. NMOSDs manifest predominantly 
with attacks of optic neuritis and longitudinally extensive transverse myelitis. Correct diagnosis and 
adequate treatment is required to prevent morbidity and mortality. Corticosteroids used in relapses 
and immunosuppression with agents such as azathioprine, mycophenolate mofetil, rituximab is the 
mainstay of NMOSD’s treatment. Disease-modifying drugs effective in multiple sclerosis (MS) might 
exacerbate NMOSDs. We present the case of NMOSDs’s patient diagnosed with MS after 2 relapses in 
the form of optic neuropathy and left hemiparesis with painful dysaesthesia with incomplete recovery 
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on intravenous methylprednisolone. Serum anti-AQP4 antibody tested with indirect immunofluores-
cence assay was negative. Interferon beta 1a treatment was started, but patient kept having relapses. 
Then the treatment was shifted to dimethyl fumarate. 3 months after new treatment initiation, the 
patient experienced a severe relapse characterised by spastic hemiplegia. Spine MRI showed extensive 
demyelinisation with cord swelling of the medulla extending down to Th1 vertebral level. Clinical and 
radiological symptoms were pathognomonic for NMOSDs. Serum anti-AQP4 was tested again using 
a cellular method and a positive result was obtained. Azathioprine treatment was started, dosed 50 mg 
twice a day. Exacerbation and even more severe relapses have been previously reported in NMOSD 
during the use of interferons, natalizumab, fingolimod and alemtuzumab, but there are few reports of 
such worsening using dimethyl fumarate.
A case report of oligodendroglioma and multiple  
sclerosis: Occam’s razor or Hickam’s dictum? 
A. Shirani, G. Wu, A. Cross
Department of Neurology, Washington University School of Medicine, USA
Tumefactive lesions on brain imaging can pose a diagnostic dilemma in patients with or without 
known multiple sclerosis (MS). It is important to differentiate tumefactive demyelinating lesions 
from intracranial neoplasms. Here we report on the case of a middle-aged man who presented with 
acute unilateral optic neuritis. Brain MRI showed enhancement of the right optic nerve, and multi-
ple non-enhancing supratentorial white matter lesions including a three cm focal lesion in the right 
frontal lobe with adjacent gyral expansion. Cerebrospinal fluid (CSF) analysis showed more than 5 
CSF-restricted oligoclonal bands and an elevated IgG index. The patient was treated with a short course 
of high dose intravenous methylprednisolone and started on glatiramer acetate for likely tumefactive 
MS. A follow-up brain MRI six months later showed no new or enlarging lesions, but persistence of 
the frontal gyral expansion. Brain biopsy led to the diagnosis of a grade II oligodendroglioma (with 
isocitrate dehydrogenase-1 mutation and 1p/19q co-deletion) managed with surgical resection and 
radiotherapy. A post-operative follow-up brain MRI showed a new enhancing periventricular lesion, 
making the choice of optimal disease modifying therapy for MS more challenging. This case highlights 
the possibility of co-existence of MS and oligodendroglioma in the absence of a preceding diagnosis of 
MS, emphasises the importance of a tissue diagnosis in the presence of atypical imaging features for 
MS, and underlines the challenges of choosing an appropriate disease modifying therapy when MS is 
concurrent with a brain tumour.
Does the nature of nutrition affect the development and 
course of relapsing-remitting multiple sclerosis (RRMS)?
L. Sokolova, K. Potapova
Neurology Department, Bogomolets National Medical University, Ukraine
Introduction: Considering the connection between microbiota and immune system, nutrition rec-
ommendations for patients with multiple sclerosis can lead to immune modulation and positive effect. 
Objectives: Determine the main models of nutrition dominating among patients with RRMS with 
different activity.
Material and methods: 30 women with RRMS who did not change their dietary habits, and thirty 
healthy women at the age 25.0 ± 5.0 and 26.0 ± 5.0, respectively, were examined. The diagnosis was 
established in accordance with the McDonald’s criteria, EDSS = 2–3. The FFQ-based questionnaire 
was used, where nutrition products were grouped into clusters and five types of dietary models were 
derived. 
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Results: All 5 types of dietary patterns were identified in the examined patients: western, high-fat, 
vegetarian, lactovegetarian and traditional models. Most patients followed the western model (odds 
ratio [OR] = 1.97; 95% confidence interval CI: 1.61–2.92, P 0.005) and high-fat model ([OR] = 1.87; 
95% CI: 1.61–2.92, P 0.005). Minority of the patients preferred the traditional ([OR] = 0.17; 95% [CI]: 
0.05–0.20, P = 0.028), vegetarian ([OR] = 0.40; 95% ; [CI]: 0.17–0.78, P = 0.026) lactovegetarian diet 
([OR] = 0.33; 95%; [CI]: 0.14–0.84, P = 0.018). During 6 months, the patients who followed the western 
model had 1–2 exacerbations with new periventricular Gd+ lesions on MRI, while patients on other 
diets did not have exacerbations. 
Conclusions: The western and high-fat models dominate among the RRMS patients, which probably 
causes the bigger activity of the disease.
Efficacy of a third course of alemtuzumab in patients  
with active relapsing-remitting multiple sclerosis who  
experienced disease activity after the initial two courses: 
pooled analysis of CARE-MS I and II
P. Vermersch1, A. Traboulsee2, A. Boster3, A. Bass4, R. Berkovich5, G. Comi6,  
O. Fernández7, H.J. Kim8, V. Limmroth9, J. Lycke10, R. Macdonell11, B. Sharrack12,  
H. Wiendl13, T. Ziemssen14, M. Melanson15, N. Daizadeh15, B. Singer16
1Service de Neurologie Générale et Pathologie Neuro-Inflammatoire, University of Lille, France 
2MS/NMO Clinic and Clinical Trials Research Group, University of British Columbia, Canada 
3Clinical Neuroimmunology, OhioHealth Neurological Physicians, USA 
4Department of Neurology, Neurology Center of San Antonio, USA 
5Keck School of Medicine, University of Southern California, USA 
6Department of Neurology, University Vita-Salute San Raffaele, Italy 
7Department of Neurology, Fundación IMABIS Hospital Universitario Carlos Haya, Spain 
8Research Institute, National Cancer Center, South Korea 
9Klinik für Neurologie und Palliativmedizin, Kliniken Köln, Germany 
10Department of Clinical Neuroscience, University of Gothenburg, Sweden 
11Department of Neuroscience and Mental Health, Austin Health and The Florey Institute, Australia 
12Department of Neuroscience, Sheffield Teaching Hospitals NHS Foundation Trust, UK 
13Department of Neurology, University of Münster, Germany 
14Center of Clinical Neuroscience, University Hospital Carl Gustav Carus, Germany 
15Sanofi Genzyme, Sanofi, USA 
16MS Center for Innovations in Care, Missouri Baptist Medical Center, USA
Introduction: Alemtuzumab improved efficacy outcomes in 2-year (y), phase 3 trials vs SC IFNB-1a 
in RRMS patients (CARE-MS I: treatment-naive [NCT00530348]; CARE-MS II: inadequate response 
to prior therapy [NCT00548405]). Patients continuing in an extension (NCT00930553) demonstrated 
durable 6-y efficacy; 27% (pooled CARE-MS I/II) received only one alemtuzumab retreatment (Course 
3 [C3]) through Y6. 
Objectives: Evaluate alemtuzumab retreatment efficacy in pooled CARE-MS I/II patients, who re-
ceived C3. 
Material and methods: Patients received 2 courses of alemtuzumab 12 mg/day (baseline: 5 days; 
Month 12: 3 days) in CARE-MS I/II, and could receive as-needed alemtuzumab retreatment (for relapse/
MRI activity) or another DMT (investigator discretion) in the extension. Assessments: annualised relapse 
rate (ARR); mean EDSS change; improved/stable EDSS; 6-month confirmed disability improvement 
(CDI). Patients receiving > C3 or another DMT were excluded. 
Conclusions: 3rd alemtuzumab course effectively reduced relapses and improved disability without 
further treatment. These data support administering C3 in patients with disease activity to achieve 
durable disease control.
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Serum levels of inflammatory cytokines after  
supplementation of vitamin D in patient with multiple  
sclerosis (MS) treated by interferon — b (IFNb)
A. Walawska-Hrycek, E. Krzystanek
Department of Neurology, Medical University of Silesia, School of Medicine in Katowice, Poland
Introduction: In this study concerning IFNb treated MS patients, the effect of vitamin D on the serum 
levels of inflammatory cytokines was evaluated. 
Materials and methods: 33 IFNb treated patients (age from 18 to 50) with relapsing-remitting MS, 
EDSS ≤ 4.0 were enrolled to the study. They received orally 1000 IU of vitamin D for 9 months. Serum 
concentrations of 25(OH)D, interleukin 10, 17a, TGFb and IFNϒ were analysed before and after the 
supplementation of vitamin D. 
Results: Under supplementation of vitamin D the increased level of 25(OH)D was noticed (relatively 
43.8 ± 21.5 before and 106.7 ± 41.1 nmol/L after supplementation, p0.001). Levels of anti-inflammatory 
cytokines TGFb and IL10 measured at baseline (relatively 75.2 ± 23.1, 13 ± 5.5 pg/mL) in comparison 
to the results obtained after 9-month supplementation (relatively 111 ± 28.6, 17.5 ± 5.6 pg/mL) turned 
out significantly increased. In relation to the concentration of proinflammatory cytokine IL17a, a sta-
tistically significant difference was not observed when the results were compared before and after the 
supplementation of vitamin D (p = 0.3). The levels of IFNg were increased (from 3.35 ± 6.2 to 4.51 ± 
7.1 pg/mL relatively before and after supplemtation) (p = 0.0005).  
Conclusions: Vitamin D application in dose of 1000 IU daily is sufficient to compensate vitamin 
D deficiency in MS patients. It is accompanied by the increased level in anti-inflammatory cytokines 
(IL10,TGFb). It may be assumed that the lack of endogenous IFNb reduces the effect of vitamin D on 
IFNϒ production by T cells. Moreover, the increased level of IFNϒ in serum may result from a stable 
level of IL17a.
Durable efficacy outcome improvements over six years in 
alemtuzumab-treated RRMS patients who relapsed  
between courses 1 and 2 (CARE-MS I) 
H. Wiendl1, S. Broadley2, O. Fernández3, M. Freedman4, G. Izquierdo5, J. Lycke6,  
C. Pozzilli7, B. Sharrack8, B. Singer9, B. Steingo10, P. Vermersch11, S. Wray12,  
B.-V. Wijmeersch13, T. Ziemssen14, L. Chung15, N. Daizadeh15, K. Thangavelu15, A. Boster16
1Department of Neurology, University of Münster, Germany 
2School of Medicine, Griffith University School, Gold Coast Campus, Australia 
3Department of Neurology, Fundación IMABIS Hospital Universitario Carlos Haya, Spain 
4Ottawa Hospital Research Institute, University of Ottawa, Canada 
5Department of Neurology, Virgen Macarena University Hospital, Spain 
6Department of Clinical Neuroscience, University of Gothenburg, Sweden 
7Department of Neurology, University of Rome, Italy 
8Department of Neuroscience, Sheffield Teaching Hospitals NHS Foundation Trust, UK 
9MS Center for Innovations in Care, Missouri Baptist Medical Center, USA 
10Department of Neurology, Fort Lauderdale Multiple Sclerosis Center, USA 
11Service de Neurologie Générale et Pathologie Neuro-Inflammatoire, University of Lille, France 
12Department of Neurology, Hope Neurology, USA 
13Rehabilitation and MS Centre Overpelt BIOMED, Hasselt University, Belgium 
14Center of Clinical Neuroscience, University Hospital Carl Gustav Carus, Germany 
15Sanofi Genzyme, Sanofi, USA 
16Clinical Neuroimmunology, OhioHealth Neurological Physicians, USA
Introduction: In CARE-MS I (NCT00530348), 2 alemtuzumab courses (baseline: 5 days; Month 12: 
3 days) improved efficacy outcomes vs SC IFNB-1a over 2 years in treatment-naive RRMS patients. Durable 
6-year efficacy in the absence of continuous treatment was demonstrated in an extension (NCT00930553).
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Objectives: Evaluate the 6-year alemtuzumab efficacy in CARE-MS I patients, who relapsed between 
Courses 1 and 2. 
Material and methods: Assessments: annualised relapse rate (ARR); 6-month confirmed disability 
worsening (CDW) and disability improvement (CDI); MRI disease activity (gadolinium [Gd]-enhancing 
and new/enlarging T2 lesions); new T1 hypointense lesions; brain volume loss (BVL). 
Conclusions: In patients, who relapsed between alemtuzumab Courses 1 and 2, clinical and MRI 
outcomes, including BVL measures, were favourable over six years. These data indicate that relapse 
after Course 1 is not indicative of subsequent limited treatment response and support administering 
the approved 2 alemtuzumab courses to achieve the optimal clinical benefit.
Slowing of cortical gray matter atrophy with  
teriflunomide is associated with delayed  
conversion to clinically definite MS
R. Zivadinov1, 2, M.-G. Dwyer1, E. Carl1, K. Thangavelu3, S. Cavalier4, N. Bergsland1
1Buffalo Neuroimaging Analysis Center, University at Buffalo, USA 
2Center for Biomedical Imaging at Clinical Translational Science Institute, University at Buffalo, USA 
3Department of Biostatistics, Sanofi, USA 
4MS Global Scientific Communications, Sanofi, USA
Introduction: In TOPIC (NCT00622700), teriflunomide significantly reduced risk of conversion to 
clinically definite MS (CDMS) vs placebo in patients with a first clinical episode suggestive of MS. Gray 
matter (GM) atrophy after a first clinical event is associated with conversion to CDMS and disability 
accumulation. Here, we explore the effect of cortical GM volume (CGMV) change on risk of conversion 
to CDMS in the TOPIC study. 
Material and methods: Patients received placebo (n = 197) or teriflunomide 14 mg (n = 214) for ≤ 
108 weeks. CGMV change was evaluated using the SIENAX-MTP (Structural Image Evaluation using 
Normalisation of Atrophy, Cross-sectional, multi–time-point) analysis. Data at Month (M)6, M12, M18, 
and M24, standardised for follow-up duration, were analysed relative to baseline. Statistical models 
were used to assess the treatment effects (nonparametric ANCOVA) and relationship of CGMV loss to 
CDMS conversion (Cox proportional hazards models). 
Results: Teriflunomide 14 mg reduced CGMV change vs placebo by ≥40% (PP = 0.0052 for cumu-
lative difference over two years). For every 1% decrease in CGMV, there was a 12.4% increased risk of 
conversion to CDMS at M12 (P = 0.0099), 14.2% at M18 (P = 0.0009), and 14.5% at M24 (P = 0.0005). 
Teriflunomide 14 mg also reduced risk of CDMS vs placebo: 46.3% (P = 0.0220) at M12, 42.1% (P = 
0.0260) at M18, and 46.6% (P = 0.0085) at M24. 
Conclusions: Consistent effects of teriflunomide on reducing CGMV loss, together with the correla-
tion between conversion to CDMS and CGMV loss indicate how teriflunomide may favourably impact 
early inflammatory and neurodegenerative components of MS.
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Targeting key signaling factors as a way to control  
microglial activation and induction of neuroinflammation
B. Badyra, A. Tejchman, M. Hereta, M. Majka
Department of Transplantation, Medical College Jagiellonian University, Poland
Neuroinflammation is co-occurring phenomenon during pathological processes in the nervous system. 
Key player in this process is microglia. As moderate activation of microglia is beneficial, excessive one 
however, leads to more severe degeneration of tissue and inhibition of its endogenous regeneration. One 
way to prevent this situation is to modulate or inhibit microglia activation. The aim of this study was 
to use gene silencing technique to influence microglial activation. By targeting key proteins — NF-kB, 
MyD-88 and TRIF, we intended to decrease inflammatory signaling network. Gene silencing was op-
timised on stable murine microglia BV-2 cell line. Before stimulation with lipopolysaccharide (LPS), 
the cells were transfected with designed siRNA sequences. Efficacy of transfection was assessed by 
evaluating expression of NF-kB, MyD-88, TRIF, as well as IL-1b, IL-6, TNF-a, TREM1, TREM2 at mRNA 
and protein level. Optimised sequences of siRNA were then used on primary microglia. Our results 
showed that siRNA can successfully inhibit activation of microglia in vitro after stimulation with LPS. 
Significant decrease was observed in expression of signaling proteins. However, depending on targeted 
factor, different decrease patterns were observed for IL-1b, IL-6 and TNF-a. Thus, a mixture of siRNA 
was combined to achieve most successful effect. Our results provide a new method to successfully limit 
microglia activation with siRNA technique. This approach will be further used in vivo, in our models of 
Parkinson’s disease and hypoxia-ischaemia encephalopathy, in which severe inflammation is observed. 
Acknowledgements: The project was supported by the research grant from the Jagiellonian University 
Medical College: 2015/17/B/NZ5/00294.
Demyelinating disease during anti-tumour  
necrosis factor a therapy — case report
B. Bielecki, M. Kowalska-Galecka, M. Pawelczyk, K. Turobos, S. Janiak, A. Glabinski
Department of Neurology and Stroke, University Clinical Hospital — Military Medical Academy Memorial, Medical University of Lodz, Poland
Tumour necrosis factor alpha (TNFa) is a cytokine that plays a key role in inflammatory response 
in various autoimmune diseases also in the central nervous system (CNS). This potent agent with 
pleiotropic actions can be present both as a transmembrane protein as well as soluble cytokine. Bi-
ological effects of both forms are mediated through interaction with receptors TNFR1 and TNFR2 
with distinct functions. Multiple sclerosis (MS) is a chronic and progressive disease of the CNS with 
a complex aetiology. Its main pathological features include neuroinflammation, demyelination and 
axonal loss. There is a strong evidence of role of tumour necrosis factor alpha (TNFa) in pathogenesis 
of the disease. Despite data suggesting that TNF-a intrinsically causes primary demyelination, apop-
tosis and neurological damage, previous attempts of treatment of MS with TNFa antagonists led to 
an increase of disease activity. Moreover, neurological adverse events have been reported among the 
patients which received anti-TNFa treatment for other autoimmune and inflammatory diseases. Here 
we present a case of patient suffering from rheumatoid arthritis treated with recombinant monoclonal 
human anti-TNFaantibody (adalimumab). During therapy, neurological symptoms developed suggestive 
of the CNS demyelination. Neurological deficits correlated with magnetic resonance imaging showing 
hyperintensities on T2-weighted images without gadolinium enhancement. Cerebro-spinal fluid analysis 
supported hypothesis of present neuroinflammation with positive oligoclonal bands, however with 
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normal IgG index. In this study we also discuss dualistic role of TNFa in the process of CNS myelin 
damage and repair with emphasis on different roles of TNFR1 and TNFR2.
Stiff person syndrome as initial manifestation  
of systemic lupus erythaematosus: a case report
D. Filimonov1, S. Yevtushenko2, L. Kardashevskaya3, D. Diuba2, E. Marusichenko2
1Department of Experimental Surgery, V.K. Gusak Institute of Urgent and Reparative Surgery, Ukraine 
2Department of Reconstructive Angioneurology and Neurorehabilitation, V.K. Gusak Institute of Urgent and Reparative Surgery, Ukraine 
3Department of Haematology, V.K. Gusak Institute of Urgent and Reparative Surgery, Ukraine
Introduction: Stiff person syndrome (SPS) is a rare, but disabling neurological syndrome, associated 
with various autoimmune pathologies. 
Objectives: This is a case-report of possible SPS, manifesting a year before the full-clinic of systemic 
lupus (SLE). 
Material and methods: 67-year-old Caucasian female patient admitted to the clinic in February 
2016 with acute gaze apraxia and unilateral blepharospasm. She had a history of hypertension and no 
autoimmune pathology. EMG showed periorbicular dystonia. MRI revealed vascular foci in the right 
frontal lobe. Symptoms regressed after few weeks. After 6 months the condition suddenly deteriorated. 
The patient had painful stiffness of her legs, and she was restricted to the wheelchair. EMG revealed 
dystonia of lower extremities. There was CRP elevation to 22 mg/l, CSF protein 0.56 g/l, positive ANA 
1:100. Paraneoplastic antibodies were negative. There was no opportunity to test GAD-antibodies, but 
due to the suspicion of SPS, an immunotherapy was performed — methylprednisolone 500 mg IV, then 
per os intake from 32 mg. There was a dramatical improvement — the functions of lower extremities 
recovered completely. Her condition remained normal for a year. The exacerbation developed acute-
ly in autumn 2017 after hyperinsolation with photodermatitis, legs rash, arthritis, heart failure, and 
painful legs stiffness. Carditis, atrial fibrillation, pneumonitis, nephritis, anaemia, ESR 60 mm/h, CRP 
56 mg/L, ANA 1:320 were revealed. SLE was diagnosed based on SLICC criteria. The patient received 
methylprednisolone 24 mg, hydroxychloroquine 200 mg, gabapentin with positive somatic and neu-
rological dynamics. 
Conclusions: This case supports that SPS can outpace other symptoms of systemic autoimmune 
diseases.
Haptenic diseases
J. Grzeszczuk
Institute of Haptenology, Poland
Introduction: This study was undertaken to verify the hypothesis on toxic interactions of humans 
through water-soluble antigens, also called haptens: A, B, H, Lea and Le, which are present in secre-
tions and odour of the human body. 
Material and methods: Subjects showing pathologic symptoms when inhaling the odour of some 
persons were studied. Knowledge of haptens, present in saliva, sweat, urine, milk and semen was 
obtained from contemporary scientific literature. The haptens were analysed in multiple sclerosis, 
epilepsy, depression, headache, sudden death and some other conditions. The study methods were 
modified and improved over time. The patients were visited in their environment. Blood and saliva 
samples were collected from the patients and persons staying often with them. The results served to 
determine persons interacting toxically through haptens. Altogether, 213 subjects were studied, in-
cluding 83 patients with multiple sclerosis. 
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Results: The hypothesis on toxic interactions of humans through water-soluble antigens, called 
haptens: A, B, H, Lea and Le was explanatory in approximately 80% of cases of multiple sclerosis and 
other diseases. 
Conclusions: On the basis of tests of blood and saliva it is possible to predict the onset and potency 
of human−human interactions caused by haptens. Multiple sclerosis and other neurological diseases 
can be foreseen, prevented, arrested in their progression, and causally treated by avoiding toxic haptens. 
The results of the present and similar studies deserve greater attention of physicians and scientists. 
Fungal infections: complication of immunosuppressive 
therapy of myasthenia gravis
M. Makowska
Neurology, Nordwest Krankenhaus, Germany
Myasthenia gravis is an agent-mediated autoimmune disease. In its most severe form, the life-threat-
ening myasthenic crisis is accompanied by a respiratory failure. In addition to the symptomatic treat-
ment with pyridostygmin, immunosuppressive therapy using glucocorticosteroids and azathioprine is 
therapy of choice. The typical side effects of immunosuppressive therapy are infections, although very 
rare in their occurrence, particularly opportunistic infections are a severe, undiagnosed complication 
of the therapy of myasthenia gravis. A consistent risk management is necessary to prevent them.
Neuroinflammatory markers in dementia with  
Lewy bodies and dementia in Parkinson’s disease
N. Mikhaylova1, L. Androsova2, I. Otman2, T. Klyushnik2
1Geriatric Psychiatry Department, Mental Health Research Centre, Russia 
2Immunology Laboratory, Mental Health Research Centre, Russia
Introduction: Investigation of inflammation reactions in dementias of neurodegenerative genesis and 
detection of their biological markers are considered to be urgent. According to the current conceptions, 
Parkinson’s disease with dementia (PDD) is a part of DLB spectrum. 
Objectives: The aim of the study was to determine the values of peripheral markers of neuroinflam-
mation in blood plasma of DLB and PDD patients compared to healthy controls. 
Material and methods: Blood samples of 7 DLB patients (74,4 ± 8,8 years) and 10 PDD patients (73,6 
± 7,6 years). The patients were diagnosed according to DLB and PDD diagnostic criteria (Miller B.L., 
Boeve B.F. 2017; Budson A.E., Solomon P.R.B 2016). 42 healthy subjects of the same age were included in 
the control group. Enzymatic activity of leucocyte elastase (LE) and functional activity of a1-proteinase 
inhibitor (a1-PI) were determined by spectrophotometric method. Concentration of IL-6 and the level 
of AAB to neurospecific myelin basic protein (MBP) were measured by using immune-enzyme method. 
Results: Significant increase in activity of a1-PI and IL-6 level in DLB and PDD compared to control 
(p = 0.0001, p0.05 resp.) was revealed, while LE activity and the level of AAB to MBP reduced (p = 
0.01, p0.01 resp.). 
Conclusions: The increase in the level of anti-inflammatory cytokines of the acute phase of inflam-
mation in DLB and PDD confirms involvement of neuroinflammation in the pathogenesis. Reduction 
of LE activity may be due to decrease in degranulation activity of neutrophils. Identification of inflam-
matory markers will make it possible to improve reliability of diagnostics and laboratory monitoring 
of the disease progression.
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Implication of autoantibodies against lactosylceramide  
in a neuroinflammatory disorder, EMRN
T. Mutoh, S. Shima, Y. Niimi, Y. Mizutani, A. Ueda, S. Ito 
Neurology, Fujita Health University School of Medicine, Japan
Previous studies have shown that encephalomyeloradiculoneuropathy (EMRN) involves both central 
and peripheral nervous systems. The detailed molecular mechanisms of this disorder, however, still 
remain to be elucidated. Our previous study has demonstrated that EMRN patients exhibit autoanti-
bodies against neutral glycosphingolipids, especially lactosylceramide (LacCer) in the acute phase of 
the disease and these autoantibodies disappeared after extensive immunomodulatory therapies, sug-
gesting these autoantibodies can be an excellent biomarker for EMRN (Neurology, 2014). Intriguingly, 
a recent report indicated that astrocytes in plaque lesions of MS model mice extensively produce Lac-
Cer and its content was significantly upregulated in the lesions of both mice model and MS patients 
(Nat Med, 2014). In the present study, with LC/MS/MS analyses of cerebrospinal fluid (CSF), we found 
statistically significant increase of LacCer levels in CSF from EMRN patients than neurologically free 
individuals. Moreover, anti-LacCer antibodies induced the upregulation of inflammatory cytokines 
mRNA expression from cultured astrocytes. These data strongly suggest the same story as recently 
reported by Grabowsky’s group on Gaucher’s disease also hold on EMRN, where they demonstrated 
that increased amount of glucosylceramide induced the production of autoantibodies against glucosyl-
ceramide and these autoantibodies in turn induce neuroinflammatory reactions (Nature, 2017). Thus, 
there should be some abnormalities in neutral glycosphingolipids metabolism, especially LacCer in 
EMRN patients and these abnormalities result in an alteration of the tuning in immune system of the 
patients, provoking neuroinflammatory reactions.
Immune response against neural antigens  
and paraneoplastic neurological syndromes  
in endometrial cancer patients 
K. Poplawska-Domaszewicz1, S. Michalak3, D. Szpurek2, A. Paluch2, S. Sajdak2, W. Kozubski1
1Department of Neurology, Poznan University of Medical Sciences, Poland 
2Department of Gynaecological Surgery, Poznan University of Medical Sciences, Poland 
3Neuroimmunological Unit, Polish Academy of Sciences, Poznan, Department of Neurochemistry  
and Neuropathology Poznan University of Medical Sciences, Poznan, Poland
Introduction: The purpose of this study was to analyse the spectrum of paraneoplastic neurological 
syndromes and onconeuronal/antineural antibodies and antibodies against nucleoplasm in women 
with endometrial cancer and breast cancer. 
Materials and methods: The study included 75 patients with endometrial cancer and 22 patients 
with breast cancer. Onconeuronal, antineural antibodies and antibodies against nucleoplasm in se-
rum were assessed with the use of indirect immunofluorescence. Western blotting was performed as 
a confirmation test for the presence of onconeural antibodies in patients’ sera. 
Results: Antineural antibodies (12 patients, 16,1%) and antibodies against nucleoplasm (14 patients, 
18,7%) were the most frequent. Onconeuronal antibodies were detected in two cases (2,6%). The neu-
ropathy/polyneuropathy predominate in endometrial cancer patients. Autoantibodies were present in 
16 patients with breast cancer and neurological symptoms. Sensory neuropathy and subacute cerebel-
lar syndrome were the most frequent. The presence of antineural, onconeuronal or antibodies against 
nucleoplasm antigens did not depended on grading or staging of endometrial cancer. All antibodies 
were the most frequent among endometrial cancer patients with low grading (mainly in the course of 
endometrial adenocarcinoma). Neurological deficit is associated with low clinical stage and high grade. 
Conlusions: The detection of antineural antibodies and anti-nucleosome antibodies in a woman with 
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peripheral nervous system deficit should be an indication for gynaecological neoplasm screening. In 
a patient with already diagnosed endometrial cancer and coexisting neuropathy/polyneuropathy, the 
detection of autoantibodies can be helpful in the decision on immunomodulating treatment. 
A case of localised variant of Guillain-Carré syndrome  
associated with IGM anti-b2-GPI antibodies
H. Rhee1, Y. Kwon2, S. Kim1, S. Yoon2, K. Park2, J. Lee2
1Neurology, Kyung Hee University Hospital at Gangdong, South Korea 
2Neurology, Kyung Hee University Hospital, South Korea
Facial diplegia and paresthesias (FDP) is a rare localised subtype of Guillain-Barré Syndrome (GBS), which 
is characterised by simultaneous facial diplegia, distal paresthesias and minimal or no motor weakness. 
We report a patient who presented with simultaneous weakness of bilateral facial nerve and paresthesias. 
A 73-year-old man presented with acute bilateral facial palsy and paresthesias in distal extremities preceded 
by flu-like symptoms. Extensive investigations were performed to evaluate the cause of his symptoms. Nerve 
conduction study (NCS) of upper and lower limbs showed sensory-motor polyneuropathy, which was both 
axonal and demyelinating. In addition, facial NCS revealed absent of compound muscle and sensory nerve 
action potentials. Considering his clinical manifestation and relevant investigations, a diagnosis of FDP, 
a localised variant of GBS, was made. Interestingly, the patient was found to have serum IgM anti-b2-GPI 
antibodies, although other anti-ganglioside antibodies were all normal. Intravenous immunoglobulin was 
started at a dose of 0.4 g/kg/day for five days. After ten weeks of treatment, his facial diplegia improved 
with mild residual facial weakness. Anti-b2-GPI antibodies are the main antiphospholipid antibodies, along 
with anticardiolipin and lupusanticoagulant, that characterise the autoimmune disease antiphospholipid 
syndrome (APS). Although APS was known to be associated with a variety of neurological manifestations, 
including stroke, multiple sclerosis, and transverse myelitis, its association with GBS and variants of GBS 
was not well studied. We report a rare case of anti-b2-GPI antibody detected in a patient, who complied 
with the typical clinical features of FDP, a localised variant of GBS.
Olfactory deficits in mice with experimental autoimmune 
encepharomyelititis, a model of human multiple sclerosis
T. Shin1, J. Kim1, Y. Choi1, M. Ahn1, K. Jung2
1Department of Veterinary Medicine, Jeju National University, South Korea 
2Immonoregulatory Materials Research Center, KRIBB, South Korea
Olfactory deficits are commonly recognised in a variety of human neuro-inflammatory diseases, including 
multiple sclerosis (MS). The relationship between autoimmune CNS disease multiple sclerosis and olfactory 
deficits is under debate. To address this question in human MS, we induced experimental autoimmune 
encephalomyelitis (EAE) in mice, as an animal model of human MS, and compared the behavioural per-
formance of food searching, and neuropathologically examined olfactory bulbs, which are one of central 
tissues of odour processing. Neuro-inflammatory lesions, including the infiltration of inflammatory cells 
and activation of glial cells were found in the olfactory bulbs of EAE-affected mice, as do in the spinal cords. 
Some inflammatory cells were found along the olfactory nerves and in the submucosa of olfactory mucosa. 
Analysis of differentially expressed genes revealed that olfaction related genes including olfactory marker 
protein were significantly down-regulated in the olfactory bulbs of EAE. Behaviourally, the searching time 
for a bait pellet was significantly delayed in EAE mice. These findings all together suggest that neuro-in-
flammation in the olfactory bulbs in EAE-mice would be related with olfactory deficits as far as mice EAE 
is concerned. This research was supported by the National Research Foundation of Korea.
Acknowledgements: Grant number: NRF-2017R1A2B4012487.
138
Polski Przegląd Neurologiczny, 2018, vol. 14, supplement A
www.journals.viamedica.pl
OTHER
Ultrasonography may be more valuable to localise  
ulnar nerve entrapment without conduction  
block in electrodiagnosis
J.Y. An
Department of Neurology, St. Vincent’s Hospital, The Catholic University of Korea, South Korea
Ulnar neuropathy at the elbow (UNE) is thought to most often occur from compression of the nerve 
within the cubital tunnel. The sensitivity of electrodiagnosis for UNE is much lower than for median 
mononeuropathy at the wrist. The reasons for false-negative electrodiagnostic results are not always 
known, but may include improper elbow position and early or mild ulnar nerve involvement. Ultra-
sound (US) is an emerging tool for the evaluation of neuromuscular conditions. US findings in patients 
with UNE and no conduction block have been rarely reported. We describe electrodiagnosis and US 
findings in a 23-year-old man with pain and numbness in his left 4th and 5th fingers. There was no 
definite weakness. His symptoms had begun three months ago, when he exercised heavily for several 
months. Nerve conduction study (NCS) revealed reduced amplitude of left dorsal ulnar cutaneous 
nerve and distal ulnar sensory nerve without definite conduction block in inching study at the elbow. 
Electromyography showed mild denervation potentials in left adductor digiti minimi and first dorsal 
interossei muscle. US showed increased cross sectional area of ulnar nerve below the elbow. He received 
surgical treatment and his symptoms nearly fully recovered four months after surgery. This indicates 
that ultrasound may be a useful tool for assessing an entrapment site in UNE symptoms without exact 
localisation in electrodiagnosis.
Polycythaemia vera a potential cause of spinal  
cord infarction — case report
O. Çibuku1, 2, E. Rraklli1, 2, A. Kuqo2, A. Quka2, A. Tela1, 2, I. Buxhelaj1, 2, A. Rroji2, J. Kruja1, 2
1Neuroscience, Faculty of Medicine, University of Medicine, Albania 
2Neurology, UHC Mother Teresa, Albania
Introduction: Polycythaemia vera (PV) is a myeloproliferative disorder that results in an excess of 
RBC in the bloodstream, and thus increased blood viscosity and platelet activation, leading to an in-
creased risk for vase-occlusive events. Spinal cord ischaemia is a very rare complication, considering 
the large anastomotic net of spinal cord blood vessels. 
Material and method: A 62-year-old woman presented in the emergency room with complaints of 
proximal muscle weakness of the lower extremities with subacute onset, four weeks following a be-
nign gastrointestinal illness. The deep tendon reflexes were absent and there was a level of sensibility 
T12, with urinary retention. A thoraco-lumbar MRI study performed in the first day of hospitalisation 
was unremarkable. Blood work showed a high RBC and haemoglobin levels. All the other blood lab-
oratory tests and cerebrospinal fluid analysis, total body CT scan, were unremarkable. In the 6th day 
of hospitalisation the situation was complicated with DVT of the right leg. Two days after, the motor 
deficits worsened, and the patient became paraplegic. A repeated thoracolumbar MRI study revealed 
spinal cord the presence of acute infarction in T12-L4 levels. The bone marrow biopsy and myelogram 
confirmed the presence mutations in JAK2V617F blood test analysis, compatible with PV diagnosis. 
Conclusions: Although this is a rare haematological disorder, PV should be considered when dealing 
with acute myelopathies or classical spinal cord syndromes. Physicians should be more alert on this 
possible disorder, which can be easily identified by a simple blood test analysis.
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Angioblastoma in the cervical segment of the spinal  
cord in a 50-year-old patient with peripheral  
symptoms — case report
K. Gniadek-Olejniczak
Klinika Rehabilitacji, Wojskowy Instytut Medyczny, Poland
Introduction: CNS imaging examinations with the use of the electromagnetic field in patients with 
a cardiac pacemaker still generate controversies in Poland, though these examinations are routinely 
performed in the USA. 
Material and methods: The report presents a 50-year-old female patient with an implanted cardiac 
pacemaker, with a 1-year history of aggravation of symptoms seemingly linked to peripheral nervous 
system injury. In accordance with procedures foreseen for CIED patients, an MRI was performed. The 
MRI revealed the presence of a tumour in the cervical region of the spinal cord — angioblastoma. 
Conclusions: Angioblastoma is a rare, slowly growing benign tumour developing usually in the 
posterior cranial cavity and spinal cord. The patient’s case shows what variable an array of symptoms 
and signs intraspinal changes angioblastoma can generate, what great a role MRI can play in the diag-
nostic procedure and in planning a surgical intervention, also in the growing number of CIED patients.
Transverse myelitis as a first symptom  
of lupus erythaematosus
I. Ionescu, O. Rujan, A. Enachi, G. Mihailescu, C. Baetu, I. Buraga
Neurology, Colentina Clinical Hospital, Romania
Introduction: Lupus erythaematosus (SLE) represents the prototype of autoimmune diseases, and 
can lead to neurological manifestations. Transverse myelitis is a rare (1–2%) and severe complication 
of SLE and it usually appears in the later stages of this disease. Our patient presented transverse my-
elitits as a first symptom. 
Material and methods: Our patient is a 29-year-old female, who, since childhood, presented pho-
tosensitivity. She was hospitalised for interstitial pneumonia and left pleural effusion. Soon after that, 
her left leg became warm, erithaematous, oedematous and painful. Two weeks later, she was paraplegic, 
with sensory impairment and urinary incontinence. On admittance in our neurological department 
she presented: paraplegia, lower limb reflexes were absent, superficial sensory impairment with T8−T9 
level, urinary incontinence. Biological tests showed: mild anaemia, thrombocytopenia, inflammatory 
syndrome, nephritic syndrome, ANA and ANDdc antibodies were positive, C3 was low and the lupic 
anticoagulant factor was positive. Doppler echography presented ileofemural thrombosis. A medullar 
MRI showed multiple hyperintense areas in T2-weighted sequences in the whole cervical and thoracic 
segment. We tested for infections (viral, bacterial and parasitic), tumours, other autoimmune diseases, 
EMG and cerebral MRI were performed and everything was within normal parameters. At this mo-
ment, we established the SLE diagnosis with secondary SAFL, and cortisone therapy was initiated. 
The patient mildly recovered: the sensory impairment and urinary incontinence were remitted and 
the motor deficit was ameliorated. 
Conclusions: In conclusion, we cannot disregard SLE when confronted with a transverse myelitis 
just because this is a rare manifestation of the disease.
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BDNF level in vascular depression  
and the therapeutic role of Actovegin
L. Kruglov1, 2, M. Kumov3, M. Molodtsova3, I. Goloschapova3
1Department of Geriatric Psychiatry, National Medical Research Center of Psychiatry and Neurology named after V. M. Bekhterev, Russia 
2Chair of Psychiatry and Neurology, St. Petersburg University, Russia 
3Department of Geriatric Psychiatry, Psychiatric Hospital named after P. P. Kaschenko, Russia
Introduction: The BDNF deficit in organic brain insufficiency and depression is actively discussed. 
The aim was to analyse the possibility of enhancing the outcome by Actovegin similar in some aspects 
of structure to BDNF. 
Material and methods: 30 patients (age — 71.6 ± 3,9 years) with vascular depression observed. Main 
group (n = 15) received antidepressants (SSRI) and Actovegin 400 mg in intravenous infusions daily 
for ten days followed by oral treatment 600 mg per day during three weeks. Control group (n = 15) 
received antidepressants only. Clinical data and BDNF concentration assessed at the beginning and on 
the 30th day. Cornell and CGI scale were used. Statistics included Fisher (F) and Mann-Whitney (U) tests. 
Results: Significant improvement (assessed by CGI) noted in 65.7% of the main group compared 
to 44.1% in the controls (F = 2.4; p0.05). More prominent effect concerned feeling of sorrow, every-
day activity, inhibition and diurnal variation of affect (p0,05). Median BDNF level among all patients 
increased from 92,1 ± 5,7 to 124,1 ± 7,1 (U = 135,8; p0,05). No statistical difference found in BDNF 
concentration between highlighted groups at both stages of the study. 
Conclusions: Results of vascular depression therapy can be augmented by Actovegin. It is possibly 
related to neuroplasticity activation significant in depression (especially organic) regress. Underlying 
neurochemical mechanisms are complex and not only BDNF-dependent.
A retrospective two-year analysis of the diagnosis  
of paraplegia made in the emergency room
E. Kurmaku, G. Vyshka, J. Kruja
Neuroscience, Faculty of Medicine, University of Medicine, Albania 
Neurology, UHC Mother Teresa, Albania
Introduction: The presenting of paraplegia in the emergency room is an occurrence of extreme se-
verity. However, a consistent number of cases although treated as peripheral nervous system injuries, 
have another background diagnosis. Such a diagnosis might be difficult to clarify in the emergency 
conditions; however the medical first responders should bear in mind the diagnostic diversity. 
Material and methods: We have controlled the admission files on the ER of “Mother Teresa” UHC 
of Tirana for 2015 and 2016 with the diagnosis “paraplegia”. Notes were made on the gender and age 
profile of the patients, with a special focus on the final (discharge) diagnosis. 
Results: 88 cases (47 males) were registered during the year 2015 and 77 cases (38 males) during 
2016 with admission diagnosis “paraplegia”. The gender profile was clearly in equilibrium; with the 
month of May registering the largest number of cases presenting with paraplegia for both consecutive 
years. A minority of cases (total 28/165) had a diagnosis of Guillain-Barré syndrome or myelitis. 41 cases 
represented a tumoural condition, with the majority of those having the characteristic of metastatic 
processes. Few cases were diagnosed during hospitalisation and treated duly as stroke-like occurrences. 
Conclusions: In spite of the fact that paraplegia needs a careful diagnostic workup of the peripheral 
nervous system, remote causes should be hold in mind and included in the differential diagnoses. 
Several imaging and electrophysiological methods are available for ensuring a high accuracy, that 
cannot however be warranted always and simply in ER.
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Serum lactate and pyruvate in relation to clinical  
severity rate in paediatric facial nerve neuropathy
I. Liskevych, M. Pityk
Department of Neurology and Neurosurgery, Ivano-Frankivsk National Medical University, Ukraine
The assessment of lactate and pyruvate in paediatric facial nerve neuropathy would be advisable, as 
these markers of hypoxia reflect changes in decrease of tissue oxygenation. Trials have demonstrated 
the prognostic value of lactate and pyruvate levels in many pathological conditions, including cystic 
fibrosis, acute bleeding and pancreatitis, intestinal obstruction, septic shock. The aim of the study was 
to find the correlation of lactate and pyruvate in children with facial nerve neuropathy with severity of 
the dysfunction of the “facial nerve — facial muscles” according to the House-Brackmann scale. The 
study involved 122 children with acute facial nerve neuropathy. According to the severity of the defeat 
of the “facial nerve — facial muscles” in 12 children (9.8%) was observed the 3rd degree, 97 children 
(79.5%) had the 4th degree and 13 children (10.7%) had 5th degree by House-Brackmann scale. We 
found a direct correlation between the severity of facial palsy and lactate level (Pearson’s coefficient + 
0.35): the level of lactate in the blood of patients with facial nerve neuropathy at baseline was increased 
and most pronounced in case of 5th degree by House-Brackmann scale. In all patients with severe fa-
cial palsy was observed a significant reduction of pyruvate (Pearson’s coefficient + 0.82). Correlations 
between biochemical changes and clinical severity rate indicate a significant role of violation of redox 
processes in the dynamics of the disease and provide a suggestion that correction of redox processes 
can improve the outcomes of treatment.
Neurological aspects in a case of amyloidosis  
transthyretin type variant Glu54Gln
D. Mirela1–5, M. Draghici5
1Neurology, Valciu Crisanda, Romania 
2Haematology, Andreea Jercan, Romania 
3Haematology, Daniel Coriu, Romania 
4Haematology, Badelita Sorina Nicoleta, Romania 
5Haematology, Daniel Coriu, Romania
Transthyretin hereditary amyloidosis is a rare disease and, so far, this has considered limited to 
certain geographical areas. Recently, with the intensification of genetic screening possibilities, new 
cases, new mutation and endemic areas (e.g. the Balkan area in Europe) have been found — this shows 
that this disease is more widespread than was believed, so doctors need to be warned and think more 
often about this disease. We present the case of a 51-year-old male patient that had a sister, who died 
at the age of 49 from a cardiac disease and his mother died at the age of 50. The onset of his disease 
was in 2012 with diarrhea of unknown cause (rectum biopsy — Congo Red negative). Afterwards, in 
2014, he presented paresthesias and muscle weakness in the lower limbs. In March 2016 he was ad-
mitted to the Neurology Clinic-Fundeni and the EMG established the diagnosis of sensorimotor axonal 
polyneuropathy. The patient was then admitted to the Haematology Clinic with peripheral oedema, 
painful lower limb paresthesias that progressed to knee-level, orthostatic hypotension, bowel disorders 
and cachexia. It was established to be familial amyloidosis transthyretin type (Glu54Gln) with sys-
temic involvement: cardiac (restrictive cardiomyopathy), SNP (sensorimotor axonal polyneuropathy), 
SNV(orthostatic hypotension). Familial amyloidosis transthyretine type is an incurable disease, with 
a median survival of 7–10 years after the onset of symptoms. Liver transplantation is the standard 
therapy for eligible patients, because it stops the synthesis of the mutant TTR. Tafimidis and other 
transthyretin stabilisers are new agents, still under investigation.
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Posterior reversible encephalopathy syndrome  
in rapid progressive glomerulonephritis 
S.M. Noh
Neurology, The Catholic University of Korea, St. Vincent’s Hospital, South Korea
Posterior reversible encephalopathy syndrome (PRES) is a disease that developed reversible vasogen-
ic oedema on brain. Although the pathophysiology of PRES is not fully understood, several clinical 
conditions are related with the development of PRES, for example renal failure, use of cytotoxic drugs 
or eclampsia, which associated with endothelial dysfunction. Here we report a case of PRES related 
with rapid progressive glomerulonephritis (RPGN), that associated with P-ANCA. A 66-year-old woman 
with history of P-ANCA related RPGN was consulted for generalised seizure. She admitted on nephrol-
ogy because of AKI and was taking immunosuppressive agents. Brain MRI demonstrated high signal 
intensity, which suggested vasogenic oedema on T2 weighted image in both frontoparietal lobes, pos-
terior temporal and occipital lobes and right cerebellum. EEG suggested diffuse cortical dysfunction. 
Follow up brain MRI revealed improved vasogenic oedema. PRES is a benign and reversible when the 
causative factor can be treatable. In this case, improvement of renal failure and discontinuation of 
immunosuppressive agents seem to have improved PRES.
Brain atrophy correlates with optic nerve atrophy in LHON 
with MS-like disease — Harding’s syndrome — case report
I. Rosciszewska-Zukowska, M. Dziki
Department of Neurology, The Holy Family Specialist Hospital, Poland
Introduction: Leber’s hereditary optic neuropaty (LHON) is maternally inherited mitochondrial optic 
nerve degeneration with bilateral optic atrophy that very rare is associated with multiple sclerosis-like 
disease. 
Objectives: To report on an optic nerve atrophy coexist with severe brain atrophy in case of a young 
female with multiple sclerosis (MS-like) disease with LHON confirmed by genetic testing with m. 
117778GA mutation. 
Material and methods: 22-year-old female experienced two episodes of right and left painless pro-
gressive decrease of visual acuity with subsequent bilateral profound optic nerve atrophy with pale 
discs on ophthalmoscopy and two recovered, steroid response exacerbation of numbness in right arm, 
left lower limb and weakness of lower limbs. Harding’s syndrome was diagnosed by typical MS brain 
and thoracic spinal cord lesions, positive CSF with oligoclonal bands and m.117778GA mutation. Brain 
MRI after ten years of first symptoms (visual) appearing showed significant brain atrophy in addition to 
the patient’s age and gender information estimated by percentile generation program of CorTechs Labs. 
Results: Results showed advanced brain atrophy with loss whole and regional volume: whole brain 
and thalami volume in 1st percentile for age with lateral ventricles, inferior lateral ventricles and 3rd 
ventricle volume in 99th percentile. Cerebral white matter volume was in 61st percentile with high 
cerebral white hypointensities volume in 99th percentile. 
Conclusions: Optic nerve atrophy correlates with advanced whole and regional brain atrophy in 
LHON with MS-like disease.
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Diagnostic pitfalls in Creutzfeldt-Jakob disease
O. Rujan, I. Ionescu, A. Enachi, G. Mihailescu, C. Baetu, I. Buraga
Neurology, Colentina Clinical Hospital, Romania
Introduction: Creutzfeldt-Jakob disease (CJD) is a very rare neurodegenerative disease of the brain. 
One of the main characteristics of CJD is the rapidly progressive dementia. The clinical tableau consists 
in: rapidly progressive dementia, myoclonic jerks and a variety of neurological abnormalities. The par-
ticularity of our case is the lack of dementia, which raised the difficulty level in establishing a diagnosis. 
Material and methods: Our patient is a 55-year-old female who suddenly presented gait disturbance 
and left limb ataxia. She was hospitalised for what was supposed to be a stroke, performed a CT without 
any abnormalities. Almost immediately she developed myoclonic contractions on her left limb. We 
found: paraparesis, myoclonia on her left limbs, bilateral horizontal nystagmus, dysmetria, dysarthria 
and bilateral Noica sign and all her intellectual functions were preserved. The laboratory tests were 
normal, the cerebral MRI showed a hyperintensity in T2 and FLAIR -weighted images of the basal 
ganglia and right occipital cortex. The EEG was suggestive for CJD. The spinal fluid was positive for the 
“14–3–3” protein. At this point the diagnosis of CJD was established. The seizures gradually became 
generalised in spite of the maximal antiepileptic treatment. She became comatose due to this state, 
was intubated and died within two months since onset. 
Conclusions: Till the moment on which our patient became comatose, she did not present any signs 
of dementia. We should not disregard the CJD diagnosis in the absence of cognitive impairment.
Wernicke’s encephalopathy in a young man as  
a complication of Crohn’s disease — case report
M. Switonska, R. Sokolowski, V. Palacz-Duda
Stroke Intervention Treatment Center, Department of Neurology, University Hospital No. 2, Poland
Introduction: Wernicke’s encephalopathy (WE) is a medical emergency characterised by ataxia, con-
fusion, nystagmus and ophtalmoplegia resulting from thiamine deficiency. Alcoholism is the common 
cause for this disease. WE may be present in the general population with a prevalence of around 2%. 
Material and methods: A young patient (21 years old) was admitted to the Department of Neurology 
with the pertaining of balance disorders and double vision. The patient had suffered from Crohn’s dis-
ease (CD) from childhood. A month before his admission to the hospital he had an increase in Crohn’s 
disease activity. On admission to the department he presented ataxia of the lower limbs, horizontal and 
vertical nystagmus and memory loss. At the admission, the MRI of the brain scan result was normal. 
The EMG excluded polyneuropathy. Due to the suspicion of Miller-Fisher syndrome, he had triple 
plasmapheresis, but without any improvement. Memory loss symptoms exacerbated. The follow-up 
MRI revealed symmetric lesions involving bilateral tegmentum of the pons and periaqueductal area, 
mammillary bodies and the medial thalamus. The WE was suspected. Vitamin B1 was administered 
parenterally. After a week, the follow-up MRI was concluded with the lesions eliminated. Neurological 
symptoms were substantially reduced. By the end of the patient’s stay in the department, deep vein 
thrombosis was observed and subsequently treated with anticoagulant therapy. On day five of the 
ongoing anticoagulant therapy, the patient suffered massive pulmonary embolism, which led to his 
death. Despite the rapid reversal of WE the patient died due to another complication of CD.
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Prevalence of diabetes sensory neuropathy by a question-
naire interview in a cohort of Taiwanese diabetes patients
C.H. Tseng1, C.K. Chong2, J.J. Sheu3, T.H. Wu1, D. Wang4
1Department of Internal Medicine, National Taiwan University Hospital, Taiwan 
2Department of Rehabilitation, Chong’s Physical Medicine and Rehabilitation Center, Taiwan 
3Department of Neurology, Taipei Medical University Hospital, Taiwan 
4Pfizer Innovative Health Medical, Pfizer Limited, Taiwan
A cohort of 1403 Taiwanese diabetes patients were screened for diabetes sensory neuropathy by ques-
tionnaire interview based on 3 categories of abnormal sensation, i.e.: 1) numbness or tingling pain; 2) 
electric shock; and 3) skin thickness sensation. 7 sites on each upper limb (i.e., finger tips, finger, palm, 
dorsum of hand, wrist, lower arm and upper arm) and 6 sites on each lower limb (toe tips, toe, plantar 
surface of foot, dorsum of foot, lower leg and thigh) were recorded for the respective symptoms. At the 
beginning of the screening, the questionnaire did not discern the right and left sides (Cohort I, n = 680), 
but at a later time, the questionnaire was revised to separate the right and left sides (Cohort II, n = 723). 
Results showed that 47.9% of the patients in Cohort I and 59.6% in Cohort II had any one of the symptoms 
on any limb. The questionnaires with and without discerning the right and left sides were then combined 
together (i.e., combining Cohort I and Cohort II) and diabetes sensory neuropathy was defined by using 
different definitions. The prevalence of diabetes sensory neuropathy was 54.0% if it was defined as “any 
positive symptoms on one or more sites”. It was 41.7% if the definition was “any positive symptom on 
at least one site involving the lower limb”. In conclusion, Taiwanese diabetes patients may have a high 
prevalence of diabetes sensory neuropathy if a structured questionnaire is used for screening.
Neuroimaging features of structural changes  
in the brain and their relationship with different  
forms of the cerebral palsy in children
O. Yevtushenko1, S. Yevtushenko2, E. Fomicheva3, E. Savchenko4, D. Filimonov5
1Director, Regional Paediatric Neurorehabilitation Centre, Ukraine 
2Chief Researcher, Regional Paediatric Neurorehabilitation Centre, Ukraine 
3Department of Cerebral Palsy, Regional Paediatric Neurorehabilitation Centre, Ukraine 
4Department of Radiological Diagnostics, V. K. Gusak Institute of Urgent and Reparative Surgery, Ukraine 
5Department of Experimental Surgery, V. K. Gusak Institute of Urgent and Reparative Surgery, Ukraine
Introduction: Cerebral palsy (CP) is one of the most disabling diseases of childhood, but its patho-
genesis is still controversial. 
Objectives: To compare various forms of CP with location and type of brain lesions. 
Material and methods: Under our supervision, there were 134 children (boys — 80, girls — 54) at 
the age 3–10 years with different forms of CP: 1st group with double hemiplegia — 55 patients (41.5%), 
2nd group with spastic diplegia — 43 patients (32%), 3rd group with hemiparetic form — 21 patients 
(15.6%), 4th group with atonic-astatic form — 15 patients (11.1%). 
Results: The following MRI abnormalities were detected: in the 1st group: cystic degeneration — 17 
patients (12.6%); microcephaly — 6 patients (4.4%); polymicrogyria — 5 patients (3.7%), focal cortical 
dysplasia — 3 patients (2.2%). In the 2nd group periventricular leucomalacia was detected predom-
inantly — 38 patients (28.3%). In the 3rd group haemiatrophy of the brain was detected in 6 cases 
(4.4%), cystic degeneration in 6 cases (4.4%), schizencephaly in 2 cases (1.49%) and pachygyria in 6 
cases (4.4%). In the 4th group, cerebellar hypoplasia was revealed in 5 cases (3.7%) and in 4 children 
(2.9%) Dandy-Walker anomaly was detected. In 36 patients (26.9%) MRI did not reveal any detectable 
brain changes, despite the reliable diagnosis of CP. 
Conclusions: Periventricular leucomalacia was the most frequent MRI abnormality and it was associ-
ated with a diplegic form of CP. Apparently, for each form of CP, there is the most vulnerable “critical” 
zone in the process of neuroonthogenesis, which requires further investigation. 
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Post-traumatic cervical dystonia in a patient  
with neurofibromatosis type 1
T. Yoon, J. Yun, J. Lee, S. Yoon
Department of Neurology, Kyung Hee University Medical Center, South Korea
A 6-year-old boy without any past medical history visited to our hospital, complaining of spasmodic 
torticollis. The symptom has come suddenly after he slipped down in bathroom. Although three months 
of treatment with soft collar apply and halter traction, the patient’s symptom did not improve. On 
neurological examination, we could not find any focal neurological sign except spasmodic torticollis. 
Cervical spine x-ray and computed tomography scans revealed atlantoaxial rotatory subluxation. MRI 
of the cervical spine demonstrated extensive intramedullary hyperintensities without enhancement at 
the C1−C4 levels on sagittal T2-weighted image. Cerebrospinal fluid analysis was within normal range 
and anti-aquaporin-4 antibody test was also negative. Brain MRI demonstrated multifocal hyperinten-
sities in the bilateral basal ganglia and left cerebellar peduncle on T2-weighted and fluid-attenuated 
inversion recovery images, suggesting neurofibromatosis-associated multiple gliomas. The patient has 7 
cafe’-au-lait spots on his abdomen, back, and hip. In addition, NF1 gene mutation was found by genetic 
testing. Any abnormality or trauma of the cervical spine can present with spasmodic torticollis. Trau-
ma, including minor trauma (sprains/strains), fractures, dislocations, and subluxations, often result in 
spasms of cervical musculature. It has been known that most cases of post-traumatic cervical dystonia 
are self-limited, and symptoms resolve in 1–2 weeks. However, our patient’s symptom lasted more than 
three months without improvement. We assume that not only minor trauma, but also NF contributed to 
the development of acute cervical dystonia in this case, since pathologic and neuroradiologic studies 
revealed focal lesions involving the basal ganglia, suggesting a pathogenic mechanism of focal dystonia.
Changing vertical nystagmus in the opposite direction:  
is the transition from upbeat to downbeat nystagmus  
a diagnostic clue for Wernicke’s encephalopathy?
W.T. Yoon
Neurology, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, South Korea
Introduction: Changes of vertical nystagmus in the opposite direction are very rarely reported. This 
study aimed to report an unusual case of Wernicke’s encephalopathy (WE) presenting with a transition 
from upbeat nystagmus (UN) to downbeat nystagmus (DN) and to investigate the clinical pattern of 
changing vertical nystagmus in the opposite direction reported in the literature. 
Material and methods: We present a WE patient with primary position UN that changed to DN with 
an upward or horizontal lateral gaze. Additionally, we review previously reported cases and analyse 
the clinical patterns of changing vertical nystagmus in the opposite direction. 
Results: Among ten cases, including our case, the most common type of changing vertical nystagmus 
in the opposite direction was a transition from UN to DN (n = 9, 90%). The most common diagnosis 
was WE, which is accompanied by changes in vertical nystagmus from UN to DN (n = 6, 60%). The 
most commonly associated neuro-radiological localisations for the changing of vertical nystagmus were 
the brainstem and the cerebellum. 
Conclusions: The results of this clinical investigation may provide support for the diagnosis of 
WE. In addition, if young or middle-aged patients exhibit transitions from UN to DN with brainstem 
or cerebellar signs, a diagnosis of WE should be considered. Furthermore, clonazepam and thiamine 
might be helpful for improving nystagmus symptoms.
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PARKINSON’S DISEASES AND OTHER 
MOVEMENT DISORDERS
Frequency and associations of Tardive Dyskinesia  
in a cohort of patients with chronic mental disorders  
in North West Ireland
D. Adamis, J. Tan, F. Saleem, B. McCafferty
Psychiatry, Sligo Mental Health Services, Ireland
Introduction: Tardive dyskinesia (TD) is a form of abnormal involuntary muscle movements. TD is 
an antipsychotics medication-induced movement disorder that can be developed after long-term use, 
reduction, or discontinuation of antipsychotics. It affects the social functioning of patients and their 
compliance with treatment. 
Objectives: The aim was to evaluate TD in a cohort of patients with Chronic Mental Illness (Schiz-
ophrenia, Schizoaffective or Bipolar) who are in a long time on antipsychotic medications. 
Material and methods: Consecutive patients attending outpatient clinics. Data were collected re-
garding demographics, diagnosis, medications and the abnormal movements were evaluated with the 
Abnormal Involuntary Movement Scale (AIMS). 
Results: A 122 participants, mean age 55.03 (SD: 12.74), 74 (60.7%) males. 88 (73%) had a diagnosis 
in the F20 ICD-10 category, 27 (22.1%) in F30 and 6 (4.9%) in others. A new generation antipsychotic 
was prescribed in 100 (82%) and an old one in 22 (18%), 36 (29.5%) had 2 antipsychotics and the rest 
were on monotherapy. AIMS was 0 on 59 (48.4%) participants while 63 (51.6%) had identified with 
TD. TD was significantly more often to those with more than one antipsychotic and to those who tak-
en the old ones (t = 3.055, df:120, p = 0.003, x2 = 25.136, df:1, p = 0.001 respectively). Significantly 
more likely to develop TD those on Zuclopenthixol, Risperdal, Fluphenazine and Flupenthixol and 
less likely those on Olanzapine and Amisulpride (x2 = 43.802, df:9, p = 0.001).
Conclusions: It was expected that new generation antipsychotics are less likely to cause TD, but in 
long term some of them can still cause TD.
Parkinson’s disease: network analysis  
of publications’ activity
A. Buldyaev1, F. Aleskerov2, 3, O. Khutorskaya3, A. Yamilov1
1Faculty of Computer Science, National Research University Higher School of Economics, Russia 
2Faculty of Economic Sciences / Department of Mathematics, National Research University Higher School of Economics, Russia 
3Research Department, Institute of Control Sciences of Russian Academy of Sciences, Russia
Work of any researcher involves a continuous need to obtain information on research topics over 
the world. It is important to understand what has already been done and what is most relevant in 
the research thematic area. Such kind of information can be obtained using huge knowledge bases, 
however, new approaches to their analysis are required. The presented models of network analysis 
of publications on various aspects of Parkinson’s disease allow to reveal the links between research 
clusters, rank its importance and track changes. Recently developed network analysis algorithms, 
including new centrality indices have been applied for publications databases on different aspects 
of Parkinson’s disease. Articles with keywords “Parkinson’s disease” were analysed. Data were taken 
from Web of Science publications database and consist of more than 75 000 articles dated from 1980 
to 2017. Networks of publications are modeled as graphs, where the nodes are identification numbers 
147
E-Poster Abstracts
www.journals.viamedica.pl
(and other information, which can be received from the database), and the edges of the graph carry 
the information about the citations between them. New approaches and methods of centrality anal-
ysis are used to identify pivotal works. The key advantage of these approaches with comparison to 
existing methods is that we consider long-distance connections as well as special attributes of papers 
and group influence on them. This allows to detect hidden key publications: while classical measures 
detect explicit powerful works, our methods also detect works that influence other papers in groups.
Newly diagnosed extrapyramidal and movement  
disorders in Croatia throughout eleven years (2006–2016)
L. Filipovic-Grcic, F. Derke
School of Medicine, University of Zagreb, Croatia
Movement disorders collectively affect approximately ten million people in Europe, Parkinson’s 
disease, essential tremor and primary dystonia being the three most common of these. They are con-
sidered to affect primarily older generation, although there are cases across all age groups. We intended 
to analyse the number of newly discovered cases of extrapyramidal and movement disorders in Croatia 
by age groups since 2006 to 2016. Thus we conducted a research of Croatian health statistics yearbook 
editions since 2006 to 2016. The ICD-10 version codes G20−G26 were taken into consideration. The 
population was distributed in four groups so as to be comparable to GBD; group 1 (0–6 yr.), group 2 
(7–19 yr.), group 3 (20–64 yr.), group 4 (65+ yr.). Since 2006 to 2016 the total of newly discovered cases 
of extrapyramidal and movement disorders was 186 309, with an average of 16 937 cases for each year. 
When distributed across age groups, the greatest trend of increase in incidence can be seen in group 
4 (65+ yr.), the least increasing trend is shown by the group 1 (0–6 yr.). The other two groups (2 and 
3) also show a steady increase of new cases. The findings of this research are in correlation with other 
developed countries, and European yearbooks.
148
Polski Przegląd Neurologiczny, 2018, vol. 14, supplement A
www.journals.viamedica.pl
27-hydroxycholesterol increases a-synuclein protein levels 
through proteasomal inhibition in human dopaminergic 
neurons
O. Ghribi
Biomedical Sciences, The University Of North Dakota School of Medicine, USA
Accumulation of the a-synuclein (a-syn) protein is a hallmark of a group of brain disorders collec-
tively known as synucleinopathies. The mechanisms responsible for a-syn accumulation are not well 
understood. Several studies suggest a link between synucleinopathies and the cholesterol metabolite 
27-hydroxycholesterol (27-OHC). 27-OHC is the major cholesterol metabolite in the blood that crosses 
the blood-brain barrier, and its levels can increase following hypercholesterolaemia, aging, and oxi-
dative stress, which are all factors for increased synucleinopathy risk. In this study, we determined 
the extent to which 27-OHC regulates a-syn levels in human dopaminergic neurons, the cell type in 
which a-syn accumulates in PD, a major synucleinopathy disorder. Our results show that 27-OHC 
significantly increases the protein levels, not the mRNA expression of a-syn. The effects of 27-OHC 
appear to be independent of an action through liver X receptors (LXR), its cognate receptors, as the 
LXR agonist, GW3965, or the LXR antagonist ECHS did not affect a-syn protein or mRNA levels. Fur-
thermore, our data strongly suggest that the 27-OHC-induced increase in a-syn protein levels emanates 
from inhibition of the proteasomal degradation of this protein and a decrease in the heat shock protein 
70 (HSP70). Identifying 27-OHC as a factor that can increase a-syn levels and the inhibition of the 
proteasomal function and reduction in HSP70 levels as potential cellular mechanisms involved in 
regulation of a-syn. This may help in targeting the correct degradation of a-syn as a potential avenue 
to preclude a-syn accumulation.
Metabolism of lipids in Parkinson’s disease
V. Gryb, S. Genyk
Neurology and Neurosurgery, Ivano-Frankivsk National Medical University, Ukraine
Studies of recent years show the possibility of hyper- and hypocholesterolaemia effects on both 
development and progression of Parkinson’s disease (PD). The mechanism of lipid effects remains in-
sufficiently studied, but recent researches point to a tendency towards a decrease in lipid metabolism in 
patients with PD. The purpose of this study was to evaluate the association of the lipid spectrum with 
the clinical features of the PD. Two hundred and fifty-five patients with PD were examined. The control 
group was 30 healthy people. The mean level of total cholesterol (TC) in the control group was 5.4 ± 
1.2 mmol/L, triglycerides (TG) was 1.7 ± 0.8 mmol/L. Patients with PD showed a tendency to decrease 
these datas in comparison with the control group (PD stage 1: TC — 5.2 ± 1.1 mmol/L, TG — 1.0 ± 
0.2 mmol/L; PD stage 1.5: TC — 5,0 ± 1,1 mmol/L, TG — 1,2 ± 0,4 mmol/L; PD stage 2: TC — 5,1 ± 
1,0 mmol/L, TG — 1,5 ± 0,6 mmol/L, PD stage 2,5: TC — 4,9 ± 0,9 mmol/L, TG — 1,0 ± 0,2 mmol/L). 
More pronounced changes were observed at stages 3 and 4 of the disease. The level of TC in patients 
with disease stage 3 significantly decreased compared with the control group to 4.5 ± 0.8 mmol/L, TG 
to 0.9 ± 0.3 mmol/L (p0.05), in patients with PD stage 4 TC decreased to 4.5 ± 0.8 mmol/L, TG to 0.9 
± 0.3 mmol/L (p0.05). Thus, we confirmed the hypothesis of a decrease in lipid metabolism in patients 
with PD and it was shown, that in more severe stages hypocholesterolaemia increases.
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Changing the game for treating Parkinson’s  
disease dementia 
Y.-J. Ho, A.-C. Chen, C.-H. Tai, P.-F. Kao, C.-Y. Shen, W.-H. Wang, C.-C. Kuo,  
M.-A. Tikhonova, T.-G. Amstislavskaya
Department of Psychology, Chung Shan Medical University, Taiwan
Ceftriaxone (CEF) has long been used as antibiotic and has recently been shown to increase expres-
sion of glutamate transporter-1. Glutamatergic hyper-activity is involved in neuronal loss in Parkinson’s 
disease (PD). By treating PD rats with CEF, we demonstrated that CEF improve motor and cognitive 
functions. In addition, our histological, electrical, and MRI data showed that CEF increases neuronal 
density and activity in the hippocampus and dopaminergic system. Interestingly, elevation of neuro-
genesis in the above areas was also observed. Moreover, receiving CEF treatment, PD patient earned 
motor, emotion, cognitive, and neuronal benefits. Except dopamine agonist, for example, L-dopa, 
treatment effect being not satisfied, there is a lack of medicine for treating PD. Our data support that 
CEF may has potential for effectively treating dementia in PD. 
Keywords: Parkinson’s disease, dementia, glutamate
Patient with Essential Palatal Tremor and coexisting  
bipolar disorder successfully treated with botulinum  
toxin injection — case report
W. Ibrahim, N. Merghany
Neurology Department, Kasralainy Hospital, Faculty of Medicine, Cairo University, Egypt
Introduction: Palatal tremor is an abnormal movement of the soft palate, classified into two subtypes, 
“symptomatic form”, and an “essential form”. There is a small, but growing body of evidence suggesting 
that botulinum toxin may be useful for treatment of depression. 
Material and method: F. M. 30 years-old-male, complained of click sounds in both ears and abnormal 
movements in palate; 3 years later — psychiatric symptoms — diagnosed as bipolar disorder. At our 
Movement Disorder Clinic — MRI Brain done to exclude secondary causes — diagnosed as “Essential 
Palatal Tremor” (EPT). A total of 11 U of BoTX type A was injected (on each side) in the tensor veli 
palatini muscle without any local anaesthetic. Follow-up — decreased severity and frequency of pala-
tal tremor and click sound in the ear. Patient developed nasal tonation and nasal regurgitation, but no 
dysphagia; 6 weeks later — marked improvement with no bulbar symptoms. 
Discussion: At present no specific treatment has been established, although successful treatment by 
botulinum has recently been reported. BoTX injection showed antidepressant effect both when used as 
an ancillary treatment and by itself. BoTX treatment of the face can impact on mood and affect. There 
has been no known aetiological correlation between EPT and bipolar disorder. The rarity of palatal 
tremor and its coexistence with bipolar mood disorder with psychotic features, resulted in misdiagnosis 
of the sound as an auditory hallucination. Thus, injection of BoTX not only improved palatal tremor 
but also improved comorbid psychiatric disorder. 
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Anodal transcranial direct current stimulation prevents 
methyl-4-phenyl-1,2,3,6-tetrahydropyridine induced neuro-
toxicity as a in vivo mouse model of Parkinson’s disease 
through autophagy modulation
W. Jang
Neurology, Gangneung Asan Hospital, University of Ulsan College of Medicine, South Korea
Introduction: Parkinson’s disease (PD) is a neurodegenerative disorder characterised by accumulation 
of protein inclusions and loss of dopaminergic neurons. Transcranial direct current stimulation (tDCS) 
is a non-invasive brain stimulation technique that has demonstrated promising results in clinical stud-
ies of PD. Despite accumulating evidence have proved the protective effect of tDCS, the mechanism of 
action is still unknown. Autophagy is thought to be one of the important mechanism in the develop-
ment of PD, and recent studies have demonstrated dysregulation of the autophagy pathway in the PD 
patients and animal PD models. In the present study, we firstly investigated the neuroprotective effect 
of tDCS in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) induced PD mouse model, and then 
evaluated the effect of tDCS on autophagy pathway. 
Material and methods: Mice were stimulated for consecutive five days with MPTP treatment. After 
observation of behavioural alteration using Rota-rod test, mice were sacrificed for the measurement of 
the PD and autophagy-related protein levels in substantia nigra. 
Results: tDCS improved the behavioural alteration and tyrosine hydroxylase protein level and sup-
pressed a-synuclein protein level in MPTP-treated mice. MPTP-treated mice with tDCS also decreased 
the level of autophagy-related protein, such as microtubule-associated protein 1 light chain 3 and 
AMP-activated protein kinase and increased the level of mechanistic target of rapamycin and p62. In 
addition, the protein level of phosphoinositide 3-kinase and brain derived neurotrophic factor were 
enhanced and unc-51-like kinase 1 was suppressed by tDCS in MPTP-treated mice. 
Conclusions: Our findings suggested that tDCS protects against MPTP-induced PD mouse model 
through modulation of autophagy.
Can miglustat halt the progression  
of Niemann-Pick disease type C?
J. Kim
Neurology, Dong-A University Hospital, South Korea
Miglustat has been known the only medical treatment to improve or halt the neurological symptoms 
in Niemann-Pick type C (NP-C). The efficacy of miglustat was evaluated for the first two Korean patients. 
Case 1 developed delusion and abnormal posturing on both hands at the age of 18. All symptoms were 
gradually aggravated. At 24, he became completely dependent on caregivers and wheelchair bound. Case 
2 was the younger sister of case 1. Her symptoms began with dystonia in the right hand at 19 years old 
and were milder than her brother. Both patients were evaluated for dystonia and ataxia using the Dystonia 
Movement Scale (DMS, maximum score 120) and Scale for the assessment and rating of ataxia (SARA, 
maximum score 37) before and 18 months after the administration of miglustat. 600 mg of miglustat a day 
was given to both patients. The baseline scores of DMS were 74 and 29 for case 1 and 2, respectively. They 
changed to 96 and 27 after the administration of miglustat for 18 months. The baseline scores of SARA 
were 26.5 and 13. They changed to 39 and 14. After miglustat therapy, case 1 worsened for both dystonia 
and ataxia. However, case 2 demonstrated stabilisation of her symptoms. Our results show that miglustat 
treatment can halt the disease progression at least for a period of time in the early stage of the illness. The 
earlier detection of the condition seemed to be important for the better efficacy of miglustat in NP-C.
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Fatigue in idiopathic Parkinson’s disease:  
clinical characteristics and risk factors
S.M. Kim, Y. Yang, S.W. Ha, J.H. Han, D.E. Kim
Neurology, Veterans Health Service Medical Center, South Korea
Introduction: Fatigue is a common nonmotor symptom in patients with Parkinson’s disease (PD). 
Although it develops in every stage of PD and has a major impact on quality of life, fatigue is not fully 
studied.
Objectives: The purpose of this study was to elucidate the characteristics and risk factors of fatigue 
in PD. 
Material and methods: We studied 148 patients at an average of 3.6 years after the diagnosis of PD. 
The presence of fatigue was assessed using Parkinson Fatigue scale. A cut-off point of 3.3 was used for 
diagnosis of fatigue. The presence of other nonmotor symptoms, including depression, was also identi-
fied. The relationship among demographic characteristics, clinical features and fatigue was evaluated. 
Results: Fatigue was observed in 99 patients (66.9%). In univariate analysis, diabetes, history of 
stroke, disease duration, Hoehn-Yahr stage, presence of depression and constipation were significantly 
associated with fatigue. Multivariate analyses showed that history of stroke (P = 0.044, OR 2.35) and 
presence of depression (P = 0.012, OR = 2.88) were independent factors related to fatigue. 
Conclusions: Fatigue is a fairly common nonmotor symptom in patients with PD. The presence of 
depression is the most important factor related to fatigue, followed by history of stroke. Strategies to 
improve the fatigue should be individualised according to the associated factors.
A qualitative assessment of dynamic balance reactions  
in patients with Parkinson’s disease 
K. Krzyszton, J. Stolarski, J. Kochanowski
Department of Neurology of the Second Faculty of Medicine with the English Division and the Physiotherapy Division, Medical University of Warsaw, Poland
Introduction: To evaluate balance disorders in Parkinson’s Disease (PD) many tools can be used, 
however the majority of them does not take into account the dynamic balance reactions (DBR). The 
aim of this study was a qualitative assessment of DBR in patients with PD, thus authors proposed two 
functional tests. 
Materials and methods: A study group consisted of 19 PD patients was compared to a control group 
— 19 healthy subjects. In this study new methods — a trial on a balance platform (rocker board) and 
a reach-to-side test (RST) — were proposed and compared to the Activities-Specific Balance Confi-
dence (ABC) Scale. Study on the balance platform assessed postural control mechanisms in a standing 
position; RST completed this evaluation in sitting. 
Results: In the test on the balance platform, the average results achieved by the study group (55%) 
was statistically significantly different (p0.05) than in the control group (91.25%). In RST, the average 
result in the study group was 62.5%, whereas in the control group was 87.5%. In both functional tests, 
the correct order of DBR in PD patients was significantly less frequent (p0.05). Comparing the average 
results of functional tests with ABC scale there is no statistically significant correlation. 
Conclusions: The ABS scale provides information about the patient`s subjective assessment, which 
is not always confirmed during motor tasks. It can be concluded that this scale is only good comple-
ment for motor tests. Both proposed methods are based on simple instruments and could be used in 
every consulting room.
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Autosomal dominant spinocerebellar ataxia type 40 
caused by mutations in the CCDC88C gene -— report of the 
first European family
M. Lenska-Mieciek1, A. Charzewska2, D. Hoffman-Zacharska2, U. Fiszer1
1Department of Neurology and Epileptology, Centre of Postgraduate Medical Education, Poland 
2Department of Medical Genetics, Institute of Mother and Child, Poland
Autosomal dominant spinocerebellar ataxias form a group of clinically and genetically diverse disor-
ders. There has been only one report of the spinocerebellar ataxia 40 in a Chinese family. We identify 
four-generation Polish family with tremor, cerebellar ataxia, Parkinsonism and dementia history. The 
proband is a 59-year-old man with a 10-year history of asymmetric upper limb tremor as a prevailing 
symptom. Neurological examination also indicates negligible: ataxia, dysdiadochokinesia, bradykine-
sia, hyperreflexia and mild cognition function impairment. MRI of the proband’s brain is normal. The 
whole exome sequencing analysis was done in four individuals of this family, including three affected 
and one unaffected. The mutations in genes associated with Parkinson’s disease and Wilson’s disease 
were not confirmed. The genes associated with tremor and ataxia were analysed. The analysis revealed 
missense mutation in the CCDC88C gene. Bioinformatic analysis shows that the Asp43Asn mutation 
of CCDC88C is pathogenic. Cosegregation analysis was done and the mutation cosegregates with the 
phenotype. Referring to OMIM database, this mutation is related with SCA 40.
Encephalitis lethargica syndrome: clinical features  
and management of two cases
S. Lobzin, I. Kula
Neurology, North-Western State Medical University n.a. I. I. Mechnikov, Russia
Introduction: Lethargic encephalitis (LE) (Economo’s disease) — enigma of 20th century, caused 
pandemic observed from 1915 to 1927, since then occurs sporadically. Despite numerous researches, 
so far true nature (virus) of LE is unknown. Autoimmune nature of LE with lesions in basal ganglia 
and subthalamic area was revealed in many researches. Acute oculolethargic form of LE is mostly 
known. Postencephalitic Parkinsonism and other extrapyramidal forms (choreoathetosis) are mostly 
often in chronic LE. 
Material and methods: We observed two patients (25-year-old male and 31-year-old female) with 
subacute onset with moderate infectious symptoms, pharyngalgia, followed by diplopia and hypersom-
nia. Gradually focal neurological symptoms, disturbances of the endocrine and autonomic functions 
appeared. In first case, this were hemiparkinsonism corresponded with focal subcortical lesions on MRI, 
moderate lymphocytic pleocytosis, suddenly formed sweating, obesity and priapism. In second case 
after pharyngalgias, subfebrile fever and acute diplopia, hypersomnia, cachexia and choreoathetosis 
appeared. CSF analysis revealed mild inflammatory changes. Focal encephalitis in deep brain structures 
was confirmed on MRI. Screening investigations did not find actual viral infections. Pathogenetic role 
of S. aureus was established in both cases. 
Results: After etiotropic, immunosuppressive and neuroprotective treatment both patients noted 
significant improvement. 
Conclusions: Oculolethargic syndrome appeared after bacterial infection, focal lesions of deep brain 
structures, inflammatory changes in CSF followed by extrapyramidal disturbances; improvement after 
complex therapy permit us to make conclusion of LE- syndrome autoimmune nature induced by S. 
aureus.
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Glucose transporter type 1 (GLUT-1) Deficiency Syndrome 
— delayed diagnosis and treatment — case report
E. Naganska1, P. Bogucki2, D. Hoffman-Zacharska3, M. Jurek3, U. Fiszer2
1Department of Neurology and Epileptology, Professor Witold Orlowski Independent Public Clinical Hospital, Warsaw, Poland 
2Department of Neurology and Epileptology, Centre of Postgraduate Medical Education, Warsaw, Poland 
3Department of Medical Genetics, Institute of Mother and Child, Warsaw, Poland
Glucose transporter type 1 deficiency syndrome (GLUT1-DS) is a treatable metabolic disorder caused 
by a mutation in SLC2A1 gene. The most severe classic phenotype comprises infantile-onset epileptic 
encephalopathy associated with delayed development, acquired microcephaly, motor coordination 
disturbances, and spasticity. There are also observed the less severe clinical features, associated with 
paroxysmal exercise-induced dystonia with or without epileptic seizures. We describe the woman, 
who was diagnosed as epileptic patient and treated for years with different antiepileptic drugs with no 
clinical effect. She had the only two generalised tonic clonic seizures in her life. Instead of them, she 
suffered from increasing frequency of the paroxysmal involuntary movements of lower limbs, leading 
to gait disturbances and falls, which were wrongly diagnosed as epileptic seizures, too. The jerks of 
the head and limbs were observed for the first months of her life. The symptoms were provoked by 
stress and exertion. Additionally, slight mental retardation was observed during her growth. Due to 
similarity of seizures symptomatology, as well as paroxysmal dystonic movements, related to them 
status epilepticus and dystonic status, clinical differentiation may be difficult. The lumbar puncture 
was performed, then low glucose concentrations in cerebrospinal fluid was set. The results of genetic 
tests revealed the missense mutation of protein p.Arg333Trp, and confirmed the diagnosis of GLUT-
1-DS1 syndrome. Delayed diagnosis caused the great problems with acceptance of the ketogenic diet, 
which is suggested as the treatment of choice in GLUT-1 deficiency syndrome.
De novo ADCY5 mutation in patient who showed early  
onset dystonia and paroxysmal choreoathetosis in Korea
E. Oh1, D. Kim2, J. Park3, C. Lee5, J. Youn4
1Neurology, Chungnam National University Hospital, South Korea 
2Neurology, Dong-A University Hospital, South Korea 
3Neurology, Soonchunhyang University Hospital, South Korea 
4Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine, South Korea 
5Health Sciences and Technology, Samsung Genome Institute, Samsung Medical Center, South Korea
Introduction: Adenylyl cyclase 5 (ADCY5) mutations are associated with heterogenous hyperkinetic 
movement disorders: familial dyskinesia, paroxysmal chorea and dystonia; autosomal-dominant chorea 
and dystonia; and benign hereditary chorea. We observed a patient, who identified ADCY5 mutation 
for the first time in Korea. 
Material and methods: This 20-year-old man presented motor mile stone delaying since nine month 
of age. He had difficulty in sitting, grab and standing, and walking difficulty in his 17 month of age. 
Psychomotor development was normal. The plasma amino acid, urine organic acid, X-ray and brain 
magnetic resonance image (MRI) was checked, but specific findings did not observed. At 2-year-old 
age, he had difficulty in supporting his neck, and he maintained head dropped posture. He had no 
pre- and postpartum injury, but diagnosed athetoid cerebral palsy at that time. He was hospitalised 
for comprehensive rehabilitation at the age of 20 years and cooperated with neurologist. Neurological 
examination confirmed axial hypotonia (neck) and mild dystonic posture of the four limbs. Gait is 
unsteady or nearly impossible because of the head drop. He showed hyperreflexia and episodic, par-
oxysmal choreoathetosis during sleep and when he fall asleep. The laboratory tests, EEG, EP, cognition 
test and follow up brain MRI were normal. De novo ADCY5 gene mutation (c.2088+1GT) was found 
by trio exome sequencing, and he was treated with clonazepam and clobazam. 
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Conclusions: ADCY5 genetic analyses may be relevant in the diagnostic workup of early-onset dys-
tonia and hyperkinetic movement disorders.
Doctor, researcher or a friend?
T. Rogalski
Neurology, Self study, Poland
Journey on the other side of the mirror — is it worth to endure the hardships of traveling through 
“terra incognita” to limit the destructive influence of stereotypes? I was taken by PD Travel Agency for 
a package tour as I was diagnosed with Parkinson’s disease eight years ago. An educated patient can 
help neurologists if they are equipped to allow it. This is an invitation to discuss on how to effectively 
do doctor−patient communication while we are out on our journey. Patient, through a long travel with 
Mr. PD, had to get to know his habits and whims, as well as the increasingly rude behaviour of this 
stowaway passenger. How can they recognise what is just a symptoms fluctuation of disease, and what 
is a real response to medications? Do patients understand well what the neurologist recommended 
to them? Do they have the inner conviction about the implementation of the recommended strategy, 
and are aware of the limitations and expected effects? What a patient can do to select relevant infor-
mation to report changes in an efficient manner and not omitting important information about their 
state? Clinical trial procedures define individual roles and responsibilities, like in a theater script. Is it 
enough for each of team members to learn how to play our roles in order to ensure reliable results? If 
you are ready to accept an invitation to a discussion, we might find something beneficial to everyone 
involved. Let me put you in a PD patient shoes.
COPPADIS-2015: an ongoing global Parkinson’s disease 
project about disease progression with more  
than 700 patients included. Preliminary results  
of baseline evaluations
D. Santos1, S. Escalante2, E. Cubo3, F. Carrillo4, J.-C. Martínez Castrillo5,  
P. Sánchez Alonso6, M. Gemma, A. Losada7, N. López Aríztegui8,  
M. Itziar Gastón9, J. Kulisevsky10, M. Menéndez González11, M. Seijo12, J. Ruíz Martínez13,  
C. Valero14, M. Kurtis15, B. Galeano16, O. De Fábregues-Boixar17, J. González Ardura18,  
C. Prieto19, P. Martínez Martín20, COPPADIS Study Group21
1Neurology, Hospital Arquitecto Marcide y Hospital Naval, Complejo Hospitalario Universitario de Ferrol (CHUF), Spain; 2Neurology, Hospital de Tortosa 
Verge de la Cinta (HTVC), Spain; 3Neurology, Complejo Asistencial Universitario de Burgos, Spain; 4Neurology, Hospital Universitario de Canarias,  
San Cristóbal de la Laguna, Spain; 5Neurology, Hospital Universitario Ramón y Cajal, Spain; 6Neurology, Hospital Universitario Puerta de Hierro, Spain;  
7Neurology, Hospital Álvaro Cunqueiro, Complejo Hospitalario Universitario de Vigo (CHUVI), Spain8Neurology, Complejo Hospitalario de Toledo, Spain; 
9Neurology, Complejo Hospitalario de Navarra, Spain; 10Neurology, Hospital de Sant Pau, Spain; 11Neurology, Hospital Universitario Central de Asturias, 
Spain; 12Neurology, Complejo Hospitalario Universitario de Pontevedra (CHOP), Spain; 13Neurology, Hospital Universitario Donostia, Spain; 14Neurology, 
Hospital Arnau de Vilanova, Spain; 15Neurology, Hospital Ruber Internacional, Spain; 16Neurology, Hospital Universitario de Ceuta, Spain; 17Neurology, 
Hospital Universitario Vall d´Hebron, Spain; 18Neurology, Hospital Universitario Lucus Augusti (HULA), Spain; 19Neurology, Hospital Rey Juan Carlos, Spain; 
20Centro Nacional de Epidemiología y CIBERNED, Instituto de Salud Carlos III, Spain; 21Neurology, Other Centres from Spain, Spain
Introduction: To describe preliminary results of baseline evaluations of a Spanish ongoing global 
Parkinson’s disease (PD) Project, COPPADIS-2015 (Cohort of Patient’s with Parkinson’s Disease in 
Spain, 2015). 
Material and methods: Observational, descriptive, non-interventional, 5-year follow-up, national 
(Spain), multicenter, evaluation study (Santos-Garcia D et al. BMC Neurol, 2016). PD patients, prin-
cipal caregivers and controls will be assessed in detail during follow-up. Here, we presented general 
preliminary results about baseline visits. 
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Results: A total of 717 PD patients (59.8% males; 62.8 ± 9 years old), 302 caregivers and 209 controls 
(49.5% males; 61.2 ± 8.5 years old) were included in the study between January, 2016 and October, 
2017. The mean disease duration was 5.5 ± 4.4 years. Hoehn and Yahr stage was 1 or 2 in 88.9% (Uni-
fied Parkinson’s Disease Rating Scale-part III 22.7 ± 11.5) of the patients, while 28.1% and 17.5% of 
them presented with motor fluctuations and dyskinesias, respectively. Mean Non-Motor Symptoms 
Scale (NMSS) total score was 45.5 ± 38 and 25.9% of the patients presented cognitive impairment, 
14.1% major depression, 19.8% impulse control disorder and 56.5% pain. Compared to the control 
group, PD patients presented a significant higher burden of non-motor symptoms and a worse quality 
of life. More than 340 subjects have undergone complementary studies (serum biomarkers, genetic 
and neuroimaging) so far. 
Conclusions: COPPADIS-2015 would have to provide important knowledge about PD progression. 
Currently, we have extensive information about the baseline visits (cross-sectional study), that will be 
analysed in detail in the short-term future.
Neuromodulatory role of subthalamic nucleus deep brain 
stimulation (STN-DBS) in Parkinson’s disease (PD) patients
S. Szlufik1, A. Przybyszewski2, K. Duszynska-Was1, I. Laskowska-Levy3, J. Dutkiewicz1,  
A. Drzewinska1, P. Habela2, T. Mandat4, D. Koziorowski1
1Department of Neurology, Faculty of Health Science, Medical University of Warsaw, Poland 
2Department of Informatics, Polish Japanese Academy of Information Technology, Poland 
3Department of Psychology, University of Finance and Management, Poland 
4Department of Neurosurgery, Institute of Psychiatrics and Neurology, Poland
Introduction: STN-DBS has been claimed to change progression symptoms in animal models of PD, 
but there are lacking information about the possible neuromodulatory role of STN-DBS in humans. 
Objectives: The aim of the study was to evaluate the impact of STN-DBS on the motor disabilities 
and cognitive alterations in PD patients in comparison to Medical-Therapy-only (MED) and Post-Op-
erative-Patient (POP) groups. 
Material and methods: DBS-group consisted of 20 PD patients (7F, 13M) who underwent bilateral 
STN-DBS. POP-group consisted of 15 post-DBS PD patients (6F, 9M) in median 24 month-time after 
surgery. Control group (MED-group) consisted of 24 patients (13F, 11M). UPDRS III scale and RS (reflex-
ive saccades) parameters (latency, amplitude, duration, peak of velocity) were measured during three 
visits in 9 ± 3-months periods (V1, V2, V3) in total OFF phase. Cognitive assessment was performed 
during each visit in ON phase. 
Results: The comparable UPDRS III OFF gain in V3/V2/V1 visits (p < 0.05) in both MED-group and 
POP-group was observed. UPDRS III OFF results in DBS-group revealed significant UPDRS III OFF 
worsening in V2/V1 DBS-group visits (p < 0.05) with no UPDRS III OFF change in V3/V2 DBS-group 
visit. Similar general relations were observed in the increase of RS latencies in V2 compared to V1 
DBS-group (p < 0.05), but no change in the latency was observed in V3/V2 DBS-group and V3/V2/V1 
visits in MED-group and POP-group. Cognitive assessment revealed significant V3/V1 changes between 
DBS-group and MED-group in verbal fluency tests (p < 0.05). 
Conclusions: The impact of STN-DBS on UPDRS III OFF, RS latency and cognitive changes can 
suggest its neuromodulative role, mainly during first 6–12 months after surgery. 
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Levodopa: prescription errors  
in the use of antiparkinsonian drugs
Y. Takeuchi1, 2, J. Valderrama1, 3, M. Molina2, S. Prada4, J. Orozco1–3
1Neurología, Fundación Valle del Lili, Colombia 
2Facultad de Ciencias de la Salud, Universidad Icesi, Colombia 
3Centro de Investigaciones Clínicas, Fundación Valle del Lili, Colombia 
4PROESA, Universidad Icesi, Colombia
Introduction: The introduction of levodopa (LD) in 1960 revolutionised the management of Parkin-
son’s disease (PD). As it is a drug with few indications (PD, dystonia, and other movement disorders), it 
facilitates identification of associated prescription mistakes, which are frequent in general practice. No 
study has analysed levodopa prescription errors, but drug warning letters have been reported since 1971. 
Material and methods: A cross-sectional study was conducted using de-identified administrative 
data of two Colombian Health Maintenance Organisations (HMO). 4 306 042 subjects were included 
from a 2 year period (2014–2015). To identify PD patients, a filter using ICD-10 (G20X,G258,G259,F023) 
and levodopa ATC codes (N04BA01,N04BA02,N04BA03) was applied. All subjects with at least one 
code were included. A descriptive analysis of the drug prescription relevance was carried out. 
Results: 4 952 PD patients were included. The age median was 72 years (IQR: 62−80). Ninety point 
thirty-three per cent of the sample were 50 years or older. Three thousand six hundred and twenty-sev-
en subjects had Levodopa prescription, of these 58.7% had at least one inclusion diagnosis associated 
and 0.77% had dystonia (ICD-10:G24). These prescriptions were considered “adequate”. 692 patients 
(13.79%) with levodopa, but without ICD-10 code diagnosis were considered as “inadequately pre-
scribed”. The most common diagnoses associated with levodopa misprescription were: non-specific 
diagnosis (ICD-10: R688, R69, Z) 64.60%, hypertension 10.84%, other neurological disorders 9.54%. 
Formulation errors were more frequent in women (15.7% vs 13.44%) and patients younger than 50 
years (50.24% vs 18.03%), 4 pregnant patients were misprescribed instead of methyldopa. 
Conclusions: A high proportion of patients receive levodopa without having an adequate ICD-10 
diagnosis that justifies the prescription.
Immobilisation test as an assessment of the treatment  
effectiveness in patients with restless legs syndrome  
on the basis of diabetic polyneuropathy
N. Tkachuk, V. Gryb
Neurology, Ivano-Frankivsk National Medical University, Ukraine
Introduction: Restless legs syndrome (RLS) is characterised by unpleasant sensations and motor dis-
turbances in the lower extremities. The aim of the study was to examine the efficacy of pramipexole in 
patients with RLS on the basis of diabeticpolyneuropathy (DPN) with the use of immobilisation test (IT). 
Material and methods: The study involved 76 patients with type 2 diabetes mellitus complicated 
with DPN. In 19 (25%) patients RLS was found. All patients received the standard therapy of DPN 
and pramipexole 0.750 mg once a day and were examined with IT before and 30 days after treatment. 
Results: The following data received: on the basis of treatment average movement index (MI) de-
creased from 47.2 ± 1.5 to 19.6 ± 1.2 (p = 0.04). After the treatment, decrease in the number of PLM 
(-72%) was noted more in the first 30 minutes of the test, as opposed to the last 30 minutes (-28%). 
Treatment with pramipexole increased the average interval between movements in seconds (p = 0,035). 
According to the MI, two (10.4%) patients had a mild form of RLS, four (21.1%) patients — severe and 
13 (68.5%) patients — moderate form of RLS. After 30 days of therapy, 6 (31.5%) patients had mild, 9 
(47.4%) — moderate stage of RLS, in 4 (21.1%) patients number of PLM was less than 10 per 1 hour. 
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Conclusions: Our research showed the efficacy of pramipexole in patients with RLS on the basis of 
DPN, which was proven by IT, as a reliable and probable test for determining the severity of RLS and 
the response to treatment.
Ghrelin reduces A-type potassium channels in nigral  
dopaminergic neurons via PKC but not PKA pathway
J. Xie, L. Shi, B. Xue 
Department of Physiology, Shandong Provincial Key Laboratory of Pathogenesis and Prevention of Neurological Disorders, Shandong Provincial  
Collaborative Innovation Center for Neurodegenerative Disorders and State Key Disciplines: Physiology, Qingdao University, China
Introduction: The excitability of dopaminergic neurons in the substantia nigra pars compacta (SNc), 
that supplies the striatum with dopamine, determines the function of nigrostriatal system for motor 
coordination. Our previous studies showed that the brain-gut peptide ghrelin could enhance pacemaker 
firing of nigral dopaminergic neurons by inhibiting voltage-gated potassium Kv7/KCNQ/M-channels. 
However, whether the other potassium channels are also involved in the ghrelin-induced excitability 
of dopaminergic neurons still remains unclear. In this study, we focus on A-type potassium channels 
(IA), which has a wide expression on dopaminergic neurons and play a key role in pacemaker control. 
Material and methods: Brain slices of the SNc were prepared from C57BL/6 mice of postnatal 15–20 
days. The effects of ghrelin on discharge frequency and IA current of dopaminergic neurons were ob-
served by whole cell patch clamp technique. 
Results: Ghrelin (100 nM) can significantly increase the discharge frequency of dopaminergic neu-
rons and inhibit the amplitude of IA current. Application of either PKA selective inhibitor H89 or 
PKC inhibitor GF109203X alone had no effect on IA; However, GF109203X abolished ghrelin-induced 
inhibition of IA. In addition, GF109203X and the IA specific blocker 4-AP could occlude the excitatory 
effects of ghrelin. 
Conclusions: These results demonstrated that inhibition of IA may contribute to the ghrelin-induced 
excitation of dopaminergic neurons. Ghrelin reduces IA by activation of PKC but not PKA pathway.
Lactoferrin shows protective effects in a MPTP-induced 
mouse model of Parkinson’s disease
J. Xie, J. Wang, H. Liu, H. Wu 
Department of Physiology, Shandong Provincial Key Laboratory of Pathogenesis and Prevention of Neurological Disorders, Shandong Provincial  
Collaborative Innovation Center for Neurodegenerative Disorders and State Key Disciplines: Physiology, Qingdao University, China
Introduction: Lactoferrin (Lf), and the lactoferrin receptor (LfR), regulate cell membrane iron 
transport, are synthesised in the brain by activated microglia, and their expression is increased in 
dopaminergic neurons in Parkinson’s disease (PD). We investigated the effects of iron-free Lf (apo-Lf) 
and iron-saturated Lf (holo-Lf) in a mouse model of PD and hypothesised that Lf protects against PD 
through altered iron metabolism. 
Material and methods: We examined the effect of daily intragastric doses of apo-Lf and holo-Lf for 
7 days in an experimental 1-Methyl-4-phenyl-1,2,3,6-etrahydropyridine(MPTP)-induced mouse model 
of PD. 
Results: Apo-Lf and holo-Lf antagonised MPTP-induced symptoms including shortening pole 
climbing time, reducing weight loss, preventing tyrosine hydroxylase immunoreactive (TH-ir) neuron 
loss in the substantianigra (SN), and restoring dopamine in the striatum. Lf increased SOD1 and Bcl-2 
expression, and decreased cleaved caspase-3 expression in the SN. Lf treatment down-regulated iron 
import protein divalent metal transporter (DMT1) and up-regulated iron export protein ferroportin1 
(FPN1) normalising MPTP-induced accumulation of nigral iron. Lf alleviated MPTP-induced increases 
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in serum iron and ferritin, and decreased serum TIBC, spleen weight, and spleen iron content. Liver 
iron routine blood test remained unchanged. 
Conclusions: Apo-Lf and holo-Lf have a protective effect against MPTP-induced PD, with apo-Lf 
showing greater efficacy. Therefore, Lf is a new potential treatment for PD. More importantly, we put 
forward a hypothesis that spleen weight loss and lower spleen iron levels might be the original source 
of iron overload in SN.
Comparison of gait parameters between drug-naïve  
patients with multiple system atrophy with predominant 
parkinsonism and Parkinson’s disease
J.-Y. Youn, J.-W. Cho, J.-S. Kim, B. Na
Neurology, Samsung Medical Center, South Korea
Even though more gait symptoms present from early stage in the patients with multiple system at-
rophy with predominant parkinsonism (MSA-P) compared to those with Parkinson’s disease (PD), the 
gait patterns of MSA-P were not clearly elucidated yet. We enrolled drug-naïve 34 PD patients and 26 
MSA-P patients at the Movement Disorders Clinic, Samsung Medical Center. Parkinsonism was evaluated 
with Unified Parkinson’s disease rating scale (UPDRS) part III and cognition with mini-mental status 
exam (MMSE). All enrolled subjects underwent DIERS Pedoscan and GAITRite to measure postural 
instability and gait. We compared the results of posturography and gait analysis between MSA-P and 
PD patients, and performed correlation analysis with UPDRS part III and MMSE scores. Although there 
was no difference in demographic and clinical variables between two groups, MSA-P patients showed 
larger total anterior-posterior and lateral movement of center of pressure (COP) than PD patients. In 
terms of gait analysis, MSA-P group had slower velocity, decreased step/stride length, and increased 
base compared with PD patients. In correlation analysis, MMSE score was correlated with step/stride 
length and single/double support time in PD patients after controlling age, sex, height, body weight, 
education year, disease duration, and UPDRS part III score. Even from early stage, MSA-P patients 
demonstrated more involvement of postural instability and gait disturbance compared with PD patients. 
Particularly, because of more severe postural instability in MSA-P patients, MSA-P patients showed 
larger movement of COP and wide base during gait than PD patients.
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REHABILITATION
Nucleo CMP forte in the treatment of patients with  
radiculopathy: clinical and neurophysiologic studies
S. Huseynova
Laboratory of Clinical Neurophysiology, Scientific Research Institute of Medical Rehabilitation, Azerbaijan
Introduction: Nucleo CMP forte, which is an external source of pyrimidine nucleotides (PN) nec-
essary for reparation of a nerve tissue, is widely used in the treatment of peripheral neuropathy, in 
particular, vertebrogenic radiculopathies (VR). Purpose: to study the effects of Nucleo CMP forte for 
patients with VR. 
Material and methods: 60 patients were involved in the study. They were divided into two groups. 
The patients in the first group (40 persons) received interference therapy (IT) with intramuscular in-
jection of Nucleo CMP forte during 15 days, afterwards they received capsules of the same medicine 
orally (twice in a day each time one capsule) for one month period. The patients in the second group 
(20 persons) were treated with IT for 15 days. Neurophysiologic studies were conducted before, on 
the 15th day and at the end of the treatment. Neurophysiologic studies included evaluation of impulse 
conduction velocity (ICVeff) and the parameters of F-wave on motor fibers of peripheral nerves, ICVaff 
on sural nerve, also, amplitudes of motor and sensory responses. 
Results: As a result of the treatment, no statistically significant changes were observed in the indica-
tors of M-response and sensory responses were not found. In the group, which received Nucleo CMP 
forte, significant increase of ICVeff was observed on motor fibers of fibular and tibial nerves (p0,05 and 
p0,01), also ICVaff on sural nerves by the end of the second step of the treatment. 
Conclusions: The use of Nucleo CMP forte with IT contributes to the improvement of neurophysi-
ologic indicators of peripheral nerves.
Protective effect of agomelatine on traumatic brain  
injury induced cognitive deficit in rats: possible  
role of neurotransmitters 
P. Kumar1, T. Kaur2
1Department Pharmaceutical Sciences and Technology, Maharaja Ranjit Singh Punjab Technical University, India 
2Pharmacology, ISF College of Pharmacy, India
Traumatic brain injury (TBI) is the leading cause of death and disability among children and young 
adults worldwide. These patients often have short and long term cognitive, behavioural and emo-
tional impairments. The 5-HT2C and melatonin receptors are known to have involvement in memory 
functions. The aim of the present study is to find the beneficial effect of agomelatine (selective 5HT2C 
antagonist and melatonin receptor agonist) against weight drop induced traumatic brain injury in rats. 
The weight-drop model closely mimics the real life TBI. The injury was induced by dropping a weight 
of 450 gm from a height of one metre through a hollow metallic tube onto the exposed skull of rats 
under anaesthesia. After 14 days of TBI, the agomelatine (10, 20, and 40 mg/kg p.o. daily) treatment 
was given for next 14 days (i.e. till 28th day). The cognitive impairment was observed in Morris wa-
ter maze (from 24th to 28th day) and novel object recognition (on 27th and 28th day) test. Immediately 
after behavioural parameters animals were sacrificed and hippocampus and cortex were isolated for 
biochemical (LPO, nitrite, GSH, AChE), neuroinflammatory (TNF-a, IL-1b, IL-6) and neurochemical 
(serotonin, DA, NA and their metabolites) estimation. The weight drop model significantly induced 
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memory impairment in TBI rats that has been assessed by Morris water maze and object recognition 
task. A significant rise in acetylcholinesterase activity, neuroinflammatory markers, oxidative stress 
(lipid peroxidation and nitrite, GSH) was found in both cortex and hippocampal regions of traumatised 
rat brain, while agomelatine treated rats has been shown to reverse the injury effects and significant 
increase in serotonin, dopamine and norepinephrine levels in TBI rat brain. Agomelatine has shown to 
possess memory-enhancing effects, that might be due to involvement of MT1/MT2 and 5-HT2C receptors. 
Hence agomelatine represents a promising new neuroprotective drug for cognitive enhancing effects.
Cognitive interventions and cognitive training  
in adults with HIV: a state of the science
D. Vance, P. Fazeli, S. Morrison, J. Cheatwood, C. Nicholson
School of Nursing, University of Alabama at Birmingham, USA
Introduction: Combination antiretroviral therapies hinder HIV viral replication, allowing people to 
age with HIV. With over 50% of adults with HIV over 50+, this challenges the concept of successful 
neurocognitive aging. Unfortunately, over 50% of HIV+ adults experience HIV-Associated Neurocog-
nitive Disorder ranging from milder forms (i.e., Asymptomatic Neurocognitive Impairment or Mild 
Neurocognitive Disorder) to a more severe form (i.e., HIV-Associated Dementia). Yet, even such milder 
neurocognitive impairments can interfere with financial and medication management, driving, and 
other instrumental activities of daily living that impact quality of life and survival. As this clinical 
population continues to age well into late adulthood, these milder forms of neurocognitive impairment 
may be accelerated or accentuated resulting in more severe neurocognitive and functional loss. 
Objectives: Researchers and clinicians need to identify medical and lifestyle factors that facilitate 
positive and negative neuroplasticity in this population in order to promote cognitive reserve. 
Material and methods: In an ongoing review of the literature, factors that promote positive neuro-
plasticity include good sleep hygiene, physical exercise, good nutrition, social engagement, and cog-
nitive stimulation. Factors that promote negative neuroplasticity include comorbidities (i.e., diabetes, 
cardiovascular disease), substance abuse, trauma and stress, social isolation, and loneliness. In this 
presentation, current research to improve positive neuroplasticity in older adults with HIV empha-
sises the use of computerised speed of processing, transcranial direct current stimulation, and their 
combined used. 
Conclusions: Emerging insights from the first large longitudinal study (The Think Fast Study) in-
vestigating a cognitive training protocol in older adults (40+) with HIV are provided as an exemplar.
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SLEEP
A case of restless legs syndrome in patient  
with neurogenic sciatic nerve tumour
S. Cho1, J. Lee2, H. Rhee3, S. Yoon2, K. Hwang2, J. Lee2
1Neurology, SM Christianity Hospital, South Korea 
2Neurology, Kyung Hee University Hospital, South Korea 
3Neurology, Kyung Hee University Hospital at Gangdong, South Korea
Restless legs syndrome (RLS) is chronic neurological disorder, in which the primary symptoms is 
unpleasant and disturbing sensation accompanied by urge to move in multiple body parts, especially in 
legs. RLS may present in distinct phenotypes, often described as “primary” vs “secondary”. Secondary 
RLS can arise from aetiologies such as iron deficiency, pregnancy, peripheral neuropathy, and end-stage 
renal disease. We report a rare case of RLS associated with neurogenic tumour of the sciatic nerve. 
A 72-year-old man complained of recurrent and worsening RLS symptoms in his right lower extrem-
ity, despite medical treatment. The patient showed no signs of any neurological deficit. Interestingly, 
we found a nodular lesion (about 2.2 cm in diameter) at the right greater sciatic notch region on hip 
magnetic resonance imaging (MRI). Even if patients fulfills with the diagnostic criteria for typical RLS, 
if the progression is different from typical course and the secondary cause is not completely excluded, 
extensive work-up including MRI may be required to confirm the structural lesion of lower limbs. We 
report a rare case of secondary RLS, which is thought to be neurogenic tumour invasion of sciatic nerve.
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STROKE
Diagnostic of rare form of acute stroke (venous stroke)  
in early postpartum period
N. Chemer, N. Ruda
Stroke Unit, Department of Neurology, Kyiv Regional Clinical Hospital, Ukraine
Objectives: To improve the diagnosis and treatment of acute stroke in women in the early postpartum 
as a rare, but possible cause of maternal mortality and disability. 
Material and methods: Observation, diagnosis and treatment of two cases of acute stroke rare form 
— a venous stroke (VS) as a thrombosis of Trolard vein (the frequency is 0.1% to 3–5%) in women in 
early postpartum. In our observations postpartum women, delivered by CS under general anaesthesia, 
complained only of general weakness and diffuse unexpressed headache during first hours of disease. 
After 5 hours, the 27-year-old (G1P1) postpartum woman had a nausea, vomiting, numbness of the 
hand. After examination of neurologist, CT neuroimaging was performed, and patient was transferred 
to the stroke unit with a diagnosis of haemorrhagic transformation of ischaemic stroke. In the second 
case, the 32-year-old (G1P1) postpartum woman continued to stay in the obstetric hospital for another 
24 hours. After generalised convulsive attack, with suspicion of acute viral encephalitis (according to 
the conclusion of CT), she was transferred to the neurological department. 
Conclusions: In both cases there were a late referral to neurologist, which is most likely due to 
vagueness of clinical symptoms of the disease. Women of young age with risk factors for hypercoagu-
lation are at risk. VS causes difficulties in diagnosis due to prevalence of general symptoms over local 
manifestation. Haemorrhagic transformation and development of epilepsy are frequent complications 
of VS. Given these facts and the early postpartum period, anticoagulant therapy should be discussed.
Spinal cord infarction or acute myelitis? Fibrocartilaginous 
embolisation as a rare cause of spinal cord infarction
A. Damiza-Detmer1, M. Pawelczyk2, A. Glabinski2
1Department of Neurology and Stroke, University Clinical Hospital Military Memorial Medical Academy — Central Veteran’s Hospital in Lodz, Poland 
2Department of Neurology and Stroke, Medical University of Lodz, Poland
Fibrocartilaginous embolisation (FCE) is an extremely rare cause of spinal cord infarction, however 
it should be considered in a diagnostic process. The mechanism results from the expulsion of fibro-
cartilaginous nucleus pulposus material to the vessels that supply the spinal cord. We would like to 
present two cases of spinal cord infarction. The 1st patient with a hemiparesis and lesion in dorsal 
spinal cord at C4 level in magnetic resonance and second one with tetraparesis due to anterior spinal 
artery occlusion with typical owl’s eye sign in magnetic resonance. In both cases, the features of dis-
copathy at level of lesions in spinal cord were described. Both of patients developed symptoms after 
hard physical work and had only one risk factor of stroke. During diagnostic process, we excluded 
central nervous system infection, demyelinating diseases, autoimmune diseases and other spinal cord 
inflammation. Clinically suspected FCE was recognised in our patients mostly based on the exclusion 
of other diseases mimicking transverse myelitis of the spinal cord and presence of a disc disease. Based 
on the diagnostic process of our patients we would like to propose the containing criteria that increase 
the probability of FCE.
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Nuclear abnormalities as a manifestation of mitotic  
instability of vascular myocytes in cerebral autosomal 
dominant arteriopathy with subcortical infarcts  
and leucoencephalopathy (CADASIL)
D. Dziewulska1, 2, E. Nycz3
1Neurology, Medical University of Warsaw, Poland 
2Experimental and Clinical Neuropathology, Mossakowski Medical Research Center, PAS, Poland 
3Neurology, Medical Center, Poland
Introduction: Cerebral autosomal dominant arteriopathy with subcortical infarcts and leucoenceph-
alopathy (CADASIL) is a stroke and dementia syndrome with degeneration and loss of vascular smooth 
muscle cells (VSMC). The disease is associated with mutations in the NOTCH3 gene playing a role 
in VSMC differentiation, proliferation and apoptosis. Since one of the possible pathomechanism of 
CADASIL may involve alterations in cell proliferation that are governed by the activity of the Notch-3 
receptor-signaling pathway, to verify that hypothesis we performed morphological studies of VSMC. 
Material and methods: In autopsy and skin-muscle biopsy material of patients with CADASIL 
diagnosis, assessment of VSMC in arterial vessels at the level of light and electron microscopy was 
performed. Proliferative activity of VSMC was evaluated in immune reactions to proliferative markers: 
PCNA, and cyclins B1 and D. 
Results: In CADASIL, a part of VSMC revealed abnormal nuclear morphology. The affected myocytes 
showed variability in nuclear size, irregularity in nuclear shape, and abnormal chromatin appearance. 
Frequently, double nuclei of equal size or micronuclei were observed. Sometimes, even multinucleat-
ed myocytes were found. In some VSMC nuclei, the immune reactions to PCNA and studied cyclins 
were positive. 
Conclusions: Aberrant structure and number of VSCM nuclei, as well as their immunoreactivity to 
proliferative markers suggest mitotic instability of vascular myocytes in CADASIL. Mutated NOTCH 3 
gene, which is unable to control properly VSMC proliferation, may be responsible for their premature 
or inappropriate entry of into mitosis, irreversible arrest of the cell cycle, senescence or degeneration 
and loss.
Clinical correlates of post-stroke apathy
V. Gerasymchuk
Department of Neurology and Neurosurgery, Ivano-Frankivsk National Medical University, Ukraine
Post-stroke emotional disorders are widely discussed during the recent decade, but the post-stroke 
apathy remains the least studied among them. One hundred and forty-seven patients in the early recovery 
period of first-ever atherotrombotic anterior circulation ischaemic stroke and 30 healthy individuals 
(control group [CG]) were examined. Neurophyschologycal examination of cognitive and emotional 
status, sonography of extra- and intracranial vessels and non-parametric data analysis (Statistica 8.0) 
were used. The mean apathy level in Starkstein Apathy Scale (SAS) score was 12 (9; 16) compared to 
5 (4; 7) in CG (p0.05); patients with right-hemispheric stroke (RHS) manifested significantly higher 
SAS score of 13 (11; 19) (p0.05) compared to 10 (9; 13) in patients with left-hemispheric stroke (LHS). 
Comorbidity of apathy and depression was observed in 14.9% of RHS patients and exceeded the LHS 
indices (2.5%) (p0.05). SAS score correlated with the degree of stroke severity on the Scandinavian 
Stroke Scale (r = -0.34; p = 0.027), cognitive functioning on MMSE (r = -0.34; p = 0.048), FAB (r = 
-0.49; p = 0.036) and MoCA (r = -0.41; p = 0.0068), and the depression severity according to HADS 
(r = 0.61; p0.001) and ZSDS (r = 0.6; p0.001). Increase of SAS score was also associated with ipsilat-
eral internal carotid artery stenosis (r = 0.32; p = 0.027) and decrease of peak velocity in the middle 
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cerebral artery (r = -0.31; p = 0.036). These results allow suggesting that patients after RHS are more 
predisposed to post-stroke apathy. At the same time, apathy was associated with cognitive dysfunction, 
that may be a result of some common links of underlying pathogenesis chain of these neuropsycho-
logical syndromes.
Insufficient physical activity among  
population of Azerbaijan
K-H. Hasanov1, R. Shiraliyeva2, R. Aliyev2, D. Aliyeva3
1Neurology 2, Republican Clinic Hospital, Azerbaijan 
2Neurology and Clinical Neurophysiology, Azerbaijan State Advanced Training Institute for Doctors named after A. Aliyev, Azerbaijan 
3Normal Physiology, Azerbaijan Medical University, Azerbaijan
Introduction: Lack of physical activity has clearly been shown to be a risk factor for stroke. Less 
active and less fit people have a greater risk of developing high blood pressure. 
Material and methods: In the offered article by means of International Physical Activity Question-
naire it was studied prevalence of insufficient physical activity among 40–49 years old population of the 
Guba-Khachmas economic region of Azerbaijan Republic during 2008–2010. In the study participated 
1821 persons (3% of 40–49 years old population). From them 1164 (575 women, 589 men) lived in 
rural settlements, 657 (348 women, 309 men) in the city. Also, we studied other most common stroke 
risk factors among these persons. 
Results: Among risk factors, an insufficient physical activity met more often — 37.3 ± 1.1%. It was 
revealed, that men (68.0 ± 1.9%) conduct more physically an active way of life, than women (57.5 ± 
1.6%). The country people conduct an active way of life (76.4 ± 1.3%) on comparison with city (38.5 
± 1.9%). 
Conclusions: The prevalence of insufficient physical activity increases according to the level of in-
come. High income countries had more than double the prevalence compared to low income countries 
for both men and women, with 41% of men and 48% of women being insufficiently physically active 
in high income countries as compared to 18% of men and 21% of women in low income countries. In 
conclusion we found, that on average, in Guba-Khachmaz region the prevalence of insufficient physical 
activity in Azerbaijan falls at the middle level in comparison with other countries.
Post-stroke care systems — comparison of organisation, 
changes and tendencies in Poland and New Zealand
K. Hennessey1, D. Budzyna-Dawidowski1, R. Czekaj2
1English Division, Uniwersytet Medyczny im Piastów Śląskich we Wrocławiu, Poland 
2Oddział Neurologiczny, Szpital im. Żeromskiego w Krakowie, Poland
Introduction: Stroke is a major health problem worldwide. Stroke mortality steadily declines in 
developed countries with the development of specialised units and early diagnosis and interventions. 
However, people who survived a stroke often have significant morbidity and live with the effects of 
the stroke. Patients need access to effective rehabilitation services that aim to enhance quality of life 
by improvement of participation in society and functional activities. 
Material and methods: Authors compared structure and accessibility of stroke services in two health 
systems (Poland and New Zealand) in the light of current guidelines. The available statistical data were 
compared including trends over last five years in prevention, morbidity and mortality. 
Conclusions: Prevention, early diagnosis, early treatment and effective, widely accessible rehabilita-
tion are crucial to improve chances of surviving and recovering from stoke. Different medical systems 
offer similar approaches and similar trends are observed over last 5 years. New Zealand experience 
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shows that further improvement in outcomes for stroke patients depends on developing increased 
awareness of prevention (minimising risk factors) and engaging all services, including primary care 
and non-governmental organisations.
Case of Hashimoto’s encephalopathy  
under mask of another diagnosis
V. Hertsev, T. Muratova, O. Kolesnyk, O. Lebid, O. Varbanets, G. Perkova
Neurological Department, Odessa National Medical University, Ukraine
Introduction: Demonstration of the importance of “orphan alertness” in everyday medical practice 
in the diagnosis of orphan diseases. In recent years, the frequency of diagnosis of Hashimoto’s enceph-
alopathy had begun to increase due to awareness of doctors. 
Material and methods: Under our supervision was the female of 1986 birth. From the anamnesis 
it was known that during the last few years she had repeated ischaemic strokes with good clinical 
recovery. She was treated in three clinics in Ukraine and in one clinic in Germany with the diagnosis: 
“antiphospholipid syndrome”, but in Germany this diagnosis was with a question mark. 
Results: As a result of our in-depth study of anamnestic data, it was found that the patient during 
recent years had been treated by endocrinologist with diagnosis: “autoimmune thyroiditis”, her levels 
of antibodies to thyroperoxidase had been increased from hundreds of times at the onset of the disease 
till ten times at the time of our assessment. The levels of thyroid hormones were within normal limits 
and so that the treatment of autoimmune thyroiditis had been stopped by endocrinologist. As a result 
of detailed study of medical records and exclusion of other possible diagnoses had been diagnosed 
Hashimoto’s encephalopathy. 
Conclusions: 1. In the everyday medical practice there should be “orphan alertness” for the timely 
diagnosis of orphan diseases, which often masked under other diagnoses. 2. There should be closer 
cooperation between specialists for diagnosis of rare diseases.
An unusual case of stroke in young adult after motor  
vehicle accident without evidence of dissection
L. Jaffe1, T. McIlvain2
1Neurology, Tripler Army Medical Center, USA 
2Internal Medicine, Tripler Army Medical Center, USA
Isolated midbrain infarctions in young adults are rare and poorly studied. Blunt cerebrovascular 
injuries with cerebrovascular dissection have been identified as a cause of stroke after trauma in young 
adults. Little is known about the aetiology of stroke following blunt cerebrovascular injury when dis-
section is not discovered. We report an isolated stroke in the posterior midbrain of a young woman 
following motor vehicle accident with unclear aetiology. A 28-year-old previously healthy female 
presented to the hospital after low-speed motor vehicle accident. She was evaluated and released. She 
returned to hospital hours later with acute onset the decreased visual acuity in right eye with dilated 
pupil and painless paresthesias on the right half of her tongue. On physical exam, associated decreased 
superior and inferior gaze, and decreased adduction were noted. CTA of the neck and repeat CT head 
were unremarkable. MRI/MRA of the brain was significant for subacute right posterior midbrain in-
farct and axonal injury with intact anterior and posterior circulation. Extensive blood work up did 
not reveal any abnormalities. Midbrain cerebrovascular accidents in young patients in the absence of 
dissection are rare. There is a correlation between blunt head trauma leading to dissection, which can 
cause stroke. In the presented case, there was no evidence of dissection, following blunt trauma. Iden-
tification of cerebrovascular dissection following blunt head trauma is important as anti-coagulation 
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has been shown to be beneficial in this setting. Cerebral infarction in the setting of blunt trauma may 
not always be due to vessel dissection.
Clinical and radiological factors associated with  
unfavourable outcome after intravenous thrombolysis  
in patients with mild ischaemic stroke
D-H. Kim1, E. Oh2, H. Nah1, J. Cha1
1Department of Neurology, Dong-A University Hospital, South Korea 
2Department of Neurology, Chungnam National University Hospital, South Korea
Introduction: A significant proportion of patients with mild ischaemic stroke become disabled 
despite receiving intravenous thrombolytic therapy. The purpose of this study was to assess factors 
associated with unfavourable outcomes in patients with minor ischaemic stroke that received intra-
venous recombinant tissue plasminogen activator (rt-PA) therapy. 
Material and methods: We identified anterior circulation stroke patients with initial NIHSS scores 
≤ 5 who received intravenous thrombolysis within 4.5 hours of stroke onset and had pretreatment 
magnetic resonance (MR)/MR angiography using our prospective stroke database. Logistic regression 
was used to determine independent predictors of unfavourable outcomes. 
Results: Among 121 patients (85 men; mean age, 63.4 ± 11.3 years) included in this study, 46 (38%) 
had unfavourable outcomes at 90 days and diffusion-weighted imaging (DWI) lesion patterns showing 
infarction in the deep middle cerebral artery (MCA) territory involving the perforating artery area was 
observed in 47 (38.8%) patients. On multivariable analysis, unfavourable outcomes at 90 days were 
associated with diabetes (odds ratio [OR], 3.41; 95% confidence interval [CI], 1.06–10.9; P = 0.039), 
NIHSS score on admission (OR, 2.11; 95% CI, 1.35–3.30; P = 0.001), and infarction in the deep MCA 
territory on DWI (OR, 4.19; 95% CI, 1.63–10.8; P = 0.003). Lesions in the deep MCA territory was in-
dependently associated with early neurological deterioration (P = 0.032). The patients without deep 
MCA territory infarction had a higher prevalence of cardiac embolism (P = 0.009). 
Conclusions: Higher NIHSS scores, diabetes, and deep MCA territory infarction may be useful for 
predicting unfavourable outcomes in patients with minor stroke treated with intravenous rt-PA therapy.
The number of endovascular thrombectomy attempt  
is related to clinical outcomes in large artery occlusion  
in patients with acute ischaemic stroke
E. Kim, J. Seo, H. Jung
Neurology, Inje University Paik Hospital, South Korea
Introduction: It is not well known how many attempts for recanalisation it would be advisable. We 
evaluated the relationship of the number of EVT attempt and clinical outcome. 
Materials and methods: Patients who treated with EVT for large artery occlusion in anterior circula-
tion and within 24 hours from last seen normal time were included. Age, sex, comorbidities, admission 
NIHSS score, modified Thrombolysis in Cerebral Ischaemia score, time intervals from the puncture to 
recanalisation, number of EVT attempt and three months modified Rankin Scale score were analysed. 
Results: 207 patients receiving EVT for AIS in January 2012 to September 2017 were included. Suc-
cessful recanalisation was achieved in 156 (75.3%) after EVT. As the number of EVT attempt increased, 
the rate of favourable outcome (mRS 0–2) was significantly lowered. The clinical outcome of patients 
with one to three EVT attempt was more favourable than patients without successful recanalisation, 
the clinical outcome of patients with more than four EVT attempt was not better. 
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Conclusions: This study showed that an increased number of EVT attempt to achieve a good recan-
alisation is related with worse outcomes. Even though successful recanalisation is necessary to have 
good clinical outcomes, more than four EVT attempt could be futile.
Anxiety traits as predictor of stroke in general population 
in Russia/Siberia: gender features. WHO program  
MONICA-psychosocial study
E. Krymov, I. Gagulin, E. Gromova, D. Panov, A. Gafarova, V. Gafarov
Collaborative Laboratory of Cardiovascular Diseases Epidemiology, NIITP — Branch Institute of Cytology and Genetics, Russia
Introduction: To evaluate the influence of personal anxiety on risk stroke in general population of 
Russia/Siberia. 
Material and methods: In frame of the third screening WHO programme “MONICA-psychosocial” 
a random representative sample of the population aged 25–64 in Novosibirsk in 1994 (men n = 657, 
women n = 870) was surveyed. The programme included: registration of socio-demographic data; 
personal anxiety was studied with Spielberger test. Over 16-year period, cases of stroke incidence in 
women and men were identified (35 and 22, respectively). Cox regression model was used for relative 
risk assessment (HR). 
Results: Over 16 years, the risk of stroke in women with high anxiety level (HLA) was 3.5-fold higher 
compared to those with lower anxiety levels. HR was 4.43-fold higher in men. After adjustment for age 
and social parameters, HR risk of stroke was 3.5 and 3.2-fold higher for women and men with HLA, 
respectively. The greatest risk of stroke in presence of high anxiety was in divorced (HR = 5.017) and 
widowed men (HR = 3.848), aged 55–64 years (HR = 5.8). 
Conclusions: Anxiety is the most potent psychosocial risk factor for stroke in general population. The 
risk of stroke was higher in men over 16-years period in spite attenuated associations after adjustment.
Implication of calpain-mediated beta-secretase  
up-regulation for neurodegeneration in the  
postischaemic basal ganglia
H.B. Liang, Y. Minabe, T. Yamashima
Department of Restorative Neurosurgery and Psychiatry, Kanazawa University, Japan
Brain hypoperfusion may be related to the development of Alzheimer’s disease (AD), which was 
shown in some neocortex studies. However, the basal ganglia, such as putamen, caudate nucleus and 
thalamus have received less attention. Although some brain imaging studies revealed diminished 
volumes of these structures in the various neurodegenerative diseases, including AD, it still remains 
unknown how brain ischaemia affects basal ganglia. In the present study, we focused on the implication 
of brain ischaemia to elucidate the pathogenesis of sporadic AD, using the monkey experimental para-
digm. As hallmarks of neurodegeneration induced by cerebral hypoperfusion, microtubule-associated 
protein 2 (MAP2) and glial fibrillary acidic protein (GFAP) were studied by immunohistochemistry in 
the monkey brain undergoing 20min whole brain ischaemia followed by reperfusion. This showed, that 
immunoreactivity of MAP2 was decreased, while that of GFAP was increased in the basal ganglia and 
thalamus. Cerebral ischaemia/reperfusion also induced amyloid precursor protein (APP) processing due 
to µ-calpain activation, which was represented by both up-regulations of b-Site APP-cleaving enzyme 1 
(BACE1) and C-terminal fragment of 99 amino acid (b-CTF) protein levels. Moreover, decreases of the 
cAMP response element-binding protein (CREB) and brain-derived neurotrophic factor (BDNF) were 
seen in postischaemic basal ganglia and thalamus. These results suggest that brain ischaemia plays an 
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important role in the development of neurodegeneration in the basal ganglia. The µ-calpain-induced 
overexpression of BACE1 in the postischaemic basal ganglia of monkeys may suggest implication of 
brain ischaemia for the development of AD.
Carotid “web-like” stenosis as a complication  
of endarterectomy
I. Mendes, T.-B. Silvério, A.-C.Ribeiro
Neurology, Hospital Garcia de Orta, EPE, Portugal
Introduction: Carotid endarterectomy is the treatment of choice for extracranial carotid atherosclerotic 
disease. However, there is an associated potential for restenosis, which implies increased risk of stroke. 
The main pathogenesis is still unclear, but two main mechanisms are proposed: intimal hyperplasia 
and smooth muscle cell growth (early stage) and atherosclerotic process (later stage). 
Material and methods: We report a case of an 80-year-old man with multiple vascular risk factors 
and a left endarterectomy for symptomatic stenosis. Afterwards, annual imaging screening with ca-
rotid Doppler-Ultrasound (CDU) revealed a severe bilateral carotid disease, with left residual stenosis. 
The patient was later re-admitted in our hospital with an acute right ischaemic stroke. Diagnostic 
workup was performed: cranial CT scan revealed an acute right frontal ischaemic lesion; CDU showed 
significant left internal carotid artery (ICA) stenosis and right ICA atherosclerotic occlusion; digital 
subtraction angiography revealed recurrence of left carotid stenosis and confirmed right occlusion. 
After multidisciplinary discussion, endovascular repair (angioplasty with stent insertion) of the left 
ICA was performed. CDU confirmed reperfusion of the artery. He was started on double anti-aggrega-
tion and high-dose statin and, during the follow-up period, there were no recurring neurologic events. 
Conclusions: Currently, there is no consensus regarding the best approach of carotid restenosis fol-
lowing carotid revascularisation (surgical therapy vs carotid stenting). There is now a trend to choose 
endovascular approach. In our case, it was effective and without complications.
Carotid stenosis cause cognitive decline
M. Mijajlovic
Cerebrovascular Disorders, Neurology Clinic, Clinical Center of Serbia and School of Medicine University of Belgrade, Serbia
Studies have found that cerebrovascular disease could play an important role on cognitive decline 
or dementia in patients without an obvious history of stroke. Recent studies have highlighted the role 
of carotid atherosclerosis, not only as a primary cause of cognitive impairment, but also adjuvant to the 
expression dementia caused by other factors, including Alzheimer’s disease and other neurodegenerative 
pathology. Carotid intima-media thickness could predict accelerated cognitive decline, particularly in 
the domain of verbal and nonverbal memory, as well as a test of semantic association fluency and exec-
utive function. Carotid plaque biology and serologic biomarkers of vulnerability can be used to predict 
the risk of cognitive impairment. Patients with bilateral carotid stenoses have worse performance on 
the tests for executive function, attention, and memory than unilateral carotid stenosis. The difference 
in cognitive function between patients with left and right carotid artery stenosis was not significant in 
high stenosis grade, while in lower stenosis grade, badly cognitive function was observed in patients 
with left carotid stenosis than patients with right carotid stenosis. As carotid atherosclerosis always 
overlap with neurodegenerative pathology, the relationship between them still needs to be investigated 
in more studies due to multiplicity of underlying pathology.
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Stent deployment as a treatment for stent retriever failure 
in acute ischaemic stroke: an evidence-based case report
Z.F. Nafisah1, A.P. Permana2
1Faculty of Medicine, Universitas Indonesia, Indonesia 
2Neurosurgery Department, Faculty of Medicine Universitas Indonesia — Cipto Mangunkusumo National General Hospital, Indonesia
Introduction: Stent retriever has been approved as definitive therapy for acute ischaemic stroke, 
but it has various failure rates ranging from < 1%–30%. Deploying self-expandable stent can be con-
sidered in patients refractory to conventional management. A patient sustains acute ischaemic stroke 
with stenosis in middle cerebral artery, M1 & M2. After 3 attempts of stent retriever, there was no 
recanalisation. Then, the stent is deployed and TICI 2b/3 was achieved. This study aims to identify 
the outcome of stent deployment as a treatment for stent retriever failure in acute ischaemic stroke. 
Material and methods: Literature searching was performed in three databases: PubMed®, Cochrane®, 
and ScienceDirect® using keywords: stenting, failure, acute ischemic stroke, and modified Rankin Scale 
score with their acronym or abbreviations. Two articles were generated using inclusion and exclusion 
criteria. Critical appraisal was performed using validity, importance, and applicability criteria. 
Results: The randomised control trial (RCT) showed lower modified Rankin Scale score (mRS score 
0–2, 35.3%) and cerebral herniation (11.8%) in stenting group compared to non-stenting group (mRS 
score 0–2 7.1%; cerebral herniation 42.9%). In a cohort study, stent deployment results good outcome 
(mRS score 0–2) in 42% patients and moderate disability (mRS score 3) in 21% patient. 
Discussion: In atherosclerosis stenosis, the self-expandable stent minimise barotrauma to the vessel, 
more flexible to reach distal lesions, and have various sizes. Besides, it has lower acute/periprocedural 
complications with no instances of procedural stroke, vessel rupture, or stent migration. Therefore, 
deployment of stent-expandable stent in acute ischaemic stroke can be used in stent retriever failure.
Homeotic genes expression profile of peripheral blood  
leucocytes in transient ischaemic attacks and cerebral  
ischaemic strokes
K. Piasecka-Stryczynska1, A. Malinska2, M. Nowicki2
1Neurology, Szpital im. Prof. S. T. Dąbrowskiego S.A., Poland 
2Department of Histology and Embryology, Poznan University of Medical Sciences, Poland
The aim of the study was to identify homeotic genes expression profile of peripheral blood leucocytes 
in patients diagnosed with transient ischaemic attacks (TIA) and cerebral ischaemic strokes in order to 
select “gene candidates” useful in predicting the risk of subsequent ischaemic incidents in this group 
of patients. The study group included 51 subjects diagnosed with TIA (n = 24) or ischaemic stroke (n 
= 27). RNA was extracted from peripheral blood leucocytes and the panel of 168 genes belonging to 
homeotic genes family was evaluated using SABiosciences PCR Arrays (PAHS-083Z and PAHS-0501Z). 
The obtained results were then elaborated using bioinformatic tools involving heat maps, gene set 
enrichment and association studies, as well as clinical analyses. Potential genes indicating the risk 
of recurrent ischaemic episode in patients diagnosed with transient ischaemic attack were DMBX1, 
PROX1, GATA1, GATA6 and HAND1. In case of DMBX1 and PROX1, the risk of subsequent ischaemic 
attack correlated with increased expression of these genes. On the other hand, decreased expressions 
of GATA1, GATA6 and HAND1 indicated the probability of another episode of cerebral ischaemia. Ac-
cording to clinical evaluation, the most promising genes, strongly correlating with established factors 
of the cerebral ischaemia, were GATA1 and GATA6 (p0,0001; r = 0,8). They indicate, however, the risk 
of a recurrent cerebral ischaemic episode exclusively in patients diagnosed with TIA. No genes have 
been shown as the potential factors indicating the risk of re-ischaemia in patients initially diagnosed 
with cerebral ischaemic stroke.
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Cerebral venous sinus thrombosis in pregnancy
U. Rosinska1, P. Wlodarczyk2, M. Wiszniewska1
1Neurology, Szpital Specjalistyczny w Pile im. Stanislawa Staszica, Poland 
2Obstetrics and Gynaecology, Szpital Specjalistyczny w Pile im. Stanislawa Staszica, Poland
Cerebral venous sinus thrombosis is a rare, multi symptomatic and a very serious complication 
in pregnancy. About 0,5–1% of all strokes are cerebral venous sinus thrombosis. Women are at three 
times higher risk of having a cerebral venous sinus thrombosis than men. In addition to that, it occurs 
5,5 to 6 times more often during pregnancy than in general population of women. The most frequent 
symptoms and signs are headache (74%), focal seizures with or without secondary generalisation (50%), 
impairment of muscle strength (38%), disturbance of consciousness (45%), visual impairment. Mag-
netic Resonance Venography (MRV) is a key method to investigate for venous thrombosis in pregnancy. 
The first line treatment for cerebral venous sinus thrombosis in pregnancy is body-weight-adjusted 
subcutaneous low-molecular weight heparin. When CVT occurs during pregnancy, anti-thrombolysis 
treatment should be considered as soon as the diagnosis has been confirmed, until at least six weeks 
after the delivery. The shortest accepted time of treatment are three months. The presence of CVT 
in the health history is not a contraindication for next pregnancy, but only on the condition that an-
ti-thrombolysis treatment is provided. That treatment consists of body-weight-adjusted subcutaneous 
low-molecular weight heparin from the time of conception till six to eight weeks after the delivery. 
The prognosis is auspicious.
Clinical case: how to treat venous stroke  
in women in early postpartum period?
N. Ruda, N. Chemer
Neurology, Kyiv Regional Hospital, Ukraine
Introduction: Venous stroke (VS) is a rare form of stroke due thrombosis of Trolard’s and Labbe’s 
veins (the frequency is from 0.1% to 3–5%). The important risk factors of the VS are pregnancy and 
the postpartum period in young women. Differential diagnosis and treatment of the VS cause certain 
difficulties. 
Material and methods: A 27-year-old postpartum woman was admitted to our clinic complaining of 
nausea, vomiting, numbness and jerking movements of the left limbs. 5 hours before she had general 
weakness and diffuse headache. Neurological examination revealed left-sided hemiparesis and Jack-
sonian seizures in the left hand. After CT and MRI, neuroimaging was performed, and the patient was 
transferred to the stroke unit with a diagnosis of haemorrhagic transformation of ischaemic stroke (focal 
lesion of the right parietal lobe). Analysis of the cerebrospinal fluid was normal. EEG was registered 
convulsive readiness. CT angiogram showed VS due total thrombosis of the anastomotic vein of the 
right parietal lobe. She received carbamazepine, enoxaparin. After the treatment, there was a clinical 
improvement. 
Results: Verification of VS is difficult due to the following features: a later appeal to the neurologist, 
which is most possibly due to the vagueness of the clinical symptoms of the disease, necessity to do 
detailed follow-up examination by a skilled neuroradiologist. 
Conclusions: Venous stroke causes difficulties in diagnosis due to the prevalence of general symp-
toms of the focal symptoms. Haemorrhagic transformation and development of epilepsy are frequent 
complications of the venous stroke. Can we use thrombolytic therapy by VS?
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Does the spleen play a role in acute neurological injuries? 
S. Savitz, F. Vahidy, A. Zha, J. Aronowski
Institute for Stroke and Cerebrovascular Disease, UTHealth, USA
Introduction: A wealth of pre-clinical animal studies suggest that the spleen contributes to peripheral 
immune responses to injury in stroke, brain haemorrhage, and traumatic brain injury. The spleen has 
been shown to promote the migration of inflammatory cells to the brain, leading to secondary injury 
and propagating BBB disruption and CNS inflammation. We present a review of our published stud-
ies on spleen responses in patients with acute neurological disorders and define whether the spleen 
contributes to inflammatory responses and clinical outcomes. 
Material and methods: Over 100 patients with acute ischaemic stroke and brain haemorrhage have 
been prospectively studied with splenic ultrasounds, brain imaging, neurological exams and blood 
studies. Serum inflammatory cytokines and the systemic inflammatory response have been measured 
in a subset of patients. 
Results: Using nomograms of splenic volumes derived from healthy volunteers, we find that the 
spleen reduces in size in nearly half of studied patients. African-Americans, older patients, and patients 
with prior stroke have higher odds of splenic reduction. Spleen reduction is associated with elevations 
in specific inflammatory cytokines. In a subset of patients, longitudinal analyses show that the spleen 
contracts within six hours of symptom onset and re-expands after three days. 
Conclusions: The spleen may play an important biological role in patients with acute neurological 
disorders, raising the possibility for the development of new therapeutic targets to modulate inflam-
matory responses and improve outcomes. 
Search for the embolic source: a patient  
with two consecutive stroke episodes
M. Tavsanli, C. Aktan, S. Ucler
Neurology, Saglik Bilimleri University Okmeydani Education and Research Hospital, Turkey
Introduction: 70-year-old male patient was seen in the emergency room with left hemi hypoaesthesia, 
ataxia and cerebellar dysarthria and the cranial imaging showed right cerebellar acute lacunar infarct. 
Hypertension, hyperlipidaemia and diabetes mellitus were present in the medical history of the patient. 
There was no significant stenosis in the carotid-vertebral arterial system. Electrocardiogram (EKG) and 
transthoracic echocardiography (TTE) revealed no significant pathology. Acetylsalicylic acid (ASA) 300 
mg once a day was prescribed during the externation of the patient. One month later he was seen at the 
emergency department again with acute onset ataxia and the cranial imaging revealed a new lacunar 
infarct at the right side of the pons while under ASA treatment. Doppler, EKG and TTE were repeated, 
but they revealed no significant pathology. We decided to perform transoesophageal echocardiography 
(TEE) to reveal any cardioembolic source. The report of the TEE showed grade V atheroma at the aortic 
arch. Clopidogrel combined with ASA was prescribed for the patient. 
Discussion: Atheroma of the aorta is a well-known risk factor for stroke and it increases the risk four 
times. In our case, routine work-up and two separate TTE could not detect such a high grade atheroma 
at the arch and we were unable to detect the plaque until TEE was performed. In this poster we would 
like to discuss if it was possible to detect the atheroma with TTE or another technique in the first place 
and when and how should we expand our work-up to detect aortic atheroma.
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Factors associated with concomitant asymptomatic  
intracranial artery stenosis in patients with  
atherothrombotic brain infarction attributable  
to intracranial artery stenotic lesion
T. Uehara, K. Yoshida, H. Terasawa, H. Shimizu, Y. KIta
Neurology, Hyogo Brain and Heart Center at Himeji, Japan
Introduction: The purpose of this study was to identify factors associated with concomitant asymp-
tomatic intracranial artery stenotic lesion (ICAS) in patients with atherothrombotic brain infarction 
(ATBI) attributable to ICAS. 
Material and methods: Subjects of this study were 54 patients (37 men; mean age, 71.0 ± 12.9 years) 
with symptomatic ICAS, who were admitted to our department within seven days of the onset of ATBI, 
between April 2013 and August 2017. Significant ICAS was defined by the presence of ≥ 50% stenosis 
or occlusion of intracranial arteries, as detected by MR angiography. 
Results: 26 patients (48.1%) had concomitant asymptomatic ICAS. Patients with asymptomatic ICAS 
was significantly older (74.9 ± 2.4 vs 67.3 ± 2.4 years, p = 0.029) and more likely to have a history of 
ischaemic heart disease (IHD) (23.1% vs 3.6%, p = 0.033), compared to those without. The prevalence of 
current smoking habit was significantly lower in patients with asymptomatic ICAS than in those with-
out (11.5% vs 35.7%, p = 0.038). Multiple logistic regression analysis showed that advanced age (Odd 
ratio [OR], 1.83; 95% confidence interval [CI], 1.04–3.53; p = 0.034, for every 10 years) and a history of 
IHD (OR, 11.5; 95% CI, 1.42–265.5; p = 0.020) were associated with concomitant asymptomatic ICAS. 
Conclusions: Our results suggested that patients with ATBI attributable to ICAS who had concom-
itant asymptomatic ICAS were older and prone to have a history of IHD.
Mechanical thrombectomy for the posterior circulation 
stroke: analysis of outcomes and comparison to anterior 
circulation large vessel occlusion treatment
M. Wiacek1, A. Perenc1, R. Kaczorowski1, H. Bartosik-Psujek1, 2
1Department of Neurology, Clinical Regional Hospital No. 2, Poland 
2Faculty of Medicine, University of Rzeszów, Poland
Introduction: Mechanical thrombectomy (MT) is now well-established method for anterior circulation 
large vessel occlusion (LVO) treatment. There is, however, no solid evidence of its efficacy in the setting 
of posterior circulation LVO. We present the comparison of treatment outcomes and periprocedural 
complication rates in both groups. 
Material and methods: We reviewed the Clinical Regional Hospital No. 2 in Rzeszów local MT-treat-
ment database. The baseline characteristics, site of occlusion, procedural times, and presence of suc-
cessful reperfusion, procedural complications, outcomes and mortality at three months were analysed. 
Results: 77 patients (48% woman, median age 70, IQR 61–79) were treated with MT (Solitaire FR or 
Penumbra system) between January 2013 and December 2016. 14 (18%) had posterior and 63 (82%) 
anterior circulation LVO. There was no significant difference in age and baseline National Institutes 
of Health Stroke Scale (NIHSS) score in the posterior circulation cohort (p0.05). The median time 
to treatment was significantly longer than anterior circulation LVO group (median (IQR) 283 min 
(225–360) vs 220 min (180–288), p = 0.008). There was none symptomatic intracerebral haemorrhage 
(sICH) identified (0% vs 8%, p = 0.58). The posterior group showed tendency to higher reperfusion 
rates (85.7% vs 66.7%, p = 0.21) and better outcomes (mRS = 0−2) at 3 months (57.1% vs 37.7%, 
p = 0.23). Mortality rates were similar in both groups (28.6% vs 27.9%, p = 1). 
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Conclusions: MT for the posterior circulation LVO stroke is not associated with higher complication 
rates and mortality than anterior occlusion treatment. High reperfusion and good outcome rates could 
be achieved.
Repeated thrombectomy of middle cerebral artery
J. Wojczal1, P. Luchowski1, M. Sojka2, K. Pyra2, S. Stachowicz1, M. Górnik2,  
K. Buraczyńska1, J. Jaworski1, K. Rejdak1, Z. Stelmasiak1, T. Jargiello2
1Department of Neurology, Medical University of Lublin, Poland 
2Department of Interventional Radiology and Neuroradiology, Medical University of Lublin, Poland
We present a case of 79-year-old male with occlusion right middle cerebral artery (MCA), treated with 
thrombectomy and after ten months retreated because of reocclusion of the same artery. The patient 
developed the symptoms of acute ischaemic stroke of right hemisphere on 4th January 2017 with left 
side central facial palsy, hemianopia, hemiparesis, hemianaesthesia, hemineglect and coniugated gaze 
partial palsy to the left side. Total NIHSS was 16. In history, the patient had permanent atrial fibrilla-
tion, arterial hypertension and neoplasmatic process under control (carcinoma of bladder and prostate 
with bilateral ureterocutaneostomy). The occlusion of right MCA was found and thrombectomy was 
performed with complete recanalisation. On control CT, the infarction without haemorrhagic trans-
formation (HT) in the right hemisphere was seen. The patient was discharged home with 5 points in 
NIHSS, mRS after 30 days rehabilitation was scored 1. On 6th November 2017, the patient developed 
the symptoms of new acute ischaemic stroke of right hemisphere and the NIHSS was scored 16. The 
occlusion of right side M1 MCA was found and thrombectomy was performed (despite the residual old 
infarcted area in the territory of the operated MCA), with complete recanalisation. On 24h control CT 
a new infarct, next to the old one, was seen with small HT2. The patient functionally improved and 
was discharged to rehabilitation unit with 10 point in NIHSS. 30 day mRS was scored 2 (functionally 
independent). This is the first report on repeated thrombectomy on the same artery, with good clinical 
effect.
Isolated choroid plexus infarction presenting  
as acute-onset Parkinsonism
S. Yoon1, E. Kim2, H. Rhee3, J. Lee1
1Neurology, Kyung Hee University Hospital, South Korea 
2Radiology, Kyung Hee University Hospital, South Korea 
3Neurology, Kyung Hee University Hospital at Gangdong, South Korea
An isolated choroid plexus infarction presenting as acute-onset Parkinsonism has never been re-
ported. A 70-year-old woman with a history of hypertension and hyperlipidaemia visited our clinic 
complaining of sudden gait disturbance and bradykinesia, which started ten days prior. On neurolog-
ical examination, the patient’s gait showed a decrease in step height and walking speed. Symmetrical 
bradykinesia of the upper and lower limbs was also observed. Secondary Parkinsonism was suspected, 
and a laboratory and imaging diagnostic workup was performed. Interestingly, her brain MRI demon-
strated a focal hyperintense lesion in the right choroid plexus on diffusion-weighted imaging. The above 
lesion was confirmed to be an acute ischaemic stroke based on low signal intensity on the apparent 
diffusion coefficient map. To differentiate the patient’s symptoms of acute-onset Parkinsonism from 
CSF circulation disorders or underlying cerebral dopamine depletion, a diagnostic lumbar puncture 
and 18F-FP-CIT PET scan were performed. Opening CSF pressure was 56 mm H2O, which was lower 
than normal range. A 18F-FP-CIT PET scan revealed normal dopamine transporter binding. Seven weeks 
after the onset of symptoms, she had noticeable recovery with no symptoms of Parkinsonism. Follow-up 
lumbar puncture revealed a normal opening pressure. We speculated that acute-onset Parkinsonism 
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in this case might be related with low CSF pressure syndromes, such as intracranial hypotension. 
Considering the course of recovery for seven weeks after the onset of symptoms, we suggested that the 
patient’s Parkinsonism was due to choroid plexus infarction. Clinicians should be aware of this unique 
condition as a rare cause of secondary Parkinsonism.
Predictive values of neutrophil to lymphocyte and platelet 
to lymphocyte ratios in outcomes of patients with stroke
N. Zmouli1, 2, M. Benyoub2, 3, D. Badsi2, 3, W. Tidjane2, 3, H. Toumi1, 2, M. Hammadi2, 3
1Pharmacy, Faculty of Medecine, Algeria 
2University Hospital Establishment, EHUO, Algeria 
3Medecine, Faculty of Medecine, Algeria
Introduction: The systematic and local inflammation plays a key role in physiopathology of stroke. 
The aim of our study is to examine the prognostic utility in short term of neutrophil to lymphocyte ratio 
(NLR) and platelet to lymphocyte ratio (PLR) measured in the admission of the patients with stroke. 
Material and methods: 70 patients admitted in the service of neurology from March to December 
2017. Neutrophil, lymphocyte and platelet counts were obtained using Coulter ADVIA 2120i. NLR and 
PLR were then calculated and a questionnaire was completed. Patients were contacted six months later 
for research of possible recurrence. At first, a descriptive analysis was realised. Secondly, a Kaplan 
Meier survival curves and a Cox regression analysis are established, as well as the determination of 
the value of threshold for predicting recurrence by ROC. 
Results: There is a statistically significant difference of the mean age between men and women (p 
= 0,035). The Kaplan Meier survival curves are significantly different between categories low NLR 
and high NLR (p = 0,004) also for PLR (p = 0,0001). The Cox model reveals that the NLR (HR = 3, 
38) and PLR (HR = 6) are the only predictive markers of a recurrence. The cutoff NLR = 4,6 and the 
cutoff PLR = 170. 
Conclusions: NLR and PLR are biomarkers little expensive and easily available. They allow the 
stratification and the optimal monitoring of the patients risk to make a recurrence.
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WILSON’S DISEASE
Gastroscopy findings in Wilson’s disease patients before 
and during D-penicillamine or zinc sulphate treatment
M. Antczak-Kowalska1, A. Przybylkowski2, T. Litwin1, A. Czlonkowska1
12nd Department of Neurology, Institute of Psychiatry and Neurology, Poland 
2Department of Gastroenterology and Internal Medicine, Medical University of Warsaw, Poland
Gastric symptoms in Wilson’s disease (WD) may result from Helicobacter pylori infection or dis-
ease-related factors, like liver cirrhosis or adverse drug reactions. The aim of this study was to examine 
the frequency of gastropathy and gastric ulcers in WD patients, and to analyse the effects of therapy on 
these conditions. All enrolled patients underwent oesophagogastroduodenoscopy and urease test for H. 
pylori infection. Patients were divided into three study groups, treatment naive (n = 37), on D-penicil-
lamine (n = 34), or zinc sulphate (n = 24) therapy. The results of the research show that there was no 
statistically significant difference in the prevalence of gastropathy and peptic ulcers between untreated 
patients (64,9% and 10,8%), treated with D-penicillamine (52,9% and 11,8%) or zinc salts (79,2% and 
8,3%). The prevalence of H. pylori infection in all WD groups (60–70%) was similar to those reported 
in general Polish population. H. pylori infection was related with higher rate of gastropathy (73,3% vs 
48,6%), but there was no significant difference in peptic ulcers rate (11,7 % vs 8,6%). In conclusion, 
our results show that gastropathy and peptic ulcers are frequent in WD, but therapy (d-penicillamine 
or zinc) does not increase the rates of gastropathy and gastric ulcers in WD. 
Different brain pathology in neurological and hepatic 
forms of Wilson’s disease depicted by quantitative MRI
M. Dezortova1, M. Hajek1, V. Herynek1, L. Kotackova2, D. Zahorakova3,  
R. Bruha4, Z. Marecek5, P. Dusek6
1MR-Unit, Dept. Diagnostic and Interventional Radiology, Institute for Clinical and Experimental Medicine, Czech Republic 
2Institute of Clinical Biochemistry and Laboratory Diagnostics, Charles University and General University Hospital in Prague, Czech Republic 
3Dept. Paediatrics and Adolescent Medicine, Charles University and General University Hospital in Prague, Czech Republic 
44th Dept. Internal Medicine, Charles University and General University Hospital in Prague, Czech Republic 
5KlinMed, Prague, Czech Republic 
6Dept. Neurology and Centre of Clinical Neuroscience, Charles University and General University Hospital in Prague, Czech Republic
Introduction: Quantitative MRI is a sensitive tool to study microstructural changes in tissues. This 
study aims at comparison of differences in quantitative MRI metrics in the deep gray matter nuclei in 
Wilson’s disease (WD) patients with neurological and hepatic form. 
Material and methods: 40 patients with genetically confirmed WD (30 neurological WD, 10 mild 
hepatic WD) on a stable anti-copper treatment and 26 healthy controls were investigated. 3T MR 
system was used to study quantitative susceptibility and T2/T1 relaxation times in globus pallidus, 
putamen, caudate nucleus and thalamus. Serum ceruloplasmin oxidase activity was measured using 
the o-dianysine assay. 
Results: T2 relaxation times were significantly lower in neuro-WD group in globus pallidus, putamen, 
and caudate nucleus compared to controls and hep-WD, whereas T2 relaxation times in hep-WD did 
not differ from controls. T1 relaxometry revealed higher T1 values in the thalamus in neuro-WD group 
compared to both controls and hep-WD patients (p0.02). Significantly higher susceptibility values were 
found in all studied regions in neuro-WD patients compared to controls and hep-WD patients (p0.02). 
No difference was found between hep-WD patients and controls. No correlation with the ceruloplasmin 
oxidase activity was found. 
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Conclusions: Our results show that hep-WD is not associated with significant brain pathology. 
Decreased T2 relaxation time/ increased susceptibility in the basal ganglia indicate iron deposits, 
whereas increased T1 relaxation time/increased susceptibility in the thalamus correspond rather to 
demyelination in neuro-WD group. Iron accumulation is not causally related to decreased ferroxidase 
activity. Supported by MH CR 15-25602A and 00023001IKEM Institutional support.
Clinical and laboratory characteristics  
of different stages of Wilson’s disease
M. Karaseva1, T. Fedorova2, E. Panina3, S. Lobzin3, A. Nekrasova3
1Neurology, International Medical Center “SOGAZ”, Russia 
2Neurology, Saint-Petersburg Clinical Hospital of the Russian Academy of Sciences, Russia 
3Neurology, North-Western State Medical University named after I.I. Mechnikov, Russia
Introduction: Wilson’s disease (WD) is a rare hereditary disorder of copper metabolism with excellent 
prognosis, if diagnosed on time. Search of the new simple diagnostic criteria is of great importance. 
Objectives: To study the most frequent combinations of clinical and laboratory findings in patients 
with different stages of WD. 
Material and methods: Clinical, neurological, biochemical and haemostatic status was assessed in 
22 patients with hepatic and in 53 patients with neurologic stage of WD. 
Results: Initial clinical manifestations were distributed as following: signs of liver affection — 43%, 
haemorrhagic syndrome (nasal, gingival or cutaneous) — 30%, primary neurologic symptoms — 16% 
and the other variants —11%. Hyperkinesia, mixed dysarthria, haemorrhagic and menstrual disorders 
was the most typical combination in 73% of cases in the neurologic stage of WD. Haemorrhagic and 
menstrual disorders coupled with asthenic autonomic syndrome and mild action tremor in hands were 
identified in 65% of patients in the hepatic stage. Disturbances of copper metabolism (91%), cytolysis 
(59%) and cholestasis (52%), thrombocytopenia (57%), changes in platelet function (96%) and coagu-
lopathy (60%) were the leading biochemical findings. Cytolysis and cholestasis were more common (p 
= 0.04 and p = 0.03, respectively) and more evident in patients with the hepatic stage, while coagu-
lopathy and thrombocytopenia — in the neurologic stage of WD (p = 0.03 and p = 0.02, respectively). 
Conclusions: Different combination and severity of clinical and laboratory findings in patients with 
hepatic or neurologic stage of WD should be considered in diagnosing.
Pseudodominant inheritance  
of Wilson’s disease — case report
A. Krasniej-Debkowska, A. Czlonkowska
2nd Department of Neurology, Institute of Psychiatry and Neurology, Poland
Introduction: Wilson’s disease (WD) is an inherited autosomal recessive disorder of a copper me-
tabolism. The diagnosis of WD is usually made before the age of 40, so pseudo-dominant inheritance 
is observed mostly in offspring of WD patients, the risk is 4%. We describe a family, in which WD was 
firstly diagnosed in a daughter of a father who was asymptomatic up to 60 years old. 
Material and methods: Proband was diagnosed with WD upon copper at the age of 31 years, when 
she had an acute hepatic failure. Her brother, age 37, was also diagnosed with WD. He was clinically 
asymptomatic, but had abnormalities in laboratory liver tests. One year later WD was diagnosed in 
her father at the age of 62 years. During hospitalisation for an acute bronchitis, he was diagnosed with 
a liver cirrhosis and an oesophageal varices. He has never suffered from any liver symptoms before. 
He has also decreased ceruloplasmin level, Kayser-Fleischer rings, neurological symptoms and brain 
MRI abnormalities characteristic for WD. Genetic showed the same mutation as his daughter has, but 
present only on one chromosome. 
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Conclusions: This case report shows how important it is to obtain detailed family interviews after 
diagnosing WD in the proband. Information should be gained not only proband’s siblings, but also for 
other relatives, although recognition of disease in the parents of WD is very rarely described.
Transcranial sonography in Wilson’s disease patients
M. Skowronska, T. Litwin, K. Dziezyc, I. Kurkowska-Jastrzebska, A. Czlonkowska
2nd Department of Neurology, Institute of Psychiatry and Neurology, Poland
Introduction: Wilson’s disease (WD) is an autosomal recessive inherited disorder of copper me-
tabolism with hepatic and neurological symptoms. Transcranial sonography (TCS) may be useful as 
a simple and safe technique in many neurodegenerative diseases. The aim of this study was to asses 
basal ganglia changes in WD patients with TCS in two years observation period. 
Material and methods: Patients with new diagnosis of WD without previous treatment entered the 
study. TCS was performed through the preauricular acoustic bone window with a 2.5-MHz phased-array 
transducer. SN echogenic sizes ≥ 0.25 cm2 were classified as hyperechogenic for the used ultrasound 
system. The area of hyperechogenicity in the lenticular nucleus (LN) was measured by encircling the 
outer circumference of the hyperechogenic area. 
Results: 21 neurological and 20 hepatic patients entered the study. Baseline SN hyperechogenicity 
was found in nine neurological and four hepatic patients. 24 months SN hyperechogenicity was found in 
one neurological and three hepatic patients. There was no correlation between baseline and 24 months 
SN echogenicity neurological examination. Baseline LN did not reveal hyperechogenic changes in two 
neurological and five hepatic cases. One patient in neurological group and three patients in hepatic 
group did not have LN changes on 24 months TCS. 
Conclusions: SN hyperechogenicity was not observed in all WD patients and is more often seen in 
neurological group. LN echogenicity is observed in most WD patients and number of patients with LN 
changes had risen over the time. Basal ganglia changes observed in WD patients are time dependent 
probably due to drugs therapeutic effect.
Limbic encephalitis — diagnostic difficulties
T.A. Mendel1, S. Tarka2,4, A. Piechal1, D. Ryglewicz3,  
A. Bochyńska3, I. Kurkowska-Jastrzębska1, T. Wierzba-Bobrowicz2.
12nd Department of Neurology, Warsaw, Poland  
2Department of Neuropathology, Warsaw, Poland  
31st Department of Neurology, Warsaw, Poland  
4Institute of Psychiatry and Neurology, Department of Forensic Medicine, Medical University of Warsaw, Poland
Limbic encephalitis (LE) was the first described by Brierley in 1960 as a clinic-pathologic syndrome. 
LE is characteristic with various clinical signs and symptoms. Patients with LE can have memory im-
pairment, confusion, disorientation, agitation, hallucination, sleep disturbance, depression and seizures. 
In 2016 Graus et al. published the diagnostic criteria for possible autoimmune limbic encephalitis. The 
clinical diagnosis can be confirmed by investigation of cerebrospinal fluid, EEG, brain MRI. LE is often 
suspected or diagnosed, but unfortunately, not always confirmed neuropathologically.
Three clinically suspicions of LE were presented. This group consists of 2 men aged 31 and 80 years 
and 73 years old woman. Diagnosis of LE were done according to the clinical symptoms, brain MRI 
findings and in two cases with presenting paraneoplastic antibodies. In two cases in neuropathological 
examination the presence of LE was excluded. Only in 80-year-old man neuropathological changes 
confirmed the clinical suspicion of LE.
Conclusions: Only in one case neuropathological diagnosis confirmed clinically suspected limbic 
encephalitis. LE is a disease, which can cause controversy between clinical suspicion and neuropatho-
logical findings.
